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Chapter 1 
Introduction 
 
1.1. Histamine receptors  
Histamine (HIS) exerts its effects through four receptor subtypes, termed histamine 
H1 (H1R), H2 (H2R), H3 (H3R) and H4 receptors (H4R), which all belong to class 1 
(rhodopsin-like) G protein coupled receptors (GPCRs)1-3 (for a description of the 
classification of GPCRs see chapter 1.3.1). Long before their respective genes were 
cloned4-6, the H1R, H2R and H3R were pharmacologically identified. More recently, 
the gene encoding the H4R based on the sequence homology to the H3R gene (37-
43 %) was determined7, 8. Unlike the H3R and H4R, the first two histamine receptor 
subtypes have shown to be targets for blockbuster drugs. H1R antagonists 
(antihistamines) are used to treat allergic conditions like hay fever and H2R 
antagonists have been developed as antiulcer drugs1. 
The cellular expression of the 487 amino acids containing human H1R includes 
airway smooth muscles, endothelial cells, neurons, dendritic cells, mast cells, 
monocytes/macrophages and lymphocytes9, 10. Stimulation of the H1R activates 
phospholipase C via a pertussis toxin-insensitive Gq/11 protein and leads to the 
formation of inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), which yields 
in calcium mobilization from intracellular stores and activation of protein kinase C9, 11. 
H1R antagonists are commonly divided into sedating first-generation antagonists like 
chlorpheniramin and chlorpromazine, and non-sedating second-generation 
antagonists like cetirizine (Figure 1.1). Today, especially the second-generation H1R 
antagonists are used in the therapy of allergic diseases like urticaria, allergic rhinitis 
and bronchial asthma1. Important experimental tools to analyze H1R function in 
cellular and organ systems are H1R agonists, which are divided into three groups1, 12. 
1) Small agonists derived from HIS such as 2-methylhistamine and betahistine, 2) 
HIS derivatives with bulkier aromatic substituents at position 2 of the imidazole ring 
such as 2-(3-trifluoromethylphenyl)histamine and 3) the histaprodifens such as 
suprahistaprodifen13-16 (Figure 1.1). In our group, fluorescent H1R antagonists were 
developed17, 18. 
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Figure 1.1. Structures of selected H1R ligands. 
 
A detailed description for the H2R is given in chapter 1.2. 
The human H3R consists of 445 amino acids and activates Gi/o proteins, which in turn 
inhibit of adenylyl cyclase (AC), thereby lowering the cAMP level, and activate other 
effector pathways including mitogen-activated protein kinase (MAPK) and 
phosphatidylinositol 3-kinase (PI3K) pathways19, 20. Mainly expressed in the CNS, the 
H3R acts as a pre-synaptic autoreceptor that regulates the synthesis and release of 
HIS from histaminergic neurons and has also been found in low densities in some 
peripheral tissues1, 21. Furthermore, the H3R can regulate serotonergic, 
noradrenergic, cholinergic and dopaminergic neurotransmitter release in mammalian 
brain1. Because all these neurotransmitter are involved in vigilance, attention and 
cognition enhancement, food intake and sleep-wake cycles, H3R antagonists are 
proposed as potential tools for the treatment of neurological dysfunctions and 
psychiatric diseases like schizophrenia, attention-deficit hyperactivity disorder 
(ADHD), dementia, epilepsy, obesity and narcolepsy19, 22, 23. H3R antagonists can be 
divided into imidazole-containing antagonists, like thioperamide and clobenprobit, 
and non-imidazole antagonists with improved oral bioavailability and blood brain 
penetration, like JNJ-520785219, 24-26 (Figure 1.2). Recent studies with the non-
imidazole containing H3R antagonist/inverse agonist BF2.649 may indicate a 
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potential to represent a new class of antipsychotics27, 28. Selective agonists like (R)-α-
methylhistamine, imetit, immepip and methylimmepip (Figure 1.2) are 
pharmacological tools and potential drugs for insomnia, myocardial ischaemic 
arrythmias as well as inflammatory and gastric acid related diseases19, 29, 30. 
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Figure 1.2. Structures of selected H3R agonists and antagonists/inverse agonists. 
 
The human H4R is a 390 amino acid protein and shares the highest homology 
sequence to the H3R of about 40 % (58 % homology in the transmembrane regions) 
among the histamine receptors. The homology to H1R and H2R is actually lower than 
to other GPCRs7. H4Rs are predominantly expressed in bone marrow and peripheral 
hematopoietic cells, most convincingly shown for eosinophils, mast cells, basophils, 
dendritic cells and T cells suggesting that it plays a role in the inflammatory 
response31. Like the H3R, the H4R couples to pertussis toxin-sensitive Gi/o proteins 
and thereby inhibits forskolin-induced cAMP production8, activates mitogen-activated 
protein kinase32 and mobilizes calcium in eosinophils and mast cells33. Due to the 
high homology to the H3R, the pharmacologies of the H3R and H4R overlap and many 
H3R ligands also bind to the H4R. The first highly selective H4R agonist was OUP-
1634 and later 4-methylhistamine35 (Figure 1.3) as a high-affinity H4R ligand with a 
>100-fold selectivity for the hH4R over the other histamine receptor subtypes was 
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identified. The first selective H4R antagonist turned out to be the indolylpiperazine 
derivative JNJ-7777120 (Figure 1.3)36. Selective H4R agonists and antagonists may 
be useful for the treatment of allergic rhinitis, asthma, dermatitis and autoimmune 
diseases like rheumatoid arthritis, multiple sclerosis, type I diabetes and systemic 
lupus erythematosus31. 
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Figure 1.3. Structures of selected H4R ligands. 
 
1.2. Histamine H2 receptor 
To date, H2R isoforms of canine5, human37, rat38, guinea pig39 and mouse40 have 
been cloned, exhibiting an overall amino acid sequence identity of more than 80 %. 
Within the α-helical transmembrane domains exists a sequence identity of 90 % 
whereas the N-terminal domain and the C-terminus are the least conserved regions. 
As recently demonstrated, the cH2R exhibit an increased constitutive activity 
compared to hH2R, gpH2R and rH2R41, 42. The DNA sequence encodes for 358 (rat, 
mouse) and 359 (human, canine, guinea pig) amino acids.  
 
1.2.1. Distribution and function 
H2Rs are located on gastric parietal cells, exerting a potent effect on gastric acid 
secretion43. H2R antagonists like metiamide, cimetidine, ranitidine, famotidine (Figure 
1.4), tiotidine, nizatidine and roxatidine became blockbuster drugs for the treatment of 
gastric and duodenal ulcer1. The high affinity (KD = 0.3 nM) H2R radioligand 
[125I]iodoaminopotentidine44-47 was used for audioradiographic mapping of H2Rs in 
mammalian brain. The H2R was found with highest densities in the basal ganglia, 
hippocampus, amygdala and cerebral cortex and with lowest densities in the 
cerebellum and hypothalamus45. The direct action of H2R stimulation on neuronal 
membranes is usually excitatory or potentiates excitation48. In hippocampal pyramidal 
cells, HIS blocks directly the calcium-dependent potassium conductance, which 
causes a long-lasting afterhyperpolarization and affects the accommodation and 
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firing48. Synaptic transmission in the hippocampus is potentiated and the firing of 
several types of neurons is enhanced for many hours after they have been exposed 
to HIS or the H2R agonist impromidine for only a few minutes49, 50. Due to the fact that 
the function of the H2Rs in the brain has not been identified51, because most of the 
available H2R ligands do not really penetrate the blood brain barrier, centrally active 
H2R agonists and antagonists will be useful pharmacological tools to study the role of 
these receptors in the brain.  
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Figure 1.4. Structures of H2R antagonists/inverse agonists. 
 
H2Rs are also present in cardiac tissues. Stimulation of the H2R can mediate 
chronotropic and inotropic effects on atrial and ventricular tissues52. Thus, the 
spontaneously beating guinea pig right atrium was used as a standard H2R model in 
organ pharmacology while measuring the change in the heart rate upon H2R ligand 
exposure. H2R-mediated smooth muscle relaxation has been documented in airway, 
uterine, and vascular smooth muscle53. Promyelocytic leukemic cells express H2Rs 
and activation leads to functional differentiation to mature granulocytes54, 55, and 
therefore H2R agonists are discussed to be useful for the treatment of acute 
promyelocytic leukemia. Finally, the histaminergic system exerts various regulatory 
functions affecting the immune response and certain aspects of hematopoiesis56-58. 
Different patterns of histamine receptor expression on T helper 1 (TH1) and T helper 
2 (TH2) cells induces converse T cell responses following histamine stimulation. TH1 
cells show predominantly, but not exclusive, expression of H1R, while TH2 cells show 
increased expression of H2R, acting as the negative regulator of proliferation, IL-4 
and IL-13 production56. Additionally, HIS directly causes B cell antibody production as 
a co-stimulatory receptor on B cells. Whereas the humoral immune responses may 
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be blocked by HIS through the H1R mainly expressed on TH1 cells, the humoral 
immune response is enhanced through the H2R56. 
 
1.2.2. Signal transduction mechanisms 
The H2R is a Gs coupled protein and therefore activates adenylyl cyclase, resulting in 
an increase in cAMP production1, 59. Thus, cAMP activates protein kinases, which 
phosphorylate regulatory proteins, leading, for instance, to an influx of Ca2+ in cardiac 
myocytes. Furthermore, there are reports of H2Rs coupling to other signalling 
systems. H2R stimulation has been shown to increase the intracellular concentration 
of free calcium ions mediated by action of phospholipase C60, 61. Some reports 
demonstrated that the H2R couples to both the Gs and Gq/11 signalling pathways62, 63.  
 
1.2.3. Histamine H2 receptor agonists 
The H2R agonists can be divided into two structural classes, the small amine-type 
agonists corresponding to histamine-like structures and the guanidine-type agonists 
corresponding to impromidine-like structures64. 
 
1.2.3.1. Small molecule histamine H2 receptor agonists 
5-Methylhistamine (Figure 1.5) was the first H2R agonist described in literature that 
exhibited any selectivity for the H2R65, 66. Further selective H2R agonists devoid of an 
imidazole ring are dimaprit67, 68, amthamine69 and amselamine70 (Figure 1.5). These 
compounds are similar to HIS concerning both structural criteria and H2R-agonistic 
activity, but are selective to the H2R.  
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Figure 1.5. Structures of histamine and small molecule H2R agonists. 
 
During a long time a tautomeric shift of the ligand has been thought to be a structural 
requirement for the stimulation of the H2R71. This tautomerism process involved two 
proton transfers, the donation of a proton from the receptor to the agonist on one side 
and on the other side a proton would be donated from the agonist to the receptor. To 
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explain the binding modes of either tautomeric or non-tautomeric ligands such as 
dimaprit and amthamine, a new activation model was suggested72. The partially 
positively charged sulphur atom of amthamine interacts with a negatively charged 
site of the receptor whereas the double bonded nitrogen atom accepts a proton from 
the proton donating site of the receptor72. This model implies that a tautomeric shift is 
no prerequisite for H2R stimulation. Moreover, it was shown that the two mechanistic 
models of H2R activation are compatible if the amino acid residues which constitute 
the recognition centre of the receptor are present in different acid-base conjugate 
forms73.  
In vitro mutagenesis studies and modelling approaches based on rhodopsin pointed 
out the histamine binding site of the H2R. H2R mutants indicated an ionic interaction 
of the protonated amino group with Asp-98 in TM374. The second and third site of the 
widely accepted three-point model could prinicipally be formed with the couples Asp-
186/Thr-190 or Asp-186/Tyr-182in TM575, 76. Subsequently, it was revealed that the 
proposed two H-bonds of the imidazole ring with H2R are only possible with Tyr-182 
and Asp-18676. 
 
1.2.3.2. Imidazolylpropylguanidines 
The first highly potent H2R agonist was the guanidine derivative impromidine (Figure 
1.6) which combines potent H2R agonism with moderate and potent H1R and H3R 
antagonistic activity, respectively11, 77. Impromidine is about 50 times more potent 
than HIS and a full agonist on the spontaneously beating guinea pig right atrium 
(chronotropic response), but in several other H2R containing tissues its relative 
potency and efficacy was lower11, 77.  
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Figure 1.6. Structure of the first highly potent H2R agonist impromidine. 
 
This prototypical guanidine-type H2R agonist is composed of the weak partial agonist 
imidazolylpropylguanidine (SK&F 91486)78 and a cimetidine-like moiety devoid of 
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H2R agonistic activity. A large number of impromidine analogues have been 
synthesized and evaluated for H2R agonism64. Impromidine was the first clinically 
tested specific H2R agonist and turned out to be a potent inotropic stimulator in 
patients suffering from severe catecholamine-insensitive congestive heart failure79-81.  
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Figure 1.7. Structure of the H2R agonist arpromidine. 
 
The replacement of the cimetidine-like moiety in impromidine by a more lipophilic 
pheniramine-like structure resulted in arpromidine (ARP)82 (Figure 1.7) which 
became a promising new chemical lead for the development of 
´cardiohistaminergics`83, 84. This pharmacological hybrid molecule is about 100 times 
more potent than HIS on the guinea pig right atrium and turned out to be an H1R 
antagonist which is about equipotent with pheniramine on the guinea pig ileum. A 
large series of arpromidine-related imidazolylpropylguanidines were developed as 
positive inotropic vasodilators82-85. The most potent arpromidine analogues achieve 
about 400 times the activity of HIS on the isolated spontaneously beating guinea pig 
right atrium. These arpromidine-like compounds, in particular the 3,4- and 3,5-
difluorinated analogues proved to be superior to impromidine in potency, 
hemodynamic profile and side effects when tested in the guinea pig under 
physiological conditions and in a pathophysiological model of severe congestive 
heart failure (vasopressin-induced acute heart failure)84. Furthermore, such 
compounds were described as first competitive non-peptide neuropeptide Y (NPY) 
receptor antagonists with moderately low potency at the Y1 receptor (pKi up to 6.5)86, 
87.  
The interaction of guanidine-type agonists may be interpreted by analogy with the 
model proposed for HIS64. Most amino acids interacting with guanidine-type agonists 
are identical in hH2R and gpH2R species isoforms88. The complex of ARP in the 
binding site of the hH2R is shown in Figure 1.8. The imidazole moiety in the 
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imidazolylpropylguanidines interacts by building H-bonds with Asp-186 and Tyr-182 
in TM5 and the strongly basic guanidino group underwents an ionic interaction with 
Asp-98 in TM375. Moreover, residues in TM6 face the imidazolylpropylguanidine 
moiety of ARP in the H2R model41, 88.  
 
Figure 1.8. Side view of the hH2R model in complex with ARP. The putative agonist binding site and 
the extracellular components of the hH2R are shown. The carbon atoms of ARP are shown in orange, 
grey ribbons illustrate transmembrane domains TM1-TM7, thin grey lines the extracellular loops e1, e2 
and e3 and the N-terminus. Taken from Preuss, 200741. 
 
In the hH2R model, the pyridyl ring of ARP, which was predicted to point into a 
“lower” binding region where bulk mainly decreases activity64, was surrounded by a 
cluster of aromatic and hydrophobic residues in TM2, TM3 and TM7. The 4-F-phenyl 
group was proposed to point into an “upper” binding region where bulk may enhance 
agonist activity89 and amino acids in TM6 and TM7 are involved64, 88. Furthermore, 
based on the crystal structure of rhodopsin90 the participation of amino acids in the 
e2 loop to the binding pocket was proposed for members of class 1 GPCRs, as 
experimentally demonstrated for the dopamine D2 receptor91, the adenosine A2a 
receptor92 and the muscarinic M3 receptor93. Very recently, site-directed mutagenesis 
studies revealed that the residues of the e2 loop presumably do not directly face the 
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binding pocket and do not contribute to the species-selective interactions of N-[3-(1H-
imidazol-4-yl)propyl]guanidines and NG-acylated analogues41, 94. Hence, participation 
of the e2 loop to the binding pocket may apply for many95 but possibly not for all 
class 1 GPCRs.  
In contrast to small H2R agonists, guanidines are less potent and efficient agonists at 
the H2R of human neutrophils than at the H2R of the guinea pig right atrium96, 97. This 
effect could also be confirmed with a membrane steady-state GTPase activity assay 
using fusion proteins of the H2R and the short splice variant of Gα, GαS. The 
compounds proved to be less potent and efficacious at the hH2R-GsαS than at the 
gpH2R-GsαS88. Considerations from a sequence alignment suggested that the 
nonconserved Asp-271 (gpH2R) in TM7 confers to this species-selectivity and can 
directly participate in ligand binding. Moreover, an interhelical H-bond between Tyr-
17 in TM1 and Asp-271 was predicted from a three-dimensional homology model of 
the gpH2R stabilizing an active guanidine bound conformation88. Such interactions 
cannot occur with Cys-17 and Ala-271 in hH2R88. These data was initially confirmed 
by an Ala-271→Asp-271 mutation in hH2R-GsαS (hH2R-A271D-GsαS)88 and 
subsequently by an Ala-271→Asp-271 and Cys-17→Tyr-17 double mutation in hH2R-
GsαS (hH2R-C17Y-A271D-GsαS)41, 98. Hence, guanidines stabilize an active 
conformation in gpH2R more efficiently and potently than in hH2R.  
 
N
HN
N
H
N
H
NH
R2
R1
n
S
N
H2N
H3C
O
n
R1
R2
phenyl, 4-F-, 2,4-F2-,       
3,5-F2-, 3,4-Cl2-phenyl,        
methyl
1-3
2-pyridyl, 3-pyridyl, phenyl, 
2-imidazolyl, 2-thiazolyl,         
cyclohexyl
 
Figure 1.9. General structure of guandine-type H2R agonists and NG-acylated analogues. 
 
The guanidine-type agonists are strong bases (pKa~13) and are nearly quantitatively 
protonated at physiological pH. Recently, compounds with improved pharmacokinetic 
properties, particularly with regards to oral bioavailability and penetration across the 
blood brain barrier, were developed in our workgroup99. The introduction of a 
carbonyl function adjacent to the guanidine moiety reduces the basicity by 4-5 orders 
of magnitude (pKa~8). A series of NG-acylated guandines was synthesized and 
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pharmacologically characterized99-101. Such compounds are absorbed from the 
gastrointestinal tract and are capable of penetrating across the blood brain barrier 
after administration to mice102. Centrally active H2R agonists may be useful 
pharmacological tools to study the role of H2Rs in the brain. Furthermore, the 
common imidazole ring of the guanidines and NG-acylated analogues was 
bioisosterically replaced by a 2-amino-4-methylthiazole group without affecting the 
H2R agonistic activity, but resulting in increased selectivity for H2R over H3R99, 103. 
 
1.3. G protein coupled receptors and oligomerization 
1.3.1. Classification and activation of G protein coupled receptors 
G protein coupled receptors (GPCRs) represent the largest class of cell surface 
receptors and are the most important group of targets for a large number of 
therapeutic agents. GPCRs share a similar architecture of seven hydrophobic, 
membrane-spanning α-helices forming a receptor which binds an extracellular ligand 
that exert a specific effect into the cell and is able to interact with a G protein104. For 
many GPCRs G protein independent signalling pathways have also been reported104, 
105. GPCRs are known as extremely versatile receptors, hence it is difficult to obtain 
diffraction-quality crystals from a native unbound receptor106. A broad variety of 
ligands such as biogenic amines, purines and nucleic acid derivatives, lipids, 
peptides and proteins, odorants, pheromones, tastants, ions like calcium and 
protons, and even photons in the case of rhodopsin are able to mediate their 
message through these proteins104, 107. Based on phylogenetic and ligand-receptor 
relationships human GPCRs are divided into three main subclasses/families, 1, 2, 3. 
The class 1 or rhodopsin-like familiy is the largest subgroup and contains receptors 
for odorants, small molecules such as catecholamines and amines, some peptides 
and glycoprotein hormones. Endogenous small-molecule ligands interact with a 
binding pocket located within the TM bundle and binding of peptides and 
glycoproteins occurs at the N-terminus, the extracellular loop regions and the upper 
part of the TM helices108. Furthermore, class 1 receptors are characterized by several 
highly conserved amino acids and a disulphide bridge that connects the first and 
second extracellular loop109. Rhodopsin was the first GPCR for which a high-
resolution crystal structure had been determined90, 110, 111. Very recently, the crystal 
structure of the β2-adrenergic receptor was reported112-114. The class 2 or secretin-
like receptors are characterized by a relatively long N-terminus containing several 
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cystein residues, which presumably form a network of disulphide bridges, and is 
involved in ligand binding109. Ligands for class 2 receptors include hormones such as 
glucagons and parathyroid hormone. The small glutamate class 3 contains the 
metabotropic glutamate, the Ca2+-sensing and the γ–aminobutyric acid (GABA)B 
receptors and are characterized by a very long N-terminus and C-tail, a disulphide 
bridge connecting the first and second extracellular loop and a very short and well-
conserved third intracellular loop. The ligand binding-site is located in the N-terminal 
domain, which is often described as being like a ´Venus fly trap`107, 109. Finally, a 
separate group includes the frizzled/smoothened family receptors105. For many of the 
identified GPCRs the natural ligands are unknown so far and are still “orphan” 
receptors. 
GPCRs function through heterotrimeric G proteins, consisting of a Gα-subunit and a 
Gβγ-heterodimer115, 116. Connected with a G protein on the intracellular side, GPCRs 
interact with an extracellular ligand and undergo a conformational change into an 
active state. The α-subunit normally binds GDP in the resting state. Upon activation, 
GDP is replaced by GTP, which binds to Gα inducing another conformational change 
in this subunit leading to dissociation of the heterotrimer in Gα-GTP and Gβγ. Both 
subunits now can interact and activate a secondary messenger system such as 
adenylate cyclase. There are several types of G proteins such as Gs, Gi and Gq/11 
which use different secondary messenger pathways115, 117. The intrinsic GTPase 
activity of the Gα-subunit converts GTP to GDP and Pi and the dissociated subunits 
are allowed to recombine to start a new cycle. 
Some GPCRs are known to be constitutively active. This stands for the ability of a 
GPCR to adopt an active conformation in the absence of an agonist118, 119. Many 
drugs which were traditionally classified as competitive antagonists are in fact inverse 
agonists and a large number of disease-causing GPCR mutations with increased 
constitutive activity had been identified105, 120. 
 
1.3.2. GPCR oligomerization 
Almost all therapeutic agents that are directed towards GPCRs have been designed 
using assays that presume that these receptors are monomeric. Now it is widely 
accepted that these receptors exist and are active as homo-oligomeric and hetero-
oligomeric complexes and could have important implications for the development and 
screening for new drugs109, 121. Because of the fact that GPCRs exist of seven 
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hydrophobic transmembrane domains, incomplete solubilization can lead to 
aggregation and be misunderstood for dimerization117. Thus, methods verifying the 
existence of oligomers in living cells were developed. Using bioluminescence 
resonance energy transfer (BRET) and photobleaching and time-resolved 
fluorescence resonance energy transfer (FRET), dimerization in living cells for 
different GPCRs were shown, including the β2-adrenergic receptor122, the δ-opioid 
receptor123, the thyrotropin-releasing hormone receptor124 and the SSTR5-
somatostatin receptor125. The most direct demonstration of GPCR oligomerization 
provides the atomic force microscopy, which reveals that rhodopsin exists in an 
oligomeric arrangement in its native environment126-128. Support for the 
oligomerization of GPCRs has been obtained experimentally by co-
immunoprecipitation, energy transfer between two tagged receptors, disulfide cross-
linking, pharmacological enhancement of the signal arising from one receptor by the 
agonist of the second receptor in the heterodimeric complex, radiation inactivation, 
gel exclusion chromatography, and interference with intracellular trafficking129. 
Moreover, recent results pointed out that the homo-dimer of a mammalian class 1 
GPCR requires binding of only one agonist to induce internalization and therefore 
supports the idea that GPCRs internalize as dimers as it was demonstrated for the 
β2-adrenoceptor130.  
There is an evidence that GPCR oligomers are already formed in the endoplasmatic 
reticulum (ER) before they are transported to the cell surface131. Although it is unclear 
whether oligomerization during biogenesis is directed towards all GPCRs, BRET and 
FRET studies have revealed that several receptors dimerize in the ER132, 133. 
Moreover, some GPCRs oligomerize at the cell surface in a process regulated by 
ligands131, 134, 135. 
Various regions of GPCRs are thought to form an interface between monomeric 
units135, 136. Thus for the dimerization of class 3 receptors, an intermolecular 
disulphide bond between the amino termini has been shown to be crucial109. 
Because there are great differences in the structure of the amino termini of class 1 
receptors compared to those of the class 3 receptors, the sites of intermolecular 
interaction for class 1 receptors were found elsewhere109. For rhodopsin-like 
receptors, the transmembrane domains are thought to be involved in oligomerization 
include transmembrane helices 1 and 4-6 and cytoplasmic loops formed between 
transmembrane helices 1 and 2 and transmembrane helices 5 and 6135-137. 
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The fact that GPCRs are able to form oligomeric entities opens the possibility to 
improve drugs by the development of dimeric ligands acting as bivalent ligands109. 
The term “bivalent ligand” stands for a molecule that contains two pharmacophores 
linked through a spacer and also describes compounds that are not dimeric138, 139. 
One aim of developing bivalent ligands is to enhance the affinity of the fully bound 
dimeric compound compared to a monovalent ligand or a univalently bound bivalent 
ligand. The length and chemical properties of the spacer are crucial factors 
concerning the ability to bridge two neighbouring receptors. A very short or a very 
long spacer decreases the potential to occupy two vicinal receptors139. Binding of one 
pharmacophore of a dimeric ligand exhibiting an optimal spacer length to one 
recognition site of a receptor dimer might have increased affinity compared to their 
monovalent ligands because the unbound partner is arranged in closer proximity to 
neighboring binding sites109. An alternative theory for increasing affinity and/or 
potency of dimeric ligands is that these ligands might more readily induce or stabilize 
the dimeric conformation of the receptors as it was proposed for the bivalent 
endothelin peptide109, 140. In addition to increased affinity, changes in selectivity for 
bivalent opioid receptor ligands has been observed138. Changes in κ-opioid receptor 
selectivity were monitored in dependence on the spacer length 138.  
There is evidence that many rhodopsin-like GPCRs exist and act as oligomeric 
entities including the histamine H1141, 142, H2143, H3144, 145 and H47, 146 receptors. The 
synthesis and pharmacological investigations of double pharmacophore ligands with 
different spacer lengths for bridging hypothetical dimeric histamine receptors are 
subject of this work (chapter 5). 
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Chapter 2 
Scope of the Thesis 
 
N-[3-(1H-Imidazol-4-yl)propyl)guanidines such as arpromidine are the most potent 
histamine H2 receptor agonists known so far. From a therapeutic point of view, these 
compounds are possibly useful as positive inotropic and vasodilatory drugs 
(´cardiohistaminergics`) for the treatment of severe congestive heart failure, as 
agents inducing cell differentiation in acute myelogenous leukaemia and as anti-
inflammatory drugs. The strongly basic guanidino group, which is supposed to 
interact with Asp-98 in TM3 of the H2R, is essential for the agonistic activity. 
However, the guanidino group is also responsible for very low oral bioavailability, 
non-H2R-mediated effects and lack of penetration across the blood brain barrier. Very 
recently, a novel class of NG-acylated analogues with reduced basicity and therefore 
improved pharmacokinetic properties such as oral bioavailability and capability of 
penetrating across the blood brain barrier, was developed in our workgroup1, 2. As 
demonstrated for N-[3-(1H-imidazol-4-yl)propyl)guanidines, the acylated derivatives 
are less potent and efficacious at gpH2R-GsαS than at hH2R-GsαS fusion proteins in a 
membrane steady-state GTPase assay3-5. By contrast, histamine and small H2R 
agonists do not exhibit species-selectivity. Recently, N-(3-cyclohexylbutanoyl)-N´-[3-
(1H-imidazol-4-yl)propyl]guanidine (Figure 2.1, UR-AK57), a compound which was 
synthesized during the preceding diploma work6, was identified as the most potent 
hH2R agonist so far (EC50 = 23 nM in a GTPase activity assay at hH2R-GsαS fusion 
proteins). Moreover, unlike most related acylguanidines, UR-AK57 exhibits H1R 
agonistic activity5. 
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Figure 2.1. Structure of the H2R agonist UR-AK57 and the general structure of NG-acylated 
imidazolylpropylguanidines to be synthesized. 
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The aim of this work was to synthesize and characterize NG-acylated imidazolyl-
propylguanidines with different chain lengths and alkyl/aryl substituted side chains to 
identify selective and potent agonists particularly at the human histamine H2 receptor.  
Previously, the bioisosteric replacement of the imidazole ring by a 2-amino-4-
methylthiazole group in the series of NG-acylguanidine resulted in similarly potent and 
efficacious agonists at the H2R, but with a remarkably increased selectivity over the 
H3R1. To further elucidate the structure-activity relationships and the selectivity 
towards the H2R versus the H3R and the H4R, a serie of NG-acylated 3-(2-amino-4-
methylthiazol-5-yl)- and 3-(2-aminothiazol-5-yl)propylguanidines (Figure 2.2) was 
designed and synthesized. The new compounds were investigated for H2R agonistic 
potency on the isolated guinea pig right atrium, for species selective H2R agonism 
and for histamine receptor subtype selectivity in GTPase assays using membranes of 
Sf9 cells expressing human and guinea pig H2R-GsαS fusion proteins, human 
H3R+Gαo+β1γ2+RGS4 membranes and human H4R-GAIP+Gαi2+β1γ2 membranes.  
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H2N n1, n2 = 1-3, R
1 = alkyl, aryl,
R2 = phenyl, cyclohexyl,
R3 = CH3, H
Het N
H
N
H
NH O
N
H
O
N
H
NH
Het
n
n = 4-20, Het = imidazol-4-yl,
2-amino-4-methylthiazol-5-yl,
2-aminothiazol-5-yl  
Figure 2.2. General structure of NG-acylated 2-aminothiazolylpropylguanidines and bivalent ligands. 
 
Histamine H1-H4 receptors are known to exist as oligomeric entities7-12. Hence, as 
part of this work prototypical bivalent H2R ligands with different spacer lengths 
(Figure 2.2) were synthesized to specify the distinct interactions with the human and 
guinea pig H2R and to investigate the activity at H3R and H4R in the steady-state 
GTPase activity assay.  
In summary, as part of a programme aiming at the development of centrally active 
guanidine-type selective agonists for the human histamine H2 receptor the aim of this 
thesis was to synthesize and pharmacologically characterize NG-acylated hetaryl-
propylguanidines in order to further elaborate the structure-activity relationships and 
to improve the H2R subtype selectivity.  
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Chapter 3 
 
NG-Acylated Imidazolylpropylguanidines – 
Synthesis and Histamine H2 Receptor Agonistic 
Activity 
 
3.1. Introduction 
The histamine H2 receptor (H2R) is a member of the “class A” or “rhodopsin family” of 
G protein-coupled receptors (GPCRs). H2Rs were detected in numerous peripheral 
tissues and cells, for example, in leukocytes, the heart, airways, uterus and vascular 
smooth muscles and in the brain1, 2. In the human brain, the histamine H2R is widely 
distributed in the basal ganglia, hippocampus, amygdala, and cerebral cortex as well 
as, with lower densities, in cerebellum and hypothalamus3. As H2Rs couple to the Gs 
protein, receptor stimulation results in an increase in adenylyl cylase activity. H2R-
mediated biological responses are, for instance, the stimulation of gastric acid 
secretion, an increase in cardiac contractility and the induction of myeloid cell 
differentiation1, 4. 
N-[3-(1H-Imidazol-4-yl)propyl]guanidines like arpromidine (ARP) (Figure 3.1) and 
analogues5 are the most potent H2R agonists known so far. In addition to their value 
as pharmacological tools, such compounds could be useful as drugs, for instance, for 
the treatment of severe congestive heart failure, acute myelogenous leukaemia and 
inflammatory diseases2. The major disadvantages of the arpromidine-type H2R 
agonists result from the strongly basic guanidine moiety: insufficient oral 
bioavailability and lack of penetration across the blood brain barrier. Surprisingly, the 
H2R agonistic potency was retained when the methylene group adjacent to the 
guanidine was replaced with a carbonyl group, even though the basicity was thereby 
reduced by 4-5 orders of magnitude (for comparison: pKa (guanidine) ≈ 12.5, pKa 
(acetylguanidine) ≈ 7.66)7. Obviously, the acylguanidine group in this new class of 
H2R agonists, the NG-acylated imidazolylpropylguanidines, is sufficiently basic to 
interact with Asp-98 of the histamine H2R by analogy with the suggested binding 
mode for arpromidine-like compounds. Moreover, a considerable portion of the 
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acylguanidines remains uncharged under physiological conditions so that these 
compounds are able to overcome the blood brain barrier. The brain penetration of N-
[3-(3,4-difluorophenyl)-3-(thiazol-2-yl)propanoyl]- (I) and N-[3-phenylbutanoyl]-N´-[3-
(1H-imidazol-4-yl)propyl]guanidine (II) (Figure 3.1) were studied in nude mice after 
peroral and intravenous administration. In contrast to arpromidine-type H2R agonists 
the acylated guanidines were absorbed from the gastrointestinal tract and detected in 
the brain by HPLC-MS analysis8. A slight to moderate decrease in H2R agonistic 
potency, as found in vitro for the first series of acylguanidines compared to the 
corresponding alkylguanidines, can be accepted due to improved pharmacokinetic 
properties. Centrally active H2R agonists will be useful tools to study the role of 
histamine H2 receptors in the brain.  
Guanidine-type H2R agonists show different potencies depending on the considered 
species and tissue, for instance, the potency of the guanidines is different on human 
neutrophils compared to the guinea pig right atrium. Both the guanidines and the 
acylguanidines proved to be less potent and efficacious at the human (hH2R) 
compared to the guinea pig (gpH2R) histamine H2 receptor9, 10. A homology model of 
the gpH2R suggested that an H-bond between Tyr-17 and Asp-271 stabilizes an 
active receptor conformation of the gpH2R. In particular, the presence of Ala-271 in 
the hH2R instead of Asp-271 (gpH2R) in transmembrane domain 7 accounts for this 
species-dependent difference9.  
N
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H
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H
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arpromidine, ARP
N
N
H
N
H
N
H
NH O
R1
R3
R2
n
R1, R2 =  H, alkyl, aryl, 
R3 = aryl, cyclohexyl
I: R1 = H, R2 = 3,4-F2C6H3, R3 = thiazolyl
II: R1 = H, R2 = CH3, R3 = C6H5  
Figure 3.1. Structure of arpromidine, the general structure of NG-acylated imidazolylpropylguanidines 
and structure of NG-acylated imidazolylpropylguanidines I and II absorbed from the gastrointestinal 
tract of nude mice. 
 
Previously it was shown that the alkylguanidines can be bioisosterically replaced by 
acylguanidines with a moderate decrease in potency at the guinea pig right atrium 
but improved pharmacokinetic properties7. In order to further study the structure-
activity relationships, various NG-acylated imidazolylpropylguanidines were 
synthesized and pharmacologically characterized. 
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3.2. Chemistry 
Towards the synthesis of NG-acylated imidazolylpropylguanidines, a guanidine 
building block is coupled to carboxylic acids to make use of common coupling 
reagents. N-[3-(1-Trityl-1H-imidazol-4-yl)propyl]guanidine 3.7 was synthesized with 
minor modifications as previously described7 starting from urocanic acid. After 
esterification, hydrogenation of the double bond and trityl-protection of the imidazole 
NH, the ester function was reduced with LiAlH4. The alcohol 3.4 was coupled to the 
di-Cbz-protected guanidine 3.5 under Mitsunobu conditions11 and, subsequently, the 
protecting groups were cleaved to yield the imidazolylpropylguanidine building block 
3.7 (Scheme 3.1). 
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Scheme 3.1.  Synthesis of the imidazolylpropylguanidine building block 3.7. Reagents and conditions: 
(i) anhydrous Na2SO4, H2SO4/conc., MeOH/abs, 30 h, reflux12; (ii) H2, Pd/C (10 %) (cat.), MeOH, 5 
bar, 24 h, rt; (iii) CPh3Cl (1.1 eq) , NEt3 (2.8 eq), MeCN, 12h, rt; (iv) LiAlH4 (2 eq), THF/abs, Et2O/abs, 
2 h, reflux; (v) 3.5 (1.8 eq), PPh3 (1.5 eq), DIAD (1.5 eq), THF/abs, 24 h, rt; (vi) H2, Pd/C (10 %), 
MeOH/THF (1:1), 5 bar, 24 h, rt. 
 
The arylalkylguanidine building block 3.10 was synthesized according to Scheme 3.2 
starting from 3-phenylbutyric acid. After reduction of the carboxylic acid with LiAlH4, 
the free alcohol 3.8 was coupled to di-Cbz-protected guanidine 3.5 as described in 
Scheme 3.1 to obtain 3-phenylbutylguanidine 3.10. 
Scheme 3.3 summarizes the synthesis of ketones which were required as starting 
material for the Wittig-Horner reaction. The ketones 3.11-3.14c were synthesized by 
reaction of Grignard reagents 3.11-3.14a with nitriles 3.11-3.14b.  
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Scheme 3.2. Synthesis of the arylalkylguanidine building block 3.10; Reagents and conditions: (i) 
LiAlH4 (1.2 eq), THF/abs, 2 h, rt; (ii) 3.5 (1.8 eq), PPh3 (1.5 eq), DIAD (1.4 eq), THF/abs, 24 h, rt; (iii) 
H2, Pd/C (10 %), MeOH/THF (1:1), 5 bar, 24 h, rt. 
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 No R1 R2 n No R1 R2 n 
3.11a-c C6H5 C6H5 1 3.16a-b C6H5 NHBoc 1 
3.12a-c C6H5 4-CH3-C6H4 1 3.17a-c C6H5 NHBoc 3 
3.13a-c CH3 C6H5 1 3.18a-b CH3 3-OBn-C6H4 0 
3.14a-c CH3 C6H5 3 3.19a-b CH3 4-MPM-C6H4 0 
3.15a-e cHex C6H5 1     
 
Scheme 3.3. Synthesis of ketones. Reagents and conditions: (i) Mg (1.2 eq), Et2O, HCl, 24 h, reflux; 
(ii) pyrrolidine (0.8 eq), DMAP (1.5 eq), DCM, 20 min, rt; (iii) 1-methyl-1H-imidazole (1 eq), n-BuLi (1 
eq), THF/abs, 10 min, -78 °C, 3.15b (1 eq) , 30 min, rt; (iv) Mg (2 eq), BnCl (2 eq), Et2O, 2-3 h, rt; (v) 
MeI (11 eq), EtOAc, 3-4 h, reflux, benzene, K2CO3 (1.2 eq), 2 h, 60 °C; (vi)(Boc)2O (1.2 eq), NEt3 (1 
eq), THF/abs, 20 h, rt; (vii) THF/abs, 1 h, -78 °C, rt; (viii) BnCl (1 eq), KOH (1.1 eq), EtOH, 5 h, reflux; 
(ix) 4-MPMCl (1.5 eq), K2CO3 (4 eq), acetone, overnight, reflux. 
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The synthesis of 3.15e started from cyclohexanecarbonyl chloride 3.15a, which was 
converted into the amide 3.15b with pyrrolidine and DMAP as a base. The ketone 
3.15c was obtained in good yields by treating 1-acylpyrrolidine 3.15b with 2-lithio-1-
methyl-1H-imidazole, which was synthesized from 1-methyl-1H-imidazole and n-
BuLi. The 2-acylimidazole 3.15c was converted into the alcohol 3.15d by Grignard 
reaction. Compound 3.15d was refluxed in EtOAc solution with an excess of MeI to 
give an imidazolium salt which was immediately treated with K2CO3 at elevated 
temperature to yield 3.15e in a retro-aldol reaction with the imidazolium group acting 
as a leaving group13-15. Ketone 3.16b was easily synthesized by tert-butoxycarbonyl 
protection of the free amine 3.16a. The selective ring-opening of lactam 3.17b with 
phenylmagnesium chloride produced the ketone 3.17c. Benzyl- and p-methoxybenzyl 
protection, respectively, of the p- and m-hydroxy groups resulted in the ketones 
3.18a and 3.19a.  
The pertinent carboxylic acids were synthesized using different standard methods as 
shown in Scheme 3.4. 3-(1-Trityl-1H-imidazol-4yl)propanoic acid 3.20 was 
synthesized by hydrolysis of the methyl ester 3.116. Compounds 3.21-3.39c were 
obtained via Wittig-Horner reaction of synthesized (3.11-3.19c) or commercially 
available ketones with triethyl phosphonoacetate, subsequent hydrogenation of the 
double bond and hydrolysis of the ethyl ester.  
The cyclohexylalkanoic acids 3.40-3.50 were prepared from the corresponding 
synthesized (3.21-3.23c, 3.28-3.30c, 3.51a-d) or commercially available phenyl-
alkanoic acids by hydrogenation of the phenyl ring with Rh/Al2O3 or Rh/C as a 
catalyst and AcOH as a solvent17. The α-substituted alkanoic acid 3.51d was 
prepared starting from dimethyl malonate. After treating with BnBr and EtBr, the 
methyl ester was hydrolyzed and the free dicarboxylic acid was decarboxylated at 
170-200 °C to obtain 2-benzylbutanoic acid 3.51d. 10-Benzyloxy-10-oxodecanoic 
acid 3.52 was synthesized by esterification of decanedioic acid with BnOH in the 
presence of DCC as coupling reagent.  
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No R1 R2 R3 n 
3.20 H H 1-trityl-2-imidazolyl 0 
3.21a-c H CH2CH3 C6H5 0 
3.22a-c H CH(CH3)2 C6H5 0 
3.23a-c H CH2CH(CH3)2 C6H5 0 
3.24a-c H CH2(C6H5) C6H5 0 
3.25a-c H CH2(4-CH3-C6H4) C6H5 0 
3.26a-c H CH2(C6H5) cHex 0 
3.27a-c H CH3 4-CH3-C6H4 0 
3.28a-c H CH3 C6H5 1 
3.29a-c H CH3 C6H5 2 
3.30a-c H CH3 C6H5 3 
3.31a-c H CH3 3-CH3C6H4 1 
3.32a-c H CH3 4-CH3-C6H4 1 
3.33a-c H CH3 3-F-C6H4 1 
3.34a-c H CH3 4-F-C6H4 1 
3.35a-c H CH3 3-OCH3-C6H4 1 
3.36a-c H CH3 4-OCH3-C6H4 1 
3.37a-c H CH3 4-CH2CH3-C6H4 1 
3.38a-c H CH2NHBoc C6H5 0 
3.39a-c H (CH2)3NHBoc C6H5 0 
3.40 H (R) CH3 cHex 0 
3.41 H (S) CH3 cHex 0 
3.42 CH3 H cHex 0 
Scheme 3.4 
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Scheme 3.4 (continued)
3.43 H CH2CH3 cHex 0 
3.44 CH2CH3 H cHex 0 
3.45 H CH(CH3)2 cHex 0 
3.46 H CH2CH(CH3)2 cHex 0 
3.47 H CH3 cHex 1 
3.48 H CH3 cHex 2 
3.49 H CH3 cHex 3 
3.50 H CH2CH3 cHex 1 
3.51a-d CH2CH3 H C6H5 0 
3.52 H H COBn 6 
3.53a, b H CH3 3-OBn-C6H4 0 
3.54a, b H CH3 4-MPM-C6H4 0 
  
Scheme 3.4. Synthesis of alkanoic acids. Reagents and conditions: (i) LiOH/aq (1N) (1.2 eq), THF, 24 
h, rt; (ii) NaH (60 % dispersion in mineraloil) (1.56 eq), triethyl phosphonoacetate (1.4-1.5 eq), 
THF/abs, 24 h, reflux; (iii) H2, Pd/C (10 %) (cat.), EtOH, 24 h, rt; (iv) 20 % NaOH/aq, 2-3 h, reflux; (v) 
H2, Rh/C or Rh/Al2O3 (cat.), AcOH, 8 bar, 48 h, rt; (vi) BnBr (1 eq), NaH (60 % dispersion in mineral 
oil) (1 eq) , THF/abs, overnight, reflux; (vii) EtBr (1.2 eq), NaH (60 % dispersion in mineral oil) (1.2 eq), 
THF/abs, overnight, reflux; (viii) KOH (10 eq), H2O, EtOH, overnight, reflux; (ix) ∆, 3-4 h, 170-200 °C; 
(x) BnOH (1 eq), DCC (1.2 eq), DMAP (cat.), THF/abs, 48 h, rt. 
 
In the case of carboxylic acids 3.53-3.54b with a benzyl- and p-methoxybenzyl 
protected hydroxy substituted phenyl ring, the hydrogenation step in the Wittig-
Horner reaction was skipped to avoid deprotection and the (E/Z) ethyl ester was 
directly converted into the free acid (Scheme 3.5). 
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Scheme 3.5. Synthesis of unsaturated carboxylic acids 3.53-3.54b. Reagents and conditions: (i) NaH 
(60 % dispersion in mineral oil) (1.56 eq), triethyl phosphonoacetate (1.4-1.5 eq), THF/abs, 24 h, 
reflux; (ii) 20 % NaOH/aq, 2-3 h, reflux. 
 
3-Phenylbutylguanidine 3.10 was coupled with 3-(1-trityl-1H-imidazol-4yl)propanoic 
acid 3.20 using N,N´-carbonyldiimidazole as an acylation activating agent18 (Scheme 
3.6). Subsequently, compound 3.55a was deprotected by treatment with TFA in DCM 
to yield N-[3-(1H-imidazol-4-yl)propanoyl]-N´-(3-phenylbutyl)guanidine 3.55.  
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Scheme 3.6. Synthesis of the NG-acylated arylalkylpropylguanidine 3.55. (i) CDI (1.2 eq), NaH (60 % 
dispersion in mineral oil) (2 eq), THF/abs, 3-4 h, rt; (ii) 20 % TFA, DCM, 5-6 h, rt. 
 
According to Scheme 3.7, the NG-acylated imidazolylpropylguanidines 3.56-3.89 
were synthesized by a reaction of the trityl-protected imidazolylpropylguanidine 
building block 3.7 with synthesized (3.20, 3.21-3.39c, 3.40-3.50, 3.51d, 3.52, 3.53b 
and 3.54b) and commercially available carboxylic acids. The guanidine building block 
3.7 was deprotonated with NaH and coupled to the pertinent carboxylic acid, which 
was activated by CDI, to yield the building trityl-protected precursors 3.56-3.89a.  
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No R1 R2 R3 n 
3.56 H CH2CH3 C6H5 0 
3.57 CH2CH3 H C6H5 0 
3.58 H CH(CH3)2 C6H5 0 
3.59 H CH2CH(CH3)2 C6H5 0 
3.60 H CH2(C6H5) C6H5 0 
3.61 H CH2(4-CH3-C6H4) C6H5 0 
3.62 H CH2(C6H5) cHex 0 
3.63 H H 4-CH3-C6H4 0 
3.64 H CH3 4-CH3-C6H4 0 
Scheme 3.7  
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Scheme 3.7 (continued) 
3.65 H CH3 C6H5 1 
3.66 H CH3 C6H5 2 
3.67 H CH3 C6H5 3 
3.68 H CH3 3-CH3-C6H4 1 
3.69 H CH3 4-CH3-C6H4 1 
3.70 H CH3 3-F-C6H4 1 
3.71 H CH3 4-F-C6H4 1 
3.72 H CH3 3-OCH3-C6H4 1 
3.73 H CH3 4-OCH3-C6H4 1 
3.74 H CH3 4-CH2CH3-C6H4 1 
3.75 H (R) CH3 cHex 0 
3.76 H (S) CH3 cHex 0 
3.77 CH3 H cHex 0 
3.78 H CH2CH3 cHex 0 
3.79 CH2CH3 H cHex 0 
3.80 H CH(CH3)2 cHex 0 
3.81 H CH2CH(CH3)2 cHex 0 
3.82 H CH3 cHex 1 
3.83 H CH3 cHex 2 
3.84 H CH3 cHex 3 
3.85 H CH2CH3 cHex 1 
3.86 H CH3 3-OH-C6H4 0 
3.87 H CH3 4-OH-C6H4 0 
3.88 H CH2NH2 C6H5 0 
3.89 H (CH2)3NH2 C6H5 0 
  
Scheme 3.7. General procedure for the coupling of carboxylic acids with the imidazolylpropyl-
guanidine building block 3.7. Reagents and conditions: (i) CDI (1.2 eq), NaH (60 % dispersion in 
mineral oil) (2 eq), THF/abs, 3-4 h, rt, (ii) 20 % TFA, DCM, 5-6 h, rt, (iii) H2, Pd/C, EtOH, 8 bar, 6 d or 
50 % TFA, DCM, 4 h, rt 
 
The trityl group was removed under acidic conditions to give the NG-acylated 
imidazolylpropylguanidines 3.56-3.89. Prior to TFA treatment, the benzyl- and MPM 
protecting group in 3.86a and 3.87a were cleaved off by hydrogenation over Pd/C (10 
%). Unfortunately, the hydrogenolysis was rather inefficient: the benzyl group could 
be removed after six days at 8 bar in low yield, and the reaction time was not shorter 
with the MPM protecting group. Finally, MPM was removed under acidic conditions 
with 50 % TFA together with the trityl-protecting group.  
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The free amino group in compound 3.89 was acylated by stirring with the pertinent 
succinimidyl ester for a few hours at room temperature yielding the compounds 3.90-
3.91 according to Scheme 3.8. 
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Scheme 3.8. Synthesis of compounds 3.90-3.92. Reagents and conditions: (i) 3.89 (1 eq), a or b (0.8 
eq), NEt3 (3 eq), MeCN, 4-5 h, rt; (ii) py-1 (1 eq), 3.89 (2 eq), NEt3 (7.5 eq), MeCN, DMF, 1 h, rt. 
 
The fluorescent compound 3.92 was easily synthesized from 3.89 and the 
fluorescent pyrylium dye py-1 by ring transformation within one hour at room 
temperature. 
 
 
3.3. Pharmacological results and discussion 
Since the definition of H2R by Black et al. in 197219, the isolated guinea pig right 
atrium is widely accepted as a pharmacological standard model for the functional 
characterisation of H2R ligands. For the investigation of the H2R agonists the positive 
chronotropic response was determined versus histamine as the reference compound 
(Table 3.1). In addition to the new chemical entities previously reported H2R agonists 
are included in Table 3.1 with respect to the discussion of the structure-activity 
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relationships. Additionally, all substances were investigated in GTPase assays on 
human and guinea pig histamine H2R-GsαS fusion proteins with respect to possible 
species selective ligand H2R interactions. These studies were performed using 
membrane preparations of hH2R-GsαS and gpH2R-GsαS expressing Sf9 insect cells 
(Table 3.2). As H2R agonists such as arpromidine are known to have weak to 
moderate H1R antagonistic activity, selected compounds were also investigated for 
H1R antagonism in a calcium assay (fura-2 assay) on human U-373 glioma cells 
(Table 3.3).  
To further study the histamine receptor subtype selectivity, selected compounds were 
also tested for histamine H3 and H4 receptor activity in the GTPase assay (Table 3.4). 
 
3.3.1. Histamine H2 receptor agonism  
3.3.1.1. H2R agonism on the isolated guinea pig right atrium 
Most of the synthesized acylguanidines proved to be full or nearly full histamine H2 
receptor agonists on the spontaneously beating guinea pig right atrium. “Oxo-
impromidine” (3.93) and “oxo-arpromidine” (3.94) show 2- to 5-fold lower potency at 
the guinea pig right atrium than the alkylguanidines impromidine and arpromidine7. 
But, with respect to in vivo application, this minor decrease in potency is acceptable 
due to improved pharmacokinetic properties. 
The change of the position of the carbonyl function results in a loss of agonistic 
activity. Compound 3.55 is a weak antagonist (pA2 = 5.10) on the guinea pig right 
atrium as well as in the GTPase assay (Table 3.2). The most potent compound in this 
series is the 3-phenylbutanoylguanidine 3.96, a full agonist which is 28 times more 
potent than histamine at the guinea pig right atrium. Substitution in α-postion is also 
well tolerated. The 2-methyl-3-phenylpropanoyl derivative 3.97 shows a slight 
decrease in potency whereas efficacy is not affected. Compared to the 
corresponding phenylalkanoylguanidines the potency is decreased for the racemic 3-
cyclohexylbutanoyl and 2-methyl-3-cyclohexylpropanoyl analogues. The (S)-
configured enantiomer (3.76) is three times more potent than the (R) enantiomer 
(3.75) and about equipotent with the chiral phenyl analogue 3.96. By contrast, in the 
corresponding phenylalkanoylguanidines, higher potency resides in the (R)-
configured enantiomer (data not shown)7. However, this difference should not be 
overinterpreted as the eudismic ratios are low for both the phenyl and the cyclohexyl 
substituted compounds. 
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Table 3.1. Histamine H2 receptor agonism on the guinea pig right atrium.  
N
H
N
HN
N
H
NH
X
O R2
R3
R1 n
N
H
N
HN
N
H
NH R2
R3
R1 n
O
3.55
N
H
N
HN
N
H
NH
X
R2
R3
R1 n
IMP, ARP
3.56-3.102  
      
H2R agonism - isolated guinea 
pig right atrium 
No X R1 R2 R3 n 
pEC50 ± 
SEMa 
rel. 
pot.b 
Emax ± 
SEM 
(%)c 
HIS - - - - - 6.00 ± 0.10 100 100 ± 2 
IMP S H - 5-methyl-4-imidazolyl 1 7.70 ± 0.10 5,000 100 
ARP CH H 2-pyridyl 4-F- C6H4 0 8.01 ± 0.10 10,200 100 
3.937 S H - 5-methyl-4-imidazolyl 1 7.38 ±0.09 2,370 101± 2 
3.947 CH H 2-pyridyl 4-F-C6H4 0 7.34 ± 0.12 2,170 100 ± 1 
3.55 CH H CH3 C6H5 0 5.10 ± 0.19d - 7 ± 1e 
3.9620 CH H CH3 C6H5 0 7.43 ± 0.07 2,710 99 ± 2 
3.9721 CH CH3 H C6H5 0 7.30 ± 0.10 1,980 96 ± 2 
3.56 CH H CH2CH3 C6H5 0 6.97 ± 0.13 927 93 ± 5 
3.57 CH CH2CH3 H C6H5 0 7.03 ± 0.15 1,060 101 ± 2 
3.58 CH H CH(CH3)2 C6H5 0 6.98 ± 0.14 955 99 ± 7 
3.59 CH H CH2CH(CH3)2 C6H5 0 6.73 ± 0.10 541 88 ± 3 
3.60 CH H CH2(C6H5) C6H5 0 6.30 ± 0.12 200 81 ± 4 
3.1017 CH H C6H5 C6H5 0 7.22 ± 0.09 1650 85 ± 3 
3.61 CH H CH2(4-CH3-C6H4) 
C6H5 0 6.55 ± 0.12 357 82 ± 5 
3.62 CH H CH2(C6H5) cHex 0 6.12 ± 0.02 132 83 ± 6 
3.63 CH H H 4-CH3-C6H4 0 6.52 ± 0.03 327 101 ± 2 
3.64 CH H CH3 4-CH3-C6H4 0 7.10 ± 0.09 1,270 97 ± 1 
3.9921 CH H CH3 
4-CH(CH3)2-
C6H4 
0 6.14 ± 0.11 137 85 ± 4 
3.65 CH H CH3 C6H5 1 7.11 ± 0.14 1,300 101 ± 3 
3.66 CH H CH3 C6H5 2 6.07 ± 0.19 117 80 ± 3 
3.67 CH H CH3 C6H5 3 6.08 ± 0.13 119 80 ± 4 
3.9521 CH H H C6H5 3 5.67 ± 0.17 46 62 ± 6 
3.9821 CH H CH2CH3 C6H5 1 6.39 ± 0.11 247 86 ± 3 
3.10021 CH H CH2(C6H5) C6H5 1 5.97 ± 0.02 92 67 ± 4 
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Table 3.1. (continued)      
3.68 CH H CH3 3-CH3-C6H4 1 6.49 ±0.02 311 85 ± 4 
3.69 CH H CH3 4-CH3-C6H4 1 6.21 ± 0.08 162 95 ± 4 
3.70 CH H CH3 3-F-C6H4 1 6.86 ± 0.11 724 100 ± 2 
3.71 CH H CH3 4-F-C6H4 1 6.32 ± 0.08 209 90 ± 1 
3.72 CH H CH3 3-OCH3-C6H4 1 6.69 ± 0.08 490 92 ± 5 
3.73 CH H CH3 4-OCH3-C6H4 1 6.44 ± 0.09 277 81 ± 4 
3.74 CH H CH3 4-CH2CH3-C6H4 1 5.84 ± 0.01 69 72 ± 2 
3.10220 CH H CH3 cHex 0 6.81 ± 0.07 641 101 ± 3 
3.75 CH H (R) CH3 cHex 0 6.86 ± 0.07 721 82 ± 4 
3.76 CH H (S) CH3 cHex 0 7.35 ± 0.12 2,230 103 ± 2 
3.77 CH CH3 H cHex 0 6.88 ± 0.15 764 94 ± 2 
3.78 CH H CH2CH3 cHex 0 6.46 ± 0.04 290 95 ± 1 
3.79 CH CH2CH3 H cHex 0 6.21 ± 0.13 161 77 ± 5 
3.80 CH H CH(CH3)2 cHex 0 6.42 ± 0.05 263 85 ± 5 
3.81 CH H CH2CH(CH3)2 cHex 0 6.70 ± 0.09 501 83 ± 3 
3.82 CH H CH3 cHex 1 6.11 ± 0.10 128 85 ± 3 
3.83 CH H CH3 cHex 2 5.97 ± 0.15 94 59 ± 4 
3.84 CH H CH3 cHex 3 4.93 ± 0.09 9 74 ± 10 
3.85 CH H CH2CH3 cHex 1 6.32 ± 0.08 210 79 ± 6 
3.86 CH H CH3 3-OH-C6H4 0 nd nd nd 
3.87 CH H CH3 4-OH-C6H4 0 nd nd nd 
3.88 CH H CH2NH2 C6H5 0 6.42 ± 0.05 261 100 ± 3 
3.89 CH H (CH2)3NH2 C6H5 0 7.20 ± 0.05 1,580 102 ± 3 
a pEC50 was calculated from the mean shift ∆pEC50 of the agonist curve relative to the histamine reference curve by equation: 
pEC50 = 6.00 + ∆pEC50; data shown are the ± SEM of three to seven experiments; b potency, relative to histamine = 100 %; c 
efficacy, maximal response (%), relative to the maximal increase in heart rate induced by the reference compound histamine; d 
antagonist (pA2); eEmax at 100 µM, Emax of histamine in the presence of 100 µM 3.55 was 45 ± 5 %. 
 
The introduction of bulkier side chains reduces the potency as well as efficacy (3.56-
3.62) for cyclohexyl- and phenylalkanoylguanidines. Substances bearing methyl, 
fluoro or methoxy substituent in meta position of the phenyl ring are slightly superior 
to the corresponding para substituted analogues (3.68-3.73). A 3-phenyl- or 3-
benzylbutanoyl moiety, respectively, is optimal in affording high potency and efficacy 
at the guinea pig right atrium, whereas a cyclohexyl substituent is less well tolerated 
(except the (S)-enantiomer 3.76). Interestingly, in the GTPase assay (Table 3.2) the 
3-cyclohexylpentanoylguanidine (3.77) turned out to be one of the most potent 
compounds in this series, whereas at the guinea pig right atrium 3-phenyl- (3.96) and 
(S)-3-cyclohexylbutanoyl (3.76) substituted compounds proved to be the most potent 
ones. 3-Phenyl-6-aminohexanoyl guanidine (3.89) is about six times more potent 
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than the lower homologue, the 3-phenyl-4-aminobutanoylguanidine 3.88. Both 
amino-functionalized compounds are full H2R agonists. 
 
3.3.1.2. Agonist potencies and efficacies at hH2R-GsαS and gpH2R-GsαS fusion 
proteins 
To study species selectivity, the compounds were tested at human and guinea pig 
H2R-GsαS fusion proteins in the GTPase assay. The results are summerized in Table 
3.2. NG-acylated imidazolylpropylguanidines with two aromatic ringsystems exhibit 
high agonistic potency at H2R membranes7, 22. However, acylguanidines with only 
one aromatic or cyclohexyl ring, respectively, and aliphatic side chains show similar 
unless higher agonistic potency at both, human and guinea pig H2R as well23. At 
compounds with a phenyl ring and a connecting chain ranging from none to four 
methylene groups (3.103-3.107), minor changes in potency at hH2R or gpH2R, 
respectively, but different effects on the efficacy were noted (data not shown)23. 
Further increase of the chain (3.95) results in a tenfold increase in potency at the 
hH2R, whereas the potency at the gpH2R only triplicates. Compound 3.95 turned out 
to be the first guanidine-type (acylguanidine and alkylguanidine) H2R agonist which 
has a higher potency at the human H2 receptor (EC50 = 6.3 nM) than at the guinea 
pig H2 receptor (EC50 = 18.9 nM). This data also supports the concept of a bigger and 
more flexible binding pocket in hH2R than in gpH2R9. Though, the efficacy is 
decreasing, shifting from strong partial to weak partial agonists (eff. = 0.44 for 3.95) 
at hH2R and from full to partial agonists (eff. = 0.42 for 3.95) at the gpH2R with 
increasing the chain length. At both species, the potency slightly increases by 
introduction of a methyl group in β-position (3.105→3.96, 3.106→3.65, 3.107→3.66), 
but again the efficacy drops. However, this is not true for compound 3.95. In this 
case, a methyl introduction decreases potency fivefold at the hH2R, whereas at the 
gpH2R potency is nearly the same. An alkyl substituent in α-position (3.97, 3.57, 3.77 
and 3.79) was tolerated as well with similar potency and similar (3.97 and 3.57) or 
slight decrease in efficacy (3.77 and 3.79) compared to the β-substituted analogues. 
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Table 3.2. Agonist efficacies and potencies at hH2R-GsαS and gpH2R-GsαS expressed in Sf9 cell 
membranes. 
hH2R-GsαS gpH2R-GsαS 
No 
efficacy EC50 [nM] 
rel. 
pot. 
efficacy EC50 [nM] 
rel. 
pot. 
EC50 hH2R-
GsαS/ EC50 
gpH2R-GsαS 
His9 1.00 1260 ± 250 100 1.00 1200 ± 240 100 1.05 
IMP9 0.84 ± 0.04 200 ± 20 641 1.00 ± 0.12 40 ± 10 3,060 5.00 
ARP9 0.79 ± 0.07 190 ± 0.04 659 1.02 ± 0.04 70 ± 10 1,600 2.71 
3.9322 0.79 ± 0.04 270 ± 38 440 0.93 ± 0.01 60 ± 1 2,000 4.44 
3.9422 0.73 ± 0.03 420 ± 90 290 0.93 ± 0.04 45 ± 4 2,700 9.21 
3.55 - (1220)a - - (1240)a - - 
3.9623 0.87 ± 0.01 67 ± 2 1,800 1.03 ± 0.06 12 ± 1 10,000 5.58 
3.9721 0.85 ± 0.04 22.8 ± 2.9 5,530 0.92 ± 0.11 7.9 ± 3.4 15,190 2.89 
3.56 0.64 ± 0.18 36.9 ± 20.6 3,420 0.78 ± 0.08 11 ± 4.2 10,910 3.35 
3.57 0.71 ± 0.05 31.3 ± 3.1 4,025 0.80 6.2 19,354 5.04 
3.58 0.49  33.2 ± 2.3 3,800 0.72 ± 0.08 32.4 ± 0.8 3,700 1.02 
3.59 0.3 ± 0.04 24.3 ± 3.9 5,190 0.72 ± 0.08 13.5 ± 7.9 8,890 1.8 
3.60 0.34 ± 0.02 41.2 ± 12.1 3,060 0.65 ± 0.01 22.7 ± 13.7 5,290 1.81 
3.61 0.48 ± 0.01 42.7 ± 2 2,950 0.46 ± 0.03 19.8 ± 11.9 6,060 2.16 
3.62 0.35 ± 0.09 58.9 ± 1.4 2,140 0.68 ± 0.09 30.4 ± 23.3 3,950 1.94 
3.63 0.87 ± 0.05 58.8 ± 22.5 2,140 0.9 ± 0.02 28.6 ± 4.6 4,200 2.06 
3.64 0.95 ± 0.04 78.8 ± 21.3 1,600 0.85 ± 0.05 31.5 ± 4 3,810 2.5 
3.9921 0.70 ± 0.12 50.2 ± 23.9 2,510 0.5 ± 0.2 9.1 ± 0.75 13,190 5.52 
3.65 0.61 ± 0.06 26.4 ± 3 4,770 0.86 ± 0.06 9.9 ± 1.4 12,120 2.67 
3.66 0.46 ± 0.1 45.8 ± 26.5 2,750 0.59 ± 0.14 23.2 ± 8.4 5,170 1.97 
3.67 0.31 ± 0.01 30.5 ± 16.4 4,130 0.58 ± 0.1 12.4 ± 2.4 9,680 2.46 
3.9521 0.44 ± 0.16 6.3 ± 0.35 20,000 0.42 ± 0.07 18.9 ± 9.9 6,350 0.33 
3.9821 0.51 ± 0.02 38.1 ± 2.6 3,310 0.73 ± 0.01 24.8 ± 9.9 4,840 1.54 
3.10021 (-0.06)b - - 0.32 19.5 6,154 - 
3.68 0.58 ± 0.17 34.8 ± 5.9 3,620 0.77 ± 0.01 56 ± 39.5 2,140 0.6 
3.69 0.34 ± 0.08 51.1 ± 32.1 2,465 0.58 ± 0.05 78.9 ± 56 1,520 0.65 
3.70 0.67 ± 0.01 16.2 ± 2.4 7,780 0.98 ± 0.02 13.3 ± 11.2 9,020 1.22 
3.71 0.86 ± 0.07 96.9 ± 54.4 1,300 0.84 ± 0.01 40.7 ± 18.3 2,950 2.38 
3.72 0.84 ± 0.02 22.2 ± 0.75 5,675 0.80 ± 0.09 18.5 ± 5.6 6,490 1.2 
3.73 0.68 ± 0.03 43 ± 21.6 2,930 0.57 ± 0.09 67.8 ± 4.7 1,770 0.63 
3.74 0.34 ± 0.02 38.4 ± 20.5 3,280 0.19 ± 0.04 33.9 ± 3.4 3,540 1.13 
3.10223 0.87 ± 0.05 23 ± 3 5,200 1.11 ± 0.16 9 ± 1 13,300 2.56 
3.75 0.83 ± 0 18.6 ± 3.8 6,775 0.9 ± 0.03 23.5 ± 6.1 5,110 0.79 
3.76 0.99 ± 0.01 6.5 ± 0.45 19,385 0.93 ± 0 8.5 ± 2.8 14,120 0.76 
3.77 0.61 ± 0.06 9.7 ± 0.8 12,990 0.71 ± 0.06 4.1 ± 1.5 29,270 2.37 
3.78 0.65 ± 0.1 7.4 ± 3.4 17,030 0.89 ± 0.05 3.5 ± 0.70 34,290 2.11 
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Table 3.2 (continued)     
3.79 0.34 ± 0.09 21.4 ± 10.9 5,888 0.54 ± 0.06 6.4 ± 0.2 18,750 3.34 
3.80 0.76 ± 0.2 67.6 ± 0 1,860 0.58 ± 0.09 22.4 ± 14.8 5,360 3.02 
3.81 0.56 ± 0.04 105.1 ± 9.7 1,200 0.69 ± 0.01 10.8 ± 7.1 11,110 9.73 
3.82 0.72 ± 0.04 21.6 ± 8.7 5,830 0.82 ± 0.05 16.4 ± 2.3 7,320 1.32 
3.83 0.55 ± 0.03 17.2 ± 5.2 7,325 0.36 ± 0.08 15.5 ± 2 7,740 1.11 
3.84 (-0.05)b - - 0.18 nd nd - 
3.85 0.40 ± 0.04 12.6 ± 2.5 10,000 0.41 ± 0.01 10.2 ± 3 11,760 1.24 
3.86 0.82 ± 0.09 46.8 ± 29 2,690 0.97 ± 0.01 4 ± 0.9 30,000 11.7 
3.87 0.84 ± 0.15 30.9 ± 10.5 4,078 0.73 1.7 70,588 18.2 
3.88 0.62 ± 0.05 752 ± 295 170 0.82 ± 0.03 102 ± 46 1,180 7.37 
3.89 0.68 ± 0.01 172 ± 57 730 0.86 ± 0.06 21 ± 6 5,710 8.19 
3.90 0.75 ± 0.16 58.3 ± 9.4 2,161 0.60 6.3 19,048 7.76 
3.91 0.59 91.2 1,380 0.61 19.5 6,154 4.68 
3.92 0.48 25.9 4,865 0.66 19.5 6,154 1.32 
a Antagonist, IC50; b no agonistic activity at a concentration of 10 µM; for structures of previously synthesized compounds, which 
are included in Table 3.2 with respect to the discussion of structure-acitivity relationships, see Table 3.1. 
 
Steady state GTPase activity in Sf9 membranes expressing hH2R-GsαS and gpH2R-GsαS was determined as described in the 
literature9. Reaction mixtures contained ligands at concentrations from 1 nM to 10 µM as appropriate to generate saturated 
concentration-response curves. Data were analyzed by nonlinear regression and were best fitted to sigmoidal concentration-
response curves. Typical basal GTPase activities ranged between ~ 0.5 and 2.5 pmol/mg/min, and activities stimulated by 
histamine (100 µM) ranged between ~ 2 and 13 pmol/mg/min. The efficacy (Emax) of histamine was determined by nonlinear 
regression and was set to 1.0. The Emax values of other agonists were referred to this value. Data shown are the ± SEM of two 
to three experiments or one experiment performed in duplicates each. The relative potency of histamine was set to 100, and the 
potencies of other agonists were referred to this value. The ratio of the EC50 values of H2R agonists for hH2R-GsαS and gpH2R-
GsαS were also continued.  
 
Concerning efficacy β-substituents larger than methyl (3.96) are unfavourable at both 
hH2R and gpH2R. However, for more space-filling substituents in β-position, such as 
ethyl (3.56), isopropyl (3.58), isobutyl (3.59), benzyl (3.60), p-methylbenzyl (3.61) and 
cyclohexylmethyl (3.62) the influence on agonistic potency at human and guinea pig 
H2R is different. There appears to be an optimum size with an isobutyl residue at the 
hH2R: compound 3.59 is more potent than 3-phenylbutanoylguanidine 3.96, whereas 
further increase in bulk (cf. 3.61 and 3.62) results in reduced potency. At the gpH2R, 
generally, the potency slightly decreases with introducing bulky side chains. 
Consequently, for these compounds the ratio of EC50 values (hH2R versus gpH2R) is 
smaller. There appears to be a different conformational flexibility of human and 
guinea pig H2R. Compared to the 3-phenylpentanoylguanidine 3.56, the introduction 
of a 3-benzylpentanoyl substituent (3.98) leads to nearly the same potency and 
efficacy at the hH2R, but to only about half the potency at the gpH2R. The 3-benzyl-4-
phenylbutanoyl compound (3.100) is inactive at the hH2R but not at the gpH2R. 
Introduction of a methyl group at the phenyl ring of the 3-phenylpropanoyl (3.105) 
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and 3-phenylbutanoyl compound (3.96) has no significant effect on the potency at the 
hH2R, but decreases the potency at the gpH2R and the efficacy at both receptors. An 
isopropyl residue at the phenyl ring (3.99, EC50 = 9.1 nM) is tolerated, resulting in 
about the same gpH2R agonistic potency as that of the 3-phenylbutanoylguanidine 
3.96 (EC50 = 12 nM) but with lower efficacy (eff. = 0.5 for 3.99, compared to 1.03 for 
3.96). Analogues of 3-methyl-4-phenylbutanoylguanidine 3.65 bearing a methyl, 
fluoro or methoxy substituent in meta or para position of the phenyl ring (except p-F-
substituted compound 3.71) show similar potencies at hH2R and gpH2R. Meta 
substitution is more favourable at both receptors compared to para substitution. 
Again at the gpH2R, the introduction of a substituent at the phenyl ring led to a 
significant drop in potency; this effect is not as much pronounced at the hH2R. 
Changing the position of the carbonyl function results in a complete loss of agonistic 
activity (3.55) at the hH2R (antagonism, IC50 = 1.22 µM) as well as at the gpH2R 
(antagonism, IC50 = 1.24 µM). Exchange of the phenyl against a cyclohexyl ring 
increases in the main the potency at both, hH2R and gpH2R without affecting efficacy. 
Compound 3.78 (hH2R: EC50 = 7.4 nM, gpH2R: EC50 = 3.5 nM) with a 3-
cyclohexylpentanoyl moiety is about five and three times more potent than its phenyl 
analogue (3.56) at the hH2R (EC50 = 36.9 nM) and the gpH2R (EC50 = 11 nM), 
respectively, whereas the efficacy remains unchanged compared to the 3-phenyl-
pentanoyl compound. The enantiomers of the 3-cyclohexylbutanoyl- and the 3-
phenylbutanoylguanidine7 derivative show opposing preference for H2Rs: higher 
potency resides in the (S)-configured cyclohexyl substituted enantiomer (3.76) with a 
eudismic ratio of about three, whereas for the phenyl substituted analogues higher 
potency was found for the (R)-configured enantiomer. Whereas in the arpromidine 
series of H2R agonists eudismic ratios up to 40 were found in favour of the (S)-
enantiomer24, the acylguanidine-type H2R agonists show rather low eudismic ratios in 
the range of 2 - 3.5. Thus the stereochemistry of the acyl moiety seems to play only a 
minor role in this series of H2R agonists. The introduction of a methyl group in β-
position of the acyl group (3.111→3.102, 3.112→3.82) has no significant influence on 
potency and efficacy in the cyclohexyl series (data for 3.102, 3.111 and 3.112: see 
reference23). The same is found for bulkier substituents (3.80, 3.81; except for 3.78). 
A primary amine group at the end of the alkanoyl side chain (3.88 and 3.89) results in 
poor agonistic activity, especially at hH2R. Introduction of a hydroxy function at the 
phenyl ring (3.86 and 3.87) is much better tolerated. Unlike the methyl-, fluoro- or 
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methoxy-substituted compounds, the para position was preferred for the phenolic OH 
group. Polar groups in compounds 3.86-3.89 explicitly increased the selectivity 
towards the gpH2R. In a first attempt to modify the structure of the acylguanidines 
with respect to the future development of radiotracers and fluorescence-labelled 
agonists, the free amino group in compound 3.89 was acylated with succinimidyl 
proprionate and 4-F-benzoate, respectively, and derivatized with the fluorescent 
pyrylium dye py-1. The decrease in basicity due to conversion of the amine to the 4-
F-benzamide 3.90 and the propionamide 3.91 results in a significant increase in 
potency, whereas the efficacy is lowered (except for 3.90, hH2R) at both receptors. 
The fluorescent pyridinium compound 3.92 is considerably more potent than the 
amine 3.89 at the hH2R (EC50 29 vs. 172 nM) but equipotent with 3.89 at the gpH2R 
(EC50 about 20 nM).  
In agreement with previous results for alkylguanidines and other acylguanidines, the 
potencies and efficacies for most of the compounds of this new series are higher at 
gpH2R-GsαS than at hH2R-GsαS9, 22, 23. Figure 3.2 shows the correlation between 
potencies and efficacies of a selected number of acyguanidines (data taken from 
Table 3.2). However, surprisingly some compounds exhibit slightly higher potency at 
the human compared to the guinea pig H2 receptor. These exceptions are very 
stimulating with respect to the search for potent and selective agonists for the hH2R. 
Generally, compared to the results from GTPase assay on gpH2R-GsαS fusion 
proteins (Table 3.2) the potencies of acylated compounds are lower at the guinea pig 
right atrium (Figure 3.3), but the orders of potencies are in good agreement. 
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Figure 3.2. Correlation between the potencies and efficacies of selected acylated imidazolyl-
propylguanidines at the hH2R-GsαS and gpH2R-GsαS fusion proteins in the GTPase assay. Agonist 
potencies and efficacies were taken from Table 3.2. The pEC50 values were derived from the EC50 
shown in Table 3.2. The straight dashed line represents the correlation that would have been obtained 
if pEC50 values had been identical in the two systems. 
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Figure 3.3. Correlation between the potencies of acylated imidazolylpropylguanidines at the guinea 
pig right atrium and in GTPase assay on gpH2R-GsαS fusion proteins. Agonist potencies were taken 
from Table 3.1 and Table 3.2 and pEC50 values were derived from the EC50 shown in Table 3.2. The 
straight dashed line represents the correlation that would have been obtained if pEC50 values had 
been identical in the two systems. 
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3.3.2. Receptor selectivity 
3.3.2.1. Activity on the human histamine H1 receptor on U-373 MG human cells  
In the calcium assay on human U-373 MG cells all investigated acylguanidines 
proved to be weak histamine H1R antagonists (Table 3.3). This is in accordance with 
previous investigations on the guinea pig ileum, where NG-acylated imidazolyl-
propylguanidines proved to be weak H1R antagonists, too (pA2 values ~ 5-6)7, 20. 
Most strikingly, 3.102 turned out to be a potent partial agonist at the hH1R with much 
higher efficacy than at gpH1R (GTPase assay)23. This is surprising since antagonistic 
rather than agonistic effects were found at the guinea pig ileum and human H1R 
expressing cells. In terms of efficacy and potency, 3.102 (eff. = 0.56, EC50 = 280 nM) 
is comparable to classic H1R agonists like the most potent derivatives of 2-
phenylhistamines25. Direct G protein activation can be excluded and the agonistic 
effect can be blocked by H1 antagonists23. Possibly, the observed agonism is 
dependent on the artificial assay system (Sf9 insect cells, membrane preparations). 
 
Table 3.3. H1 receptor antagonism on U-373 MG human cells (Ca2+-assay). 
Histamine H1 receptor antagonism 
U-373 MG cells (Ca2+-assay) 
No IC50 [µM]a No IC50 [µM]a No IC50 [µM]a 
3.937 56 3.65 16.5 3.77 0.95 
3.947 34 3.66 7 3.78 5 
3.55 61 3.67 9 3.79 0.5 
3.9620 19.5 3.9521 7 3.80 5 
3.9721 18 3.9821 16 3.81 4 
3.56 30 3.10021 5 3.82 4 
3.57 >30 3.68 14 3.83 7 
3.58 24 3.69 17 3.84 7 
3.59 16 3.70 19 3.85 7 
3.60 6 3.71 14 3.86 nd 
3.1017 nd 3.72 12 3.87 nd 
3.61 12 3.73 24 3.88 95 
3.62 12 3.74 18 3.89 >100 
3.63 12 3.10220 0.95 3.90 nd 
3.64 36 3.75 5 3.91 nd 
3.9921 >30 3.76 0.5 3.92 nd 
a IC50 values for the inhibition of the histamine (30 µM) induced increase in cellular calcium, one experiment or the mean of two 
experiments, SEM < 10 %; procedure as described from Kracht, 200126. 
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3.3.2.2. Agonist potencies and efficacies at the hH3R and hH4R  
Surprisingly, most of the compounds (except for 3.103, 3.106, 3.107 and 3.112) show 
agonistic activities at the hH3R+Gαo+β1γ2+RGS4 membrane in GTPase assay in the 
subnanomolar range. 
  
Table 3.4. Agonist/antagonist activity on hH3+Gαo+β1γ2+RGS4- and hH4-GAIP+Gαi2+β1γ2 receptor 
membranes. 
N
H
N
HN
N
H
NH
X
O
N
H
N
HN
N
H
NH
X
O R1
R2
n
3.103, 3.109 3.56, 3.102-3.108, 3.110-3.113  
 
     hH3R + Gαo + β1γ2 + RGS4 hH4R-GAIP + Gαi2 + β1γ2 
No X R1 R2 n efficacy 
EC50 [nM]/ 
(KB [nM]) 
rel. 
pot. 
effi-
cacy 
EC50 [nM]/ 
(KB [nM]) 
rel. 
pot. 
His - - - - 1.00 25.8 ± 3.1 100 1.00 11.6 ± 2.5 100 
3.103 C6H5 - - - - (8.8 ± 0.4) - 0.7 13.3 87 
3.104 - H C6H5 0 0.49 ± 0.02 2.0 ± 0.6 1290 0.7 7.0 166 
3.105 CH2 H C6H5 0 0.41 ± 0.04 0.6 ± 0.2 4300 0.7 17.5 66 
3.106 CH2 H C6H5 1 - (2.7 ± 0.6) - 0.9 7.8 149 
3.107 CH2 H C6H5 2 - (3.5 ± 0.5) - 0.8 3.6 322 
3.108 - CH3 C6H5 - 0.28 ± 0.04 1.2 ± 0.3 2150 1.1 19.7 59 
3.96 CH2 CH3 C6H5 0 0.27 ± 0.03 0.9 ± 0.3 2867 0.9 15.2 76 
3.109 - - cHex - 0.48 ± 0.01 0.7 ± 0.1 3886 0.9 5.6 207 
3.110 - H cHex 0 0.69 ± 0.09 0.8 ± 0.2 3225 1.0 6.5 179 
3.111 CH2 H cHex 0 0.74 ± 0.05 2.1 ± 0.9 1229 0.91 11.6 100 
3.112 CH2 H cHex 1 - (2.3 ± 0.1) - - (8.8) - 
3.113 - CH3 cHex - 0.71 ± 0.03 3.4 ± 1.0 759 1.2 20.5 57 
3.102 CH2 CH3 cHex 0 0.44 ± 0.06 1.0 ± 0.4 2580  (16.1) - 
3.56 CH2 CH2CH3 C6H5 0 nd nd nd 0.56 9.7 119 
Steady state GTPase activity in Sf9 membranes expressing hH3R + Gαo + β1γ2 + RGS4 and hH4R-GAIP + Gαi2 + β1γ2 was 
determined as described in literature9. Reaction mixtures contained ligands at concentrations from 0.1 nM to 100 µM as 
appropriate to generate saturated concentration-response curves. Data were analyzed by nonlinear regression and were best 
fitted to sigmoidal concentration-response curves. Typical basal GTPase activities ranged between ~ 1.5 and 2.5 pmol/mg/min, 
and activities stimulated by histamine (10 µM) ranged between ~ 3.5 and 4.5 pmol/mg/min. The efficacy (Emax) of histamine was 
determined by nonlinear regression and was set to 1.0. The Emax values of other agonists were referred to this value. Data 
shown are the ± SEM of one to three experiments performed in duplicates each. The relative potency of histamine was set to 
100, and the potencies of other agonists were referred to this value. For antagonism, reaction mixtures contained histamine 
(100 nM) and ligands at concentrations from 0.1 nM to 100 µM. 
 
In large part, these acylguanidines exhibit higher potencies for the hH3R than for the 
hH2R (data not shown)23, but lower efficacies. The most potent substance in this 
series is the 3-phenylpropanoyl analogue which is 43 times more potent than 
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histamine at the hH3R and 12 times more potent at the hH2R. In contrast, acylated 
imidazolylpropylguanidines proved to be moderate to potent H3R antagonists on the 
guinea pig ileum (data not shown)7. The agonistic response may also be due to the 
artifical assay conditions; this effect was never observed on the guinea pig ileum. At 
the hH4R, all compounds are nearly full agonists (except for 3.112 and 3.102) with 
high potencies. Hence, imidazolylpropylguanidines are not only H2 receptor agonists, 
but show also agonistic (or antagonistic) activity, respectively, on human H3R and 
H4R in the GTPase assay.  
 
3.4. Summary 
A variety of NG-acylated imidazolylpropylguanidines was synthesized in order to 
study the species selectivity for human versus guinea pig histamine H2 receptors and 
to elaborate the structure-activity relationships. All compounds proved to be full or 
nearly full H2R agonists at the spontaneously beating guinea pig right atrium. The 
potencies are somewhat lower for all acylated imidazolylpropylguanidines compared 
to the corresponding alkylated imidazolylpropylguanidines on the guinea pig right 
atrium, however the order of potency on the atrium is generally in good agreement 
with the data derived from gpH2R-GsαS in GTPase assay. The 3-phenylbutanoyl- 
(3.96) and the (S)-3-cyclohexylbutanoylguanidine (3.76) derivatives are the most 
active compounds at the guinea pig right atrium, achieving 27 and 22 times higher 
potency than histamine. At the gpH2R-GsαS fusion protein, the 2-methyl-3-
cyclohexylpropanoyl- (3.77), 3-cyclohexylpentanoyl- (3.78) and 3- and 4-
(hydroxyphenyl)butanoylguanidine (3.86 and 3.87) derivatives are the most potent 
compounds in the series of acylated imidazolylpropylguanidines. This result indicates 
that a methyl or ethyl substituted three-membered carbon chain between the 
guanidine moiety and the ring system favours high potencies at the guinea pig H2R. 
As also found for the alkylguanidines, the acylguanidines are more potent and 
efficious at the gpH2R-GsαS compared to the hH2R-GsαS9, 22, 23. Interestingly, the 6-
phenylhexanoyl (3.95) analogue shows the highest agonistic activity at the hH2R-
GsαS, stimulating speculations about a higher conformational flexibility of the hH2R9. 
This compound turned out to be the first one among all investigated alkyl- and 
acylguanidines which possesses a slightly higher potency at the human compared to 
the guinea pig H2 receptor in the GTPase assay. In addition, the introduction of ring 
substituents such as methyl, ethyl, methoxy or fluoro at the 3-methyl-4-
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phenylbutanoyl moiety (3.65) is better tolerated by the hH2R-GsαS. Again, this may be 
interpreted a hint to a bigger and more flexible binding pocket9. The correlation of 
potencies and efficacies of all acylated imidazolylpropylguanidines between the 
human and guinea pig H2 receptor suggests that some compounds show a similar or 
even slight higher potency or efficacy at the human receptor. This result suggests the 
development of potent and selective compounds for the hH2R.  
The insertion of a primary amino group in the side chain (3.88-3.89) results in a 
considerable decrease in potency at the hH2R, whereas hydroxy functions (3.86-
3.87) at the phenyl ring were much better tolerated. These compounds were 7-12 
times more potent at the gpH2R. Hence, the introduction of polar substituents (3.86-
3.89) strongly enhanced the selectivity for guinea pig versus human H2R. The gpH2R 
model, suggesting interactions between Asp-271, Tyr-17, Trp-275 and Lys-173 in 
TM1, TM7 and e2, is supported by these results while a positively charged amino 
group or H-bond donor may directly or indirectly participate in this network9, 27. 
Aliphatic substituents are more preferred in the case of the hH2R due to a more 
hydrophobic binding pocket27. 
Furthermore, selected compounds were tested for receptor selectivity at human H1R 
(calcium assay on U373 cells) as well as human H3R and H4R expressed in Sf9 
insect cells. Generally, on the human H1R the compounds proved to be weakly active 
antagonists. Most strikingly, 3.102 turned out to be a potent partial agonist at the 
hH1R in the GTPase assay23. An imidazol-4-yl ring favours binding to the histamine 
H3 receptor. The endogenous ligand histamine has higher affinity for H3R than for the 
other histamine receptors, numerous imidazole-type H3R antagonists28, 29 and 
agonists30 are described in literature, and the H2R agonists arpromidine and 
impromidine are also known as H3R antagonists. As expected, the NG-acylated 
imidazolylpropylguanidines synthesized as H2R agonists, proved to be moderate to 
potent H3R antagonists at the guinea pig ileum (data not shown7) and, surprisingly, 
exhibit H3R agonism (except for 3.103, 3.106, 3.107 and 3.112) at the 
hH3R+Gαo+β1γ2+RGS4 membrane in the GTPase assay. Moreover, the compounds 
also proved to be potent agonists (except for 3.112 and 3.102) at the hH4-
GAIP+Gαi2+β1γ2- and hH1R23 expressing Sf9 membranes in the GTPase assay, and 
the 3-cyclohexylpropanoyl derivative (3.111) was discovered as the first nonpeptidic 
NPY Y4 receptor antagonist (pKi = 4.17)31, 32.  
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3.5. Experimental section 
3.5.1. General conditions 
Commercially available reagents were purchased from Acros Organics (Belgium), 
Lancaster Synthesis GmbH (Germany), Sigma-Aldrich Chemie GmbH (Germany), 
Alfa Aesar GmbH & Co KG (Germany) or Merck (Germany) and used as received. 
Where indicated, reactions were carried out under a dry, oxygen-free argon 
atmosphere. All solvents used were of analytical grade or distilled before use. THF 
and Et2O were distilled over Na, CH2Cl2 was predried over CaCl2 or distilled from 
P2O5 and stored under argon atmosphere over molecular sieves 3 Å. Column 
chromatography was carried out using Merck silica gel Geduran 60 (0.063-0.200) 
and Merck silica gel 60 (0.040-0.063) for flash column chromatography. Reactions 
were monitored by thin layer chromatography (TLC) on Merck silica gel 60 F254 
aluminium sheets and spots were visualized with UV light at 254 nm.  
Nuclear Magnetic Resonance (1H-NMR and 13C-NMR) spectra were recorded on a 
Bruker Avance 300 spectrometer with per-deuterated solvents. The chemical shift δ 
is given in parts per million (ppm) with reference to the chemical shift of the residual 
protic solvent compared to tetramethylsilane (δ = 0 ppm). Multiplicities were specified 
with the following abbreviations: s (singlet), d (doublet), t (triplet), q (quartet), m 
(multiplet) and br (broad signal) as well as combinations thereof. The multiplicity of 
carbon atoms (13C-NMR) were determined by DEPT 135 and DEPT 90 (distortionless 
enhancement by polarization transfer): “+” primary and tertiary carbon atom (positive 
DEPT 135 signal), “-“ secondary carbon atom (negative DEPT 135 signal), “quart” 
quaternary carbon atom. Mass spectrometry analysis (MS) was performed on a 
Finnigan MAT 95, a Finnigan SSQ 710A and on a Finnigan ThermoQuest TSQ 7000 
spectrometer. Melting points (mp) were measured on a BÜCHI 530 electrically 
heated copper block apparatus using an open capillary and are uncorrected. The 
Department of Microanalysis, University of Regensburg, carried out elemental 
analysis. Compounds were dried in vacuo at room temperature or with heating up to 
50 °C for at least 24 h prior to submission for elemental analysis. Preparative HPLC 
was performed with a pump model K-1800 (Knauer, Berlin, Germany), the column 
was Eurosphere-100 (250 x 32 mm) (Knauer), which was attached to the UV-
detector model K-2000 (Knauer). UV-detection was done at 254 and 210 or 220 nm, 
respectively. The temperature was 25 °C and the flow rate 37 ml/min. The mobile 
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phase was 0.1% TFA in millipore water and MeCN. Analytical HPLC purity data: see 
appendix (chapter 8). 
 
3.5.2. Preparation of ketones 3.11-3.14c, 3.15e, 3.16b, 3.17c and 3.18-
3.19b 
General procedure  
To a Grignard reagent, prepared from Mg and the pertinent chloride in diethyl 
ether/abs, was added under stirring a solution of benzonitrile or acetonitrile in diethyl 
ether/abs under argon and refluxed for 16 h. After cooling, the mixture was poured 
into a mixture of concentrated HCl and ice and extracted three to five times with 
diethyl ether. The organic phase was dried over MgSO4 and the solvent removed in 
vacuo. The crude product was subjected to flash chromatography (PE/EtOAc 100/0-
90/10 v/v) to obtain the ketones. 
1,2-Diphenylethanone (3.11c) 33  
The title compound was prepared from Mg (1.16 g, 48 mmol), benzyl chloride (6.15 
g, 4.6 ml, 48 mmol) in 40 ml diethyl ether and benzonitrile (4 g, 4 ml, 39 mmol) in 10 
ml diethyl ether to obtain 3.11c (3.41 g, 41 %) as a pale yellow solid. mp = 47 °C 
(ref.33: mp = 55-56 °C); 1H-NMR (CDCl3) δ ppm: 8.02 (m, 2H, Ar-H), 7.56-7.45 (m, 
3H, Ar-H), 7.35-7.28 (m, 4H, Ar-H), 4.29 (s, 2H, CH2-Ar); PI-EIMS (70 eV) m/z (%): 
196 (M+•, 6). C14H12O (196.24) 
2-(4-Methylphenyl)-1-phenylethanone (3.12c)34  
The title compound was prepared from Mg (1.2 g, 48 mmol), p-methylbenzyl chloride 
(6.75 g, 6.3 ml, 48 mmol) in 40 ml diethyl ether and benzonitrile (4 g, 4 ml, 39 mmol) 
in 10 ml diethyl ether to obtain 3.12c (6.22 g, 76 %) as a pale yellow solid. mp = 87-
88 °C (ref.34: 95-96 °C); 1H-NMR (CDCl3) δ ppm: 8.01 (m, 2H, Ar-H), 7.49 (m, 3H, Ar-
H), 7.13 (m, 4H, Ar-H), 4.24 (s, 2H, CH2-Ar), 2.32 (s, 3H, (p-CH3)Ar); EI-MS (70 eV) 
m/z (%): 210 (M+•, 8). C15H14O (210.27) 
1-Phenylpropan-2-one (3.13c)35  
The title compound was prepared from Mg (3.5 g, 140 mmol), benzyl chloride (18.7 
g, 17 ml, 150 mmol) in 50 ml diethyl ether and acetonitrile (4.91 g, 6.3 ml, 120 mmol) 
in 10 ml diethyl ether to obtain 3.13c (1.76 g, 11 %) as a pale yellow oil. 1H-NMR 
(CDCl3) δ ppm: 7.34-7.21 (m, 5H, Ar-H), 3.69 (s, 2H, CH2-Ar), 2.15 (s, 3H, CH3); EI-
MS (70 eV) m/z (%): 134 (M+•, 19). C9H10O (134.17) 
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5-Phenylpentan-2-one (3.14c)36  
The title compound was prepared from Mg (5.6 g, 230 mmol), 1-(3-chloropropyl)-
benzene (36.2 g, 35 ml, 230 mmol) in 200 ml diethyl ether and acetonitrile (7.8 g, 10 
ml, 190 mmol) in 50 ml diethyl ether to obtain 3.14c (4.33 g, 14 %) as a yellow oil. 1H-
NMR (CDCl3) δ ppm: 7.29-7.16 (m, 5H, Ar-H),  2.62 (t, 2H, 3J = 7.5 Hz, CH2-Ar), 2.43 
(t, 2H, 3J = 7.4 Hz, COCH2), 2.11 (s, 3H, CH3), 1.91 (m, 2H, COCH2CH2); PI-EIMS 
(70 eV) m/z (%): 162 (M+•, 26). C11H14O (162.23) 
N-(Cyclohexylcarbonyl)pyrrolidine (3.15b)13 
To a solution of cyclohexancarbonyl chloride (2.5 g, 17 mmol) in 10 ml DCM/abs was 
added under argon a solution of pyrrolidine (0.92 g, 1.1 ml, 13 mmol) and DMAP (3.1 
g, 25 mmol) in 15 ml DCM/abs and stirred for 20 min at room temperature. 
Subsequently, brine was added and the organic layer separated. The aqueous phase 
was extracted three times with EtOAc and the combined organic layers washed with 
3 N HCl, 1 N NaOH and brine. After drying over MgSO4, the solvent was removed 
under reduced pressure and the crude product subjected to flash chromatography 
(PE/EtOAc 70/30-50/50 v/v) to obtain 3.15b (2.03 g, 86 %) as a white solid. mp = 63 
°C (ref.13: mp = 66-67 °C); 1H-NMR (CDCl3) δ ppm: 3.46 (m, 4H, pyrrolidine-CH2), 
2.33 (tt, 1H, 3J = 3.3 Hz, 3J = 11.5 Hz, cHex-CH), 1.94-1.28 (m, 14H, cHex-CH, cHex-
CH2, pyrrolidine-CH2); EI-MS (70 eV) m/z (%): 181 (M+•, 33). C11H19NO (181.27) 
Cyclohexyl(1-methyl-1H-imidazol-2-yl)methanone (3.15c)14 
To a solution of 1-methyl-1H-imidazole (1.92 g, 1.86 ml, 23.4 mmol) in 40 ml 
THF/abs was added n-BuLi/15 % (14.6 ml, 23.4 mmol) at -78 °C. After 10 min, 3.15b 
(4.24 g, 23.4 mmol) in 30 ml THF/abs was added and stirred for 30 min at room 
temperature. Subsequently, 50 ml diethyl ether and 50 ml 10 % HCl/aq were added. 
The aqueous phase was washed with diethyl ether and K2CO3 was added to adjust 
to pH > 10. The aqueous phase was extracted three times with EtOAc and dried over 
MgSO4. The solvent was removed under reduced pressure and the crude product 
purified with flash chromatography (PE/EtOAc 70/30 v/v) to obtain 3.15c (4.29 g, 95 
%) as a colourless oil. mp = 49-50 °C; 1H-NMR (CDCl3) δ ppm: 7.14 (d, 1H, 4J = 0.8 
Hz, Im-5-H), 7.02 (s, 1H, Im-4-H), 3.99 (s, 3H, CH3), 1.93-1.71 (m, 5H, cHex-CH, 
cHex-CH2), 1.47-1.23 (m, 6H, cHex-CH2); PI-EIMS (70 eV) m/z (%): 192 (M+•, 38). 
C11H16N2O (192.26) 
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1-Cyclohexyl-1-(1-methyl-1H-imidazol-2-yl)-2-phenylethanol (3.15d)37 
To a Grignard reagent, prepared from Mg (0.505 g, 20.8 mmol) and benzyl chloride 
(2.64 g, 2.4 ml, 20.8 mmol) in 60 ml diethyl ether/abs, was added 3.15c (2 g, 10.4 
mmol) in 20 ml diethyl ether/abs under ice cooling and stirred for 2-3 h at room 
temperature. Subsequently, 10 % HCl/aq was added to this mixture until pH < 3, 
washed with diethyl ether and K2CO3 was added. After extracting three times with 
EtOAc, the organic phase was dried over MgSO4 and the solvent removed in vacuo 
to obtain the crude product as a white solid, which was recrystallised from toluene to 
obtain 3.15d (1.54 g, 60 %) as a white cotton-like solid. mp = 170-171 °C (ref.37: mp 
= 185-186 °C); 1H-NMR (CDCl3) δ ppm: 7.15 (m, 6H, Ar-H,  Im-5-H), 6.88 (d, 1H, 4J = 
1.1 Hz, Im-4-H), 3.45 (s, 3H, CH3), 3.16 (d, 2H, 3J = 13.5 Hz, CH2-Ar), 2.05 (s, 1H, 
OH), 1.84-1.22 (m, 11H, cHex-CH,  cHex-CH2); CI-MS (NH3) m/z (%): 285 (MH+, 
100). C18H24N2O (284.39) 
1-Cyclohexyl-2-phenylethanone (3.15e)37 
MeI (12 ml, 79 mmol) was added to a solution of 3.15d (1.53 g, 6.16 mmol) in 40 ml 
EtOAc and refluxed for 3-4 h. The solvent was removed under reduced pressure, 40 
ml benzene and K2CO3 (1 g, 7.2 mmol) were added under argon resulting and the 
mixture was heated to 60 °C for 2 h. After drying over MgSO4, the solvent was 
removed in vacuo and the crude product subjected to flash chromatography 
(PE/EtOAc 95/5 v/v) to abtain 3.15e (0.7 g, 56 %) as a light brown oil. 1H-NMR 
(CDCl3) δ ppm: 7.32-7.19 (m, 5H, Ar-H), 3.73 (s, 2H, CH2-Ar), 2.46 (tt, 1H, 3J = 3.3 
Hz, 2J = 11.4 Hz, cHex-CH), 1.73-1.26 (m, 10H, cHex-CH2); EI-MS (70 eV) m/z (%): 
202 (M+•, 8). C14H18O (202.29) 
(2-Oxo-2-phenylethyl)carbamic acid tert-butyl ester (3.16b)38  
To a solution of 2-amino-1-phenylethanone hydrochloride (4.52 g, 26.4 mmol) in 80 
ml THF/abs was added NEt3 (2.67 g, 3.66 ml, 26.4 mmol) and (Boc)2O (7.02 g, 32 
mmol) in 20 ml THF/abs and stirred for 20 h at room temperature. Subsequently, 
water and EtOAc were added and the aqueous layer was extracted three times with 
EtOAc. The organic phase was washed with 1N NaOH, dried over MgSO4 and 
evaporated in vacuo. The crude product was purified by flash chromatography 
(PE/EtOAc 80/20 v/v) to obtain 3.16b (5.56 g, 90 %) as a yellow oil. 1H-NMR (CDCl3) 
δ ppm: 7.96 (m, 2H, Ar-H), 7.62-7.49 (m, 3H, Ar-H), 5.55 (br s, 1H, NH), 4.67 (d, 2H, 
3J = 4.5 Hz, CH2NH), 1.48 (s, 9H, C(CH3)3); CI-MS (NH3) m/z (%): 253 (M+NH4+, 15). 
C13H16NO3 (235.28) 
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(5-Oxo-5-phenylbutyl)carbamic acid tert-butyl ester (3.17c)39 
A solution of tert-butyl 2-oxopyrrolidine-1-carboxylate (9.3 g, 8.5 ml, 50 mmol) in 200 
ml THF/abs was cooled to -78 °C and PhMgBr in diethyl ether (20 ml of 3M solution 
corresponding to 60 mmol) was added dropwise within 1 h (the temperature in the 
flask should be kept at -70 °C during the addition). At the end of the addition of 
PhMgBr, the mixture is allowed to warm up to room temperature. Subsequently, the 
solution was adjusted to pH = 1-3 by addition of 2M HCl. The aqueous layer was 
separated and extracted three times with CH2Cl2. After drying over MgSO4, the 
solvent was removed in vacuo and the crude product subjected to flash 
chromatography (PE/EtOAc 90/10-85/15) to obtain 3.17c (8.95 g, 68 %) as a white 
solid. mp = 88 °C (ref.39: 95-96 °C); 1H-NMR (CDCl3) δ ppm: 7.96 (m, 2H, Ar-H), 
7.56-7.45 (m, 3H, Ar-H), 4.69 (br s, 1H, NH), 3.23 (m, 2H, CH2NH), 3.03 (t, 2H, 3J = 
7.1 Hz, COCH2), 1.95 (m, 2H, COCH2CH2), 1.42 (s, 9H, C(CH3)3); CI-MS (NH3) m/z 
(%): 281 (M+NH4+, 13). C15H21NO3 (263.15) 
1-(3-Benzyloxyphenyl)ethanone (3.18b)40  
To a solution of 1-(3-hydroxyphenyl)ethanone (3 g, 22 mmol) and KOH (1.35 g, 24.2 
mmol) in 15 ml EtOH was added BnCl (2.77 g, 2.5 ml, 22 mmol) and refluxed for 5 h. 
The solvent was removed under reduced pressure. Subsequently, water was added 
and extracted three times with CHCl3. After drying over MgSO4, the solvent was 
removed in vacuo and the crude product subjected to flash chromatography 
(PE/EtOAc 80/20 v/v) to obtain 3.18b (4.19 g, 84 %) as a yellow oil. 1H-NMR (CDCl3) 
δ ppm: 7.56-7.21 (m, 9H, Ar-H), 5.10 (s, 1H, CH2-Ar), 2.57 (s, 3H, CH3); EI-MS (70 
eV) m/z (%): 226 (M+•, 43). C15H14O2 (226.27) 
1-[4-(4-Methoxybenzyloxy)phenyl]ethanone (3.19b)41  
To a solution of 1-(3-hydroxyphenyl)ethanone (3 g, 22 mmol) and K2CO3 (12.2 g, 88 
mmol) in 150 ml acetone/pA was added p-methoxybenzyl chloride (5.17 g, 4.5 ml, 33 
mmol) and refluxed overnight. After filtration of the precipitate, the solvent was 
removed under reduced pressure and subjected to flash chromatography (PE/EtOAc 
80/20-60/40 v/v) to obtain 3.19b  (4.14 g, 73 %) as a white solid. mp = 118 °C; 1H-
NMR (CDCl3) δ ppm: 7.93 (m, 2H, Ar-H), 7.36 (m, 2H, Ar-H), 6.96 (m, 4H, Ar-H), 5.05 
(s, 2H, CH2-Ar), 3.82 (s, 3H, (p-OCH3)-Ar), 2.55 (s, 3H, CH3); EI-MS (70 eV) m/z (%): 
256 (M+•, 1). C16H16O3 (256.11) 
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3.5.3. Preparation of ethyl (E,Z)-alkenoates 3.21-3.39a and 3.53-3.54a 
General procedure  
To a stirred suspension of NaH (60 % dispersion in mineral oil) (1.56 eq) in THF/abs 
was carefully added triethyl phosphonoacetate (1.4 - 1.5 eq) under argon and was 
stirred at 30-35 °C for 1.5 h. Subsequently, the pertinent ketone (1 eq) was added 
dropwise and the mixture refluxed overnight (12-16 h). After cooling to room 
temperature, the mixture was poured into ice water, extracted three times with diethyl 
ether and the organic phase dried over MgSO4. After removing the solvent under 
reduced pressure, the crude product was subjected to flash chromatography 
(PE/EtOAc 100/0-95/5 v/v) to obtain a mixture of E/Z isomeric ethyl ester. 
Ethyl (E,Z)- 3-phenylpent-2-enoate (3.21a)42, 43  
The title compound was prepared from propiophenone (2 g, 1.98 ml, 14.1 mmol), 
triethyl phosphonoacetate (4.4 ml, 20 mmol) and NaH (60 % dispersion in mineral oil) 
(0.6 g, 22 mmol) in 25 ml THF/abs according to the general procedure yielding 3.21a 
(2.9 g, 100 %) as a colourless liquid. EI-MS (70 eV) m/z (%): 204 (M+•, 87). C13H16O2 
(204.27) 
Ethyl (E,Z)-4-methyl-3-phenylpent-2-enoate (3.22a)44  
The title compound was prepared from 2-methyl-1-phenylpropan-1-one (2 g, 2.1 ml, 
13.5 mmol), triethyl phosphonoacetate (4.08 ml, 20 mmol) and NaH (60 % dispersion 
in mineral oil) (0.84 g, 21 mmol) in 25 ml THF/abs according to the general procedure 
yielding 3.22a (2.5 g, 85 %) as a colourless liquid. PI-EIMS (70 eV) m/z (%): 218 
(M+•, 100). C14H18O2 (218.29) 
Ethyl (E,Z)-5-methyl-3-phenylhex-2-enoate (3.23a)45  
The title compound was prepared from 3-methyl-1-phenylbutan-1-one (2.27 g, 2.35 
ml, 14 mmol), triethyl phosphonoacetate (4.08 ml, 20.9 mmol) and NaH (60 % 
dispersion in mineral oil) (0.87 g, 21.8 mmol) in 25 ml THF/abs according to the 
general procedure yielding 3.23a (2.75 g, 84 %) as a colourless liquid. EI-MS (70 eV) 
m/z (%): 232 (M+•, 100). C15H20O2 (232.32) 
Ethyl (E,Z)-3,4-diphenylbut-2-enoate (3.24a)46  
The title compound was prepared from 3.11c (2.75 g, 14 mmol), triethyl 
phosphonoacetate (4.08 ml, 20.9 mmol) and NaH (60 % dispersion in mineral oil) 
(0.84 g, 21 mmol) in 25 ml THF/abs according to the general procedure yielding 
3.24a (3.21 g, 86 %) as a colourless liquid. PI-EIMS (70 eV) m/z (%): 266 (M+•, 100). 
C18H18O2 (266.33) 
Chapter 3: NG-Acylated Imidazolylpropylguanidines 58 
Ethyl (E,Z)-3-phenyl-4-(4-methylphenyl)but-2-enoate (3.25a)  
The title compound was prepared from 3.12c (4 g, 19 mmol), triethyl 
phosphonoacetate (5.5 ml, 28 mmol) and NaH (60 % dispersion in mineral oil) (1.18 
g, 29.4 mmol) in 60 ml THF/abs according to the general procedure yielding 3.25a 
(2.64 g, 50 %) as a yellow solid. EI-MS (70 eV) m/z (%): 280 (M+•, 100). C19H20O2 
(280.36) 
Ethyl (E,Z)-3-cyclohexyl-4-phenylbut-2-enoate (3.26a)  
The title compound was prepared from 3.15e (0.7 g, 3.5 mmol), triethyl 
phosphonoacetate (1.03 ml, 5.2 mmol) and NaH (60 % dispersion in mineral oil) 
(0.22 g, 5.46 mmol) in 10 ml THF/abs according to the general procedure yielding 
3.26a (0.67 g, 70 %) as a yellow liquid. EI-MS (70 eV) m/z (%): 272 (M+•, 26). 
C18H24O2 (272.18) 
Ethyl (E,Z)-3-(4-methylphenyl)but-2-enoate (3.27a)47  
The title compound was prepared from 1-(4-methylphenyl)ethanone (4.6 g, 4.6 ml, 
4.5 mmol), triethyl phosphonoacetate (9.6 ml, 49 mmol) and NaH (60 % dispersion in 
mineral oil) (2.23 g, 55.7 mmol) in 60 ml THF/abs according to the general procedure 
yielding 3.27a (7.2 g, 100 %) as a yellow oil. CI-MS (NH3) m/z (%): 222 (M+NH4+, 
100). C13H16O2 (204.27) 
Ethyl (E,Z)-3-methyl-4-phenylbut-2-enoate (3.28a)48  
The title compound was prepared from 3.13c (1.5 g, 11 mmol), triethyl 
phosphonoacetate (3.1 ml, 15.6 mmol) and NaH (60 % dispersion in mineral oil) (0.7 
g, 17.6 mmol) in 25 ml THF/abs according to the general procedure yielding 3.28a 
(2.05 g, 91 %) as a pale yellow liquid. PI-EIMS (70 eV) m/z (%): 204 (M+•, 57). 
C13H16O2 (204.27) 
Ethyl (E,Z)-3-methyl-5-phenylpent-2-enoate (3.29a)49  
The title compound was prepared from 4-phenylbutan-2-one (2.1 g, 2.1 ml, 14 mmol), 
triethyl phosphonoacetate (4.08 ml, 20.9 mmol) and NaH (60 % dispersion in mineral 
oil) (0.84 g, 21 mmol) in 25 ml THF/abs according to the general procedure yielding 
3.29a (3.09 g, 99 %) as a colourless liquid. EI-MS (70 eV) m/z (%): 218 (M+•, 3). 
C14H18O2 (218.29) 
Ethyl (E,Z)-3-methyl-6-phenylhex-2-enoate (3.30a) 
The title compound was prepared from 3.14c (2.88 g, 14 mmol), triethyl 
phosphonoacetate (4.08 ml, 20.9 mmol) and NaH (60 % dispersion in mineral oil) 
(0.84 g, 21 mmol) in 25 ml THF/abs according to the general procedure yielding 
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3.30a (2.18 g, 67 %) as a colourless liquid. CI-MS (NH3) m/z (%): 250 (M+NH4+, 100). 
C15H20O2 (232.32) 
Ethyl (E,Z)-3-methyl-4-(3-methylphenyl)but-2-enoate (3.31a)  
The title compound was prepared from 1-(3-methylphenyl)propan-2-one (2.5 g, 16.9 
mmol), triethyl phosphonoacetate (4.5 ml, 23.2 mmol) and NaH (60 % dispersion in 
mineral oil) (1 g, 25.3 mmol) in 40 ml THF/abs according to the general procedure 
yielding 3.31a (1.25 g, 34 %) as a colourless liquid. EI-MS (70 eV) m/z (%): 218 (M+•, 
16). C14H18O2 (218.13) 
Ethyl (E,Z)-3-methyl-4-(4-methylphenyl)but-2-enoate (3.32a)50  
The title compound was prepared from 1-(4-methylphenyl)propan-2-one (2.5 g, 16.9 
mmol), triethyl phosphonoacetate (4.5 ml, 23.2 mmol) and NaH (60 % dispersion in 
mineral oil) (1 g, 25.3 mmol) in 40 ml THF/abs according to the general procedure 
yielding 3.32a (1.9 g, 58 %) as a colourless oil. EI-MS (70 eV) m/z (%): 218 (M+•, 45). 
C14H18O2 (218.13) 
Ethyl (E,Z)-3-(3-fluorobenzyl)but-2-enoate (3.33a)  
The title compound was prepared from 1-(3-fluorophenyl)propan-2-one (2.5 g, 16.4 
mmol), triethyl phosphonoacetate (4.4 ml, 22.7 mmol) and NaH (60 % dispersion in 
mineral oil) (0.99 g, 24.8 mmol) in 40 ml THF/abs according to the general procedure 
yielding 3.33a (2.03 g, 56 %) as a pale yellow oil. CI-MS (NH3) m/z (%): 240 
(M+NH4+, 100). C13H15FO2 (222.25) 
Ethyl (E,Z)-3-(4-fluorobenzyl)but-2-enoate (3.34a)  
The title compound was prepared from 1-(4-fluorophenyl)propan-2-one (2 g, 1.8 ml, 
13.1 mmol), triethyl phosphonoacetate (3.5 ml, 18.1 mmol) and NaH (60 % 
dispersion in mineral oil) (0.79 g, 19.8 mmol) in 35 ml THF/abs according to the 
general procedure yielding 3.34a (1.32 g, 45 %) as a pale yellow liquid. EI-MS (70 
eV) m/z (%): 222 (M+•, 55). C13H15FO2 (222.25) 
Ethyl (E,Z)-3-(3-methoxybenzyl)but-2-enoate (3.35a)51  
The title compound was prepared from 1-(3-methoxyphenyl)propan-2-one (1.91 g, 1 
ml, 11.6 mmol), triethyl phosphonoacetate (3.1 ml, 15.9 mmol) and NaH (60 % 
dispersion in mineral oil) (0.7 g, 17.4 mmol) in 35 ml THF/abs according to the 
general procedure yielding 3.35a (1.03 g, 38 %) as a pale yellow oil. EI-MS (70 eV) 
m/z (%): 234 (M+•, 69). C14H18O3 (234.29) 
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Ethyl (E,Z)-3-(4-methoxybenzyl)but-2-enoate (3.36a)52  
The title compound was prepared from 1-(4-methoxyphenyl)propan-2-one (2 g, 1.87 
ml, 12.2 mmol), triethyl phosphonoacetate (3.3 ml, 16.8 mmol) and NaH (60 % 
dispersion in mineral oil) (0.73 g, 18.3 mmol) in 35 ml THF/abs according to the 
general procedure yielding 3.36a (1.18 g, 41 %) as a colourless liquid. EI-MS (70 eV) 
m/z (%): 234 (M+•, 79). C14H18O3 (234.29) 
Ethyl (E,Z)-3-(3-ethylbenzyl)but-2-enoate (3.37a)53 
The title compound was prepared from 1-(3-ethylphenyl)propan-2-one (2.5 g, 15.4 
mmol), triethyl phosphonoacetate (4.12 ml, 21.1 mmol) and NaH (60 % dispersion in 
mineral oil) (0.92 g, 23 mmol) in 40 ml THF/abs according to the general procedure 
yielding 3.37a (1.86 g, 52 %) as a pale yellow liquid. EI-MS (70 eV) m/z (%): 232 
(M+•, 72). C15H20O2 (232.15) 
Ethyl (E,Z)-4-(tert-butoxycarbonylamino)-3-phenylbut-2-enoate (3.38a)54  
The title compound was prepared from 3.16b (2 g, 8.54 mmol), triethyl 
phosphonoacetate (2.4 ml, 12 mmol) and NaH (60 % dispersion in mineral oil) (0.52 
g, 13 mmol) in 25 ml THF/abs according to the general procedure yielding 3.38a 
(0.31 g, 12 %) as a yellow oil. CI-MS (NH3) m/z (%): 323 (M+NH4+, 81). C17H23NO4 
(305.37) 
Ethyl (E,Z)-6-(tert-butoxycarbonylamino)-3-phenylhex-2-enoate (3.39a)55 
The title compound was prepared from 3.17c (4 g, 15 mmol), triethyl 
phosphonoacetate (4.1 ml, 21 mmol) and NaH (60 % dispersion in mineral oil) (0.92 
g, 23 mmol) in 60 ml THF/abs according to the general procedure yielding 3.39a 
(1.21 g, 24 %) as a yellow oil. CI-MS (NH3) m/z (%): 351 (M+NH4+, 57). C19H27NO4 
(333.19) 
Ethyl (E,Z)-3-(3-benzyloxyphenyl)but-2-enoate (3.53a)56  
The title compound was prepared from 3.18b (3 g, 13 mmol), triethyl 
phosphonoacetate (3.6 ml, 18 mmol) and NaH (60 % dispersion in mineral oil) (0.79 
g, 19.7 mmol) in 45 ml THF/abs according to the general procedure yielding 3.53a 
(1.51 g, 40 %) as a pale yellow liquid. EI-MS (70 eV) m/z (%): 296 (M+•, 11). 
C19H20O3 (296.14) 
Ethyl (E,Z)-3-[4-(4-methoxybenzyloxy)phenyl]but-2-enoate (3.54a)57  
The title compound was prepared from 3.19b (3 g, 11.8 mmol), triethyl 
phosphonoacetate (3.4 ml, 17.5 mmol) and NaH (60 % dispersion in mineral oil) 
(0.73 g, 18.3 mmol) in ml THF/abs according to the general procedure yielding 3.54a 
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(2.14 g, 56 %) as a pale yellow oil. EI-MS (70 eV) m/z (%): 326 (M+•, 1). C20H22O4 
(326.15) 
 
3.5.4. Preparation of ethyl alkanoates 3.21-3.39b 
General procedure  
The ethyl (E,Z)-alkenoates were dissolved in EtOH, Pd/C (10 %) was added and 
stirred for 24 h at room temperature under hydrogen atmosphere. The catalyst was 
removed by filtration over Celite and washed with EtOH. The solvent was removed in 
vacuo to obtain the ethyl alkanoates. 
Ethyl 3-phenylpentanoate (3.21b)42, 58  
The title compound was prepared from 3.21a (2.9 g, 14.1 mmol), Pd/C (10 %) (0.3 g, 
cat.) and 20 ml EtOH according to the general procedure yielding 3.21b (2.9 g, 100 
%) as a pale yellow liquid. 1H-NMR (CDCl3) δ ppm: 7.31-7.18 (m, 5H, Ar-H), 4.03 (q, 
2H, 3J = 7.1 Hz, CH2CH3), 3.00 (m, 1H, CH2CH), 2.64 (dd, 1H, 3J = 7.1 Hz, 2J = 15.0 
Hz, COCHH), 2.55 (dd, 1H, 3J = 8.2 Hz, 2J = 15.0 Hz, COCHH), 1.66 (m, 2H, 
CH2CH3), 1.13 (t, 3H, 3J = 7.1 Hz, CH2CH3), 0.79 (t, 3H, 3J = 7.4 Hz, CH2CH3); EI-MS 
(70 eV) m/z (%): 206 (M+•, 29). C13H18O2 (206.28) 
Ethyl 4-methyl-3-phenylpentanoate (3.22b)59  
The title compound was prepared from 3.22a (2.5 g, 11.4 mmol), Pd/C (10 %) (0.3 g, 
cat.) and 20 ml EtOH according to the general procedure yielding 3.22b (2.5 g, 99 %) 
as a pale yellow liquid. 1H-NMR (CDCl3) δ ppm: 7.25-7.16 (m, 5H, Ar-H), 3.95 (q, 2H, 
3J = 7.1 Hz, CH2CH3), 2.88 (m, 1H, CH2CH), 2.77 (dd, 1H, 3J = 5.5 Hz, 3J = 14.9 Hz, 
COCHH), 2.58 (dd, 1H, 3J = 9.9 Hz, 3J = 14.9 Hz, COCHH), 1.85 (m, 1H, CH(CH3)2), 
1.06 (t, 3H, 3J = 7.1 Hz, CH2CH3), 0.95 (d, 3H, 3J = 6.7 Hz, CH3), 0.76 (d, 3H, 3J = 6.7 
Hz, CH3); PI-EIMS (70 eV) m/z (%): 220 (M+•, 42). C14H20O2 (220.31) 
Ethyl 5-methyl-3-phenylhexanoate (3.23b)60  
The title compound was prepared from 3.23a (2.67 g, 11.4 mmol), Pd/C (10 %) (0.3 
g, cat.) and 20 ml EtOH according to the general procedure yielding 3.23b (2.7 g, 
100 %) as a pale yellow liquid. 1H-NMR (CDCl3) δ ppm: 7.30 - 7.19 (m, 5H, Ar-H), 
4.02 (q, 2H, 3J = 7.1 Hz, CH2CH3), 3.19 (m, 1H, CH2CH), 2.59 (dd, 1H, 3J = 5.5 Hz, 
3J = 13.4 Hz, COCHH), 2.52 (dd, 1H, 3J = 6.6 Hz, 3J = 13.4 Hz, COCHH), 1.41-1.30 
(m, 2H, CH2CH(CH3)2), 1.30 (m, 1H, CH(CH3)2), 1.13 (t, 3H, 3J = 7.1 Hz, CH2CH3), 
0.88 (d, 3H, 3J = 6.3 Hz, CH3), 0.83 (d, 3H, 3J = 6.4 Hz, CH3); EI-MS (70 eV) m/z (%): 
234 (M+•, 69). C15H22O2 (234.15) 
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Ethyl 3,4-diphenylbutanoate (3.24b)58  
The title compound was prepared from 3.24a (3.21 g, 12 mmol), Pd/C (10 %) (0.3 g, 
cat.) and 30 ml EtOH according to the general procedure yielding 3.24b (2.98 g, 92 
%) as a pale yellow liquid. 1H-NMR (CDCl3) δ ppm: 7.25-7.05 (m, 10H, Ar-H)), 3.97 
(q, 2H, 3J = 7.1 Hz, CH2CH3), 3.41 (m, 1H, CH2CH), 2.91 (m, 2H, CH2-Ar), 2.67 (dd, 
1H, 3J = 5.8 Hz, 3J = 14.4 Hz, COCHH), 2.59 (dd, 1H, 3J = 7.5 Hz, 3J = 14.4 Hz, 
COCHH), 1.10 (t, 3H, 3J = 7.1 Hz, CH2CH3); PI-EIMS (70 eV) m/z (%): 268 (M+•, 23). 
C18H20O2 (268.35) 
Ethyl 3-phenyl-4-(4-methylphenyl)butanoate (3.25b)  
The title compound was prepared from 3.25a (2.5 g, 8.9 mmol), Pd/C (10 %) (0.3 g, 
cat.) and 30 ml EtOH according to the general procedure yielding 3.25b (2.06 g, 
82%) as a pale yellow liquid. 1H-NMR (CDCl3) δ ppm: 7.13-6.96 (m, 9H, Ar-H), 3.97 
(q, 2H, 3J = 7.1Hz, CH2CH3), 3.38 (m, 1H, CH2CH), 2.90 (dd, 1H, 3J = 6.9 Hz, 3J = 
13.2 Hz, CHH-Ar), 2.83 (dd, 1H, 3J = 5.6 Hz, 3J = 11.44 Hz, CHH-Ar), 2.61 (m, 2H, 
COCH2), 2.28 (s, 3H, (p-CH3)-Ar), 1.09 (t, 3H, 3J = 7.1 Hz, CH2CH3); EI-MS (70 eV) 
m/z (%): 282 (M+•, 10). C19H22O2 (282.38) 
Ethyl 3-cyclohexyl-4-phenylbutanoate (3.26b)  
The title compound was prepared from 3.26a (0.61 g, 2.24 mmol), Pd/C (10 %) 
(0.1 g, cat.) and 10 ml EtOH according to the general procedure yielding 3.26b (0.6 
g, 98 %) as a yellow liquid. 1H-NMR (CDCl3) δ ppm: 7.25 (m, 5H, Ar-H), 4.02 (q, 2H, 
3J = 7.1 Hz, CH2CH3), 2.87 (dd, 1H, 3J = 3.4 Hz, 2J = 13.6 Hz, CHH-Ar), 2.72 (dd, 1H, 
3J = 6.0 Hz, 2J = 13.6 Hz, CHH-Ar), 2.59 (dd, 1H, 3J = 9.5 Hz, 3J = 13.6 Hz, COCHH), 
2.44 (dd, 1H, 3J = 8.0 Hz, 3J = 13.5 Hz, COCHH), 2.12 (m, 1H, CH2CH), 1.72 (m, 5H, 
cHex-CH, cHex-CH2), 1.32 (m, 2H, cHex-CH2), 1.20 (t, 3H, 3J = 7.1 Hz, CH2CH3), 
1.08 (m, 2H, cHex-CH2). C18H26O2 (274.30) 
Ethyl 3-(4-methylphenyl)butanoate (3.27b)61, 62  
The title compound was prepared from 3.27a (7 g, 34.3 mmol), Pd/C (10 %) (0.7 g, 
cat.) and 50 ml EtOH according to the general procedure yielding 3.27b (6.58 g, 93 
%) as a colourless oil. 1H-NMR (CDCl3) δ ppm: 7.11 (m, 4H, Ar-H), 4.07 (q, 2H, 3J = 
7.1 Hz, CH2CH3), 3.24 (m, 1H, CH2CH), 2.59 (dd, 1H, 3J = 7.0 Hz, 3J = 15.0 Hz, 
COCHH), 2.50 (dd, 1H, 3J = 8.2 Hz, 3J = 15.0 Hz, COCHH), 2.31 (s, 3H, (p-CH3)-Ar), 
1.28 (d, 3H, 3J = 7.0 Hz, CH3) ppm 1.19 (t, 3H, 3J = 7.1 Hz, CH2CH3); EI-MS (70 eV) 
m/z (%): 206 (M+•, 23). C13H18O2 (206.28) 
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Ethyl 3-methyl-4-phenylbutanoate (3.28b)63 
The title compound was prepared from 3.28a (2 g, 9.8 mmol), Pd/C (10 %) (0.2 g, 
cat.) and 20 ml EtOH according to the general procedure yielding 3.28b (1.9 g, 94 %) 
as a pale yellow liquid. 1H-NMR (CDCl3) δ ppm: 7.27-7.16 (m, 5H, Ar-H), 4.11 (q, 2H, 
3J = 7.1 Hz, CH2CH3), 2.63 (dd, 1H, 3J = 6.4 Hz, 3J = 13.4 Hz, CHH-Ar), 2.49 (dd, 1H, 
3J = 7.3 Hz, 3J = 13.4 Hz, CHH-Ar), 2.29 (m, 2H, COCH2), 2.14 (m, 1H, CH2CH), 1.25 
(t, 3H, 3J = 7.1 Hz, CH2CH3), 0.94 (d, 3H, 3J = 6.6 Hz, CH3); EI-MS (70 eV) m/z (%): 
206 (M+•, 28). C13H18O2 (206.28) 
Ethyl 3-methyl-5-phenylpentanoate (3.29b)64  
The title compound was prepared from 3.29a (3.09 g, 14 mmol), Pd/C (10 %) (0.3 g, 
cat.) and 30 ml EtOH according to the general procedure yielding 3.29b (2.9 g, 94 %) 
as a pale yellow liquid. 1H-NMR (CDCl3) δ ppm: 7.28-7.17 (m, 5H, Ar-H), 4.13 (q, 2H, 
3J = 7.1 Hz, CH2CH3), 2.63 (m, 2H, CH2-Ar), 2.35 (dd, 1H, 3J = 6.1 Hz, 3J = 14.6 Hz, 
COCHH), 2.17 (dd, 1H, 3J = 7.9 Hz, 3J = 14.6 Hz, COCHH), 2.03 (m, 1H, CH2CH), 
1.68-1.51 (m, 2H, CH2CH2-Ar), 1.26 (t, 3H, 3J = 7.1 Hz, CH2CH3), 1.02 (d, 3H, 3J = 
6.6 Hz, CH3); PI-EIMS (70 eV) m/z (%): 220 (M+•, 11). C14H20O2 (220.31) 
Ethyl 3-methyl-6-phenylhexanoate (3.30b)  
The title compound was prepared from 3.30a (2.11 g, 9.1 mmol), Pd/C (10 %) (0.2 g, 
cat.) and 20 ml EtOH according to the general procedure yielding 3.30b (2.11 g, 99 
%) as a colourless liquid. 1H-NMR (CDCl3) δ ppm: 7.27-7.16 (m, 5H, Ar-H) 4.11 (q, 
2H, 3J = 7.1 Hz, CH2CH3), 2.59 (m, 2H, CH2-Ar), 2.28 (dd, 1H, 3J = 6.0 Hz, 3J = 14.4 
Hz, COCHH), 2.09 (dd, 1H, 3J = 8.0 Hz, 3J = 14.5 Hz, COCHH), 1.94 (m, 1H, 
CH2CH), 1.62 (m, 4H, CH2CH2CH2-Ar, CH2CH2CH2-Ar), 1.23 (t, 3H, 3J = 7.0 Hz, 
CH2CH3), 0.93 (d, 3H, 3J = 6.6 Hz, CH3); CI-MS (NH3) m/z (%): 252 (M+NH4+, 100). 
C15H22O2 (234.33) 
Ethyl 3-methyl-4-(3-methylphenyl)butanoate (3.31b)  
The title compound was prepared from 3.31a (1.2 g, 5.5 mmol), Pd/C (10 %) (0.1 g, 
cat.) and 15 ml EtOH according to the general procedure yielding 3.31b (1.16 g, 96 
%) as a colourless liquid. 1H-NMR (CDCl3) δ ppm: 7.17 (m, 1H, Ar-H), 6.99 (m, 3H, 
Ar-H), 4.12 (q, 2H, 3J = 7.1 Hz, CH2CH3), 2.60 (dd, 1H, 3J = 6.5 Hz, 3J = 13.3 Hz, 
CHH-Ar), 2.46 (dd, 1H, 3J = 7.3 Hz, 3J = 13.3 Hz, CHH-Ar), 2.33 (s, 3H, (m-CH3)Ar), 
2.34-2.13 (m, 3H, COCH2, CHCH3), 1.26 (t, 3H, 3J = 7.1 Hz, CH2CH3), 0.95 (d, 3H, 3J 
= 6.5 Hz, CH3); CI-MS (NH3) m/z (%): 238 (M+NH4+, 100). C14H20O2 (220.31) 
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Ethyl 3-methyl-4-(4-methylphenyl)butanoate (3.32b)65  
The title compound was prepared from 3.32a (1.84 g, 8.4 mmol), Pd/C (10 %) (0.2 g, 
cat.) and 30 ml EtOH according to the general procedure yielding 3.32b (1.84 g, 84 
%) as a colourless oil. 1H-NMR (CDCl3) δ ppm: 7.08 (m, 4H, Ar-H), 4.12 (q, 2H, 3J = 
7.1 Hz, CH2CH3), 2.60 (dd, 1H, 3J = 6.5 Hz, 3J = 13.4 Hz, CHH-Ar), 2.46 (dd, 1H, 3J = 
7.2 Hz, 3J = 13.4 Hz, CHH-Ar), 2.33 (s, 3H, (p-CH3)Ar) 2.34-2.12 (m, 3H, COCH2, 
CHCH3), 1.25 (t, 3H, 3J = 7.1 Hz, CH2CH3), 0.94 (d, 3H, 3J = 6.5 Hz, CH3); EI-MS (70 
eV) m/z (%): 220 (M+•, 14). C14H20O2 (220.31) 
Ethyl 3-(3-fluorobenzyl)butanoate (3.33b)  
The title compound was prepared from 3.33a (2.03 g, 9.1 mmol), Pd/C (10 %) (0.2 g, 
cat.) and 25 ml EtOH according to the general procedure yielding 3.33b (1.97 g, 96 
%) as a colourless liquid. 1H-NMR (CDCl3) δ ppm: 7.22 (m, 1H, Ar-H), 6.90 (m, 3H, 
Ar-H), 4.12 (q, 2H, 3J = 7.1 Hz, CH2CH3), 2.64 (dd, 1H, 3J = 6.3 Hz, 3J = 13.4 Hz, 
CHH-Ar), 2.48 (dd, 1H, 3J = 7.3 Hz, 3J = 13.4 Hz, CHH-Ar), 2.31-2.14 (m, 3H, 
COCH2, CHCH3), 1.25 (t, 3H, 3J = 7.1 Hz, CH2CH3), 0.94 (d, 3H, 3J = 6.6 Hz, CH3). 
C13H17FO2 (224.27) 
Ethyl 3-(4-fluorobenzyl)butanoate (3.34b)  
The title compound was prepared from 3.34a (1.26 g, 5.7 mmol), Pd/C (10 %) (0.1 g, 
cat.) and 15 ml EtOH according to the general procedure yielding 3.34b (1.29 g, 100 
%) as a pale yellow liquid. 1H-NMR (CDCl3) δ ppm: 7.11 (m, 2H, Ar-H), 6.96 (m, 2H, 
Ar-H), 4.11 (q, 2H, 3J = 7.1 Hz, CH2CH3), 2.61 (dd, 1H, 3J = 6.3 Hz, 3J = 13.5 Hz, 
CHH-Ar), 2.46 (dd, 1H, 3J = 7.2 Hz, 3J = 13.5 Hz, CHH-Ar), 2.29-2.14 (m, 3H, 
COCH2, CHCH3), 1.25 (t, 3H, 3J = 7.1 Hz, CH2CH3), 0.93 (d, 3H, 3J = 6.5 Hz, CH3); 
EI-MS (70 eV) m/z (%): 224 (M+•, 20). C13H17FO2 (224.27) 
Ethyl 3-(3-methoxybenzyl)butanoate (3.35b)51  
The title compound was prepared from 3.35a (1 g, 4.3 mmol), Pd/C (10 %) (0.1 g, 
cat.) and 20 ml EtOH according to the general procedure yielding 3.35b (0.99 g, 97 
%) as a colourless oil. 1H-NMR (CDCl3) δ ppm: 7.20 (m, 1H, Ar-H), 6.75 (m, 3H, Ar-
H), 4.12 (q, 2H, 3J = 7.1 Hz, CH2CH3), 3.80 (s, 3H, (m-OCH3)Ar), 2.61 (dd, 1H, 3J = 
6.5 Hz, 3J = 13.3 Hz, COCHH), 2.47 (dd, 1H, 3J = 7.3 Hz, 3J = 13.3 Hz, COCHH), 
2.33-2.13 (m, 3H, CH2-Ar, CHCH3), 1.25 (t, 3H, 3J = 7.1 Hz, CH2CH3), 0.95 (d, 3H, 3J 
= 6.6 Hz, CH3). C14H20O3 (236.31) 
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Ethyl 3-(4-methoxybenzyl)butanoate (3.36b)66  
The title compound was prepared from 3.36a (1.1 g, 4.7 mmol), Pd/C (10 %) (0.1 g, 
cat.) and 15 ml EtOH according to the general procedure yielding 3.36b (1.13 g, 95 
%) as a pale yellow liquid. 1H-NMR (CDCl3) δ ppm: 7.07 (m, 2H, Ar-H), 6.82 (m, 2H, 
Ar-H), 4.11 (q, 2H, 3J = 7.1 Hz, CH2CH3), 3.79 (s, 3H, (p-OCH3)Ar), 2.57 (dd, 1H, 3J = 
6.5 Hz, 3J = 13.5 Hz, CHH-Ar), 2.45 (dd, 1H, 3J = 7.1 Hz, 3J = 13.5 Hz, CHH-Ar), 
2.30-2.11 (m, 3H, COCH2, CHCH3), 1.25 (t, 3H, 3J = 7.1 Hz, CH2CH3), 0.93 (d, 3H, 3J 
= 6.4 Hz, CH3); EI-MS (70 eV) m/z (%): 236 (M+•, 24). C14H20O3 (236.31) 
Ethyl 3-(3-ethylbenzyl)butanoate (3.37b)  
The title compound was prepared from 3.37a (1.81 g, 7.84 mmol), Pd/C (10 %) (0.2 
g, cat.) and 30 ml EtOH according to the general procedure yielding 3.37b (1.79 g, 
98 %) as a colourless liquid. 1H-NMR (CDCl3) δ ppm: 7.10 (m, 4H, Ar-H), 4.11 (q, 2H, 
3J = 7.1 Hz, CH2CH3), 2.61 (m, 3H, CHH-Ar, (p-CH2CH3)Ar), 2.47 (dd, 1H, 3J = 7.1 
Hz, 3J = 13.4 Hz, CHH-Ar), 2.33-2.12 (m, 3H, COCH2, CHCH3), 1.24 (m, 6H, 
CH2CH3, (p-CH2CH3)Ar), 0.95 (d, 3H, 3J = 6.5 Hz, CH3); EI-MS (70 eV) m/z (%): 234 
(M+•, 21). C15H22O2 (234.33) 
Ethyl 4-(tert-butoxycarbonylamino)-3-phenylbutanoate (3.38b)67  
The title compound was prepared from 3.38a (0.31 g, 0.98 mmol), Pd/C (10 %) ( cat.) 
and 15 ml EtOH according to the general procedure yielding 3.38b (0.3 g, 97 %) as a 
pale yellow oil. 1H-NMR (CDCl3) δ ppm: 7.34-7.20 (m, 5H, Ar-H), 4.05 (q, 2H, 3J = 7.1 
Hz, CH2CH3), 3.48 (m, 1H, CH2CH), 3.33 (dd, 1H, 3J = 5.6 Hz, 3J = 13.0 Hz, 
CHHNH), 3.26 (dd, 1H, 3J = 7.0 Hz, 3J = 12.1 Hz, CHHNH), 2.70 (dd, 1H, 3J = 6.4 Hz, 
3J = 15.5 Hz, COCHH), 2.60 (dd, 1H, 3J = 7.8 Hz, 3J = 15.5 Hz, COCHH), 1.41 (s, 
9H, C(CH3)3), 1.14 (t, 3H, 3J = 7.1 Hz, CH2CH3); CI-MS (NH3) m/z (%): 325 (M+NH4+, 
4). C17H25NO4 (307.38) 
Ethyl 6-(tert-butoxycarbonylamino)-3-phenylhexanoate (3.39b)55  
The title compound was prepared from 3.39a (1.21 g, 9.8 mmol), Pd/C (10 %) (0.1 g, 
cat.) and 25 ml EtOH according to the general procedure yielding 3.39b (1.17 g, 97 
%) as a white solid. 1H-NMR (CDCl3) δ ppm: 7.29-7.18 (m, 5H, Ar-H), 4.03 (q, 2H, 3J 
= 7.1 Hz, CH2CH3), 3.06 (m, 3H, CH2CH, CH2NH), 2.62 (dd, 1H, 3J = 5.9 Hz, 3J = 
13.8 Hz, COCHH), 2.55 (dd, 1H, 3J = 6.6 Hz, 3J = 13.8 Hz, COCHH), 1.61 (m, 4H, 
CH2CH2CH2NH, CH2CH2CH2NH), 1.42 (s, 9H, C(CH3)3), 1.14 (t, 3H, 3J = 7.1 Hz, 
CH2CH3); CI-MS (NH3) m/z (%): 353 (M+NH4+, 29). C19H29NO4 (335.44) 
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3.5.5. Preparation of phenylalkanoic acids 3.20, 3.21-3.39c and 3.53-3.54b 
3-(1-Trityl-1H-imidazol-4-yl)propanoic acid (3.20)68  
To a solution of Methyl 3-(1-trityl-1H-imidazol-4-yl)propanoate (1 g, 2.5 mmol) in 25 
ml THF were added 4 ml of a 1M solution of LiOH/aq and stirred overnight. 
Subsequently, 10 % HCl/aq were added under ice cooling to adjust the solution to pH 
4-5. The product was extracted with EtOAc, the organic layer washed with saturated 
NaCl/aq, dried over MgSO4 and evaporated in vacuo. The crude product was 
recrystallised from EtOAc/THF to obtain 3.20 (0.79 g, 83 %) as a pale yellow solid. 
mp = 185 °C (ref.68: 188-190 °C); 1H-NMR (CDCl3) δ (ppm): 7.41 (d, 1H, J4 = 1.4 Hz, 
Im-2-H), 7.37-7.13 (m, 15H, CPh3), 6.70 (s, 1H, Im-5-H), 2.82 (t, 2H, J3 = 7.4 Hz, Im-
4-CH2), 2.58 (t, 2H, J3 = 7.3 Hz, CH2CO); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
383 (MH+, 100); anal (C25H22N2O2) C, H, N. C25H22N2O2 (382.1) 
General procedure for the preparation of 3.21-3.39c and 3.53-3.54b  
The ethyl alkanoates were suspended in 20 % NaOH/aq and refluxed for 2-4 h 
(unless otherwise indicated). After cooling, 10 % HCl/aq was added to adjust to pH < 
2. Subsequently, EtOAc was added and the water phase extracted three times with 
EtOAc. The organic phase was dried over MgSO4 and the solvent removed under 
reduced pressure. For combustion analysis data, a small amount of acid was 
recrystallized from hexane or precipitated as salt with dicyclohexylamine.  
3-Phenylpentanoic acid (3.21c)69 
The title compound was prepared from 3.21b (2.85 g, 13.8 mmol) and 20 ml 20 % 
NaOH/aq according to the general procedure yielding 3.21c (2.3 g, 91 %) as a pale 
yellow solid. mp = 44 °C; 1H-NMR (CDCl3) δ ppm: 10.33 (br s, 1H, COOH), 7.29-7.16 
(m, 5H, Ar-H), 3.00 (m, 1H, CH2CH), 2.68 (dd, 1H, 3J = 6.4 Hz, 3J = 14.8 Hz, 
COCHH), 2.60 (dd, 1H, 3J = 7.2 Hz, 3J = 14.8 Hz, COCHH), 1.67 (m, 2H, CH2CH3), 
0.79 (t, 3H, 3J = 7.4 Hz, CH2CH3); 13C-NMR (CDCl3) δ ppm: 178.96 (quat. C=O), 
143.63 (quat. Ar-C), 128.58 (+, 2 Ar-CH), 128.44 (+, 2 Ar-CH), 127.49 (+, Ar-CH), 
43.50 (+, CH2CH), 41.16 (-, COCH2), 29.12 (-, CH2CH3), 11.85(+, CH2CH3); PI-EIMS 
(70 eV) m/z (%): 178 (M+•, 45); anal. (C11H14O2) C, H. C11H14O2 (178.23) 
4-Methyl-3-phenylpentanoic acid (3.22c)44  
The title compound was prepared from 3.22b (2.1 g, 9.5 mmol) and 20 ml 20 % 
NaOH/aq according to the general procedure yielding 3.22c (1.63 g, 89 %) as a pale 
yellow solid. mp = 47 °C; 1H-NMR (CDCl3) δ ppm: 7.26-7.14 (m, 5H, Ar-H), 2.87 (m, 
1H, CH2CH), 2.79 (dd, 1H, 3J = 5.4 Hz, 3J = 15.3 Hz, COCHH), 2.61 (dd, 1H, 3J = 9.4 
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Hz, 3J = 15.3 Hz, COCHH), 1.84 (m, 1H, CH(CH3)2), 0.93 (d, 3H, 3J = 6.7 Hz, CH3), 
0.75 (d, 3H, 3J = 6.7 Hz, CH3); 13C-NMR (CDCl3) δ ppm: 178.11 (quat. C=O), 142.52 
(quat. Ar-C), 128.18 (+, 2 Ar-CH), 128.11 (+, 2 Ar-CH), 126.41 (+, Ar-CH), 48.42 (+, 
CH2CH), 37.95 (-, COCH2), 33.08 (+, CH(CH3)2), 20.54 (+, CH3), 20.17 (+, CH3); EI-
MS (70 eV) m/z (%): 192 (M+•, 27); anal. (C12H16O2) C, H. C12H16O2 (192.25) 
5-Methyl-3-phenylhexanoic acid (3.23c)70 
The title compound was prepared from 3.23b (2.63 g, 11.2 mmol) and 20 ml 20 % 
NaOH/aq according to the general procedure yielding 3.23c (1.81 g, 78 %) as a pale 
yellow solid. mp = 58 °C (ref.70: 52-55 °C); 1H-NMR (CDCl3) δ ppm: 10.37 (br s, 1H, 
COOH), 7.28-7.18 (m, 5H, Ar-H), 3.18 (m, 1H, CHCH2), 2.63 (dd, 1H, 3J = 4.4 Hz, 3J 
= 12.8 Hz, COCHH), 2.56 (dd, 1H, 3J = 5.2 Hz, 3J = 12.8 Hz, COCHH), 1.44-1.29 (m, 
2H, CH2CH(CH3)2), 1.31 (m, 1H, CH(CH3)2), 0.88 (d, 3H, 3J = 6.4 Hz, CH3), 0.83 (d, 
3H, 3J = 6.5 Hz, CH3); 13C-NMR (CDCl3) δ ppm: 177.58 (quat. C=O), 143.79 (quat. 
Ar-C), 128.47 (+, 2 Ar-CH), 127.93 (+, Ar-CH), 127.42 (+, 2 Ar-CH), 45.34 (-, 
CH2CH(CH3)2), 41.87 (-, COCH2), 39.63 (+,CH2CH), 25.24 (+, CH(CH3)2), 22.25 (-, 
CH3), 21.55 (-, CH3); PI-EIMS (70 eV) m/z (%): 206 (M+•, 53); anal. (C13H18O2) C, H. 
C13H18O2 (206.28) 
3,4-Diphenylbutanoic acid (3.24c)71  
The title compound was prepared from 3.24b (2.95 g, 11 mmol) and 20 ml 20 % 
NaOH/aq according to the general procedure yielding 3.24c (2.4 g, 90 %) as a pale 
yellow solid. mp = 93 °C; 1H-NMR (CDCl3) δ ppm: 7.25-7.05 (m, 10H, Ar-H), 3.38 (m, 
1H, CH2CH), 2.90 (m, 2H, CH2-Ar), 2.70 (dd, 1H, 3J = 5.3 Hz, 3J = 14.5 Hz, COCHH), 
2.62 (dd, 1H, 3J = 6.9 Hz, 3J = 14.5 Hz, COCHH); 13C-NMR (CDCl3) δ ppm: 177.78 
(quat. C=O), 143.09 (quat. Ar-C), 139.28 (quat. Ar-C), 129.20 (+, 2 Ar-CH), 128.42 
(+, 2 Ar-CH), 128.22 (+, 2 Ar-CH), 127.44 (+, 2 Ar-CH), 126.67 (+, Ar-CH), 126.22 (+, 
Ar-CH), 43.57 (+, CH2CH), 42.96 (-, CH2), 39.60 (-, CH2); PI-EIMS (70 eV) m/z (%): 
240 (M+•, 13); anal. (C16H16O2) C, H. C16H16O2 (240.30) 
3-Phenyl-4-(4-methylphenyl)butanoic acid (3.25c)72  
The title compound was prepared from 3.25b (2 g, 7.1 mmol) and 25 ml 20 % 
NaOH/aq according to the general procedure yielding 3.25c (1.75 g, 99 %) as a white 
solid. mp = 106 °C; 1H-NMR (CDCl3) δ ppm: 7.20-6.97 (m, 9H, Ar-H), 3.35 (m, 1H, 
CH2CH), 2.84 (m, 2H, CH2-Ar), 2.64 (m, 2H, COCH2), 2.27 (s, 3H, (p-CH3)-Ar); 13C-
NMR (CDCl3) δ ppm: 178.18 (quat. C=O), 143.24 (quat. Ar-C), 136.16 (quat. Ar-C), 
129.06 (+, Ar-CH), 128.99 (+, Ar-CH), 128.91 (+, Ar-CH), 128.40 (+, 2 Ar-CH), 
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128.28 (+, Ar-CH), 127.45 (+, Ar-CH), 126.61 (+, Ar-CH), 43.59 (+, CH2CH), 42.51 (-, 
CH2-Ar), 39.61 (-, COCH2), 21.01 (+, (p-CH3)-Ar); EI-MS (70 eV) m/z (%): 254 (M+•, 
16); anal. (C17H18O2) C, H. C17H18O2 (254.34) 
3-Cyclohexyl-4-phenylbutanoic acid (3.26c)73  
The title compound was prepared from 3.26b (0.6 g, 2.19 mmol) and 15 ml 20 % 
NaOH/aq according to the general procedure yielding 3.26c (0.5 g, 92 %) as a brown 
oil. 1H-NMR (CDCl3) δ ppm: 7.26 (m, 5H, Ar-H), 2.76 (dd, 1H, 3J = 6.2 Hz, 2J = 13.6 
Hz, CHH-Ar), 2.46 (m, 2H, CHH-Ar, COCHH), 2.36 (dd, 1H, 3J = 6.5 Hz, 2J = 15.5 
Hz, COCHH), 2.12 (m, 1H, CH2CH), 1.81-1.65 (m, 5H, cHex-CH, cHex-CH2), 1.35 
(m, 2H, cHex-CH2), 0.88 (m, 2H, cHex-CH2); 13C-NMR (CDCl3) δ ppm: 178.76 (quat. 
C=O), 139.69 (quat. Ar-C), 128.44 (+, Ar-CH), 128.18 (+, Ar-CH), 127.56 (+, Ar-CH), 
127.28 (+, Ar-CH), 46.83 (-, COCH2), 41.33 (+, cHex-CH), 38.92 (+, CHCH2-Ar), 
36.27 (-, CH2-Ar), 28.90 (-, cHex-CH2), 28.25 (-, cHex-CH2), 27.74 (-, cHex-CH2), 
27.53 (-, cHex-CH2), 25.62 (-, cHex-CH2); EI-MS (70 eV) m/z (%): 246 (M+•, 20); anal. 
(C16H22O2 ·C12H23N·0.25 H2O) C, H, N. C16H22O2 (246.34) 
3-(4-Methylphenyl)butanoic acid (3.27c)62  
The title compound was prepared from 3.27b (6.5 g, 31.5 mmol) and 45 ml 20 % 
NaOH/aq according to the general procedure yielding 3.27c) (5.09 g, 91 %) as a 
white solid. mp = 88 °C; 1H-NMR (CDCl3) δ ppm: 7.11 (m, 4H, Ar-H), 3.24 (m, 1H, 
CH2CH), 2.65 (dd, 1H, 3J = 6.9 Hz, 3J = 15.5 Hz, COCHH), 2.55 (dd, 1H, 3J = 8.2 Hz, 
3J = 15.5 Hz, COCHH), 2.32 (s, 3H, (p-CH3)-Ar), 1.30 (d, 3H, 3J = 7.0 Hz, CH3); 13C-
NMR (CDCl3) δ ppm: 178.33 (quat. C=O), 142.42 (quat. Ar-C), 136.01 (quat. Ar-C), 
129.23 (+, 2 Ar-CH), 126.55 (+, 2 Ar-CH), 42.59 (-, COCH2), 35.74 (+, CHCH3), 21.95 
(+, (p-CH3)-Ar), 21.00 (+, CH3); EI-MS (70 eV) m/z (%): 178 (M+•, 28); anal. 
(C11H14O2) C, H. C11H14O2 (178.23) 
3-Methyl-4-phenylbutanoic acid (3.28c)74  
The title compound was prepared from 3.28b (1.85 g, 8.97 mmol) and 15 ml 20 % 
NaOH/aq according to the general procedure yielding 3.28c (1.5 g, 94 %) as a yellow 
oil. 1H-NMR (CDCl3) δ ppm: 9.23 (br s, 1H, COOH), 7.29-7.16 (m, 5H, Ar-H), 2.64 
(dd, 1H, 3J = 6.6 Hz, 3J = 13.4 Hz, CHH-Ar), 2.52 (dd, 1H, 3J = 7.1 Hz, 3J = 13.4 Hz, 
CHH-Ar), 2.32 (m, 2H, COCH2), 2.18 (m, 1H, CH2CH), 0.98 (d, 3H, 3J = 6.4 Hz, CH3); 
13C-NMR (CDCl3) δ ppm: 179.48 (quat. C=O), 140.06 (quat. Ar-C), 129.22 (+, 2 Ar-
CH), 128.32 (+, 2 Ar-CH), 126.13 (+, Ar-CH), 42.92 (-, COCH2), 40.75 (-, CH2-Ar), 
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32.10 (+, CHCH3), 19.60 (+, CH3); PI-EIMS (70 eV) m/z (%): 178 (M+•, 23); anal. 
(C11H14O2·C12H23N) C, H, N. C11H14O2 (178.23) 
3-Methyl-5-phenylpentanoic acid (3.29c)75  
The title compound was prepared from 3.29b (2.7 g, 12.3 mmol) and 20 ml 20 % 
NaOH/aq according to the general procedure yielding 3.29c (2.08 g, 88 %) as a 
yellow oil. 1H-NMR (CDCl3) δ ppm: 7.29-7.18 (m, 5H, Ar-H), 2.64 (m, 2H, CH2-Ar), 
2.41 (dd, 1H, 3J = 5.9 Hz, 3J = 15.0 Hz, COCHH), 2.21 (dd, 1H, 3J = 8.0 Hz, 3J = 15.0 
Hz, COCHH), 2.03 (m, 1H, CH2CH), 1.69-1.54 (m, 2H, CH2CH2-Ar), 1.05 (d, 3H, 3J = 
6.6 Hz, CH3); 13C-NMR (CDCl3) δ ppm: 179.07 (quat. C=O), 142.21 (quat. Ar-C), 
128.36 (+, 2 Ar-CH), 128.30 (+, 2 Ar-CH), 125.78 (+, Ar-CH), 41.36 (-, COCH2), 
38.43 (-, CH2CH2-Ar), 33.29 (-, CH2-Ar), 29.91 (+, CHCH3), 19.59 (+, CH3); PI-EIMS 
(70 eV) m/z (%): 192 (M+•, 30); anal. (C12H16O2·C12H23N) C, H, N. C12H16O2 (192.25) 
3-Methyl-6-phenylhexanoic acid (3.30c)  
The title compound was prepared from 3.30b (2.05 g, 8.75 mmol) and 15 ml 20 % 
NaOH/aq according to the general procedure yielding 3.30c (1.64 g, 91 %) as a 
yellow oil. 1H-NMR (CDCl3) δ ppm: 7.28-7.18 (m, 5H, Ar-H), 2.61 (m, 2H, CH2-Ar), 
2.36 (dd, 1H, 3J = 5.9 Hz, 3J = 15.0 Hz, COCHH), 2.16 (dd, 1H, 3J = 8.1 Hz, 3J = 14.9 
Hz, COCHH), 1.99 (m, 1H, CH2CH), 1.64 (m, 2H, CH2CH2-Ar), 1.45-1.25 (m, 2H, 
CH2CH2CH2-Ar), 0.98 (d, 3H, 3J = 6.6 Hz, CH3); 13C-NMR (CDCl3) δ ppm: 179.05 
(quat. C=O), 142.48 (quat. Ar-C), 128.38 (+, 2 Ar-CH), 128.30 (+, 2 Ar-CH), 125.72 
(+, Ar-CH), 41.45 (-, COCH2), 36.24 (-, CH2CH2CH2-Ar), 35.97 (-, CH2CH2CH2-Ar), 
30.05 (+, CH2CH), 28.83 (-, CH2CH2CH2-Ar), 19.64 (+, CH3); ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 205 ([M-H]-, 100); anal. (C13H18O2 ·C12H23N) C, H, N. C13H18O2 
(206.28) 
3-Methyl-4-(3-methylphenyl)butanoic acid (3.31c)76  
The title compound was prepared from 3.31b (1.11 g, 5 mmol) and 15 ml 20 % 
NaOH/aq according to the general procedure yielding 3.31c (0.87 g, 90 %) as a 
yellow oil. 1H-NMR (CDCl3) δ ppm: 10.73 (br s, 1H, COOH), 7.18 (m, 1H, Ar-H), 7.00 
(m, 3H, Ar-H), 2.61 (dd, 1H, 3J = 6.7 Hz, 3J = 13.4 Hz, CHH-Ar), 2.49 (dd, 1H, 3J = 
7.1 Hz, 3J = 13.3 Hz, CHH-Ar), 2.34 (s, 1H, (m-CH3)Ar), 2.39 (dd, 1H, 3J = 5.1 Hz, 3J 
= 14.4 Hz, COCHH), 2.21 (m, 2H, COCHH, CHCH3), 0.99 (d, 3H, 3J = 6.4 Hz, CH3); 
13C-NMR (CDCl3) δ ppm: 179.54 (quat. C=O), 140.02 (quat. Ar-C), 137.85 (quat. Ar-
C), 129.99 (+, Ar-CH), 128.19 (+, Ar-CH), 126.86 (+, Ar-CH), 126.25 (+, Ar-CH), 
42.89 (-, COCH2), 40.81 (-, CH2-Ar), 32.09 (+, CHCH3), 21.42 (+, (m-CH3)Ar), 19.64 
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(+, CH3); EI-MS (70 eV) m/z (%): 192 (M+•, 36); anal. (C12H16O2 ·C12H23N·H2O) C, H, 
N. C12H16O2 (192.25) 
3-Methyl-4-(4-methylphenyl)butanoic acid (3.32c)77  
The title compound was prepared from 3.32b (1.8 g, 8.2 mmol) and 30 ml 20 % 
NaOH/aq according to the general procedure yielding 3.32c (1.5 g, 95 %) as a yellow 
oil. 1H-NMR (CDCl3) δ ppm: 11.14 (br s, 1H, COOH), 7.07 (m, 4H, Ar-H), 2.61 (dd, 
1H, 3J = 6.7 Hz, 3J = 13.5 Hz, CHH-Ar), 2.49 (dd, 1H, 3J = 7.1 Hz, 3J = 13.5 Hz, CHH-
Ar), 2.38 (dd, 1H, 3J = 5.1 Hz, 3J = 14.4 Hz, COCHH), 2.32 (s, 3H, (p-CH3)Ar), 2.21 
(m, 2H, COCHH, CHCH3), 0.98 (d, 3H, 3J = 6.4 Hz, CH3); 13C-NMR (CDCl3) δ ppm: 
179.21 (quat. C=O), 136.95 (quat. Ar-C), 135.56 (quat. Ar-C), 129.09 (+, 2 Ar-CH), 
128.98 (+, 2 Ar-CH), 42.48 (-, COCH2), 40.69 (-, CH2-Ar), 32.13 (+, CHCH3), 21.00 
(+, (p-CH3)Ar), 19.57 (+, CH3); EI-MS (70 eV) m/z (%): 192 (M+•, 22); anal. (C12H16O2 
·C12H23N·0.5 H2O) calculated C (75.35), H (10.54), N (3.66), found C (75.36), H 
(10.20), N (3.14). C12H16O2 (192.25) 
3-(3-Fluorobenzyl)butanoic acid (3.33c)  
The title compound was prepared from 3.33b (1.94 g, 8.66 mmol) and 15 ml 20 % 
NaOH/aq according to the general procedure yielding 3.33c (1.6 g, 94 %) as a pale 
yellow oil. 1H-NMR (CDCl3) δ ppm: 9.87 (br s, 1H, COOH), 7.24 (m, 1H, Ar-H), 6.91 
(m, 3H, Ar-H), 2.66 (dd, 1H, 3J = 6.3 Hz, 3J = 13.4 Hz, CHH-Ar), 2.51 (dd, 1H, 3J = 
7.1 Hz, 3J = 13.4 Hz, CHH-Ar), 2.29-2.14 (m, 3H, COCH2, CHCH3), 0.98 (d, 3H, 3J = 
6.3 Hz, CH3); 13C-NMR (CDCl3) δ ppm: 179.19 (quat. C=O), 162.87 (d, quart., 1J = 
245.4 Hz,  Ar-CF), 142.65 (d, quart., 3J = 7.0 Hz, Ar-C), 129.72 (+, d, 3J = 8.2 Hz, Ar-
CH), 124.85 (+, d, 4J = 2.8 Hz, Ar-CH), 115.98 (+, d, 2J = 20.8 Hz, Ar-CH), 113.05 (+, 
d, 2J = 20.9 Hz, Ar-CH), 42.53 (-, COCH2), 40.65 (-, CH2-Ar), 31.92 (+, CHCH3), 
19.50 (+, CH3); EI-MS (70 eV) m/z (%): 196 (M+•, 26); anal. (C11H13FO2·C12H23N·0.25 
H2O) C, H, N. C11H13FO2 (196.22) 
3-(4-Fluorobenzyl)butanoic acid (3.34c)78  
The title compound was prepared from 3.34cb (1.24 g, 5.5 mmol) and 15 ml 20 % 
NaOH/aq according to the general procedure yielding 3.34c (0.99 g, 92 %) as a pale 
yellow oil. 1H-NMR (CDCl3) δ ppm: 11.46 (br s, 1H, COOH), 7.12 (m, 2H, Ar-H), 6.97 
(m, 2H, Ar-H), 2.63 (dd, 1H, 3J = 6.6 Hz, 3J = 13.6 Hz, CHH-Ar), 2.49 (dd, 1H, 3J = 
7.0 Hz, 3J = 13.5 Hz, CHH-Ar), 2.36-2.18 (m, 3H, COCH2, CHCH3), 0.97 (d, 3H, 3J = 
6.4 Hz, CH3); 13C-NMR (CDCl3) δ ppm: 179.42 (quat. C=O), 161.46  (d, quart., 1J = 
247.6 Hz, Ar-CF), 135.66 (d, quart., 4J = 3.5 Hz, Ar-C), 130.54 (+, d, 3J = 7.9 Hz, 2 
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Ar-CH), 115.07 (+, d, 2J = 20.9 Hz, 2 Ar-CH), 42.02 (-, COCH2), 40.66 (-, CH2-Ar), 
32.17 (+, CHCH3), 19.49 (+, CH3); EI-MS (70 eV) m/z (%): 196 (M+•, 25); anal. 
(C11H13FO2·C12H23N·0.15 H2O) C, H, N. C11H13FO2 (196.22) 
3-(3-Methoxybenzyl)butanoic acid (3.35c)51  
The title compound was prepared from 3.35b (0.97 g, 4.1 mmol) and 15 ml 20 % 
NaOH/aq according to the general procedure yielding 3.35c (0.82 g, 91 %) as a pale 
yellow oil. 1H-NMR (CDCl3) δ ppm: 7.20 (m, 1H, Ar-H), 6.75 (m, 3H, Ar-H), 3.80 (s, 
3H, (m-OCH3)Ar), 2.63 (dd, 1H, 3J = 6.7 Hz, 3J = 13.4 Hz, CHH-Ar), 2.50 (dd, 1H, 3J 
= 7.1 Hz, 3J = 13.3 Hz, CHH-Ar), 2.39 (dd, 1H, 3J = 5.1 Hz, 3J = 14.3 Hz, COCHH), 
2.28 (m, 1H, CHCH3), 2.16 (dd, 1H, 3J = 7.7 Hz, 3J = 14.3 Hz, COCHH), 0.98 (d, 3H, 
3J = 6.4 Hz, CH3); 13C-NMR (CDCl3) δ ppm: 179.43 (quat. C=O), 159.57 (quat. Ar-C), 
141.70 (quat. Ar-C), 129.27 (+, Ar-CH), 121.66 (+, Ar-CH), 114.94 (+, Ar-CH), 111.40 
(+, Ar-CH), 55.15 (+, (m-OCH3)Ar), 42.94 (-, COCH2), 40.74 (-, CH2-Ar), 32.00 (+, 
CHCH3), 19.63 (+, CH3); EI-MS (70 eV) m/z (%): 208 (M+•, 36); anal. (C12H16O3 
·C12H23N·0.5 H2O) C, H, N. C12H16O3 (208.25) 
3-(4-Methoxybenzyl)butanoic acid (3.36c)79 
The title compound was prepared from 3.36b (1.06 g, 4.5 mmol) and 10 ml 20 % 
NaOH/aq according to the general procedure yielding 3.36c (0.89 g, 95 %) as a pale 
yellow oil. 1H-NMR (CDCl3) δ ppm: 7.08 (m, 2H, Ar-H), 6.83 (m, 2H, Ar-H), 3.79 (s, 
3H, (p-OCH3)Ar), 2.58 (dd, 1H, 3J = 6.7 Hz, 3J = 13.5 Hz, CHH-Ar), 2.48 (dd, 1H, 3J = 
7.0 Hz, 3J = 13.5 Hz, CHH-Ar) 2.38-2.15 (m, 3H, COCH2, CHCH3), 0.97 (d, 3H, 3J = 
6.3 Hz, CH3); 13C-NMR (CDCl3) δ ppm: 179.53 (quat. C=O), 158.00 (quat. Ar-C), 
132.12 (quat. Ar-C), 130.13 2 (+, 2 Ar-CH), 113.72 (+, 2 Ar-CH), 55.24 (+, (p-
OCH3)Ar), 42.02 (-, COCH2), 40.69 (-, CH2-Ar), 32.26 (+, CHCH3), 19.55 (+, CH3); EI-
MS (70 eV) m/z (%): 208 (M+•, 16); anal. (C12H16O3·C12H23N·0.75H2O) C, H, N. 
C12H16O3 (208.25) 
3-(3-Ethylbenzyl)butanoic acid (3.37c)80  
The title compound was prepared from 3.37b (1.77 g, 7.56 mmol) and 20 ml 20 % 
NaOH/aq according to the general procedure yielding 3.37c (1.45 g, 93 %) as a 
yellow oil. 1H-NMR (CDCl3) δ ppm: 11.21 (br s, 1H, COOH), 7.10 (m, 4H, Ar-H), 2.62 
(m, 3H, CHH-Ar, (p-CH2CH3)Ar), 2.52 (dd, 1H, 3J = 7.0 Hz, 3J = 13.5 Hz, CHH-Ar), 
2.39 (dd, 1H, 3J = 5.1 Hz, 3J = 14.5 Hz, COCHH), 2.22 (m, 2H, COCHH, CHCH3), 
1.23 (t, 3H, 3J = 7.6 Hz, (p-CH2CH3)Ar), 0.99 (d, 3H, 3J = 6.4 Hz, CH3); 13C-NMR 
(CDCl3) δ ppm: 179.42 (quat. C=O), 141.99 (quat. Ar-C), 137.19 (quat. Ar-C), 129.14 
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(+, 2 Ar-CH), 127.77 (+, 2 Ar-CH), 42.52 (-, COCH2), 40.73 (-, CH2-Ar), 32.11 (+, 
CHCH3), 28.44 (-, (p-CH2CH3)Ar), 19.61 (+, CH3), 15.59 (+, (p-CH2CH3)Ar); EI-MS 
(70 eV) m/z (%): 206 (M+•, 30); anal. (C13H18O2·C12H23N·0.3 H2O) calculated C 
(76.40), H (10.67), N (3.56), found C (76.61), H (10.23), N (3.14). C13H18O2 (206.28) 
4-(tert-Butoxycarbonylamino)-3-phenylbutanoic acid (3.38c)81  
The title compound was prepared from 3.38b (0.28 g, 9.11 mmol), 5 ml 1N NaOH/aq 
and 5 ml THF. The mixture was stirred by room temperature overnight  yielding 3.38c 
(0.26 g, 93 %) as a yellow oil. 1H-NMR (CDCl3) δ ppm: 7.34-7.20 (m, 5H, Ar-H), 3.48 
(m, 1H, CH2CH), 3.32 (m, 2H, CH2NH), 2.74 (dd, 1H, 3J = 5.8 Hz, 3J = 15.9 Hz, 
COCHH), 2.65 (dd, 1H, 3J = 6.8 Hz, 3J = 15.7 Hz, COCHH), 1.41 (s, 9H, C(CH3)3); 
ES-MS (DCM/MeOH + NH4OAc) m/z (%): 278 ([M-H]-, 100). C15H21NO4 (279.33) 
6-(tert-Butoxycarbonylamino)-3-phenylhexanoic acid (3.39c)  
The title compound was prepared from 3.39b (1.15 g, 3.43 mmol), 20 ml 1N 
NaOH/aq and 20 ml THF. The mixture was stirred by room temperature overnight  
yielding 3.39c (0.55 g, 52 %) as a pale yellow oil. 1H-NMR (CDCl3) δ ppm: 7.29-7.17 
(m, 5H, Ar-H), 3.06 (m, 3H, CH2CH, CH2NH), 2.66 (dd, 1H, 3J = 4.0 Hz, 3J = 12.7 Hz, 
COCHH), 2.59 (dd, 1H, 3J = 4.5 Hz, 3J = 12.6 Hz, COCHH), 1.62 (m, 2H, 
CH2CH2CH2NH), 1.41 (s, 9H, C(CH3)3), 1.33 (m, 2H, CH2CH2CH2NH); 13C-NMR 
(CDCl3) δ ppm: 176.98 (quat. C=O), 143.41 (quat. Ar-C), 128.59 (+, 2 Ar-CH), 127.41 
(+, 2 Ar-CH), 126.68 (+, Ar-CH), 79.19 (quat. C(CH3)3), 41.50 (+, CH2CH), 41.36 (-, 
CH2NH), 40.34 (-, COCH2), 33.18 (CH2CH2CH2NH), 28.39 (+, 3 C(CH3)3), 27.82 (-, 
CH2CH2CH2NH); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 306 ([M-H]-, 100). 
C17H25NO4 (307.38) 
(E,Z)-3-(3-Benzyloxyphenyl)but-2-enoic acid (3.53b)  
The title compound was prepared from 3.53a (1.47 g, 4.96 mmol) and 20 ml 20 % 
NaOH/aq according to the general procedure yielding 3.53b (0.8 g, 60 %) as a white 
solid. mp = 116 °C; 1H-NMR (CDCl3) δ ppm: 7.43-7.08 (m, 9H, Ar-H), 6.17 (d, 1H, 4J 
= 1.3 Hz, COCH), 5.10 (s, 2H, CH2-Ar), 2.58 (d, 3H, 4J = 1.2 Hz, CH3); 13C-NMR 
(CDCl3) δ ppm: 171.41 (quat. C=O), 158.87 (quat. Ar-C), 158.24 (quat. CCH3), 
143.55 (quat. Ar-C), 136.72 (quat. Ar-C), 129.61 (+, Ar-CH), 128.65 (+, 2 Ar-CH), 
128.10 (+, Ar-CH), 127.53 (+, 2 Ar-CH), 119.14 (+, Ar-CH), 116.45 (+, Ar-CH), 
115.54 (+, COCH), 113.31 (+, Ar-CH), 70.17 (-, CH2-Ar), 18.36 (+, CH3); EI-MS (70 
eV) m/z (%): 268 (M+•, 15); anal (C17H16O3·0.25 H2O) C, H. C17H16O3 (268.31)  
 
Chapter 3: NG-Acylated Imidazolylpropylguanidines 73 
(E,Z)-3-[4-(4-Methoxybenzyloxy)phenyl]but-2-enoic acid (3.54b)  
The title compound was prepared from 3.54a (2.1 g, 6.4 mmol) and 20 ml 20 % 
NaOH/aq according to the general procedure yielding 3.54b (1.5 g, 79 %) as a white 
solid. mp = 148-151 °C; 1H-NMR (CDCl3) δ ppm: 7.50-6.94 (m, 8H, Ar-H), 6.07 (d, 
1H, 4J = 1.2 Hz, COCH), 5.05 (s, 2H, CH2-Ar), 3.75 (s, 3H, (p-OCH3)-Ar), 2.47 (d, 3H, 
4J = 1.0 Hz, CH3); EI-MS (70 eV) m/z (%): 298 (M+•, 1). C18H18O4 (298.12) 
Dimethyl 2-benzylmalonate (3.51a)82  
To a solution of dimethyl malonate (2.64 g, 2.28 ml, 20 mmol) in 50 ml THF/abs was 
added NaH (60 % dispersion in mineral oil) (0.8 g, 20 mmol) in small amounts and 
stirred for 30-45 min at room temperature. Subsequently, benzyl bromide (3.42 g, 2.4 
ml, 20 mmol) was added and refluxed overnight. After cooling, water was added and 
the mixture was extracted three times with diethyl ether. After drying over MgSO4, the 
solvent was removed in vacuo and the crude product subjected to flash 
chromatography (PE) to obtain 3.51a 2.13 g, 48 %) as a colourless liquid. 1H-NMR 
(CDCl3) δ ppm: 7.28-7.18 (m, 5H, Ar-H), 3.69 (m, 7H, CHCH2, CH3), 3.22 (d, 2H, 3J = 
7.8 Hz, CH2-Ar); EI-MS (70 eV) m/z (%): 222 (M+•, 53). C12H14O4 (222.24) 
Dimethyl 2-benzyl-2-ethylmalonate (3.51b)83  
To a solution of 3.51a (2.1 g, 9.4 mmol) in 40 ml THF/abs was added NaH (60 % 
dispersion in mineral oil) (0.45 g, 11.3 mmol) in small amounts and stirred for 3-4 h at 
room temperature. Subsequently, ethyl bromide (1.22 g, 0.84 ml, 11.3 mmol) was 
added and refluxed over night. After cooling, water was added and the mixture 
extracted three times with EtOAc. The combined organic layers were dried over 
MgSO4 and evaporated under reduced pressure. The crude product was subjected to 
flash chromatography (PE/EtOAc 100/0-95/5 v/v) to obtain 3.51b (1.33 g, 56 %) as a 
yellow oil. 1H-NMR (CDCl3) δ ppm: 7.62-7.06 (m, 5H, Ar-H), 3.72 (s, 6H, CH3), 3.24 
(s, 2H, CH2-Ar), 1.84 (q, 2H, 3J = 7.5 Hz, CH2CH3), 0.92 (t, 3H, 3J = 7.5 Hz, CH2CH3); 
EI-MS (70 eV) m/z (%): 250 (M+•, 31). C14H18O4 (250.29) 
2-Benzyl-2-ethylmalonic acid (3.51c)84  
3.51b (1.32 g, 5.27 mmol) was dissolved in 15 ml EtOH, KOH (2.96 g, 52.7 mmol) 
and 15 ml H2O were added and the solution was refluxed overnight. After cooling, 
EtOH was removed in vacuo, H2O was added and extracted with diethylether. The 
aqueous layer was acidified with 6 N HCl/aq and extracted three times with EtOAc. 
The solvent was removed under reduced pressure to obtain 3.51c (1.17 g, 100 %) as 
a pale yellow oil, which was used in the next step without further purification. 1H-NMR 
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(CDCl3) δ ppm: 9.51 (br s, 2H, COOH), 7.26-7.18 (m, 5H, Ar-H), 3.29 (s, 1H, CH2-Ar), 
2.04 (q, 2H, 3J = 7.4 Hz, CH2CH3), 1.26 (t, 3H, 3J = 7.1 Hz, CH2CH3). C12H14O4 
(222.24) 
2-Benzylbutanoic acid (3.51d)85  
3.51c (1.45 g, 6.5 mmol) was heated to 170-200 °C in a sandbath for 3-4 h. After 
cooling, the crude product was subjected to flash chromatography (PE) to obtain 
3.51d (0.75 g, 65 %) as a pale yellow oil. 1H-NMR (CDCl3) δ ppm: 11.33 (br s, 1H, 
COOH), 7.24 (m, 5H, Ar-H), 2.99 (dd, 1H, 3J = 7.8 Hz, 3J = 13.6 Hz, CHH-Ar), 2.76 
(dd, 1H, 3J = 6.9 Hz, 3J = 13.7 Hz, CHH-Ar), 2.62 (m, 1H, COCH), 1.64 (m, 2H, 
CH2CH3), 0.97 (t, 3H, 3J = 7.4 Hz, CH3); 13C-NMR (CDCl3) δ ppm: 181.68 (quat. 
COOH), 139.16 (quat. Ar-C), 128.91 (+, 2 Ar-CH), 128.44 (+, 2 Ar-CH), 126.40 (+, Ar-
CH), 48.86 (-, COCH), 37.71 (-, CH2-Ar), 24.78 (-, CH2CH3), 11.63 (+, CH3); EI-MS 
(70 eV) m/z (%): 178 (M+•, 7); anal. (C11H14O2 ·C12H23N·0.25 H2O) C, H, N. C11H14O2 
(178.23) 
9-(Benzyloxycarbonyl)nonanoic acid (3.52)86  
Phenylmethanol (0.27 g, 0.25 ml, 2.47 mmol) was dropwise added to a cooled 
suspension of decanedioic acid (0.5 g, 2.47 mmol) and DMAP (cat.) in 3 ml THF/abs. 
A solution of DCC (0.61 g, 2.96 mmol),in 3 ml THF/abs was dropwise added to this 
mixture and stirred over the weekend at ambient temperature. Subsequently, DCU 
was filtered and the solvent removed under reduced pressure. The crude product 
was subjected to flash chromatography (PE/EtOAc 90/10 v/v)) to obtain 3.52 (0.34 g, 
47 %) as a colourless solid. 1H-NMR (CDCl3) δ ppm: 10.88 (s, 1H, COOH), 7.34 (m, 
5H, Ar-H), 5.11 (s, 2H, CH2-Ar), 2.34 (m, 4H, COCH2), 1.61 (m, 4H, COCH2CH2), 
1.29 (s, 8H, CH2); 13C-NMR (CDCl3) δ ppm: 179.80 (quat. COOH), 173.72 (quat. 
C=O), 136.12 (quat. Ar-C), 128.55 (+, 2 Ar-CH), 128.18 (+, 3 Ar-CH), 66.11 (-, CH2-
Ar), 34.30 (-, COOH-CH2), 34.04 (-, CH2CO), 29.02 (-, 3 CH2), 28.96 (-, CH2), 24.90 
(-, CH2CH2CO), 24.64 (-, COOH-CH2CH2); EI-MS (70 eV) m/z (%): 292 (M+•, 3). 
C17H24O4 (292.37) 
 
3.5.6. Preparation of cyclohexylalkanoic acids 3.40-3.50 
General procedure  
To a solution of the pertinent phenylalkanoic acid in AcOH was added a catalytic 
amount of Rh/C or Rh/Al2O3 and hydrogenated at 6-8 bar for 48 h. The catalyst was 
removed by filtration over Celite and washed with AcOH. The solvent was removed in 
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vacuo and the crude product purified by flash chromatography (PE/EtOAc 90/10 v/v). 
For combustion analysis data, a small amount of acid was precipitated as salt with 
dicyclohexylamine. 
(R)-3-Cyclohexylbutanoic acid (3.40)87  
The title compound was prepared from (R)-3-phenylbutanoic acid (0.5 g, 3 mmol) by 
hydrogenation over Rh/C (0.25 g) in 15 ml AcOH according to the general procedure 
yielding 3.40 as a colourless oil (0.49 g, 96 %). 1H-NMR (CDCl3): δ (ppm): 2.43 (dd, 
1H, 3J = 5.10 Hz, 2J = 14.9 Hz, COCHH), 2.11 (dd, 1H, 3J = 9.3 Hz, 2J = 14.9 Hz, 
COCHH), 1.87 (m, 1H, CH3CH), 1.74-1.64 (m, 5H, cHex-CH2, cHex-CH), 1.01-1.20 
(m, 6H, cHex-CH2), 0.93 (d, 3H, 3J = 6.8 Hz, CH3); 13C-NMR (CDCl3) δ ppm: 180.30 
(quat. C=O), 42.54 (+, cHex-CH), 39.00 (-, COCH2), 35.19 (+, CH2CH), 30.25 (-, 
cHex-CH2), 28.92 (-, cHex-CH2), 26.66 (-, cHex-CH2), 26.62 (-, cHex-CH2), 26.56 (-, 
cHex-CH2), 16.48 (+, CH3); EI-MS (70 eV) m/z (%): 170 (M+•, 1); anal. (C10H18O2 
·C12H23N) C, H, N. C10H18O2 (170.11) 
(S)-3-Cyclohexylbutanoic acid (3.41)88  
The title compound was prepared from (S)-3-phenylbutanoic acid (0.51 g, 3.1 mmol) 
by hydrogenation over Rh/C (0.25 g) in 15 ml AcOH according to the general 
procedure yielding 3.41 as a colourless oil (0.49 g, 93 %). 1H-NMR (CDCl3) δ ppm: 
2.43 (dd, 1H, 3J = 5.0 Hz, 2J = 14.9 Hz, COCHH), 2.11 (dd, 1H, 3J = 9.3 Hz, 2J = 14.9 
Hz, COCHH), 1.86 (m, 1H, CH3CH), 1.69 (m, 5H, cHex-CH2, cHex-CH), 1.24-1.01 
(m, 6H, cHex-CH2), 0.93 (d, 3H, 3J = 6.8 Hz, CH3); 13C-NMR (CDCl3) δ ppm: 180.64 
(quat. C=O), 42.54 (+,cHex-CH), 39.06 (-, COCH2), 35.19 (+,CH2CH), 30.26 (-, cHex-
CH2), 28.93 (-, cHex-CH2), 26.67 (-, cHex-CH2), 26.63 (-, cHex-CH2), 26.57 (-, cHex-
CH2), 16.48 (+, CH3); EI-MS (70 eV) m/z (%): 170 (M+•, 1); anal. (C10H18O2 ·C12H23N) 
C, H, N. C10H18O2 (170.11) 
2-(Cyclohexylmethyl)propanoic acid (3.42)89  
The title compound was prepared from 2-benzylpropanoic acid (0.5 g, 3.04 mmol) by 
hydrogenation over Rh/C (0.25 g) in 25 ml AcOH according to the general procedure 
yielding 3.42 as a yellow oil (0.51 g, 98 %). 1H-NMR (CDCl3) δ ppm: 2.57 (m, 1H, 
CHCH3), 1.64 (m, 6H, cHex-CH2), 1.29 (m, 5H, cHex-CH2, cHex-CH, CH2-cHex), 1.16 
(d 3H, 3J = 6.9 Hz, CH3), 0.87 (m, 2H, cHex-CH2); 13C-NMR (CDCl3) δ ppm: 183.70 
(quat. C=O), 41.26 (-, CH2-cHex), 36.66 (+, CHCH3), 35.25 (+, cHex-CH), 33.30 (-, 
cHex-CH2), 33.08 (-, cHex-CH2), 26.54 (-, cHex-CH2), 26.22 (-, cHex-CH2), 26.19 (-, 
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cHex-CH2), 17.37 (+, CH3); EI-MS (70 eV) m/z (%): 170 (M+•, 1); anal. (C10H18O2 
·C12H23N) C, H, N. C10H18O2 (170.25) 
3-Cyclohexylpentanoic acid (3.43)90  
The title compound was prepared from 3.21c (1 g, 5.61 mmol) by hydrogenation over 
Rh/C (0.46 g) in 30 ml AcOH according to the general procedure yielding 3.43 as a 
colourless oil (0.8 g, 77 %). 1H-NMR (CDCl3) δ ppm: 2.37 (dd, 1H, 3J = 6.1 Hz, 2J = 
15.4 Hz, COCHH), 2.19 (dd, 1H, 3J = 7.6 Hz, 2J = 15.4 Hz, COCHH), 1.68 (m, 6H, 
CH2CH, cHex-CH, cHex-CH2), 1.41-1.02 (m, 8H, cHex-CH2, CH2CH3), 0.89 (t, 3H, 3J 
= 7.4 Hz, CH2CH3); 13C-NMR (CDCl3) δ ppm: 180.59 (quat. C=O), 41.86 (+, cHex-
CH), 40.03 (+, CH2CH), 35.87 (-, COCH2), 30.07 (-, cHex-CH2), 29.14 (-, cHex-CH2), 
26.76 (-, cHex-CH2), 26.72 (-, cHex-CH2), 26.70 (-, cHex-CH2), 23.80 (-, CH2CH3), 
11.65 (+, CH2CH3); EI-MS (70 eV) m/z (%): 184 (M+•, 3); anal. (C11H20O2·C12H23N·0.1 
H2O) C, H, N. C11H20O2 (184.27) 
2-(Cyclohexylmethyl)butanoic acid (3.44)89  
The title compound was prepared from 3.51d (0.39 g, 2.2 mmol) by hydrogenation 
over Rh/Al2O3 (0.15 g) in 15 ml AcOH according to the general procedure yielding 
3.44 as a colourless oil (0.3 g, 74 %). 1H-NMR (CDCl3) δ ppm: 2.40 (m, 1H, COCH), 
1.60 (m, 9H, cHex-CH2, CH2-cHex, CH2CH3, cHex-CH), 1.20 (m, 4H, cHex-CH2), 
0.94 (t, 3H, 3J = 7.4 Hz, CH3), 0.83 (m, 2H, cHex-CH2); 13C-NMR (CDCl3) δ ppm: 
183.03 (quat. C=O), 44.35 (+, COCH), 39.57 (-, CH2-cHex), 35.57 (+, cHex-CH), 
33.58 (-, cHex-CH2), 32.98 (-, cHex-CH2), 26.54 (-, cHex-CH2), 26.22 (-, cHex-CH2), 
26.18 (-, cHex-CH2), 25.77 (-, CH2CH3), 11.75 (+, CH3); EI-MS (70 eV) m/z (%): 184 
(M+•, 4); anal. (C11H20O2 ·C12H23N) C, H, N. C11H20O2 (184.27) 
3-Cyclohexyl-4-methylpentanoic acid (3.45)73  
The title compound was prepared from 3.22c (0.51 g, 2.65 mmol) by hydrogenation 
over Rh/C (0.26 g) in 15 ml AcOH according to the general procedure yielding 3.45 
as a pale yellow oil (0.42 g, 80 %). 1H-NMR (CDCl3)  δ ppm: 2.24 (d, 2H, 3J = 5.8 Hz, 
COCH2), 1.83 (m, 1H, CH(CH3)2), 1.67 (m, 6H, CH2CH, cHex-CH, cHex-CH2), 1.35-
1.02 (m, 6H, cHex-CH2), 0.91 (d, 3H, 3J = 6.8 Hz, CH3), 0.82 (d, 3H, 3J = 6.8Hz, 
CH3); 13C-NMR (CDCl3) δ ppm: 181.37 (quat. C=O), 45.90 (+, cHex-CH), 39.99 
(+,CH2CH), 33.20 (-, COCH2), 31.60 (-, cHex-CH2), 29.47 (-, cHex-CH2), 28.63 
(+,CH(CH3)2), 26.78 (-, cHex-CH2), 26.68 (-, cHex-CH2), 26.62 (-, cHex-CH2), 21.37 
(+, CH3), 18.49 (+, CH3); EI-MS (70 eV) m/z (%): 198 (M+•, 5); anal. (C12H22O2 
·C12H23N) C, H, N. C12H22O2 (198.30) 
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3-Cyclohexyl-5-methylhexanoic acid (3.46)91  
The title compound was prepared from 3.23c (1 g, 4.85 mmol) by hydrogenation over 
Rh/C (0.47 g) in 30 ml AcOH according to the general procedure yielding 3.46 as a 
pale yellow oil (0.85 g, 83 %). 1H-NMR (CDCl3) δ ppm: 10.67 (br s, 1H, COOH), 2.34 
(dd, 1H, 3J = 6.6 Hz, 2J = 15.3 Hz, COCHH), 2.17 (dd, 1H, 3J = 6.9 Hz, 2J = 15.3 Hz, 
COCHH), 1.86 (m, 1H, CH(CH3)2), 1.62 (m, 6H, CH2CH, cHex-CH, cHex-CH2), 1.34-
1.01 (m, 8H, CH2CH(CH3)2, cHex-CH2), 0.89 (d, 3H, 3J = 3.5 Hz, CH3), 0.87 (d, 3H, 
3J = 3.4 Hz, CH3); 13C-NMR (CDCl3) δ ppm: 180.86 (quat. C=O), 40.70 (-, 
CH2CH(CH3)2, 40.61 (+, cHex-CH), 37.84 (+, CH2CH), 36.53 (-, COCH2), 29.81 (-, 
cHex-CH2), 28.91 (-, cHex-CH2), 26.82 (-, cHex-CH2), 26.75 (-, 2 cHex-CH2), 25.46 
(+, CH(CH3)2), 23.01 (+, CH3), 22.51 (+, CH3); EI-MS (70 eV) m/z (%): 212 (M+•, 2); 
anal. (C13H24O2 ·C12H23N·0.25H2O) calcd. C (75.42), H (12.02), N (3.52), found C 
(75.71), H, (11.20), N (3.44). C13H24O2 (212.33) 
3-(Cyclohexylmethyl)butanoic acid (3.47)87  
The title compound was prepared from 3.28c (0.51 g, 2.86 mmol) by hydrogenation 
over Rh/Al2O3 (0.29 g) in 15 ml AcOH according to the general procedure yielding 
3.47 as a colourless oil (0.27 g, 51 %). 1H-NMR (CDCl3) δ ppm: 2.31 (dd, 1H, 3J = 6.8 
Hz, 2J = 11.5 Hz, COCHH), 2.11 (dd, 1H, 3J = 5.7 Hz, 2J = 16.1 Hz, COCHH), 1.91 
(m, 1H, CH2CH), 1.66 (m, 5H, cHex-CH, cHex-CH2), 1.28-1.07 (m, 6H, cHex-CH2, 
CHCH2), 0.95 (d, 3H, 3J = 6.3 Hz, CH3), 0.86 (m, 2H, cHex-CH2); 13C-NMR (CDCl3) δ 
ppm: 179.62 (quat. C=O), 44.67 (-, COCH2), 41.92 (-, CHCH2), 34.82 (+, cHex-CH), 
33.89 (-, cHex-CH2), 32.98 (-, cHex-CH2), 28.09 (-, cHex-CH2), 27.11 (+, CHCH3), 
26.39 (-, cHex-CH2), 26.30 (-, cHex-CH2), 19.91 (+, CH3); EI-MS (70 eV) m/z (%): 
184 (M+•, 7); anal. (C11H20O2 ·C12H23N) C, H, N. C11H20O2 (184.27) 
5-Cyclohexyl-3-methylpentanoic acid (3.48)92  
The title compound was prepared from 3.29c (0.5 g, 2.6 mmol) by hydrogenation 
over Rh/Al2O3 (0.25 g) in 20 ml AcOH according to the general procedure yielding 
3.48 as a pale yellow oil (0.3 g, 58 %). 1H-NMR (CDCl3) δ ppm: 8.85 (br s, 1H, 
COOH), 2.36 (dd, 1H, 3J = 5.9 Hz, 3J = 14.9 Hz, COCHH), 2.14 (dd, 1H, 3J = 7.1 Hz, 
3J = 13.9 Hz, COCHH), 1.92 (m, 1H, CH2CH), 1.65 (m, 5H, cHex-CH, cHex-CH2), 
1.33-1.16 (m, 8H, CHCH2CH2, CHCH2CH2, cHex-CH2) 0.96 (d, 3H, 3J = 6.6 Hz, CH3), 
0.88 (m, 2H, cHex-CH2); 13C-NMR (CDCl3) δ ppm: 180.10 (quat. C=O), 44.67 (-, 
COCH2), 41.99 (-, CHCH2), 34.82 (+, cHex-CH), 33.89 (-, CHCH2CH2), 32.98 (-, 
cHex-CH2), 29.72 (-, cHex-CH2), 27.10 (+, CHCH3), 26.66 (-, cHex-CH2), 26.39 (-, 
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cHex-CH2), 26.30 (-, cHex-CH2), 19.91 (+, CH3); ES-MS (AcN/H2O + TFA)) m/z (%): 
197 ([M-H]-, 100); anal. (C12H22O2 ·C12H23N·0.1 H2O) C, H, N. C12H22O2 (198.30) 
6-Cyclohexyl-3-methylhexanoic acid (3.49)93  
The title compound was prepared from 3.30c (0.5 g, 2.42 mmol) by hydrogenation 
over Rh/Al2O3 (0.25 g) in 15 ml AcOH according to the general procedure yielding 
3.49 as a colourless oil (0.32 g, 62 %). 1H-NMR (CDCl3) δ ppm: 9.96 (br s, 1H, 
COOH), 2.35 (dd, 1H, 3J = 5.9 Hz, 2J = 14.9 Hz, COCHH), 2.14 (dd, 1H, 3J = 8.2 Hz, 
2J = 14.9 Hz, COCHH), 1.95 (m, 1H, CH2CH), 1.65 (m, 5H, cHex-CH, cHex-CH2), 
1.31-1.15 (m, 10H, CHCH2, CHCH2CH2, CHCH2CH2CH2, cHex-CH2), 0.96 (d, 3H, 3J 
= 6.6 Hz, CH3), 0.86 (m, 2H, cHex-CH2); 13C-NMR (CDCl3) δ ppm: 179.91 (quat. 
C=O), 41.64 (-, COCH2), 37.62 (+, cHex-CH), 37.52 (-, CHCH2), 36.95 (-, 
CHCH2CH2CH2), 33.46 (-, cHex-CH2), 33.37 (-, cHex-CH2), 30.17 (+, CHCH3), 26.75 
(-, cHex-CH2), 26.44 (-, cHex-CH2), 24.10 (-, CHCH2CH2), 19.69 (+, CH3); EI-MS (70 
eV) m/z (%): 212 (M+•, 20); anal. (C13H24O2 ·C12H23N·0.5 H2O) C, H, N. C13H24O2 
(212.32) 
3-(Cyclohexylmethyl)pentanoic acid (3.50)  
The title compound was prepared from 3-benzylpentanoic acid21 (0.55 g, 3.04 mmol) 
by hydrogenation over Rh/C (0.13 g) in 20 ml AcOH according to the general 
procedure yielding 3.50 as a colourless oil (0.48 g, 85 %). 1H-NMR (CDCl3) δ ppm: 
2.26 (d, 2H, 3J = 6.8 Hz, COCH2), 1.91 (m, 1H, CHCH2CH3), 1.67 (m, 5H, cHex-CH2, 
cHex-CH), 1.23 (m, 8H, CHCH2CH3, cHex-CH2), 0.87 (m, 5H, CH3, CH2-cHex); 13C-
NMR (CDCl3) δ ppm: 180.12 (quat. C=O), 41.56 (-, COCH2), 38.85 (-, CH2-cHex), 
34.82 (+, cHex-CH), 33.56 (-, cHex-CH2), 33.53 (-, cHex-CH2), 33.19 (+, CHCH2CH3), 
26.67 (-, cHex-CH2), 26.53 (-, CHCH2CH3), 26.37 (-, 2 cHex-CH2), 10.59 (+, CH3); EI-
MS (70 eV) m/z (%): 198 (M+•, 5); anal. (C12H22O2·C12H23N) C, H, N. C12H22O2 
(198.30) 
 
3.5.7. Preparation of the imidazolylpropylguanidine building blocks 3.7 
and 3.10 
(E)-Methyl 3-(1H-imidazol-4-yl)propenoate (3.1)12 
To a solution of urocanic acid (14 g, 101.3 mmol) and anhydrous Na2SO4 (2 g) in 150 
ml MeOH/abs was added H2SO4 (conc.) (8 ml), and the mixture was heated to reflux 
for 30 h. The solvent was removed under reduced pressure after cooling to room 
temperature. The residue was dissolved in a small amount of water, neutralized with 
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saturated NaHCO3/aq and extracted three times with EtOAc. After drying over 
MgSO4, the solvent was evaporated in vacuo yielding 3.1 (14.5 g, 94 %) as a white 
solid. 1H-NMR (CD3OD) δ ppm: 6.33 (s, 1H, Im-2-H), 6.18 (d, 1H, 3J = 15.9 Hz, Im-4-
CHCH), 5.93 (s, 1H, Im-5-H), 5.02 (d, 1H, 3J = 15.8 Hz, Im-4-CHCH), 2.37 (s, 3H. 
OCH3); EI-MS (70 eV) m/z (%): 152 (M+•, 50). C7H8N2O2 (152.15) 
Methyl 3-(1H-imidazol-4-yl)propanoate (3.2)94 
To a solution of 1 (9.9 g, 65.1 mmol) in 120 ml MeOH was added Pd/C (10 %) (1 g) 
under stirring. The mixture was hydrogenated at 5 bar for 24 h, subsequently filtered 
through a small pad of Celite and evaporated in vacuo to obtain 3.2 (10 g, 100 %) as 
a white solid. 1H-NMR (DMSO-d6) δ ppm: 7.51 (d, 1H, 4J = 1.0 Hz, Im-2-H), 6.75 (d, 
1H, 4J = 0.8 Hz, Im-5-H), 3.59 (s, 3H, OCH3), 2.75 (t, 2H, 3J = 7.5 Hz, Im-4-CH2), 2.60 
(t, 2H, 3J = 7.3 Hz, Im-4-CH2CH2); EI-MS (70 eV) m/z (%): 154 (M+•, 35). C7H10N2O2 
(154.17) 
Methyl 3-(1-trityl-1H-imidazol-4-yl)propanoate (3.3)95 
Trityl chloride (15 g, 53.8 mmol) was dissolved in 150 ml MeCN and added dropwise 
to a suspension of 3.2 (9.2 g, 48.3 mmol) and NEt3 (19 ml, 136 mmol) in 140 ml 
MeCN under external ice-cooling. After the addition, the mixture was allowed to warm 
to room temperature and stirring was continued for 12 h.The solvent was removed in 
vauo, the resulting solid suspended in H2O and stirred for 1 h. The solid was filtrated 
and recrystallized from EtOH yielding 3.3 (15.4 g, 80 %) as a white solid. 1H-NMR 
(CDCl3) δ ppm: 8.07 (d, 1H, 4J = 1.6 Hz, Im-2-H), 7.41-7.07 (m, 15H, CPh3), 6.77 (d, 
1H, 4J = 1.5 Hz, Im-5-H), 3.62 (s, 3H, OCH3), 3.08 (t, 2H, 3J = 6.9 Hz, Im-4-CH2), 
2.87 (t, 2H, 3J = 6.9 Hz, Im-4-CH2CH2); EI-MS (70 eV) m/z (%): 396 (M+•, 10). 
C26H24N2O2 (396.24) 
3-(1-Trityl-1H-imidazol-4-yl)propan-1-ol (3.4)95 
3.3 (10.06 g, 25.4 mmol) was added under argon atmosphere and external ice-
cooling to a suspension of LiAlH4 (1.9 g, 50 mmol) in 75 ml freshly distilled THF and 
25 ml Et2O/abs. After the addition was complete, the mixture was allowed to warm to 
room temperature and refluxed for 2 h. To destroy excess LiAlH4, 0.1N NaOH was 
carefully added. The mixture was extracted several times with DCM, dried over 
MgSO4 and the solvent removed under reduced pressure. The residue was purified 
by flash chromatography (CHCl3/MeOH 95/5 v/v) to obtain 3.4 (6.89 g, 74 %) as a 
white solid. 1H-NMR (CDCl3) δ ppm:  7.76 (d, 1H, 4J = 1.4 Hz, Im-2-H), 7.38-7.11 (m, 
15H, CPh3), 6.65 (d, 1H, 4J = 1.5 Hz, Im-5-H), 3.71 (t, 2H, 3J = 5.7 Hz, CH2NH), 2.80 
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(t, 2H, 3J = 6.9 Hz, Im-4-CH2), 1.91 (m, 2H, Im-4-CH2CH2); EI-MS (70 eV) m/z (%): 
369 (M+•, 60). C25H24N2O (368.24) 
N,N´-Bis(benzyloxycarbonyl)guanidine (3.5)11 
Guanidine hydrochloride (7.71 g, 80.7 mmol) and NaOH (16.15 g, 40.4 mmol) were 
dissolved in 40 ml H2O and 80 ml DCM and cooled to 0 °C. Benzyloxycarbonyl-
chloride (34.5 ml, 24.3 mmol) was added dropwise over 45 min and stirred at 0 °C for 
20 h. The mixture was allowed to warm to ambient temperature, extracted three 
times with DCM and washed with H2O. After drying over MgSO4, the solvent was 
removed in vacuo and the crude product recrystallized from MeOH to obtain 3.5 
(15.9 g, 60 %) as colourless crystals. 1H-NMR (DMSO-d6) δ ppm: 10.88 (br s, 1H, 
NH), 8.69 (br s, 2H, NH2), 7.34 (m, 10H, Ar-H), 5.11 (s, 4H, CH2-Ar); EI-MS (70 eV) 
m/z (%): 328 (M+•, 100). C17H17N3O5 (327.13) 
3-Phenylbutan-1-ol (3.8)96 
To a suspension of LiAlH4 (0.57 g, 15 mmol) in 30 ml THF/abs was slowly added 
under argon atmosphere a solution of 3-phenylbutyric acid (2 g, 12.2 mmol) in 20 ml 
THF/abs, and the mixture was stirred for 2 h. After cooling of the flask (icebath), 
water was added cautiously to decompose excess hydride. Then 20 ml of 10 % 
H2SO4 was added, resulting in a clear solution. The solution was extracted three 
times with CHCl3, washed with water, dried over MgSO4 and evaporated in vacuo. 
The residue was purified by flash-chromatography (CHCl3/MeOH 95/5 v/v) to obtain 
3.8 (0.82 g, 45 %) as a colourless oil. 1H-NMR (CDCl3) δ (ppm): 7.23 (m, 5H, Ar-H), 
3.54 (m, 2H, CH2OH), 2.88 (m, 1H, CH3CH), 1.85 (m, 2H, CH3CHCH2), 1.27 (d, 3H, 
J3 = 7.0 Hz, CH3); PI-EIMS m/z (%): 150 (M+•, 22). C10H14O (150.22) 
General procedure for the preparation of N1,N2-Bis(benzyloxycarbonyl)-
guanidines 
A solution of the alcohol (1 eq), di-Cbz protected guanidine (1.8 eq) and PPh3 (1.5 
eq) in THF/abs was cooled to -5 °C under argon atmosphere. DIAD (1.4-1.5 eq) was 
added dropwise at such a rate that the reaction mixture was completely colourless 
before addition of the next drop. After the addition was complete, the reaction mixture 
was stirred at room temperature for 24 h. The solvent was removed in vacuo and the 
crude product subjected to flash chromatography.  
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N1,N2-Bis(benzyloxycarbonyl)-N1-[3-(1-trityl-1H-imidazolyl-4-yl)propyl]guanidine 
(3.6) 
The title compound was prepared from 3.4 (4.4 g, 11.9 mmol), di-Cbz protected 
guanidine (6.9 g, 21.1 mmol), PPh3 (4.7 g, 18 mmol) in 100 ml THF/abs and DIAD 
(3.5 ml, 18 mmol) in 30 ml THF/abs. The crude product was subjected to flash 
chromatography (PE/EtOAc 60/40 v/v) to obtain 3.6 (1.22 g, 70 %) as a colourless 
foam-like solid. 1H-NMR (CDCl3) δ (ppm): 8.02 (d, 1H, 4J = 1.6 Hz, Im-2-H), 6.91 (d, 
1H, 4J = 1.2 Hz, Im-5-H), 5.29 (s, 2H, CH2-Ar), 5.21 (s, 2H, CH2-Ar), 4.30 (t, 2H, 3J = 
7.0 Hz, CH2NH), 3.02 (t, 2H, 3J = 8.1 Hz, Im-4-CH2), 2.27 (m, 2H, Im-4-CH2CH2); ES-
MS (DCM/MeOH + NH4OAc) m/z (%): 678 (MH+, 100). C42H39N5O4 (677.46) 
N1,N2-Bis(benzyloxycarbonyl)-N1-(3-phenylbutyl)guanidine (3.9) 
The title compound was prepared from 3.8 (0.57 g, 3.8 mmol), di-Cbz protected 
guanidine (2.2 g, 6.7 mmol), PPh3 (1.5 g, 5.7 mmol) in 20 ml THF/abs and DIAD (1.1 
ml, 5.4 mmol) in THF/abs. The crude product subjected to flash chromatography 
(PE/EtOAc 90/10 v/v) to obtain 3.9 (1.22 g, 70 %) as a colourless oil. 1H-NMR 
(CDCl3) δ (ppm): 7.36-7.12 (m, 15H, Ar-H), 5.16 (s, 2H, CH2-Ar), 5.15 (s, 2H, CH2-
Ar), 3.99-3.77 (m, 2H, CH2N), 2.74 (m, 1H, CH3CH), 1.89 (m, 2H, CH3CHCH2), 1.19 
(d, 3H, 3J = 6.9 Hz, CH3); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 460 (MH+, 100). 
C27H29N3O4 (459.31) 
General procedure for the preparation of the deprotected guanidines 
To a solution of 3.6 or 3.9 in THF: MeOH (1:1) was added Pd/C (10 %) and the 
mixture was hydrogenated at 5 bar overnight. The catalyst was filtered off through a 
small pad of Celite and washed with MeOH, and the solvent was removed in vacuo. 
N-[3-(1-Trityl-1H-imidazol-4-yl)propyl]guanidine (3.7) 
The title compound was prepared from 3.6 (6.59 g, 9.7 mmol) by hydrogenation over 
Pd/C (10 %) (0.6 g, cat.) in 165 ml THF: MeOH (1:1). 3.7 (3.9 g, 98 %) was obtained 
as a pale yellow foam-loke solid. 1H-NMR (CD3OD) δ (ppm): 7.38-7.14 (m, 16H, 
CPh3, Im-2-H), 6.70 (s, 1H, Im-5-H), 3.17 (t, 2H, 3J = 6.9 Hz, CH2NH), 2.58 (t, 2H, 3J 
= 7.4 Hz, Im-4-CH2), 1.86 (m, 2H, Im-4-CH2CH2); ES-MS (DCM/MeOH + NH4OAc) 
m/z (%): 410 (MH+, 100). C26H27N5 (409.32) 
3-Phenylbutylguanidine (3.10) 
The title compound was prepared from 3.9 (1.13 g, 2.46 mmol) in 40 ml THF: MeOH 
(1:1) was added Pd/C (10 %) (0.1 g, cat). 3.10 (0.47 g, 100 %) was obtained as a 
yellow amorphous solid. 1H-NMR (CDCl3) δ (ppm): 7.26 (m, 5H, Ar-H), 3.03 (t, 2H, J3 
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= 7.0 Hz, NHCH2), 2.81 (m, 1H, CH3CH), 1.88 (m, 2H, CH3CHCH2), 1.29 (d, 3H, J3 = 
6.9 Hz, CH3); CI-MS (NH3) m/z (%): 192 (MH+, 100). C11H17N3 (191.27) 
 
3.5.8. Preparation of trityl-protected imidazolylpropylguanidines 3.55a-
3.89a 
General procedure  
To a solution of CDI (1.1 eq) in THF/abs (5-7 ml) was added under argon the 
carboxylic acid (1 eq) and the mixture was stirred for 1 h. In a second flask, 3.7 or 
3.10 (1 eq) and NaH (60 % dispersion in mineral oil) (2 eq) in THF/abs (5-7 ml) under 
argon was heated to 30-35 °C for 30 min and was then allowed to cool to room 
temperature. The two mixtures were combined and stirred for 2 h at ambient 
temperature. Subsequently, water was added and extracted three times with EtOAc. 
The organic phase was dried over MgSO4 and evaporated in vacuo and the crude 
product purified by flash chromatography (CHCl3/MeOH/NH3 96/3/1 v/v/v). 
N-(3-Phenylbutyl)-N´-[3-(1-trityl-1H-imidazol-4-yl)propanoyl]guanidine (3.55a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.20 (380 mg, 1 
mmol), 3.10 (190 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.55a as a pale yellow 
foam-like solid (130 mg, 23 %). 1H-NMR (CDCl3) δ (ppm): 7.31-7.10 (m, 16H, CPh3, 
Im-2-H), 6.58 (d, 1H, J4= 1.0 Hz, Im-5-H), 3.05 (t, 2H, J3 = 7.1 Hz, Im-4-CH2CH2), 
2.87 (m, 2H, NHCH2), 2.75 (m, 3H, Im-4-CH2CH2, CHCH3), 1.87 (m, 2H, 
NHCH2CH2), 1.23 (d, 3H, J3 = 7.0, CH3); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
556 (MH+, 100). C36H37N5O (555.54) 
N-(3-Phenylpentanoyl)-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine (3.56a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.21c (180 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.56a as a pale yellow 
foam-like solid (370 mg, 65 %). 1H-NMR (CDCl3) δ ppm: 7.24 (m, 16H, Im-2-H, 
CPh3), 6.56 (d, 1H, 4J = 1.2 Hz, Im-5-H), 3.41 (t, 2H, 3J = 6.6 Hz, CH2NH), 3.09 (m, 
1H, CHCH2CH3), 2.75-2.53 (m, 4H, Im-4-CH2, COCH2), 1.85 (m, 2H, Im-4-CH2CH2), 
1.66 (m, 2H, CHCH2CH3), 0.78 (t, 3H, 3J = 7.3 Hz, CH3); ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 570 (MH+, 65). C37H39N5O (569.74) 
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N-(2-Benzylbutanoyl)-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine (3.57a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.51d (180 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.57a as a pale yellow 
foam-like solid (370 mg, 35 %). 1H-NMR (CDCl3) δ ppm: 7.34-7.11 (m, 21H, Im-2-H, 
CPh3, Ar-H), 6.56 (d, 1H, 4J = 1.2 Hz, Im-5- H), 3.35 (t, 2H, 3J = 6.7 Hz, CH2NH), 3.02 
(m, 1H, CHCH2CH3), 2.62 (m, 4H, Im-4-CH2, CH2-Ar), 1.87 (m, 2H, Im-4-CH2CH2), 
1.62-1.44 (m, 2H, CH2CH3), 0.88 (t, 3H, 3J = 7.4 Hz, CH3); ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 570 (MH+, 100). C37H39N5O (569.73) 
N-(4-Methyl-3-phenylpentanoyl)-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine 
(3.58a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.22c (190 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.58a as a pale yellow 
foam-like solid (310 mg, 53 %). 1H-NMR (CDCl3) δ ppm: 7.35-7.13 (m, 16H, Im-2-H, 
CPh3), 6.65 (d, 1H, 4J = 0.9 Hz, Im-5-H), 3.12 (m, 2H, CH2NH), 2.90 (m, 1H, CH2CH), 
2.72 (m, 2H, COCH2), 2.50 (t, 2H, 3J = 7.3Hz, Im-4-CH2), 1.83 (m, 3H, Im-4-CH2CH2, 
CH(CH3)2), 0.93 (d, 3H, 3J = 6.7 Hz, CH3), 0.72 (d, 3H, 3J = 6.7 Hz, CH3); ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 584 (MH+, 100). C38H41N5O (583.77) 
N-(5-Methyl-3-phenylhexanoyl)-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine 
(3.59a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.23c (210 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.59a as a colourless 
foam-like solid (340 mg, 57 %). 1H-NMR (CDCl3) δ ppm: 7.34-7.12 (m, 21H, Im-2-H, 
CPh3, Ar-H), 6.56 (d, 1H, 4J = 1.2 Hz, Im-5-H), 3.40 (t, 2H, 3J = 6.6 Hz, CH2NH), 3.29 
(m, 1H, CH2CH), 2.71 (d, 2H, 3J = 7.5 Hz, COCH2), 2.54 (m, 2H, Im-4-CH2), 1.85 (m, 
2H, Im-4-CH2CH2), 1.60-1.42 (m, 2H, CH2CH(CH3)2), 1.32 (m, 1H, CH(CH3)2), 0.88 
(d, 3H, 3J = 6.3 Hz, CH3), 0.81 (d, 3H, 3J = 6.5 Hz, CH3); ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 598 (MH+, 30). C39H43N5O (597.79) 
N-(3,4-Diphenylbutanoyl)-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine 
(3.60a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.24c (240 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
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mmol) in THF/abs according to the general procedure yielding 3.60a as a pale yellow 
foam-like solid (310 mg, 49 %). 1H-NMR (CDCl3) δ ppm: 7.34-7.11 (m, 26H, Im-2-H, 
CPh3, Ar-H) 6.56 (d, 1H, 4J = 1.2 Hz, Im-5-H), 3.57 (m, 1H, CHCH2), 3.43 (m, 2H, 
CH2NH), 2.90 (m, 2H, CH2-Ar), 2.53 (m, 4H, Im-4-CH2, COCH2), 1.85 (m, 2H, Im-4-
CH2CH2); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 632 (MH+, 80). C42H41N5O 
(631.81) 
N-[3-Phenyl-4-(4-methylphenyl)butanoyl]-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]-
guanidine (3.61a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.25c (250 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.61a as a colourless 
foam-like solid (170 mg, 26 %). 1H-NMR (CDCl3) δ ppm: 7.34-7.08 (m, 26H, Im-2-H, 
CPh3, Ar-H), 6.54 (d, 1H, 4J = 1.1 Hz, Im-5-H), 3.44 (m, 1H, CHCH2), 3.33 (t, 2H, 3J = 
6.7 Hz, CH2NH), 2.86 (m, 2H, CH2-Ar), 2.69 (m, 2H, COCH2), 2.52 (m, 2H, Im-4-
CH2), 2.24 (s, 3H, (p-CH3)-Ar), 1.83 (m, 2H, Im-4-CH2CH2); ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 646 (MH+, 100). C43H43N5O (645.83) 
N-(3-Cyclohexyl-4-phenylbutanoyl)-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]-
guanidine (3.62a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.26c (250 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.62a as a colourless 
foam-like solid (210 mg, 33 %). 1H-NMR (CDCl3) δ ppm: 7.34-7.11 (m, 21H, Im-2-H, 
CPh3, Ar-H), 6.56 (d, 1H, 4J = 1.2 Hz, Im-5-H), 3.37 (t, 2H, 3J = 6.5 Hz, CH2NH), 2.68 
(m, 2H, Im-4-CH2), 2.54 (m, 2H, CH2-Ar), 2.33-2.16 (m, 3H, CHCH2-Ar, COCH2), 1.87 
(m, 2H, Im-4-CH2CH2), 1.72-1.60 (m, 5H, cHex-CH2, cHex-CH), 1.29-1.08 (m, 6H, 
cHex-CH2); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 638 (MH+, 100). C42H47N5O 
(637.85) 
N-[3-(4-Methylphenyl)propanoyl]-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]-
guanidine (3.63a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3-(4-
methylphenyl)propanoic acid (160 mg, 1 mmol), 3.7 (410 mg, 1 mmol) and NaH (60 
% dispersion in mineral oil) (80 mg, 2 mmol) in THF/abs according to the general 
procedure yielding 3.63a as a colourless foam-like solid (240 mg, 43 %). 1H-NMR 
(CDCl3) δ ppm: 7.34-7.10 (m, 21H, Im-2-H, CPh3, Ar-H), 6.56 (d, 1H, 4J = 1.2 Hz, Im-
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5-H), 3.35 (t, 2H, 3J = 6.7 Hz, CH2NH), 2.92 (m, 2H, COCH2CH2), 2.57 (m, 4H, Im-4-
CH2, COCH2CH2), 2.29 (s, 3H, (p-CH3)-Ar), 1.87 (m, 2H, Im-4-CH2CH2); ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 556.4 (MH+, 100). C36H37N5O (555.71) 
N-[3-(4-Methylphenyl)butanoyl]-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine 
(3.64a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.27c (180 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.64a as a colourless 
foam-like solid (250 mg, 44 %). 1H-NMR (CDCl3) δ ppm: 7.34-7.11 (m, 21H, Im-2-H, 
CPh3, Ar-H), 6.56 (d, 1H, 4J = 1.0 Hz, Im-5-H), 3.30 (m, 3H, CH2NH, CHCH3), 2.54 
(m, 4H, Im-4-CH2, COCH2), 2.29 (s, 3H, (p-CH3)-Ar), 1.86 (m, 2H, Im-4-CH2CH2), 
1.25 (d, 3H, 3J = 7.0 Hz, CH3); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 570 (MH+, 
100). C37H39N5O (569.74) 
N-(3-Methyl-4-phenylbutanoyl)-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine 
(3.65a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.28c (180 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.65a as a colourless 
foam-like solid (370 mg, 65 %). 1H-NMR (CDCl3) δ ppm: 7.35-7.11 (m, 21H, Im-2-H, 
CPh3, Ar-H), 6.56 (d, 1H, 4J = 1.2 Hz, Im-5-H), 3.41 (t, 2H, 3J = 6.6 Hz, CH2NH), 2.71 
(dd, 1H, 3J = 5.3 Hz, 2J = 12.8 Hz, CHH-Ar), 2.57 (m, 2H, Im-4-CH2), 2.41-2.26 (m, 
4H, CHH-Ar, COCH2, CHCH3), 1.88 (m, 2H, Im-4-CH2CH2), 0.91 (d, 3H, 3J = 6.1 Hz, 
CH3); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 570 (MH+, 100). C37H39N5O (569.74) 
N-(3-Methyl-5-phenylpentanoyl)-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine 
(3.66a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.29c (220 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.66a as a colourless 
foam-like solid (340 mg, 58 %). 1H-NMR (CDCl3) δ ppm: 7.53-7.08 (m, 21H, Im-2-H, 
CPh3, Ar-H), 6.58 (s, 1H, Im-5- H), 3.47 (t, 2H, 3J = 6.9 Hz, CH2NH), 2.69-2.50 (m, 
5H, Im-4-CH2, CH2-Ar, COCHH), 2.30 (dd, 1H, 3J = 7.9 Hz, 3J = 15.1 Hz, COCHH), 
1.91 (m, 3H, Im-4-CH2CH2, CHCH3), 1.72-1.53 (m, 2H, CH2CH2-Ar), 0.97 (d, 3H, 3J = 
6.7 Hz, CH3); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 584 (MH+, 100). C38H41N5O 
(583.76) 
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N-(3-Methyl-6-phenylhexanoyl)-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine 
(3.67a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.30c (210 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.67a as a colourless 
foam-like solid (320 mg, 54 %). 1H-NMR (CDCl3) δ ppm: 7.35-7.11 (m, 21H, Im-2-H, 
CPh3, Ar-H), 6.58 (d, 1H, 4J = 1.1 Hz, Im-5-H), 2.58 (m, 4H, CH2NH, Im-4-CH2), 2.47 
(dd, 1H, 3J = 6.0 Hz, 2J = 14.7 Hz, COCHH), 2.27 (dd, 1H, 3J = 8.1 Hz, 2J = 14.7 Hz, 
COCHH), 2.06 (m, 2H, CH2-Ar), 1.88 (m, 2H, Im-4-CH2CH2), 1.69-1.56 (m, 3H, 
CH2CH2-Ar, CHCH3), 1.42 (m, 2H, CH2CH2CH2-Ar), 0.95 (d, 3H, 3J = 6.6 Hz, CH3); 
ES-MS (DCM/MeOH + NH4OAc) m/z (%): 598 (MH+, 100). C39H43N5O (597.79) 
N-[3-Methyl-4-(3-methylphenyl)butanoyl]-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]-
guanidine (3.68a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.31c (190 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.68a as a colourless 
oil (310 mg, 53 %). 1H-NMR (CDCl3) δ ppm: 7.34-6.97 (m, 20H, Im-2-H, CPh3, Ar-H), 
6.56 (d, 1H, 4J = 1.2 Hz, Im-5- H), 3.40 (t, 2H, 3J = 6.6 Hz, CH2NH), 2.62 (m, 3H, Im-
4-CH2, CHH-Ar), 2.41-2.29 (m, 7H, CHH-Ar, CHCH3, COCH2, (m-CH3)-Ar), 1.88 (m, 
2H, Im-4-CH2CH2), 0.90 (d, 3H, 3J = 5.9 Hz, CH3); ES-MS (DCM/MeOH + NH4OAc) 
m/z (%): 584 (MH+, 100). C38H41N5O (583.76) 
N-[3-Methyl-4-(4-methylphenyl)butanoyl]-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]-
guanidine (3.69a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.32c (190 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.69a as a yellow oil 
(480 mg, 82 %). 1H-NMR (CDCl3) δ ppm: 7.34-7.06 (m, 20H, Im-2-H, CPh3, Ar-H), 
6.56 (d, 1H, 4J = 1.2 Hz, Im-5- H), 3.40 (t, 2H, 3J = 6.6 Hz, CH2NH), 2.62 (m, 3H, Im-
4-CH2, CHH-Ar), 2.35-2.52 (m, 7H, CHH-Ar, CHCH3, COCH2, (p-CH3)-Ar), 1.88 (m, 
2H, Im-4-CH2CH2), 0.90 (d, 3H, 3J = 6.0 Hz, CH3); ES-MS (DCM/MeOH + NH4OAc) 
m/z (%): 584 (MH+, 100). C38H41N5O (583.76) 
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N-[4-(3-Fluorophenyl)-3-methylbutanoyl)-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]-
guanidine (3.70a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.33c (200 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.70a as a colourless 
foam-like solid (130 mg, 22 %). 1H-NMR (CDCl3) δ ppm: 7.34-6.89 (m, 20H, Im-2-H, 
CPh3, Ar-H), 6.56 (d, 1H, 4J = 1.2 Hz, Im-5- H), 3.36 (t, 2H, 3J = 6.7 Hz, CH2NH), 2.72 
(dd, 1H, 3J = 4.7 Hz, 2J = 12.7 Hz, CHH-Ar), 2.58 (m, 2H, Im-4-CH2), 2.33 (m, 3H, 
COCH2, CHH-Ar), 2.14 (m, 1H, CHCH3), 1.87 (m, 2H, Im-4-CH2CH2), 0.89 (d, 3H, 3J 
= 6.1 Hz, CH3); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 588 (MH+, 100). 
C37H38FN5O (587.73) 
N-[4-(4-Fluorophenyl)-3-methylbutanoyl]-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]-
guanidine (3.71a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.34c (200 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.71a as a colourless 
foam-like solid (370 mg, 63 %). 1H-NMR (CDCl3) δ ppm: 7.34-6.91 (m, 20H, Im-2-H, 
CPh3, Ar-H), 6.56 (d, 1H, 4J = 1.0 Hz, Im-5- H), 3.38 (t, 2H, 3J = 6.6 Hz, CH2NH), 2.67 
(dd, 1H, 3J = 5.3 Hz, 23J = 13.1 Hz, CHH-Ar), 2.57 (m, 2H, Im-4-CH2), 2.37-2.22 (m, 
4H, CHH-Ar, COCH2, CHCH3), 1.87 (m, 2H, Im-4-CH2CH2), 0.88 (d, 3H, 3J = 6.1 Hz, 
CH3); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 588 (MH+, 100). C37H38FN5O 
(587.73) 
N-[4-(3-Methoxyphenyl)-3-methylbutanoyl]-N´-[3-(1-trityl-1H-imidazol-4-yl)-
propyl]guanidine (3.72a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.35c (210 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.72a as a colourless 
foam-like solid (230 mg, 38 %). 1H-NMR (CDCl3) δ ppm: 7.34-6.72 (m, 20H, Im-2-H, 
CPh3, Ar-H), 6.56 (d, 1H, 4J = 1.2 Hz, Im-5- H), 3.77 (s, 3H, (m-OCH3)-Ar), 3.43 (t, 
2H, 3J = 6.6 Hz, CH2NH), 2.68-2.56 (m, 3H, Im-4-CH2, CHH-Ar), 2.37 (m, 4H, CHH-
Ar, CHCH3, COCH2), 1.87 (m, 2H, Im-4-CH2CH2), 0.91 (d, 3H, 3J = 5.9 Hz, CH3); ES-
MS (DCM/MeOH + NH4OAc) m/z (%): 600 (MH+, 100). C38H41N5O2 (599.76) 
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N-[4-(4-Methoxyphenyl)-3-methylbutanoyl]-N´-[3-(1-trityl-1H-imidazol-4-yl)-
propyl]guanidine (3.73a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.36c (210 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.73a as a colourless 
foam-like solid (310 mg, 52 %). 1H-NMR (CDCl3) δ ppm: 7.34-6.79 (m, 20H, Im-2-H, 
CPh3, Ar-H), 6.56 (d, 1H, 4J = 1.0 Hz, Im-5- H), 3.76 (s, 3H, (p-OCH3)-Ar), 3.37 (t, 2H, 
3J = 6.6 Hz, CH2NH), 2.61 (m, 4H, Im-4-CH2, CH2Ar), 2.31 (m, 3H, CHCH3, COCH2), 
1.88 (m, 2H, Im-4-CH2CH2), 0.88 (d, 3H, 3J = 6.1 Hz, CH3); ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 600 (MH+, 100). C38H41N5O2 (599.76) 
N-[4-(4-Ethylphenyl)-3-methylbutanoyl)-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]-
guanidine (3.74a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.37c (210 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.74a as a yellow oil 
(380 mg, 64 %). 1H-NMR (CDCl3) δ ppm: 7.34-7.10 (m, 20H, Im-2-H, CPh3, Ar-H), 
6.56 (d, 1H, 4J = 0.7 Hz, Im-5- H), 3.42 (t, 2H, 3J = 6.5 Hz, CH2NH), 2.65-2.11 (m, 9H, 
Im-4-CH2, CH2-Ar, (p-CH2CH3)-Ar, CHCH3, COCH2), 1.88 (m, 2H, Im-4-CH2CH2), 
1.20 (t, 3H, 3J = 7.6 Hz, (p-CH2CH3)-Ar), 0.91 (d, 3H, 3J = 5.9 Hz, CH3); ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 598 (MH+, 100). C39H43N5O (597.79) 
(R)-N-(3-Cyclohexylbutanoyl)-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine 
(3.75a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.40 (170 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.75a as a colourless 
foam-like solid (260 mg, 46 %). 1H-NMR (CDCl3) δ ppm: 7.35-7.12 (m, 16H, Im-2-H, 
CPh3), 6.56 (d, 1H, 4J = 1.0 Hz, Im-5-H), 3.44 (t, 2H, 3J = 6.5 Hz, CH2NH), 2.57 (m, 
2H, Im-4-CH2), 2.49 (dd, 1H, 3J = 5.0 Hz, 2J = 14.4 Hz, COCHH), 2.19 (dd, 1H, 3J = 
9.4 Hz, 2J = 14.2 Hz, COCHH), 1.90 (m, 3H, Im-4-CH2CH2, CHCH3), 1.73-1.62 (m, 
5H, cHex-CH2, cHex-CH), 1.23-1.03 (m, 6H, cHex-CH2), 0.88 (d, 3H, 3J = 6.8 Hz, 
CH3); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 562 (MH+, 100). C36H43N5O (561.76) 
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(S)-N-(3-Cyclohexylbutanoyl)-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine 
(3.76a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.41 (170 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.76a as a colourless 
foam-like solid (190 mg, 34 %). 1H-NMR (CDCl3) δ ppm: 7.34-7.12 (m, 16H, Im-2-H, 
CPh3),  6.56 (d, 1H, 4J = 1.2 Hz, Im-5-H), 3.37 (t, 2H, 3J = 6.7 Hz, CH2NH), 2.58 (m, 
2H, Im-4-CH2), 2.41 (dd, 1H, 3J = 4.8 Hz, 2J = 14.2 Hz, COCHH), 2.07 (dd, 1H, 3J = 
9.6 Hz, 2J = 14.1 Hz, COCHH), 1.89 (m, 3H, Im-4-CH2CH2, CHCH3), 1.72-1.62 (m, 
5H, cHex-CH2, cHex-CH), 1.21-1.00 (m, 6H, cHex-CH2), 0.88 (d, 3H, 3J = 6.8 Hz, 
CH3); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 562 (MH+, 100). C36H43N5O (561.76) 
N-(3-Cyclohexyl-2-methylpropanoyl)-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]-
guanidine (3.77a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.42 (170 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.77a as a colourless 
foam-like solid (380 mg, 68 %). 1H-NMR (CDCl3) δ ppm: 7.34-7.12 (m, 16H, Im-2-H, 
CPh3), 6.56 (d, 1H, 4J = 1.0 Hz, Im-5- H), 3.37 (t, 2H, 3J = 6.6 Hz, CH2NH), 2.57 (m, 
2H, Im-4-CH2), 1.88 (m, 2H, Im-4-CH2CH2), 1.73-1.58 (m, 6H, cHex-CH2), 1.23-1.08 
(m, 8H, cHex-CH, cHex-CH2, CH3), 0.86 (m, 2H, CH2-cHex); ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 562 (MH+, 100). C36H43N5O (561.80) 
N-(3-Cyclohexylpentanoyl)-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine 
(3.78a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.43 (180 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.78a as a colourless 
foam-like solid (260 mg, 45 %). 1H-NMR (CDCl3) δ ppm: 7.35-7.11 (m, 16H, Im-2-H, 
CPh3), 6.58 (s, 1H, Im-5-H), 3.51 (t, 2H, 3J = 6.3 Hz, CH2NH), 2.54 (m, 2H, Im-4-
CH2), 2.38 (dd, 1H, 3J = 7.7 Hz, 2J = 15.5 Hz, COCHH), 2.27 (dd, 1H, 3J = 6.0 Hz, 2J 
= 14.6 Hz, COCHH), 1.91 (m, 2H, Im-4-CH2CH2), 1.78-1.62 (m, 6H, CHCH2CH3, 
cHex-CH, cHex-CH2), 1.40-1.03 (m, 8H, CHCH2CH3, cHex-CH2), 0.88 (t, 3H, 3J = 7.4 
Hz, CH3); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 576 (MH+, 100). C37H45N5O 
(575.79) 
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N-[2-(Cyclohexylmethyl)butanoyl]-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]-
guanidine (3.79a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.44 (180 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.79a as a colourless 
foam-like solid (310 mg, 54 %). 1H-NMR (CDCl3) δ ppm: 7.34-7.11 (m, 16H, Im-2-H, 
CPh3), 6.55 (d, 1H, 4J = 0.9 Hz, Im-5- H), 3.35 (t, 2H, 3J = 6.7 Hz, CH2NH), 2.57 (m, 
2H, Im-4-CH2), 2.30 (m, 1H, CHCH2CH3), 1.87 (m, 2H, Im-4-CH2CH2), 1.67-1.48 (m, 
8H, CH2CH3, cHex-CH2), 1.24-1.14 (m, 5H, cHex-CH, cHex-CH2), 0.87 (m, 5H, CH3, 
CH2-cHex); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 562 (MH+, 100). C36H43N5O 
(561.76) 
N-(3-Cyclohexyl-4-methylpentanoyl)-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]-
guanidine (3.80a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.45 (200 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.80a as a pale yellow 
foam-like solid (180 mg, 31 %). 1H-NMR (CDCl3) δ ppm: 7.35-7.11 (m, 16H, Im-2-H, 
CPh3), 6.57 (d, 1H, 4J = 0.7 Hz, Im-5-H), 3.49 (m, 2H, CH2NH), 2.56 (m, 2H, Im-4-
CH2), 2.45 (d, 2H, 3J = 5.6Hz, COCH2), 1.86-1.63 (m, 7H, CH(CH3)2, CHCH(CH3)2, 
cHex-CH, cHex-CH2),  1.25-1.04 (m, 6H, cHex-CH2), 0.89 (t, 3H, 3J = 7.4 Hz, CH3), 
ES-MS (DCM/MeOH + NH4OAc) m/z (%): 590 (MH+, 100), C38H47N5O (589.81) 
N-(3-Cyclohexyl-5-methylhexanoyl)-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]-
guanidine (3.81a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.46 (210 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.81a as a colourless 
foam-like solid (340 mg, 56 %). 1H-NMR (CDCl3) δ ppm: 7.34-7.12 (m, 16H, Im-2-H, 
CPh3), 6.56 (d, 1H, 4J = 1.0 Hz, Im-5-H), 3.37 (t, 2H, 3J = 6.6 Hz, CH2NH), 2.57 (m, 
3H, Im-4-CH2, COCHH), 2.34 (dd, 1H, 3J = 7.0 Hz, 2J= 15.8 Hz, COCHH), 2.11 (m, 
2H, Im-4-CH2CH2), 1.89 (m, 1H, CH(CH3)2), 1.71-1.58 (m, 6H, CHCH2, cHex-CH, 
cHex-CH2), 1.21-1.03 (m, 8H, CH2CH(CH3)3, cHex-CH2), 0.87 (m, 6H, CH3); ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 604 (MH+, 100). C39H49N5O (603.83) 
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N-(4-Cyclohexyl-3-methylbutanoyl)-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]-
guanidine (3.82a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.47 (180 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.82a as a orange 
foam-like solid (270 mg, 46 %). 1H-NMR (CDCl3) δ ppm: 7.35-7.12 (m, 16H, Im-2-H, 
CPh3), 6.56 (d, 1H, 4J = 1.1 Hz, Im-5-H), 3.39 (t, 2H, 3J = 6.6 Hz, CH2NH), 2.57 (m, 
2H, Im-4-CH2), 2.33-2.05 (m, 3H, COCH2, CHCH3), 1.89 (m, 2H, Im-4-CH2CH2), 
1.71-1.58 (m, 5H, cHex-CH2, cHex-CH), 1.26-1.04 (m, 6H, cHex-CH2), 0.90 (d, 3H, 3J 
= 6.2 Hz, CH3), 0.84 (m, 2H, CH2-cHex); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
576 (MH+, 100). C37H45N5O (575.79) 
N-(5-Cyclohexyl-3-methylpentanoyl)-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]-
guanidine (3.83a) 
The title compound was prepared from CDI (140 mg, 0.89 mmol), 3.48 (160 mg, 0.81 
mmol), 3.7 (330 mg, 0.81 mmol) and NaH (60 % dispersion in mineral oil) (60 mg, 1.6 
mmol) in THF/abs according to the general procedure yielding 3.83a as a yellow oil 
(160 mg, 34 %). 1H-NMR (CDCl3) δ ppm: 7.35-7.11 (m, 16H, Im-2-H, CPh3), 6.56 (d, 
1H, 4J = 1.2 Hz, Im-5-H), 3.42 (t, 2H, 3J = 6.6 Hz, CH2NH), 2.56 (m, 2H, Im-4-CH2), 
2.42 (dd, 1H, 3J = 5.9 Hz, 2J = 14.4 Hz, COCHH), 2.26 (dd, 1H, 3J = 5.5 Hz, 2J = 13.7 
Hz, COCHH), 1.89 (m, 3H, Im-4-CH2CH2, CHCH3), 1.70-1.61 (m, 5H, cHex-CH2, 
cHex-CH), 1.32-1.14 (m, 8H, CH2CH2-cHex, cHex-CH2), 0.92 (d, 3H, 3J = 6.7 Hz, 
CH3), 0.84 (m, 2H, CH2CH2-cHex); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 590 
(MH+, 100). C38H47N5O (589.81) 
N-(6-Cyclohexyl-3-methylhexanoyl)-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]-
guanidine (3.84a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.49 (210 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.84a as a yellow oil 
(260 mg, 43 %). 1H-NMR (CDCl3) δ ppm: 7.34-7.12 (m, 16H, Im-2-H, CPh3), 6.56 (d, 
1H, 4J = 1.2 Hz, Im-5-H), 3.36 (t, 2H, 3J = 6.7 Hz, CH2NH), 2.57 (m, 2H, Im-4-CH2), 
2.32 (dd, 1H, 3J = 5.9 Hz, 2J = 13.8 Hz, COCHH), 2.10 (dd, 1H, 3J = 8.2 Hz, 2J = 13.9 
Hz, COCHH), 1.87 (m, 3H, Im-4-CH2CH2, CHCH3), 1.70-1.61 (m, 5H, cHex-CH2, 
cHex-CH), 1.31-1.13 (m, 10H, CH2CH2CH2-cHex, CH2CH2CH2-cHex, cHex-CH2), 
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0.91 (d, 3H, 3J = 6.5 Hz, CH3), 0.83 (m, 2H, CH2CH2CH2-cHex); ES-MS (DCM/MeOH 
+ NH4OAc) m/z (%): 604 (MH+, 100). C39H49N5O (603.83) 
N-[3-(Cyclohexylmethyl)pentanoyl]-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]-
guanidine (3.85a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.50 (200 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.85a as a colourless 
foam-like solid (320 mg, 56 %). 1H-NMR (CDCl3) δ ppm: 7.34-7.12 (m, 16H, Im-2-H, 
CPh3), 6.56 (d, 1H, 4J = 1.2 Hz, Im-5- H), 3.40 (t, 2H, 3J = 6.6 Hz, CH2NH), 2.58 (m, 
2H, Im-4-CH2), 2.29 (m, 2H, COCH2), 1.92 (m, 3H, Im-4-CH2CH2, CHCH2CH3), 1.72-
1.62 (m, 5H, cHex-CH, cHex-CH2), 1.34-1.11 (m, 8H, CH2CH3, cHex-CH2), 0.86 
(CH3, CH2-cHex); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 590 (MH+, 100). 
C38H47N5O (589.81) 
N-[3-(3-hydroxyphenyl)butanoyl]-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]-
guanidine (3.86a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.53b (270 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.86a-Bn as a violett 
foam-like solid (270 mg, 41 %). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 660.4 
(MH+, 100). C43H41N5O2 (659.33). Subsequently, 3.86a-Bn was dissolved in 10 ml 
EtOH, Pd/C (10 %) (cat) was added and hydrogenated at 8 bar for 6 days (TLC-
control). The catalyst was filtered over Celite, the solvent removed in vacuo and 
3.86a (160 mg) used in the next step without further purification. 
N-[3-[4-(4-Methoxybenzyloxy)phenyl]butanoyl]-N´-[3-(1-trityl-1H-imidazol-4-yl)-
propyl]guanidine (3.87a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.54b (300 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure. Subsequently, the resulting 
foam-like solid was dissolved in 10 ml MeOH, Pd/C (10 %) (cat) was added and 
hydrogenated at room temperature overnight (TLC-control). The catalyst was filtered 
over Celite, the solvent removed in vacuo and 3.87a (310 mg, 45 %) used in the next 
step without further purification. ES-MS (DCM/MeOH + NH4OAc) m/z (%): 692 (MH+, 
25). C44H45N5O3 (691.86). 
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N-(4-tert-Butoxycarbonylamino-3-phenylbutanoyl)-N´-[3-(1-trityl-1H-imidazol-4-
yl)propyl]guanidine (3.88a) 
The title compound was prepared from CDI (160 mg, 0.99 mmol), 3.38c (240 mg, 
0.86 mmol), 3.7 (350 mg, 0.86 mmol) and NaH (60 % dispersion in mineral oil) (70 
mg, 1.72 mmol) in THF/abs according to the general procedure yielding 3.88a as a 
colourless foam-like solid (220 mg, 38 %). 1H-NMR (CDCl3) δ ppm: 7.67 (s, 1H, Im-2-
H), 7.34-7.11 (CPh3, Ar-H), 6.56 (d, 1H, 4J = 1.2 Hz, Im-5-H), 3.49 (m, 1H, 
CHCH2NH2), 3.30 (m, 4H, CH2NH, CH2NH2), 2.63-2.56 (m, 4H, COCH2, Im-4-CH2), 
1.85 (m, 2H, Im-4-CH2CH2), 1.38 (s, 9H, C(CH3)3); ES-MS (DCM/MeOH + NH4OAc) 
m/z (%): 671 (MH+, 100). C41H46N6O3 (670.84) 
N-(6-tert-Butoxycarbonylamino-3-phenylhexanoyl)-N´-[3-(1-trityl-1H-imidazol-4-
yl)propyl]guanidine (3.89a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), 3.39c (310 mg, 1 
mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) (80 mg, 2 
mmol) in THF/abs according to the general procedure yielding 3.89a as a colourless 
foam-like solid (260 mg, 40 %). 1H-NMR (CDCl3) δ ppm: 7.35-7.11 (m, 21H, Im-2-H, 
CPh3, Ar-H), 6.56 (d, 1H, 4J = 1.1 Hz, Im-5- H), 3.34 (t, 2H, 3J = 6.5 Hz, CH2NH), 
3.17-3.05 (m, 3H, CHCH2CH2CH2NH2, CH2NH2), 2.56 (m, 4H, Im-4-CH2, COCH2), 
1.86 (m, 2H, Im-4-CH2CH2), 1.73-1.57 (m, 2H, CH2CH2CH2NH2), 1.40 (s, 9H, 
C(CH3)3), 1.29 (m, 2H, CH2CH2CH2NH2); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
699 (MH+, 100). C43H50N6O3 (698.89) 
 
3.5.9. Preparation of acylguanidines 3.55-3.92 
General procedure  
To a solution of the protected acylguanidine in CH2Cl2/abs were added TFA (20 %) 
and stirred at ambient temperatur until the detritylation was complete (5-7 h). 
Subsequently, the solvent was removed in vacuo and the residue was purified by 
preparative HPLC. All compounds were obtained as trifluoroacetic acid salts. 
N-[3-(1H-Imidazol-4-yl)propanoyl]-N´-(3-phenylbutyl)guanidine (3.55) 
The title compound was prepared from 3.55a (110 mg, 0.19 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.55 as a 
colourless oil (90 mg, 84 %). 1H-NMR (CD3OD) δ (ppm): 8.78 (d, 1H, J4 = 1.3 Hz, Im-
2-H), 7.36 (s, 1H, Im-5-H), 7.23 (m, 5H, Ar-H), 3.17 (t, 2H, J3 = 7.1 Hz, Im-4-
CH2CH2), 3.06 (t, 2H, J3 = 7.1 Hz, NHCH2), 2.90 (t, 2H, J3 = 7.0 Hz, Im-4-CH2CH2), 
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2.82 (m, 1H, CHCH3), 1.96 (m, 2H, NHCH2CH2) 1.28 (d, 3H, J3 = 7.0, CH3); 13C-NMR 
(CD3OD) δ (ppm): 177.89 (quart, C=O), 157.44 (quart, C=NH), 149.54 (quat. Ar-C), 
137.24 (+, Im-2-C), 136.38 (quart, Im-4-C), 132.28 (+, 2 Ar-CH), 130.53 (+, 2 Ar-CH), 
130.02 (+, Ar-CH), 119.92 (+, Im-5-C), 43.70 (-, Im-4-CH2CH2), 41.34 (+, CHCH3), 
39.41 (-, NHCH2), 38.53 (-, NHCH2CH2), 25.46 (+, CH3), 22.35 (-, Im-4-CH2); HRMS: 
EI-MS: m/z for (C17H23N5O) calcd. 313.1903, found 313.1902; prep. HPLC: 
MeOH/0.1% TFA/aq (60/40). C17H23N5O · 2 TFA (541.37) 
N-[3-(1H-Imidazol-4-yl)propyl]-N´-(3-phenylpentanoyl)guanidine (3.56) 
The title compound was prepared from 3.56a (270 mg, 0.47 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.56 as a 
colourless oil (60 mg, 23 %). 1H-NMR (CD3OD) δ ppm: 8.76 (d, 1H, 4J = 0.9 Hz, Im-2-
H), 7.33 (s, 1H, Im-5-H), 7.22 (m, 5H, Ar-H), 3.31 (t, 2H, 3J = 6.8 Hz, CH2NH), 3.03 
(m, 1H, CHCH2CH3), 2.80 (m, 4H, Im-4-CH2, COCH2), 1.98 (m, 2H, Im-4-CH2CH2), 
1.70 (m, 2H, CHCH2CH3), 0.78 (t, 3H, 3J = 7.3 Hz, CH3); 13C-NMR (CD3OD) δ (ppm): 
176.22 (quart, C=O), 155.19 (quart, C=NH), 144.47 (quat. Ar-C), 134.93 (+, Im-2-C), 
134.28 (quat. Im-4-C), 129.57 (+, 2 Ar-CH), 128.79 (+, 2 Ar-CH), 127.77 (+, Ar-CH), 
117.12 (+, Im-5-C), 45.13 (+, CHCH2CH3), 44.75 (-, CH2NH), 41.47 (-, COCH2), 
30.20 (-, CHCH2CH3), 27.87 (-, Im-4-CH2CH2), 22.51 (-, Im-4-CH2), 12.25 (+, CH3); 
HRMS: EI-MS: m/z for [C18H25N5O] calcd. 327.20591, found 327.20547; prep. HPLC: 
MeOH/0.1% TFA/aq (45/55). C18H25N5O · 2 TFA (555.40) 
N-(2-Benzylbutanoyl)-N´-[3-(1H-imidazol-4-yl)propyl]guanidine (3.57) 
The title compound was prepared from 3.57a (350 mg, 0.61 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.57 as a 
colourless oil (90 mg, 27 %), 1H-NMR (CD3OD) δ ppm: 8.77 (s, 1H, Im-2-H), 7.33 (s, 
1H, Im-5-H), 7.19 (m, 5H, Ar-H), 3.31 (t, 2H, 3J = 6.2 Hz, CH2NH), 2.90-2.78 (m, 5H, 
Im-4-CH2, CH2-Ar, CHCH2CH3), 1.98 (m, 2H, Im-4-CH2CH2), 1.65 (m, 2H, CH2CH3), 
0.94 (t, 3H, 3J = 7.4 Hz, CH3); 13C-NMR (CD3OD) δ (ppm): 179.93 (quart, C=O), 
155.10 (quart, C=NH), 140.05 (quat. Ar-C), 134.91 (+, Im-2-C), 134.28 (quat. Im-4-
C), 130.08 (+, 2 Ar-CH), 129.54 (+, 2 Ar-CH), 127.63 (+, Ar-CH), 117.13 (+, Im-5-C), 
52.51 (+, CHCH2CH3), 41.48 (-, CH2-Ar), 39.27 (-, CH2NH), 27.87 (-, Im-4-CH2CH2), 
26.24 (-, CHCH2CH3), 22.53 (-, Im-4-CH2), 11.89 (+, CH3); HRMS: EI-MS: m/z for 
[C18H25N5O] calcd. 327.2059, found 327.20549; prep. HPLC: MeCN/0.1% TFA/aq 
(25/75-45/55). C18H25N5O · 2 TFA (555.40) 
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N-[3-(1H-Imidazol-4-yl)propyl]-N´-(4-methyl-3-phenylpentanoyl)guanidine (3.58) 
The title compound was prepared from 3.58a (290 mg, 0.49 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.58 as a 
colourless oil (90 mg, 32 %). 1H-NMR (CD3OD) δ ppm: 8.77 (d, 1H, 4J = 1.3 Hz, Im-2-
H), 7.51 (s, 1H, Im-5-H), 7.20 (m, 5H, Ar-H), 3.26 (m, overlap with solvent), 2H, 
CH2NH), 2.93 (m, 3H, CH2CH, COCH2), 2.77 (t, 2H, 3J = 7.7 Hz, Im-4-CH2), 1.94 (m, 
3H, Im-4-CH2CH2, CH(CH3)2), 0.99 (d, 3H, 3J = 6.7 Hz, CH3), 0.74 (d, 3H, 3J = 6.7 
Hz, CH3); 13C-NMR (CD3OD) δ (ppm): 176.57 (quart, C=O), 155.10 (quart, C=NH), 
143.54 (quat. Ar-C), 134.96 (+, Im-2-C), 134.25 (quat. Im-4-C), 129.51 (+, 2 Ar-CH), 
129.33 (+, 2 Ar-CH), 127.73 (+, Ar-CH), 117.12 (+, Im-5-C), 50.32 (+, CH2CH), 42.08 
(-, CH2NH), 41.45 (-, COCH2), 34.43 (+, CH(CH3)2), 27.83 (-, Im-4-CH2CH2), 22.50 (-, 
Im-4-CH2), 21.05 (+, CH3), 20.86 (+, CH3); HRMS: EI-MS: m/z for [C19H27N5O] calcd. 
341.22156, found 341.22193; prep. HPLC: MeOH/0.1% TFA/aq (55/45). C19H27N5O · 
2 TFA (569.43) 
N-[3-(1H-Imidazol-4-yl)propyl]-N´-(5-methyl-3-phenylhexanoyl)guanidine (3.59) 
The title compound was prepared from 3.59a (300 mg, 0.50 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.59 as a 
colourless oil (80 mg, 27 %). 1H-NMR (CD3OD) δ ppm: 8.77 (d, 1H, 4J = 1.3 Hz, Im-2-
H), 7.33 (s, 1H, Im-5-H), 7.20 (m, 5H, Ar-H), 3.31 (t, 2H, 3J = 6.9 Hz, CH2NH), 3.21 
(m, 1H, CH2CH), 2.74 (m, 4H, Im-4-CH2, COCH2), 1.98 (m, 2H, Im-4-CH2CH2), 1.65-
1.44 (m, 2H, CH2CH(CH3)2), 1.30 (m, 1H, CH(CH3)2), 0.88 (d, 3H, 3J = 6.4 Hz, CH3), 
0.83 (d, 3H, 3J = 6.5 Hz, CH3); 13C-NMR (CD3OD) δ (ppm): 176.14 (quart, C=O), 
155.19 (quart, C=NH), 144.64 (quat. Ar-C), 134.92 (+, Im-2-C), 134.28 (quat. Im-4-
C), 129.62 (+, 2 Ar-CH), 128.76 (+, 2 Ar-CH), 127.77 (+, Ar-CH), 117.13 (+, Im-5-C), 
46.47 (-, CH2CH(CH3)2), 45.62 (-, CH2NH), 41.47 (-, COCH2), 41.19 (+, CH2CH), 
27.89 (-, Im-4-CH2CH2), 26.48 (+, CH(CH3)2), 23.79 (+, CH3), 22.51 (-, Im-4-CH2), 
21.97 (+, CH3); HRMS: EI-MS: m/z for [C20H29N5O] calcd. 355.2372, found 
355.23723; prep. HPLC: MeOH/0.1% TFA/aq (55/45). C20H29N5O · 2 TFA (583.46) 
N-(3,4-Diphenylbutanoyl)-N´-[3-(1H-imidazol-4-yl)propyl]guanidine (3.60) 
The title compound was prepared from 3.60a (280 mg, 0.44 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.60 as a 
colourless oil (60 mg, 22 %). 1H-NMR (CD3OD) δ ppm: 8.76 (d, 1H, 4J = 1.2 Hz, Im-2-
H), 7.32 (s, 1H, Im-5-H), 7.21-7.09 (m, 10H, Ar-H), 3.48 (m, 1H, CHCH2), 3.28 (m, 
overlap with solvent), 2H, CH2NH), 2.93 (m, 2H, CH2-Ar), 2.80 (m, 4H, Im-4-CH2, 
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COCH2), 1.96 (m, 2H, Im-4-CH2CH2); 13C-NMR (CD3OD) δ (ppm): 176.08 (quart, 
C=O), 155.11 (quart, C=NH), 144.28 (quat. Ar-C), 140.82 (quat. Ar-C), 134.94 (+, Im-
2-C), 134.27 (quat. Im-4-C), 130.39 (+, 2 Ar-CH), 129.51 (+, 2 Ar-CH), 129.26 (+, 2 
Ar-CH), 128.82 (+, 2 Ar-CH), 127.83 (+, Ar-CH), 127.29 (+, Ar-CH), 117.11 (+, Im-5-
C), 45.27 (+, CHCH2), 43.97 (-, CH2-Ar), 43.78 (-, CH2NH), 41.44 (-, COCH2), 27.84 
(-, Im-4-CH2CH2), 22.51 (-, Im-4-CH2); HRMS: EI-MS: m/z for [C23H27N5O] calcd. 
389.22156, found. 389.22127; prep. HPLC: MeOH/0.1% TFA/aq (55/45). C23H27N5O · 
2 TFA (617.47) 
N-[3-(1H-Imidazol-4-yl)propyl]-N´-[3-phenyl-4-(4-methylphenyl)butanoyl)-
guanidine (3.61) 
The title compound was prepared from 3.61a (150 mg, 0.23 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.61 as a 
colourless oil (110 mg, 76 %), 1H-NMR (CD3OD) δ ppm: 8.75 (d, 1H, 4J = 1.3 Hz, Im-
2-H), 7.32 (d, 1H, 4J = 0.9 Hz, Im-5-H), 7.17 (m, 5H, Ar-H), 6.97 (m, 4H, Ar-H), 3.44 
(m, 1H, CHCH2), 3.27 (t, 2H, 3J = 6.1 Hz, CH2NH), 2.88 (d, 2H, 3J = 7.6 Hz, CH2-Ar), 
2.78 (m, 4H, Im-4-CH2, COCH2), 2.23 (s, 3H, (p-CH3)-Ar), 1.96 (m, 2H, Im-4-
CH2CH2); 13C-NMR (CD3OD) δ (ppm): 176.15 (quart, C=O), 155.09 (quart, C=NH), 
144.42 (quat. Ar-C), 137.65 (quat. Ar-C), 136.84 (quat. Ar-C), 134.91 (+, Im-2-C), 
134.26 (quat. Im-4-C), 130.31 (+, 2 Ar-CH), 129.88 (+, 2 Ar-CH), 129.50 (+, 2 Ar-CH), 
128.80 (+, 2 Ar-CH), 127.79 (+, Ar-CH), 117.11 (+, Im-5-C), 45.34 (+, CHCH2), 43.73 
(-, CH2-Ar), 43.62 (-, CH2NH), 41.43 (-, COCH2), 27.86 (-, Im-4-CH2CH2), 22.50 (-, 
Im-4-CH2), 21.11 (+, (p-CH3)-Ar); HRMS: EI-MS: m/z for [C24H29N5O] calcd. 
403.2372, found 403.23712; prep. HPLC: MeCN/0.1% TFA/aq (40/60). C24H29N5O · 2 
TFA (631.22) 
N-(3-Cyclohexyl-4-phenylbutanoyl)-N´-[3-(1H-imidazol-4-yl)propyl]guanidine 
(3.62) 
The title compound was prepared from 3.62a (180 mg, 0.28 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.62 as a 
colourless oil (30 mg, 17 %), 1H-NMR (CD3OD) δ ppm: 8.82 (d, 1H, 4J = 1.3 Hz, Im-2-
H), 7.37 (s, 1H, Im-5-H), 7.18 (m, 5H, Ar-H), 3.32 (m, overlap with solvent), 2H, 
CH2NH), 2.80 (m, 3H, Im-4-CH2, CHCH2-Ar), 2.48 (m, 2H, CH2-Ar), 2.30 (m, 2H, 
COCH2), 2.00 (m, 2H, Im-4-CH2CH2), 1.71 (m, 5H, cHex-CH2, cHex-CH), 1.40-1.15 
(m, 6H, cHex-CH2); 13C-NMR (CD3OD) δ (ppm): 177.38 (quart, C=O), 155.79 (quart, 
C=NH), 141.86 (quat. Ar-C), 135.00 (+, Im-2-C), 134.29 (quat. Im-4-C), 130.51 (+, 2 
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Ar-CH), 129.37 (+, 2 Ar-CH), 127.17 (+,  Ar-CH), 117.12 (+, Im-5-C), 43.57 (+, cHex-
CH), 42.26 (+, CHCH2), 41.48 (-, COCH2), 39.68 (-, CH2-Ar), 38.75 (-, CH2NH), 31.18 
(-, cHex-CH2), 30.37 (-, cHex-CH2), 27.87 (-, Im-4-CH2CH2, cHex-CH2), 27.77 (-, 
cHex-CH2), 22.56 (-, Im-4-CH2); HRMS: EI-MS: m/z for [C23H33N5O] calcd. 395.2685, 
found 395.26886; prep. HPLC: MeCN/0.1% TFA/aq (35/65). C23H33N5O · 2 TFA 
(623.25) 
N-[3-(1H-Imidazol-4-yl)propyl]-N´-[3-(4-methylphenyl)propanoyl]guanidine (3.63) 
The title compound was prepared from 3.63a (220 mg, 0.40 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.63 as a 
colourless oil (110 mg, 51 %), 1H-NMR (CD3OD) δ ppm: 8.78 (d, 1H, 4J = 0.9 Hz, Im-
2-H), 7.35 (s, 1H, Im-5-H), 7.08 (m, 4H, Ar-H), 3.36 (t, 2H, 3J = 6.8 Hz, CH2NH), 2.91 
(t, 2H, 3J = 7.3 Hz, COCH2CH2), 2.79 (m, 4H, Im-4-CH2, COCH2CH2), 2.27 (s, 3H, (p-
CH3)-Ar), 2.01 (m, 2H, Im-4-CH2CH2); 13C-NMR (CD3OD) δ (ppm): 176.64 (quart, 
C=O), 155.33 (quart, C=NH), 138.23 (quat. Ar-C), 137.06 (quat. Ar-C), 134.94 (+, Im-
2-C), 134.32 (quat. Im-4-C), 130.20 (+, 2 Ar-CH), 129.37 (+, 2 Ar-CH), 117.13 (+, Im-
5-C), 41.53 (-, CH2NH), 39.62 (-, COCH2), 30.92 (-, COCH2CH2), 27.95 (-, Im-4-
CH2CH2), 22.54 (-, Im-4-CH2), 21.09 (+, (p-CH3)-Ar); HRMS: EI-MS: m/z for 
[C17H23N5O] calcd. 313.1903, found 313.1902; prep. HPLC: MeCN/0.1% TFA/aq 
(25/75). C17H23N5O · 2 TFA (541.17) 
N-[3-(1H-Imidazol-4-yl)propyl]-N´-[3-(4-methylphenyl)butanoyl)guanidine (3.64) 
The title compound was prepared from 3.64a (230 mg, 0.40 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.64 as a 
colourless oil (90 mg, 40 %), 1H-NMR (CD3OD) δ ppm: 8.75 (d, 1H, 4J = 1.3 Hz, Im-2-
H), 7.33 (d, 1H, 4J = 0.9 Hz, Im-5-H), 7.09 (m, 4H, Ar-H), 3.33 (m, overlap with 
solvent), 2H, CH2NH), 3.25 (m, 1H, CHCH3), 2.80 (t, 2H, 3J = 7.6 Hz, Im-4-CH2), 2.73 
(m, 2H, COCH2), 2.25 (s, 3H, (p-CH3)-Ar), 1.99 (m, 2H, Im-4-CH2CH2), 1.27 (d, 3H, 
3J = 7.0 Hz, CH3); 13C-NMR (CD3OD) δ (ppm): 176.21 (quart, C=O), 155.25 (quart, 
C=NH), 143.32 (quat. Ar-C), 137.25 (quat. Ar-C), 134.90 (+, Im-2-C), 134.29 (quat. 
Im-4-C), 130.22 (+, 2 Ar-CH), 127.81 (+, 2 Ar-CH), 117.12 (+, Im-5-C), 46.21 (-, 
COCH2), 41.48 (-, CH2NH), 37.30 (+, CHCH3), 27.91 (-, Im-4-CH2CH2), 22.52 (-, Im-
4-CH2), 22.36 (+, (p-CH3)-Ar), 21.08 (+, CH3); HRMS: EI-MS: m/z for [C18H25N5O] 
calcd. 327.2059, found 327.20512; prep. HPLC: MeCN/0.1% TFA/aq (30/70). 
C18H25N5O · 2 TFA (555.18) 
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N-[3-(1H-Imidazol-4-yl)propyl]-N´-(3-methyl-4-phenylbutanoyl)guanidine (3.65) 
The title compound was prepared from 3.65a (320 mg, 0.56 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.65 as a 
colourless oil (100 mg, 32 %). 1H-NMR (CD3OD) δ ppm: 8.80 (d, 1H, 4J = 1.3 Hz, Im-
2-H), 7.36 (d, 1H, 4J = 0.9 Hz, Im-5- H), 7.20 (m, 5H, Ar-H), 3.35 (t, 2H, 3J = 6.9 Hz, 
CH2NH), 2.83 (t, 2H, 3J = 7.7 Hz, Im-4-CH2), 2.64 (dd, 1H, 3J = 6.6 Hz, 3J = 13.3 Hz, 
CHH-Ar), 2.54-2.31 (m, 4H, CHH-Ar, COCH2, CHCH3), 2.02 (m, 2H, Im-4-CH2CH2), 
0.96 (d, 3H, 3J = 6.3 Hz, CH3); 13C-NMR (CD3OD) δ (ppm): 176.82 (quart, C=O), 
155.28 (quart, C=NH), 141.40 (quat. Ar-C), 134.95 (+, Im-2-C), 134.32 (quat. Im-4-
C), 130.37 (+, 2 Ar-CH), 129.36 (+, 2 Ar-CH), 127.25 (+, Ar-CH), 117.13 (+, Im-5-C), 
44.56 (-, COCH2), 43.92 (-, CH2-Ar), 41.52 (-, CH2NH), 33.42 (+, CHCH3), 27.94 (-, 
Im-4-CH2CH2), 22.56 (-, Im-4-CH2), 19.91 (+, CH3); HRMS: EI-MS: m/z for 
[C18H25N5O] calcd. 327.2059, found 327.20554; prep. HPLC: MeOH/0.1% TFA/aq 
(45/55). C18H25N5O · 2 TFA (555.40) 
N-[3-(1H-Imidazol-4-yl)propyl]-N´-(3-methyl-5-phenylpentanoyl)guanidine (3.66) 
The title compound was prepared from 3.66a (310 mg, 0.53 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.66 as a 
colourless oil (120 mg, 40 %). 1H-NMR (CD3OD) δ ppm: 8.77 (d, 1H, 4J = 1.3 Hz, Im-
2-H), 7.33 (s, 1H, Im-5- H), 7.17 (m, 5H, Ar-H), 3.37 (t, 2H, 3J = 6.9 Hz, CH2NH), 2.82 
(m, 2H, 3J = 7.7 Hz, Im-4-CH2), 2.66-2.53 (m, 3H, CH2-Ar, COCHH), 2.31 (dd, 1H, 3J 
= 7.9 Hz, 3J = 15.1 Hz, COCHH), 2.02 (m, 3H, Im-4-CH2CH2, CHCH3), 1.67-1.52 (m, 
2H, CH2CH2-Ar), 1.02 (d, 3H, 3J = 6.7 Hz, CH3); 13C-NMR (CD3OD) δ (ppm): 176.93 
(quart, C=O), 155.37 (quart, C=NH), 143.56 (quat. Ar-C), 134.89 (+, Im-2-C), 134.32 
(quat. Im-4-C), 129.41 (+, 4 Ar-CH), 126.82 (+,  Ar-CH), 117.13 (+, Im-5-C), 45.02 (-, 
COCH2), 41.54 (-, CH2CH2-Ar), 39.52 (-, CH2NH), 34.21 (-, CH2CH2-Ar), 31.06 (+, 
CHCH3), 27.97 (-, Im-4-CH2CH2), 22.56 (-, Im-4-CH2), 19.79 (+, CH3); HRMS: EI-MS: 
m/z for [C19H27N5O] calcd. 341.2216, found 341.2216; prep. HPLC: MeOH/0.1% 
TFA/aq (55/45). C19H27N5O · 2 TFA (569.43) 
N-[3-(1H-Imidazol-4-yl)propyl]-N´-(3-methyl-6-phenylhexanoyl)guanidine (3.67) 
The title compound was prepared from 3.67a (280 mg, 0.47 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.67 as a 
colourless oil (100 mg, 36 %), 1H-NMR (CD3OD) δ ppm: 8.80 (d, 1H, 4J = 1.4 Hz, Im-
2-H), 7.36 (d, 1H, 4J = 1.0 Hz, Im-5-H), 7.18 (m, 5H, Ar-H), 3.38 (t, 2H, 3J =7.0 Hz, 
CH2NH), 2.83 (t, 2H, 3J = 7.7 Hz, Im-4-CH2), 2.59 (m, 2H, CH2-Ar), 2.46 (dd, 1H, 3J = 
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6.1 Hz, 3J = 15.0 Hz, COCHH), 2.26 (dd, 1H, 3J = 7.9 Hz, 3J = 15.0 Hz, COCHH), 
2.02 (m, 3H, Im-4-CH2CH2, CHCH3), 1.64 (m, 2H, CH2CH2-Ar), 1.41-1.24 (m, 2H, 
CH2CH2CH2-Ar), 0.96 (d, 3H, 3J = 6.7 Hz, CH3); 13C-NMR (CD3OD) δ (ppm): 176.91 
(quart, C=O), 155.31 (quart, C=NH), 143.67 (quat. Ar-C), 135.00 (+, Im-2-C), 134.34 
(quat. Im-4-C), 129.45 (+, 2 Ar-CH), 129.33 (+, 2 Ar-CH), 126.77 (+, Ar-CH), 117.12 
(+, Im-5-C), 45.16 (-, COCH2), 41.60 (-, CH2NH), 37.11 (-, CH2CH2CH2-Ar), 36.89 (-, 
CH2CH2CH2-Ar), 31.26 (+, CHCH3), 29.94 (-,CH2CH2CH2-Ar), 27.96 (-, Im-4-
CH2CH2), 22.59 (-, Im-4-CH2), 19.86 (+, CH3); HRMS: EI-MS: m/z for [C20H29N5O] 
calcd. 355.23721, found 355.23701; prep. HPLC: MeOH/0.1% TFA/aq (55/45). 
C20H29N5O · 2 TFA (583.46) 
N-[3-(1H-Imidazol-4-yl)propyl]-N´-[3-methyl-4-(3-methylphenyl)butanoyl]-
guanidine (3.68) 
The title compound was prepared from 3.68a (290 mg, 0.50 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.68 as a 
colourless oil (90 mg, 32 %), 1H-NMR (CD3OD) δ ppm: 8.78 (d, 1H, 4J = 1.2 Hz, Im-2-
H), 7.34 (s, 1H, Im-5-H), 7.11 (m, 1H, Ar-H), 6.95 (m, 3H, Ar-H), 3.34 (t, 2H, 3J = 6.9 
Hz, CH2NH), 2.82 (t, 2H, 3J = 7.7 Hz, Im-4-CH2), 2.57-2.45 (m, 3H, CH2-Ar, CHCH3), 
2.34 (m, 2H, COCH2), 2.28 (s, 3H, (m-CH3)-Ar), 2.01 (m, 2H, Im-4-CH2CH2), 0.95 (d, 
3H, 3J = 6.2 Hz, CH3); 13C-NMR (CD3OD) δ (ppm): 176.93 (quart, C=O), 155.32 
(quart, C=NH), 141.29 (quat. Ar-C), 138.99 (quat. Ar-C), 134.90 (+, Im-2-C), 134.33 
(quat. Im-4-C), 131.07 (+, Ar-CH), 129.25 (+, Ar-CH), 127.90 (+, Ar-CH), 127.43 (+, 
Ar-CH), 117.14 (+, Im-5-C), 44.62 (-, COCH2), 43.94 (-, CH2-Ar), 41.52 (-, CH2NH), 
33.41 (+, CHCH3), 27.97 (-, Im-4-CH2CH2), 22.56 (-, Im-4-CH2), 21.50 (+, (m-CH3)-
Ar), 20.03 (+, CH3); HRMS: EI-MS: m/z for [C19H27N5O] calcd. 341.2216, found 
341.22153; prep. HPLC: MeCN/0.1% TFA/aq (30/70). C19H27N5O · 2 TFA (569.20) 
N-[3-(1H-Imidazol-4-yl)propyl]-N´-[3-methyl-4-(4-methylphenyl)butanoyl]-
guanidine (3.69) 
The title compound was prepared from 3.69a (460 mg, 0.79 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.69 as a 
colourless oil (160 mg, 35 %), 1H-NMR (CD3OD) δ ppm: 8.76 (d, 1H, 4J = 0.7 Hz, Im-
2-H), 7.33 (s, 1H, Im-5-H), 7.03 (m, 4H, Ar-H), 3.35 (t, 2H, 3J = 6.9 Hz, CH2NH), 2.82 
(t, 2H, 3J = 7.7 Hz, Im-4-CH2), 2.56-2.43 (m, 3H, CH2Ar, CHCH3), 2.31 (m, 2H, 
COCH2), 2.25 (s, 3H, (p-CH3)-Ar), 2.01 (m, 2H, Im-4-CH2CH2), 0.93 (d, 3H, 3J = 6.1 
Hz, CH3); 13C-NMR (CD3OD) δ (ppm): 176.96 (quart, C=O), 155.31 (quart, C=NH), 
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138.21 (quat. Ar-C), 136.77 (quat. Ar-C), 134.88 (+, Im-2-C), 134.32 (quat. Im-4-C), 
130.29 (+, 2 Ar-CH), 129.96 (+, 2 Ar-CH), 117.14 (+, Im-5-C), 44.58 (-, COCH2), 
43.55 (-, CH2-Ar), 41.53 (-, CH2NH), 33.48 (+, CHCH3), 28.00 (-, Im-4-CH2CH2), 
22.56 (-, Im-4-CH2), 21.14 (+, (p-CH3)-Ar), 20.00 (+, CH3); HRMS: EI-MS: m/z for 
[C19H27N5O] calcd. 341.2216, found 341.2209; prep. HPLC: MeCN/0.1% TFA/aq 
(30/70). C19H27N5O · 2 TFA (569.20) 
N-[4-(3-Fluorophenyl)-3-methylbutanoyl]-N´-[3-(1H-imidazol-4-yl)propyl]-
guanidine (3.70) 
The title compound was prepared from 3.70a (120 mg, 0.20 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.70 as a 
colourless oil (50 mg, 44 %), 1H-NMR (CD3OD) δ ppm: 8.81 (d, 1H, 4J = 1.3 Hz, Im-2-
H), 7.36 (m, 1H, Im-5-H), 7.27 (m, 1H, Ar-H), 6.93 (m, 3H, Ar-H), 3.36 (t, 2H, 3J = 6.9 
Hz, CH2NH), 2.83 (t, 2H, 3J = 7.7 Hz, Im-4-CH2), 2.68 (dd, 1H, 3J = 6.3 Hz, 3J = 13.4 
Hz, CHH-Ar), 2.55 (dd, 1H, 3J = 5.2 Hz, 3J = 11.5 Hz, CHH-Ar), 2.48 (dd, 1H, 3J = 7.2 
Hz, 3J = 16.1 Hz, COCHH), 2.34 (m, 2H, COCHH, CHCH3), 2.03 (m, 2H, Im-4-
CH2CH2), 0.96 (d, 3H, 3J = 6.2 Hz, CH3); 13C-NMR (CD3OD) δ (ppm): 176.65 (quart, 
C=O), 164.33 (d, quart., 1J = 244.1 Hz, Ar-CF), 155.28 (quart, C=NH), 144.35 (d, 
quart., 3J = 7.2 Hz, Ar-C), 134.97 (+, Im-2-C), 134.33 (quat. Im-4-C), 131.02 (d, 3J = 
8.34 Hz, Ar-CH), 126.27 (d, 4J = 2.8 Hz, Ar-CH), 117.13 (+, Im-5-C), 116.92 (d, 2J = 
21.0 Hz, Ar-CH), 113.94 (d, 2J = 21.4 Hz, Ar-CH), 44.44 (-, COCH2), 43.46 (-, CH2-
Ar), 41.55 (-, CH2NH), 33.22 (+, CHCH3), 27.93 (-, Im-4-CH2CH2), 22.56 (-, Im-4-
CH2), 19.79 (+, CH3); HRMS: FAB-MS: m/z for [C18H24FN5O + H+] calcd. 346.1965, 
found 346.20379; prep. HPLC: MeCN/0.1% TFA/aq (30/70). C18H24FN5O · 2 TFA 
(573.17) 
N-[4-(4-Fluorophenyl)-3-methylbutanoyl]-N´-[3-(1H-imidazol-4-yl)propyl] -
guanidine (3.71) 
The title compound was prepared from 3.71a (340 mg, 0.58 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.71 as a 
colourless oil (130 mg, 39 %), 1H-NMR (CD3OD) δ ppm: 8.78 (d, 1H, 4J = 1.1 Hz, Im-
2-H), 7.34 (s, 1H, Im-5-H), 7.17 (m, 2H, Ar-H), 6.97 (m, 2H, Ar-H), 3.35 (t, 2H, 3J = 
6.9 Hz, CH2NH), 2.82 (t, 2H, 3J = 7.7 Hz, Im-4-CH2), 2.62 (dd, 1H, 3J = 6.5 Hz, 3J = 
13.5 Hz, CHH-Ar), 2.49 (m, 2H, CHH-Ar, COCHH), 2.32 (m, 2H, COCHH, CHCH3), 
2.02 (m, 2H, Im-4-CH2CH2), 0.94 (d, 3H, 3J = 6.2 Hz, CH3); 13C-NMR (CD3OD) δ 
(ppm): 176.82 (quart, C=O), 162.94 (d, quart., 1J = 242.6 Hz, Ar-CF), 155.32 (quart, 
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C=NH), 137.33 (d, quart., 4J = 3.2 Hz, Ar-C), 134.89 (+, Im-2-C), 134.33 (quat. Im-4-
C), 131.99 (d, +, 3J = 7.7 Hz, 2 Ar-CH), 117.13 (+, Im-5-C), 115.90 (d, +, 2J = 21.3 
Hz, 2 Ar-CH), 44.48 (-, COCH2), 43.02 (-, CH2-Ar), 41.51 (-, CH2NH), 33.46 (+, 
CHCH3), 27.97 (-, Im-4-CH2CH2), 22.56 (-, Im-4-CH2), 19.84 (+, CH3); HRMS: EI-MS: 
m/z for [C18H24FN5O] calcd. 345.1965, found 345.19673; prep. HPLC: MeCN/0.1% 
TFA/aq (30/70). C18H24FN5O · 2 TFA (573.17) 
N-[3-(1H-Imidazol-4-yl)propyl]-N´-[4-(3-methoxyphenyl)-3-methylbutanoyl]-
guanidine (3.72) 
The title compound was prepared from 3.72a (230 mg, 0.38 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.72 as a 
colourless oil (110 mg, 49 %), 1H-NMR (CD3OD) δ ppm: 8.79 (d, 1H, 4J = 1.2 Hz, Im-
2-H), 7.35 (s, 1H, Im-5-H), 7.15 (m, 1H, Ar-H), 6.73 (m, 3H, Ar-H), 3.75 (s, 3H, (m-
OCH3)-Ar), 3.34 (t, 2H, 3J = 6.9 Hz, CH2NH), 2.82 (t, 2H, 3J = 7.7 Hz, Im-4-CH2), 2.54 
(m, 3H, CH2Ar, CHCH3), 2.32 (m, 2H, COCH2), 2.01 (m, 2H, Im-4-CH2CH2), 0.96 (d, 
3H, 3J = 6.2 Hz, CH3); 13C-NMR (CD3OD) δ (ppm): 176.87 (quart, C=O), 161.18 
(quat. Ar-C), 155.28 (quart, C=NH), 142.98 (quat. Ar-C), 134.92 (+, Im-2-C), 134.33 
(quat. Im-4-C), 130.33 (+, Ar-CH), 122.74 (+, Ar-CH), 117.13 (+, Im-5-C), 115.91 (+, 
Ar-CH), 112.69 (+, Ar-CH), 55.59 (+, (m-OCH3)-Ar), 44.55 (-, COCH2), 43.99 (-, CH2-
Ar), 41.51 (-, CH2NH), 33.34 (+, CHCH3), 27.95 (-, Im-4-CH2CH2), 22.56 (-, Im-4-
CH2), 20.08 (+, CH3); HRMS: FAB-MS: m/z for [C19H27N5O2] calcd. 357.2165, found 
357.21574; prep. HPLC: MeCN/0.1% TFA/aq (25/75-40/60). C19H27N5O2 · 2 TFA 
(585.50) 
N-[3-(1H-Imidazol-4-yl)propyl]-N´-[4-(4-methoxyphenyl)-3-methylbutanoyl]-
guanidine (3.73) 
The title compound was prepared from 3.73a (300 mg, 0.50 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.73 as a 
colourless oil (160 mg, 55 %), 1H-NMR (CD3OD) δ ppm: 8.78 (d, 1H, 4J = 1.2 Hz, Im-
2-H), 7.35 (s, 1H, Im-5-H), 7.07 (m, 2H, Ar-H), 6.79 (m, 2H, Ar-H), 3.73 (s, 3H, (p-
OCH3)-Ar), 3.34 (t, 2H, 3J = 7.1 Hz, CH2NH), 2.82 (t, 2H, 3J = 7.7 Hz, Im-4-CH2), 2.53 
(m, 2H, CH2Ar), 2.42 (m, 1H, CHCH3), 2.29 (m, 2H, COCH2), 2.01 (m, 2H, Im-4-
CH2CH2), 0.95 (d, 3H, 3J = 6.2 Hz, CH3); 13C-NMR (CD3OD) δ (ppm): 176.96 (quart, 
C=O), 159.63 (quat. Ar-C), 155.29 (quart, C=NH), 134.91 (+, Im-2-C), 134.33 (quat. 
Im-4-C), 133.31 (quat. Ar-C), 131.37 (+, 2 Ar-CH), 117.13 (+, Im-5-C), 114.74 (+, 2 
Ar-CH), 55.70 (+, (p-OCH3)-Ar), 44.58 (-, COCH2), 43.15 (-, CH2-Ar), 41.51 (-, 
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CH2NH), 33.64 (+, CHCH3), 27.96 (-, Im-4-CH2CH2), 22.56 (-, Im-4-CH2), 20.11 (+, 
CH3); HRMS: FAB-MS: m/z for [C19H27N5O2 + H+] calcd. 358.2165, found 358.22353; 
prep. HPLC: MeCN/0.1% TFA/aq (30/70). C19H27N5O2 · 2 TFA (585.50) 
N-[4-(4-Ethylphenyl)-3-methylbutanoyl]-N´-[3-(1H-imidazol-4-yl)propyl]-
guanidine (3.74) 
The title compound was prepared from 3.74a (360 mg, 0.60 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.74 as a 
colourless oil (100 mg, 28 %), 1H-NMR (CD3OD) δ ppm: 8.76 (d, 1H, 4J = 0.7 Hz, Im-
2-H), 7.33 (s, 1H, Im-5-H), 7.06 (m, 4H, Ar-H), 3.35 (t, 2H, 3J = 6.9 Hz, CH2NH), 2.82 
(t, 2H, 3J = 7.7 Hz, Im-4-CH2), 2.50 (m, 5H, CH2-Ar, (p-CH2CH3)-Ar, CHCH3), 2.30 
(m, 2H, COCH2), 2.01 (m, 2H, Im-4-CH2CH2), 1.17 (t, 3H, 3J = 7.6 Hz, (p-CH2CH3)-
Ar), 0.94 (d, 3H, 3J = 6.1 Hz, CH3); 13C-NMR (CD3OD) δ (ppm): 176.95 (quart, C=O), 
155.31 (quart, C=NH), 143.34 (quat. Ar-C), 138.48 (quat. Ar-C), 134.88 (+, Im-2-C), 
134.33 (quat. Im-4-C), 130.35 (+, 2 Ar-CH), 128.78 (+, 2 Ar-CH), 117.14 (+, Im-5-C), 
44.58 (-, COCH2), 43.57 (-, CH2-Ar), 41.54 (-, CH2NH), 33.45 (+, CHCH3), 29.48 (-, 
(p-CH2CH3)-Ar), 27.99 (-, Im-4-CH2CH2), 22.56 (-, Im-4-CH2), 19.99 (+, (p-CH2CH3)-
Ar), 16.25 (+, CH3); HRMS: EI-MS: m/z for [C20H29N5O] calcd. 355.2372, found 
355.23757; prep. HPLC: MeCN/0.1% TFA/aq (30/70). C20H29N5O · 2 TFA (583.45) 
(R)-N-(3-Cyclohexylbutanoyl)-N´-[3-(1H-imidazol-4-yl)propyl]guanidine (3.75) 
The title compound was prepared from 3.75a (240 mg, 0.43 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.75 as a 
colourless oil (80 mg, 34 %). ee = 95.65 %; 1H-NMR (CD3OD) δ (ppm): 8.80 (d, 1H, 
4J = 1.4 Hz, Im-2-H), 7.36 (s, 1H, Im-5-H), 3.38 (t, 2H, 3J = 6.90 Hz, CH2NH), 2.84 (t, 
2H, 3J = 7.7 Hz, Im-4-CH2), 2.56 (dd, 1H, 3J = 5.1 Hz, 3J = 15.0 Hz, COCHH), 2.23 
(dd, 1H, 3J = 9.1 Hz, 3J = 15.0 Hz, COCHH), 2.03 (m, 2H, Im-4-CH2CH2), 1.90 (m, 
1H, CHCH3), 1.75-1.66 (m, 5H, cHex-CH2, cHex-CH), 1.23-1.05 (m, 6H, cHex-CH2), 
0.91 (d, 3H, 3J = 6.9 Hz, CH3); 13C-NMR (CD3OD) δ (ppm): 177.51 (quart, C=O), 
155.38 (quart, C=NH), 134.96 (+, Im-2-C), 134.34 (quat. Im-4-C), 117.14 (+, Im-5-C), 
43.94 (+, cHex-CH), 42.69 (-, CH2NH), 41.55 (-, COCH2), 36.43 (+, CH3CH), 31.48 (-, 
cHex-CH2), 30.02 (-, cHex-CH2), 27.97 (-, Im-4-CH2CH2), 27.85 (-, cHex-CH2), 27.74 
(-, 2 cHex-CH2), 22.57 (-,Im-4-CH2), 16.60 (+, CH3); HRMS: EI-MS: m/z for 
[C17H29N5O] calcd. 319.2372, found 319.23666; prep. HPLC: MeCN/0.1% TFA/aq 
(35/65). C17H29N5O · 2 TFA (547.42) 
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(S)-N-(3-Cyclohexylbutanoyl)-N´-[3-(1H-imidazol-4-yl)propyl]guanidine (3.76) 
The title compound was prepared from 3.76a (160 mg, 0.29 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.76 as a 
colourless oil (140 mg, 88 %). ee = 98.17 %; 1H-NMR (CD3OD) δ (ppm): 8.81 (d, 1H, 
4J = 1.4 Hz, Im-2-H), 7.37 (s, 1H, Im-5-H), 3.39 (t, 2H, 3J = 6.90 Hz, CH2NH), 2.84 (t, 
2H, 3J = 7.7 Hz, Im-4-CH2), 2.57 (dd, 1H, 3J = 5.1 Hz, 3J = 15.0 Hz, COCHH), 2.23 
(dd, 1H, 3J J = 9.1 Hz, 3J = 15.0 Hz, COCHH), 2.04 (m, 2H, Im-4-CH2CH2), 1.90 (m, 
1H, CHCH3), 1.76-1.66 (m, 5H, cHex-CH2, cHex-CH), 1.24-1.05 (m, 6H, cHex-CH2), 
0.91 (d, 3H, 3J = 6.9 Hz, CH3); 13C-NMR (CD3OD) δ (ppm): 176.65 (quart, C=O), 
154.52 (quart, C=NH), 134.06 (+, Im-2-C), 133.45 (quat. Im-4-C), 116.26 (+, Im-5-C), 
43.05 (+, cHex-CH), 41.81 (-, CH2NH), 40.66 (-, COCH2), 35.55 (+, CH3CH), 30.60 (-, 
cHex-CH2), 29.13 (-, cHex-CH2), 27.10 (-, Im-4-CH2CH2), 26.97 (-, cHex-CH2), 26.87 
(-, 2 cHex-CH2 ), 21.86 (-,Im-4-CH2), 15.72 (+, CH3); HRMS: EI-MS: m/z for 
[C17H29N5O] calcd. 319.2372, found 319.23674; prep. HPLC: MeCN/0.1% TFA/aq 
(35/65).  C17H29N5O · 2 TFA (547.42) 
N-(3-Cyclohexyl-2-methylpropanoyl)-N´-[3-(1H-imidazol-4-yl)propyl]guanidine 
(3.77) 
The title compound was prepared from 3.77a (370 mg, 0.66 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.77 as a 
colourless oil (130 mg, 36 %), 1H-NMR (CD3OD) δ ppm: 8.79 (d, 1H, 4J = 1.3 Hz, Im-
2-H), 7.36 (s, 1H, Im-5-H), 3.39 (t, 2H, 3J = 6.9 Hz, CH2NH), 2.84 (t, 2H, 3J = 7.7 Hz, 
Im-4-CH2), 2.71 (m, 1H, CHCH3), 2.04 (m, 2H, Im-4-CH2CH2), 1.66 (m, 6H, cHex-
CH2), 1.25 (m, 5H, cHex-CH, cHex-CH2), 1.15 (d, 3H, 3J = 6.8 Hz, CH3), 0.90 (m, 2H, 
CH2-cHex); 13C-NMR (CD3OD) δ (ppm): 181.40 (quart, C=O), 155.62 (quart, C=NH), 
134.92 (+, Im-2-C), 134.33 (quat. Im-4-C), 117.14 (+, Im-5-C), 42.25 (-, CH2-chex), 
41.60 (-, CH2NH), 40.27 (+, CHCH3), 36.65 (+, cHex-CH), 34.52 (-, cHex-CH2), 34.25 
(-, cHex-CH2), 27.98 (-, Im-4-CH2CH2), 27.61 (-, cHex-CH2), 27.35 (-, cHex-CH2), 
27.32 (-, cHex-CH2), 22.58 (-, Im-4-CH2), 17.93 (+, CH3); HRMS: EI-MS: m/z for 
[C17H29N5O] calcd. 319.2372, found 319.23686; prep. HPLC: MeCN/0.1% TFA/aq 
(25/75-45-55). C17H29N5O · 2 TFA (547.42) 
N-(3-Cyclohexylpentanoyl)-N´-[3-(1H-imidazol-4-yl)propyl]guanidine (3.78) 
The title compound was prepared from 3.78a (210 mg, 0.37 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.78 as a 
colourless oil (60 mg, 29 %), 1H-NMR (CD3OD) δ ppm: 8.81 (d, 1H, 4J = 1.3 Hz, Im-2-
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H), 7.37 (d, 1H, 4J = 0.8 Hz, Im-5-H), 3.38 (t, 2H, 3J = 7.0 Hz, CH2NH), 2.83 (t, 2H, 3J 
= 7.7 Hz, Im-4-CH2), 2.50 (dd, 1H, 3J = 6.2 Hz, 3J = 15.6 Hz, COCHH), 2.32 (dd, 1H, 
3J = 7.5 Hz, 3J = 15.6 Hz, COCHH), 2.03 (m, 2H, Im-4-CH2CH2), 1.77-1.61 (m, 6H, 
CHCH2CH3, cHex-CH, cHex-CH2) 1.43-1.07 (m, 8H, cHex-CH2), 0.89 (t, 3H, 3J = 7.4 
Hz, CH3); 13C-NMR (CD3OD) δ (ppm): 177.83 (quart, C=O), 155.37 (quart, C=NH), 
134.97 (+, Im-2-C), 134.32 (quat. Im-4-C), 117.13 (+, Im-5-C), 42.96 (+, cHex-CH), 
41.56 (-, COCH2), 41.41 (+, CHCH2CH3), 39.67 (-, CH2NH), 31.15 (-, cHex-CH2), 
30.34 (-, cHex-CH2), 27.91 (-, Im-4-CH2CH2, cHex-CH2), 27.89 (-, cHex-CH2), 27.79 
(-, cHex-CH2), 24.72 (-, CH2CH3), 22.56 (-, Im-4-CH2), 12.05 (+, CH3); HRMS: EI-MS: 
m/z for [C18H31N5O] calcd. 333.2528, found 333.25275; prep. HPLC: MeCN/0.1% 
TFA/aq (35/65).  C18H31N5O · 2 TFA (561.23) 
N-[2-(Cyclohexylmethyl)butanoyl]-N´-[3-(1H-imidazol-4-yl)propyl]guanidine 
(3.79) 
The title compound was prepared from 3.79a (290 mg, 0.50 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.79 as a 
colourless oil (40 mg, 14 %), 1H-NMR (CD3OD) δ ppm: 8.81 (d, 1H, 4J = 1.3 Hz, Im-2-
H), 7.37 (d, 1H, 4J = 0.8 Hz, Im-5-H), 3.39 (t, 2H, 3J = 7.0 Hz, CH2NH), 2.84 (t, 2H, 3J 
= 7.6 Hz, Im-4-CH2), 2.56 (m, 1H, CHCH2CH3), 2.04 (m, 2H, Im-4-CH2CH2), 1.63 (m, 
8H, CH2CH3, cHex-CH2), 1.26 (m, 5H, cHex-CH, cHex-CH2), 0.92 (t, 3H, 3J = 7.4 Hz, 
CH3), 0.88 (m, 2H, CH2-cHex); 13C-NMR (CD3OD) δ (ppm): 180.85 (quart, C=O), 
155.36 (quart, C=NH), 134.96 (+, Im-2-C), 134.32 (quat. Im-4-C), 117.13 (+, Im-5-C), 
47.84 (+, CHCH2CH3)41.66 (-, CH2NH), 40.64 (-, CH2-Ar), 36.96 (+, cHex-CH), 34.79 
(-, cHex-CH2), 34.19 (-, cHex-CH2), 27.92 (-, Im-4-CH2CH2), 27.58 (-, cHex-CH2), 
27.35 (-, cHex-CH2), 27.32 (-, cHex-CH2), 27.18 (-, CHCH2CH3), 22.60 (-, Im-4-CH2), 
11.88 (+, CH3); HRMS: EI-MS: m/z for [C18H31N5O] calcd. 333.2529, found 
333.25315; prep. HPLC: MeCN/0.1% TFA/aq (30/70-45/55). C18H31N5O · 2 TFA 
(561.23) 
N-(4-Cyclohexyl-3-methylbutanoyl)-N´-[3-(1H-imidazol-4-yl)propyl]guanidine 
(3.80) 
The title compound was prepared from 3.80a (170 mg, 0.29 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.80 as a 
colourless oil (110 mg, 66 %), 1H-NMR (CD3OD) δ ppm: 8.80 (d, 1H, 4J = 1.3 Hz, Im-
2-H), 7.36 (s, 1H, Im-5-H), 3.38 (t, 2H, 3J = 7.0 Hz, CH2NH), 2.83 (t, 2H, 3J = 7.7 Hz, 
Im-4-CH2), 2.40 (d, 2H, 3J = 5.6 Hz, COCH2), 2.03 (m, 2H, Im-4-CH2CH2), 1.84 (m, 
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1H, CH(CH3)2), 1.73-1.62 (m, 6H, CHCH(CH3)2, cHex-CH, cHex-CH2), 1.39-0.99 (m, 
6H, cHex-CH2), 0.91 (d, 3H, 3J = 6.7 Hz, CH3), 0.83 (d, 3H, 3J = 6.7 Hz, CH3); 13C-
NMR (CD3OD) δ (ppm): 178.23 (quart, C=O), 155.41 (quart, C=NH), 134.95 (+, Im-2-
C), 134.32 (quat. Im-4-C), 117.13 (+, Im-5-C), 46.46 (+, CHCH(CH3)2), 41.56 (-, 
CH2NH), 41.25 (+, cHex-CH), 36.91 (-, COCH2), 32.85 (-, cHex-CH2), 30.81 (-, cHex-
CH2), 29.81 (+, CH(CH3)2), 27.97 (-, cHex-CH2), 27.89 (-, Im-4-CH2CH2), 27.79 (-, 
cHex-CH2), 27.72 (-, cHex-CH2), 22.56 (-, Im-4-CH2), 21.76 (+, CH3), 19.05 (+, CH3); 
HRMS: EI-MS: m/z for [C19H33N5O] calcd. 347.26851, found 347.26819; prep. HPLC: 
MeCN/0.1% TFA/aq (40/60). C19H33N5O · 2 TFA (575.25) 
N-(3-Cyclohexyl-5-methylhexanoyl)-N´-[3-(1H-imidazol-4-yl)propyl]guanidine 
(3.81) 
The title compound was prepared from 3.81a (300 mg, 0.50 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.81 as a 
colourless oil (110 mg, 37 %), 1H-NMR (CD3OD) δ ppm: 8.80 (d, 1H, 4J = 1.3 Hz, Im-
2-H), 7.36 (d, 1H, 4J = 0.6 Hz, Im-5-H), 3.38 (t, 2H, 3J = 7.0 Hz, CH2NH), 2.83 (t, 2H, 
3J = 7.7 Hz, Im-4-CH2), 2.49 (dd, 1H, 3J = 6.6 Hz, 3J = 15.6 Hz, COCHH), 2.29 (dd, 
1H, 3J = 6.9 Hz, 3J = 15.6 Hz, COCHH), 2.05 (m, 2H, Im-4-CH2CH2), 1.94 (m, 1H, 
CH(CH3)2), 1.75-1.57 (m, 6H, CHCH2, cHex-CH, cHex-CH2), 1.30-1.06 (m, 8H,  
CH2CH(CH3)3, cHex-CH2), 0.88 (d, 3H, 3J = 3.2 Hz, CH3), 0.86 (d, 3H, 3J = 3.2 Hz, 
CH3); 13C-NMR (CD3OD) δ (ppm): 177.81 (quart, C=O), 155.39 (quart, C=NH), 
134.93 (+, Im-2-C), 134.32 (quat. Im-4-C), 117.13 (+, Im-5-C), 42.03 (+, cHex-CH), 
41.78 (-, CH2CH(CH3)2), 41.53 (-, COCH2), 40.24 (-, CH2NH), 38.87 (+, 
CHCH2CH(CH3)2), 30.92 (-, cHex-CH2), 30.12 (-, cHex-CH2), 27.97 (-, 2 cHex-CH2), 
27.92 (-, cHex-CH2), 27.84 (-, Im-4-CH2CH2), 26.68 (+, CH(CH3)2), 23.39 (-, Im-4-
CH2), 22.97 (+, CH3), 22.55 (+, CH3); HRMS: EI-MS: m/z for [C20H35N5O] calcd. 
361.28416, found 361.28366; prep. HPLC: MeCN/0.1% TFA/aq (45/55).  C20H35N5O · 
2 TFA (589.26) 
N-(4-Cyclohexyl-3-methylbutanoyl)-N´-[3-(1H-imidazol-4-yl)propyl]guanidine 
(3.82) 
The title compound was prepared from 3.82a (230 mg, 0.39 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.82 as a 
colourless oil (110 mg, 50 %), 1H-NMR (CD3OD) δ ppm: 8.79 (d, 1H, 4J = 1.2 Hz, Im-
2-H), 7.36 (s, 1H, Im-5-H), 3.38 (t, 2H, 3J = 6.9 Hz, CH2NH), 2.83 (t, 2H, 3J = 7.7 Hz, 
Im-4-CH2), 2.44 (dd, 1H, 3J = 5. 6Hz, 3J = 14.7 Hz, COCHH), 2.23 (dd, 1H, 3J = 8.1 
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Hz, 3J = 14.7 Hz, COCHH), 2.07 (m, 3H, Im-4-CH2CH2, CHC), 1.69 (m, 5H, cHex-
CH2, cHex-CH), 1.31-1.08 (m, 6H, cHex-CH2), 0.93 (d, 3H, 3J = 6.5 Hz, CH3), 0.84 
(m, 2H, CH2-cHex); 13C-NMR (CD3OD) δ (ppm): 177.05 (quart, C=O), 155.38 (quart, 
C=NH), 134.93 (+, Im-2-C), 134.32 (quat. Im-4-C), 117.14 (+, Im-5-C), 45.80 (-, 
COCH2), 45.56 (-, CH2-cHex), 41.54 (-, CH2NH), 36.08 (+, cHex-CH), 35.11 (-, cHex-
CH2), 34.13 (-, cHex-CH2), 28.31 (+, CHCH3), 27.98 (-, cHex-CH2), 27.78 (-, Im-4-
CH2CH2), 27.47 (-, cHex-CH2), 27.40 (-, cHex-CH2), 22.56 (-, Im-4-CH2), 20.06 (+, 
CH3); HRMS: EI-MS: m/z for [C18H31N5O] calcd. 333.25286, found 333.25247; prep. 
HPLC: MeCN/0.1% TFA/aq (40/60). C18H31N5O · 2 TFA (561.23) 
N-(5-Cyclohexyl-3-methylpentanoyl)-N´-[3-(1H-imidazol-4-yl)propyl]guanidine 
(3.83) 
The title compound was prepared from 3.83a (140 mg, 0.24 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.83 as a 
colourless oil (70 mg, 51 %), 1H-NMR (CD3OD) δ ppm: 8.79 (d, 1H, 4J = 1.3 Hz, Im-2-
H), 7.37 (d, 1H, 4J = 0.9 Hz, Im-5-H), 3.38 (t, 2H, 3J = 6.9 Hz, CH2NH), 2.83 (t, 2H, 3J 
= 7.7 Hz, Im-4-CH2), 2.47 (dd, 1H, 3J = 6.1 Hz, 3J = 15.0 Hz, COCHH), 2.25 (dd, 1H, 
3J = 8.0 Hz, 3J = 15.0 Hz, COCHH), 2.04 (m, 2H, Im-4-CH2CH2), 1.94 (m, 1H, 
CHCH3), 1.69 (m, 5H, cHex-CH2, cHex-CH), 1.36-1.16 (m, 8H, CH2CH2-cHex, cHex-
CH2), 0.95 (d, 3H, 3J = 6.7 Hz, CH3), 0.88 (m, 2H, CH2CH2-cHex); 13C-NMR (CD3OD) 
δ (ppm): 177.08 (quart, C=O), 155.38 (quart, C=NH), 134.96 (+, Im-2-C), 134.32 
(quat. Im-4-C), 117.13 (+, Im-5-C), 45.21 (-, COCH2), 41.53 (-, CH2NH), 39.15 (+, 
cHex-CH), 35.80 (-, CH2CH2-cHex), 34.90 (-, cHex-CH2), 34.72 (-, cHex-CH2), 34.45 
(-, CH2CH2-cHex), 31.69 (+,  CHCH3), 27.97 (-, cHex-CH2), 27.83 (-, Im-4-CH2CH2), 
27.53 (-, 2 cHex-CH2), 22.56 (-, Im-4-CH2), 19.88 (+, CH3); HRMS: EI-MS: m/z for 
[C19H33N5O] calcd. 347.2685, found 347.2684; prep. HPLC: MeCN/0.1% TFA/aq 
(45/55). C19H33N5O · 2 TFA (575.25) 
N-(6-Cyclohexyl-3-methylhexanoyl)-N´-[3-(1H-imidazol-4-yl)propyl]guanidine 
(3.84) 
The title compound was prepared from 3.84a (200 mg, 0.33 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.84 as a 
colourless oil (90 mg, 46 %), 1H-NMR (CD3OD) δ ppm: 8.81 (d, 1H, 4J = 1.3 Hz, Im-2-
H), 7.37 (s, 1H, Im-5-H), 3.38 (t, 2H, 3J = 6.9 Hz, CH2NH),  2.84 (t, 2H, 3J = 7.7 Hz, 
Im-4-CH2), 2.47 (dd, 1H, 3J = 6.1 Hz, 3J = 15.0 Hz, COCHH), 2.26 (dd, 1H, 3J = 8.0 
Hz, 3J = 15.0 Hz, COCHH), 2.03 (m, 3H, Im-4-CH2CH2, CHCH3), 1.68 (m, 5H, cHex-
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CH2, cHex-CH), 1.33-1.18 (m, 10H, CH2CH2CH2-cHex, CH2CH2CH2-cHex, cHex-
CH2), 0.96 (d, 3H, 3J = 6.7 Hz, CH3), 0.85 (m, 2H, CH2CH2CH2-cHex); 13C-NMR 
(CD3OD) δ (ppm): 177.03 (quart, C=O), 155.37 (quart, C=NH), 134.97 (+, Im-2-C), 
134.32 (quat. Im-4-C), 117.13 (+, Im-5-C), 45.23 (-, COCH2), 41.56 (-, CH2NH), 38.97 
(+, cHex-CH), 38.76 (-, CH2CH2CH2-cHex), 37.99 (-, CH2CH2CH2-cHex), 34.66 (-, 
cHex-CH2), 34.55 (-, cHex-CH2), 31.42 (+, CHCH3), 27.97 (-, cHex-CH2), 27.85 (-, 
Im-4-CH2CH2), 27.56 (-, 2 cHex-CH2), 25.18 (-, CH2CH2CH2-cHex), 22.57 (-, Im-4-
CH2), 19.88 (+, CH3); HRMS: EI-MS: m/z for [C20H359N5O] calcd. 361.28416, found 
361.28314; prep. HPLC: MeCN/0.1% TFA/aq (45/55). C20H35N5O · 2 TFA (589.26) 
N-[3-(Cyclohexylmethyl)pentanoyl]-N´-[3-(1H-imidazol-4-yl)propyl]guanidine 
(3.85) 
The title compound was prepared from 3.85a (310 mg, 0.54 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.85 as a 
colourless oil (90 mg, 29 %), 1H-NMR (CD3OD) δ ppm: 8.80 (d, 1H, 4J = 1.4 Hz, Im-2-
H), 7.36 (d, 1H, 4J = 1.0 Hz, Im-5-H), 3.38 (t, 2H, 3J = 6.9 Hz, CH2NH), 2.84 (t, 2H, 3J 
= 7.7 Hz, Im-4-CH2), 2.42 (dd, 1H, 3J = 5.2 Hz, 3J = 13.4 Hz, COCHH), 2.35 (dd, 1H, 
3J = 4.5 Hz, 3J = 13.3 Hz, COCHH), 2.01 (m, 3H, Im-4-CH2CH2, CHCH2CH3), 1.68 
(m, 5H, cHex-CH, cHex-CH2), 1.38-1.10 (m, 8H, CH2CH3, cHex-CH2), 0.88 (t, 3H, 3J 
=7.4Hz, CH3), 0.85 (m, 2H, CH2-cHex); 13C-NMR (CD3OD) δ (ppm): 177.42 (quart, 
C=O), 155.39 (quart, C=NH), 134.94 (+, Im-2-C), 134.32 (quat. Im-4-C), 117.13 (+, 
Im-5-C), 42.65 (-, 2 COCH2, CH2-cHex), 41.53 (-, CH2NH), 36.13 (+, CHCH2CH3), 
34.80 (-, cHex-CH2), 34.70 (-, cHex-CH2), 34.38 (+, cHex-CH), 27.97 (-, Im-4-
CH2CH2), 27.78 (-, cHex-CH2), 27.54 (-, CHCH2CH3), 27.46 (-, 2 cHex-CH2), 22.55 (-, 
Im-4-CH2), 10.92 (+, CH3); HRMS: EI-MS: m/z for [C19H33N5O] calcd. 347.2685, 
found 347.26848; prep. HPLC: MeCN/0.1% TFA/aq (35/65-45/55). C19H33N5O · 2 
TFA (575.47) 
N-[3-(3-Hydroxyphenyl)butanoyl]-N´-[3-(1H-imidazol-4-yl)propyl]guanidine 
(3.86) 
The title compound was prepared from 3.86a (160 mg) in 10 ml CH2Cl2/abs and 2 ml 
TFA according to the general procedure yielding 3.86 as a colourless oil (30 mg, 13 
%, based on 3.86-Bn), 1H-NMR (CD3OD) δ ppm: 8.78 (d, 1H, 4J = 1.2 Hz, Im-2-H), 
7.34 (s, 1H, Im-5-H), 7.08 (m, 1H, Ar-H), 6.64 (m, 3H, Ar-H), 3.34 (m, overlap with 
solvent), 2H, CH2NH), 3.21 (m, 1H, CHCH3), 2.80 (t, 2H, 3J = 7.7 Hz, Im-4-CH2), 2.71 
(d, 2H, 3J = 7.5 Hz, COCH2), 2.00 (m, 2H, Im-4-CH2CH2), 1.29 (d, 3H, 3J = 7.0 Hz, 
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CH3); 13C-NMR (CD3OD) δ (ppm): 176.07 (quart, C=O), 158.68 (quat. Ar-C), 155.25 
(quart, C=NH), 148.00 (quat. Ar-C), 130.66 (+, Ar-CH), 118.98 (+, Ar-CH), 117.15 (+, 
Im-5-C), 114.85 (+, Ar-CH), 114.55 (+, Ar-CH), 46.11 (-, COCH2), 41.55 (-, CH2NH), 
37.58 (+, CHCH3), 27.90 (-, Im-4-CH2CH2), 22.56 (-, Im-4-CH2), 22.23 (+, CH3); 
HRMS: EI-MS: m/z for [C17H23N5O2] calcd. 329.1852, found 329.18541; prep. HPLC: 
MeCN/0.1% TFA/aq (20/80). C17H23N5O2 · 2 TFA (557.37) 
N-[3-(4-Hydroxyphenyl)butanoyl]-N´-[3-(1H-imidazol-4-yl)propyl]guanidine 
(3.87) 
The title compound was prepared from 3.87a (280 mg, 0.40 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.87 as a 
colourless oil (20 mg, 9 %, based on 3.87a), 1H-NMR (CD3OD) δ ppm: 8.78 (s, 1H, 
Im-2-H), 7.35 (s, 1H, Im-5-H), 7.06 (m, 2H, Ar-H), 6.69 (m, 2H, Ar-H), 3.33 (m, 2H, 
CH2NH), 3.22 (m, 1H, CHCH3), 2.79 (t, 3H, 3J = 7.6 Hz, Im-4-CH2), 2.69 (d, 2H, 3J = 
7.5 Hz, COCH2), 1.99 (m, 2H, Im-4-CH2CH2), 1.27 (d, 3H, 3J = 7.0 Hz, CH3); HRMS: 
EI-MS: m/z for [C17H23N5O2] calcd. 329.3968, found 329.18525; prep. HPLC: 
MeCN/0.1% TFA/aq (20/80-30/70). C17H23N5O2 · 2 TFA (557.37) 
N-(4-Amino-3-phenylbutanoyl)-N´-[3-(1H-imidazol-4-yl)propyl]guanidine (3.88) 
The title compound was prepared from 3.88a (200 mg, 0.30 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.88 as a 
colourless oil (60 mg, 30 %), 1H-NMR (CD3OD) δ ppm: 8.77 (d, 1H, 4J = 1.3 Hz, Im-2-
H), 7.33 (m, 6H, Im-5-H, Ar-H), 3.53 (m, 1H, CHCH2NH2), 3.34-3.21 (m, 4H, CH2NH,  
CH2NH2), 3.01 (dd, 1H, 3J = 6.2 Hz, 2J = 16.3 Hz, COCHH), 2.92 (dd, 1H, 3J = 8.4 Hz, 
2J = 16.3 Hz, COCHH), 2.80 (t, 2H, 3J = 7.7 Hz, Im-4-CH2), 1.99 (m, 2H, Im-4-
CH2CH2); 13C-NMR (CD3OD) δ (ppm): 174.77 (quart, C=O), 155.13 (quart, C=NH), 
139.92 (quat. Ar-C), 134.90 (+, Im-2-C), 134.29 (quat. Im-4-C), 130.39 (+, 2 Ar-CH), 
129.29 (+, Ar-CH), 129.08 (+, 2 Ar-CH), 117.13 (+, Im-5-C), 44.93 (-, CH2NH2), 41.71 
(-, CH2NH), 41.49 (-, COCH2), 41.19 (+, CHCH2NH2), 27.87 (-, Im-4-CH2CH2), 22.50 
(-, Im-4-CH2); HRMS: FAB-MS: m/z for [C17H24N6O + H+] calcd. 329.2012, found 
329.20864; prep. HPLC: MeCN/0.1% TFA/aq (12.5/87.5). C17H24N6O · 3 TFA 
(670.17) 
N-(6-Amino-3-phenylhexanoyl)-N´-[3-(1H-imidazol-4-yl)propyl]guanidine (3.89) 
The title compound was prepared from 3.89a (260 mg, 0.37 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 3.89 as a 
colourless oil (120 mg, 46 %), 1H-NMR (CD3OD) δ ppm: 8.74 (s, 1H, Im-2-H), 7.31 (s, 
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1H, Im-5-H), 7.21 (m, 5H, Ar-H), 3.30 (t, 2H, 3J = 6.8 Hz, CH2NH), 3.17 (m, 1H, 
CHCH2CH2CH2NH2), 2.83 (m, 6H, Im-4-CH2, COCH2, CH2NH2), 1.97 (m, 2H, Im-4-
CH2CH2), 1.76 (m, 2H, CH2CH2CH2NH2), 1.49 (m, 2H, CH2CH2CH2NH2); 13C-NMR 
(CD3OD) δ (ppm): 175.85 (quart, C=O), 155.20 (quart, C=NH), 143.72 (quat. Ar-C), 
134.87 (+, Im-2-C), 134.28 (quat. Im-4-C), 129.82 (+, 2 Ar-CH), 128.80 (+, 2 Ar-CH), 
128.12 (+, Ar-CH), 117.12 (+, Im-5-C), 44.81 (+, CHCH2), 42.84 (-, CH2NH2), 41.45 (-
, CH2NH), 40.54 (-, COCH2), 33.77 (-, CH2CH2CH2NH2), 27.88 (-, Im-4-CH2CH2), 
26.58 (-, CH2CH2CH2NH2), 22.49 (-, Im-4-CH2); HRMS: EI-MS: m/z for [C19H28N6O + 
H+] calcd. 357.2325, found 357.24061; prep. HPLC: MeCN/0.1% TFA/aq (12.5/87.5). 
C19H28N6O · 3 TFA (698.20) 
General procedure for the preparation of compounds 3.90-3.91 
To a solution of 3.89 (1 eq) in MeCN was added NEt3 (3 eq). Subsequently, a 
solution of NHS-4-F-benzoate or –propionate (0.8 eq), respectively, was added and 
stirred for 4-5 h at room temperature. The solvent was removed in vacuo and purified 
by preperative HPLC. 
N-[6-(4-Fluorobenzamido)-3-phenylhexanoyl]-N´-[3-(1H-imidazol-4-yl)propyl]-
guanidine (3.90) 
The title compound was prepared from 3.89 (43.5 mg, 0.0623 mmol) in 1.5 ml MeCN, 
NEt3 (0.026 ml, 0.187 mmol) and NHS-4-F-benzoate (11.8 mg, 0.0498 mmol) in 0.5 
ml MeCN according to the general procedure yielding 3.90 (30 mg, 85 %) as a 
colourless oil. 1H-NMR (CD3OD) δ ppm: 8.77 (d, 1H, 4J = 1.4 Hz, Im-2-H), 7.81 (m, 
2H, Ar-H), 7.29-7.16 (m, 8H, Ar-H), 3.32 (m, 4H, CH2NHCO, CH2NH), 3.19 (m, 1H, 
CHCH2CH2CH2NH), 2.81 (m, 4H, Im-4-CH2, COCH2), 1.96 (m, 2H, Im-4-CH2CH2), 
1.74 (m, 2H, CH2CH2CH2NH), 1.48 (m, 2H, CH2CH2CH2NH); 13C-NMR (CD3OD) δ 
(ppm): 176.01 (quart, C=O), 169.09 (quart, C=O), 166.16 (d, quart., 1J = 250.16 Hz, 
Ar-CF), 155.19 (quart, C=NH), 144.39 (quat. Ar-C), 134.96 (+, Im-2-C), 134.29 (quat. 
Im-4-C), 132.19 (d, +, 4J = 3.2 Hz, Ar-CH), 130.83 (d, +, 3J = 8.9 Hz, Ar-CH), 129.71 
(+, 2 Ar-CH), 128.78 (+, 2 Ar-CH), 127.91 (+, Ar-CH), 117.12 (+, Im-5-C), 116.35 (d, 
+, 2J = 22.13 Hz, Ar-CH), 45.05 (-, COCH2), 42.96 (+, CHCH2), 41.52 (-, CH2NH), 
40.71 (-, CH2NHCO), 34.45 (-, CH2CH2CH2NH2), 28.38 (-, CH2CH2CH2NH), 27.87 (-, 
Im-4-CH2CH2), 22.53 (-, Im-4-CH2); HRMS: EI-MS: m/z for [C26H31FN5O2] calcd. 
478.24925, found 478.24833; prep. HPLC: MeCN/0.1% TFA/aq (30/70-50/50). 
C26H31FN6O2 · 2 TFA (706.54) 
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N-[3-(1H-Imidazol-4-yl)propyl]-N´-(3-phenyl-6-propionamidohexanoyl)guanidine 
(3.91) 
The title compound was prepared from 3.89 (43.5 mg, 0.0623 mmol) in 1.5 ml MeCN, 
NEt3 (0.026 ml, 0.187 mmol) and NHS-propionate (8.79 mg, 0.0498 mmol) in 0.5 ml 
MeCN according to the general procedure yielding 3.91 (40 mg, 94 %) as a 
colourless oil. 1H-NMR (CD3OD) δ ppm: 8.78 (d, 1H, 4J = 1.3 Hz, Im-2-H), 7.24 (m, 
6H, Ar-H), 3.32 (m, 2H, CH2NHCO), 3.15 (m, 3H, CH2NH, CHCH2CH2CH2NH), 2.79 
(m, 4H, Im-4-CH2, COCH2), 2.14 (q, 2H, COCH2CH3), 1.97 (m, 2H, Im-4-CH2CH2), 
1.69 (m, 2H, CH2CH2CH2NH), 1.34 (m, 2H, CH2CH2CH2NH), 1.08 (t, 3H, 3J = 7.6 Hz, 
COCH2CH3); 13C-NMR (CD3OD) δ (ppm): 177.05 (quart, C=O), 175.99 (quart, C=O), 
155.20 (quart, C=NH), 144.37 (quat. Ar-C), 134.96 (+, Im-2-C), 134.30 (quat. Im-4-
C), 129.69 (+, 2 Ar-CH), 128.76 (+, 2 Ar-CH), 127.90 (+, Ar-CH), 117.13 (+, Im-5-C), 
45.02 (-, COCH2), 42.97 (+, CHCH2), 41.52 (-, CH2NH), 40.06 (-, CH2NHCO), 34.42 
(-, CH2CH2CH2NH2), 30.24 (-, CH2CH3), 28.37 (-, CH2CH2CH2NH), 27.88 (-, Im-4-
CH2CH2), 22.53 (-, Im-4-CH2), 10.60 (+, CH3); HRMS: EI-MS: m/z for [C22H32N6O2] 
calcd. 412.25867, found 412.25828; prep. HPLC: MeCN/0.1% TFA/aq (20/80-50/50). 
C22H32N6O2 · 2 TFA (640.51) 
(E)-4-[2-(1,2,3,5,6,7-Hexahydropyrido[3,2,1-ij]quinolin-9-yl)ethenyl]-2,6-dimethyl-
1-[7-[[3-(1H-Imidazol-4-yl)propyl]carbamimidoyl]amino-7-oxo-4-phenylhexyl]-
pyridinium trifluoroacetate (3.92) 
To a solution of 3.89 (5.53 mg, 7.9 µmol) in 800 µl MeCN was added NEt3 (4 µl, 29.7 
µmol). Subsequently, a solution of the dye py-197 ((E)-4-[2-(1,2,3,5,6,7-hexahydro-
pyrido[3,2,1-ij]quinolin-9-yl)ethenyl]-2,6-dimethylpyrylium tetrafluoroborate, 1.54 mg, 
3.96 µmol) in 50 µl DMF and 100 µl MeCN was added. After 1-2 min a red colour 
occurred and after 1 h 10% TFA/aq (35 µl) was added and purified by preperative 
HPLC (MeCN/0.1% TFA/aq (40/60-70/30)). 3.92 was obtained as a red oil (1.84 mg, 
53 %). HRMS: PI-LSIMS: m/z for [C40H50N7O] calcd. 644.40714, found 644.4050. 
C40H50N7O · 3 TFA (986.84). 
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Chapter 4 
NG-Acylated Aminothiazolylpropylguanidines: 
Towards Selective Histamine H2R Agonists 
 
4.1. Introduction 
The NG-acylated imidazolylpropylguanidines described in chapter 3 are highly potent 
histamine H2 receptor (H2R) agonists with improved pharmacokinetic properties 
compared to the corresponding strongly basic NG-alkylated analogues. However, 
depending on the substitution pattern, these compounds turned out to be also more 
or less active on other histamine receptors, in particular histamine H3 (H3R) and H4 
receptors (H4R). H3R affinity is very often found in compounds having an imidazol-4-
yl moiety, which is also present in numerous highly potent and selective histamine 
H3R ligands. Therefore, the bioisosteric replacement of the imidazolyl ring is the key 
to improve the selectivity for H2R over H3R.  
Amthamine (AMT) (Figure 4.1), a thiazole analogue of histamine (HIS) and a cyclic 
analogue of dimaprit (DIM), is a full histamine H2R agonist and exhibits a slightly 
higher potency than histamine (HIS) at the guinea pig right atrium1. Moreover, 
amthamine proved to be devoid of histamine H1R and H3R stimulatory activities2, 3. In 
contrast to histamine with an aromatic imidazole ring, amthamine is not qualified to 
exist in two tautomeric forms which were thought to be responsible for H2R 
activation4. A new activation model, based on quantum chemical studies, suggests 
that H2R agonists accept a proton from the proton-donating receptor site on their 
double-bonded (heteroaromatic) nitrogen atom. According to this model agonistic 
activity of tautomeric as well as nontaumeric histamine H2R agonists can be 
explained5.  
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Figure 4.1. Structures of histamine and selective H2 receptor agonists. 
 
In the 1970s methyl groups were introduced at different positions of imidazole ring 
and side chain in order to study the structure-acitivity relationships of histamine6, 7. 
4(5)-Methylhistamine was the first H2R selective agonist described at that time, when 
only H1R and H2R were known. Meanwhile 4(5)-methylhistamine turned out to be a 
high affinity H4R agonist. However, by analogy with the SAR of natural ligand the 
introduction of a 4-methyl substituent in 2-amino-5-(2-aminoethyl)thiazole led to an 
increase in agonistic activity at the guinea pig right atrium1 and the H2R selectivity of 
amthamine might be attributed to this methyl group.  
Preliminary investigations revealed that the bioisosteric replacement of the imidazole 
ring in NG-acylated imidazolylpropylguanidines against a thiazole moiety is possible 
without affecting the potency, but with increasing the selectivity for the H2R, 
particularly over the H3R8. This approach was further explored as a sub-project of this 
thesis. In this chapter, the synthesis and pharmacological investigation of NG-
acylated 2-amino- and 2-amino-4-methylthiazol-5-ylpropylguanidines is reported. 
Furthermore, the role of the 4-methyl substituent in the thiazole ring will be 
discussed. 
 
4.2. Chemistry 
The thiazole building blocks were synthesized from thiourea and N-protected α-halo-
ω-amino ketones or aldehydes, respectively. 6-Phthalimidohexan-2-one (4.2) was 
prepared from 6-chloro-2-hexanone and phthalimide (Scheme 4.1). The synthesis of 
5-phthalimidopentanal (4.3) started from 5-aminopentanol which was treated with 
phthalic anhydride to give 5-phthalimidopentanol (4.1) and then subjected to Swern9 
oxidation to yield the corresponding aldehyde 4.3. The compounds 4.2 and 4.3 were 
α-brominated in dioxane and DCM/abs, and the ring-closure reaction was carried out 
with thiourea in DMF. After tert-butoxycarbonyl (Boc) protection of the free amine 
function, the phthalimide group was cleaved by hydrazinolysis to give tert-butyl 5-(3-
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aminopropyl)-4-methylthiazol-2-ylcarbamate 4.10 and tert-butyl-5-(3-aminopropyl)-
thiazol-2-ylcarbamate 4.11, respectively (Scheme 4.1)1. 
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Scheme 4.1. Synthesis of the N2-Boc-protected 2-aminothiazol-5-ylpropylamines 4.10 and 4.11; 
Reagents and conditions: (i) phthalic anhydride (1 eq), 3 h, 80-100 °C; (ii) C2Cl2O2 (1.25 eq), DMSO 
(2.65 eq), NEt3 (5.5 eq), DCM/abs, -50 °C, 45 min; (iii) phthalimide (0.5 eq), K2CO3 (0.75 eq), DMF, 24 
h, 80 °C; (iv) Br2 (1 eq), dioxane, DCM/abs, 1h, rt; (v) thiourea (1 eq), DMF, 3 h, 100 °C; (vi) (Boc)2O 
(1.08 eq), NEt3 (1.16 eq), DMAP (cat.), CHCl3, overnight, rt; (vii) N2H2·H2O (5 eq), EtOH, overnight, rt.   
 
N,N´-Diprotected S-methylthioureas10-12 are used for guanidinylation reactions with 
amines. By the use of electron withdrawing substituents, like Boc- or Cbz-protecting 
groups, at the N-atoms, the reactivity of the S-methylthiourea can be increased. N-
Boc-N´-Cbz-S-methylthiourea 4.14 was prepared according to Scheme 4.2 by 
stepwise acylation of S-methylthiourea 4.12 using standard methods. 
 
H2N NH2
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H2N NH2
S I
BocHN NH
S
BocHN NCbz
S
(i) (ii) (iii)
4.12 4.13 4.14  
Scheme 4.2. Synthesis of N-tert-butoxycarbonyl-N´-benzyloxycarbonyl-S-methylthiourea 4.14; 
Reagents and conditions: (i) MeI (1 eq), MeOH, 1h, reflux; (ii) (Boc)2O (1 eq), NEt3 (1 eq), DCM/abs, 
overnight, rt; (iii) CbzOSu (1 eq), DCM/abs, 20 h, rt. 
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The guanidinylating reagent 4.14 was treated with the amines 4.10 and 4.11 in the 
presence of HgCl2, whereby the metal ion acts as a desulfurizing agent via a complex 
formation13, 14. Hydrogenolytic cleavage of the Cbz-protecting group yielded the Boc-
protected aminothiazolylpropylguanidine building blocks 4.17 and 4.18 in good yields 
(Scheme 4.3). 
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Scheme 4.3. General procedure for the preparation of Boc-protected aminothiazolylpropylguanidines 
4.17, 4.18; Reagents and conditions: (i) 4.14 (1 eq), HgCl2 (2 eq), NEt3 (3 eq), DCM/abs, 48 h, rt; (ii) 
H2, Pd/C (10 %), MeOH/THF (1:1), 8 bar, 3-4 d, rt. 
 
Previously, attempts to couple tert-butyl 5-(3-guanidinopropyl)-4-methylthiazol-2-
ylcarbamate to different carboxylic acids under similar conditions as described for the 
imidazolylpropylguanidine revealed unfavourable side reactions8. Due to the free 
guanidine moiety, reaction of carboxylic acids with the guanidine building block gave 
diacylated byproducts in addition to the desired monoacylated ones. To avoid 
diacylation, the synthetic route was changed and the Boc protected guanidines 4.17 
and 4.18 were used as building blocks (Scheme 4.4). tert-Butyl 5-[3-[N-tert-butoxy-
carbonylguanidino]propyl]-4-methylthiazol-2-ylcarbamate (4.17) and the analogue 
4.18, respectively, were coupled to synthesized (3.21c, 3.27-3.28c, 3.31-3.36c, 3.39, 
3.40-3.44, 3.47, 3.50, 3.52, 3.54b, substitution pattern see chapter 3) and 
commercially available carboxylic acids using standard coupling reagents (EDAC, 
HOBt and DIEA) to obtain the NG-acylated di-Boc-protected 
aminothiazolylpropylguanidines 4.19-4.39a and 4.40-4.46a. Both Boc groups can be 
easily removed in a few hours by treating with TFA in DCM to obtain the NG-acylated 
2-aminothiazolylpropylguanidines 4.19-4.46.  
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No R R1 R2 R3 n 
4.19a, 4.19 CH3 H CH3 4-CH3-C6H4 0 
4.20a, 4.20 CH3 CH3 H C6H5 0 
4.21a, 4.21 CH3 H CH2CH3 C6H5 0 
4.22a, 4.22 CH3 CH2CH3 H C6H5 0 
4.23a, 4.23 CH3 H CH3 C6H5 1 
4.24a, 4.24 CH3 H CH3 3-CH3-C6H4 1 
4.25a, 4.25 CH3 H CH3 4-CH3-C6H4 1 
4.26a, 4.26 CH3 H CH3 3-OCH3-C6H4 1 
4.27a, 4.27 CH3 H CH3 4-OCH3-C6H4 1 
4.28a, 4.28 CH3 H CH3 3-F-C6H4 1 
4.29a, 4.29 CH3 H CH3 4-F-C6H4 1 
4.30a, 4.30 CH3 H (R)CH3 cHex 0 
4.31a, 4.31 CH3 H (S)CH3 cHex 0 
4.43a, 4.32 CH3 CH3 H cHex 0 
4.33a, 4.33 CH3 H CH2CH3 cHex 0 
4.34a, 4.34 CH3 CH2CH3 H cHex 0 
4.35a, 4.35 CH3 H CH3 cHex 1 
4.36a, 4.36 CH3 H CH2CH3 cHex 1 
4.37a, 4.37 CH3 H CH3 4-OH-C6H4 0 
4.38a, 4.38 CH3 H (CH2)3NH2 C6H5 0 
4.39a, 4.39 CH3 H H COOH 6 
4.40a, 4.40 H H H C6H5 0 
4.41a, 4.41 H H CH3 C6H5 0 
4.42a, 4.42 H H CH2CH3 C6H5 0 
   Scheme 4.4 
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Scheme 4.4 (continued)    
4.43a, 4.43 H H C6H5 C6H5 0 
4.44a, 4.44 H H CH3 cHex 0 
4.45a, 4.45 H CH3 H cHex 0 
4.46a, 4.46 H H CH2CH3 cHex 0 
  
Scheme 4.4. General procedure for the coupling of carboxylic acids with aminothiazolylpropyl-
guanidine building blocks; Reagents and conditions: (i) EDAC (1 eq), HOBt (1 eq), DIEA (1 eq), 
DCM/abs, 24 h, rt; (ii) 20 % TFA, DCM/abs, 3-5 h, rt. 
 
4.3. Pharmacological results and discussion 
All compounds were tested for histamine H2R agonism on the isolated spontaneously 
beating guinea pig right atrium (positive chronotopic response) (Table 4.1) and in the 
GTPase assay on hH2R-GsαS and gpH2R-GsαS fusion proteins expressed in Sf9 insect 
cells (Table 4.2). To study receptor selectivity, the compounds were tested for 
histamine H1R antagonism in the Ca2+-assay on U-373 MG human cells (Table 4.3) 
and selected compounds were investigated in GTPase assay on human histamine H3 
and H4 receptors (Table 4.4).  
 
4.3.1. Histamine H2 receptor agonism 
4.3.1.1. Agonist potencies and efficacies at the guinea pig right atrium 
The synthesized compounds proved to be partial to nearly full agonists at the 
spontaneously beating guinea pig right atrium. As also found for the NG-acylated 
imidazolylpropylguanidines, the potencies of the aminothiazole derivatives are lower 
at the guinea pig right atrium than at gpH2R-GsαS fusion protein but the structure-
acitivity relationships derived from both assays and the order of potencies are in 
good agreement. Substitution in α-position is much better tolerated in the phenyl 
substituted compounds (4.20 and 4.22) compared to the cyclohexyl derivatives (4.32 
and 4.34). The 3-Phenylbutanoyl- (4.47), 3-cyclohexylbutanoyl- (4.50) and 3-
cyclohexylpentanoyl-substituted (4.33) guanidines are two times more potent and 
have higher intrinsic activities than the corresponding 3-methyl-4-phenylbutanoyl- 
(4.23), 4-cyclohexyl-3-methylbutanoyl- (4.35) and 3-(cyclohexylmethyl)pentanoyl-
substituted (4.36) analogues. Hence, three carbon atoms between the guanidine 
moiety and the ring system are the optimum for high potencies on the guinea pig 
right atrium. In contrast to the imidazole serie, the (R)-enantiomer (4.30) of the 3-
cyclohexylbutanoyl derivative (4.50) is 1.6 times more potent than the (S)-enantiomer 
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(4.31), whereas for enantiomeric pair of the phenyl analogue the (S)-configured 
compoud represents the eutomer (data not shown8).  
 
Table 4.1. Histamine H2 receptor agonism on the guinea pig right atrium. 
O R2
R3
nR1
N
S
H2N
N
H
R
N
H
NH
4.19-4.50  
 
    
 
 H2R agonism - isolated guinea 
pig right atrium 
No R R1 R2 R3 n 
pEC50  
± SEMa 
rel. 
pot. 
(%)b 
Emax  
± SEM 
(%)c 
HIS - - - - - 6.00 ± 0.10 100 100 ± 2 
AMT5 - - - - - 6.21 ± 0.09  162 95 ± 2 
4.4815 CH3 H H C6H5 0 nd nd nd 
4.478 CH3 H CH3 C6H5 0 7.18 ± 0.17 1520 89 ± 3 
4.19 CH3 H CH3 4-CH3-C6H4 0 7.04 ± 0.03 1100 64 ± 4 
4.20 CH3 CH3 H C6H5 0 6.98 ± 0.12 948 74 ± 6 
4.21 CH3 H CH2CH3 C6H5 0 6.84 ± 0.05 697 71 ± 3 
4.22 CH3 CH2CH3 H C6H5 0 6.69 ± 0.13 493 79 ± 4 
4.23 CH3 H CH3 C6H5 1 6.88 ± 0.06 759 89 ± 2 
4.508 CH3 H CH3 cHex 1 7.03 ± 0.06 1070 74 ± 8 
4.498 CH3 H C6H5 C6H5 1 7.14 ± 0.11 1370 71 ± 4 
4.24 CH3 H CH3 3-CH3-C6H4 1 6.23 ± 0.06 169 55 ± 3 
4.25 CH3 H CH3 4-CH3-C6H4 1 6.25 ± 0.07 177 45 ± 5 
4.26 CH3 H CH3 3-OCH3-C6H4 1 nd nd nd 
4.27 CH3 H CH3 4-OCH3-C6H4 1 nd nd nd 
4.28 CH3 H CH3 3-F-C6H4 1 7.16 ± 0.16 1440 75 ± 3 
4.29 CH3 H CH3 4-F-C6H4 1 6.63 ± 0.07 423 46 ± 6 
4.30 CH3 H (R)CH3 cHex 0 7.11 ± 0.14 1280 80 ± 4 
4.31 CH3 H (S)CH3 cHex 0 6.91 ± 0.11 804 78 ± 3 
4.32 CH3 CH3 H cHex 0 6.62 ± 0.10 420 65 ± 3 
4.33 CH3 H CH2CH3 cHex 0 7.12 ± 0.12 1300 70 ± 3 
4.34 CH3 CH2CH3 H cHex 0 6.24 ± 0.16 173 67 ± 5 
4.35 CH3 H CH3 cHex 1 6.68 ± 0.18 482 49 ± 7 
4.36 CH3 H CH2CH3 cHex 1 6.76 ± 0.14 571 26 ± 7 
4.37 CH3 H CH3 4-OH-C6H4 0 7.49 ± 0.12 3050 87 ± 4 
4.38 CH3 H (CH2)3NH2 C6H5 0 7.42 ± 0.03 2620 97 ± 2 
4.40 H H H C6H5 0 7.05 ± 0.04 1130 92 ± 2 
4.41 H H CH3 C6H5 0 7.42 ± 0.10 2600 92 ± 4 
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Table 4.1 (continued)       
4.42 H H CH2CH3 C6H5 0 7.02 ± 0.06 1040 65 ± 6 
4.43 H H C6H5 C6H5 0 7.41 ± 0.08 2570 74 ± 5 
4.44 H H CH3 cHex 0 7.14 ± 0.12 1370 84 ± 5 
4.45 H CH3 H cHex 0 6.92 ± 0.11 828 73 ± 2 
4.46 H H CH2CH3 cHex 0 7.48 ± 0.12 3020 74 ± 4 
a pEC50 was calculated from the mean shift ∆pEC50 of the agonist curve relative to the histamine reference curve by equation: 
pEC50 = 6.00 + ∆pEC50; data shown are the ± SEM of three to seven experiments; b relative potency to histamine = 100 %; c 
efficacy, maximal response (%), relative to the maximal increase in heart rate induced by the reference compound histamine;  
 
The most potent compounds among the aminothiazoles listed in Table 4.1 are 4.37 
and 4.38 containing a p-hydroxyphenyl moiety and a free amino group, respectively. 
These derivatives are full and nearly full agonists and 26 and 30 times more potent 
than histamine.  
 
pEC50
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imidazolylpropylguanidines
2-amino-4-methylthiazol-5-ylpropylguanidines
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3-cyclohexylpentanoyl
gp right atrium
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Figure 4.2. Comparison of the potencies of NG-acylated imidazolyl- (3.56, 3.77-3.78, 3.96, 3.101 and 
3.102), 2-amino-4-methylthiazol-5-yl- (4.21, 4.32-4.33 and 4.47, 4.49 and 4.50) and 2-aminothiazol-5-
ylpropylguanidines (4.41-4.46) with the same substitution patterns. 
 
Figure 4.2 demonstrates the potencies of close structural analogues at the 
spontaneously beating guinea pig right atrium: NG-acylated imidazolyl- (3.56, 3.77-
3.78, 3.96, 3.101 and 3.102), 2-amino-4-methylthiazolyl- (4.21, 4.32-4.33 and 4.47, 
4.49 and 4.50) and 2-aminothiazolylpropylguanidines (4.41-4.46) lacking the 4-
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methyl substituent. Except for the 3-cyclohexylbutanoyl and 3-cyclohexylpentanoyl 
derivatives the “demethylated” aminothiazolylpropylguanidines show similar 
potencies as the corresponding imidazolylpropylguanidines and both are more potent 
than the 2-amino-4-methylthiazolylpropylguanidines. In contrast to amthamine, the 
introduction of a methyl group results in a slight decrease in both potency and 
efficacy of the NG-acylated guanidines at the guinea pig right atrium.  
 
4.3.1.2. Agonist potencies and efficacies at hH2R-GsαS and gpH2R-GsαS in the 
GTPase assay 
All compounds proved to be full or partial agonists in the GTPase assay at hH2R-GsαS 
and gpH2R-GsαS fusion proteins expressed in Sf9 cell membranes (Table 4.2). 
Amthamine (AMT) is a nearly full to full agonist at both, the human and guinea pig 
receptor in the GTPase assay and is slightly more potent than histamine (HIS). In the 
NG-acylated serie the replacement of the imidazole ring against a 2-amino-4-
methylthiazole moiety results in a decrease in efficacy at both hH2R-GsαS and gpH2R-
GsαS fusion proteins (Figure 4.3, A and B), whereas the potencies are in good 
agreement (Figure 4.3, C and D). Again, in accordance with the results for alkylated 
and acylated imidazolylpropylguanidines16-18, the 2-amino-4-methylthiazol-5-
ylpropylguanidines exhibit higher potencies and efficacies at gpH2R-GsαS than at 
hH2R-GsαS.  
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Figure 4.3. Comparison of efficacies (A (hH2R-GsαS) and B (gpH2R-GsαS)) and potencies (C (hH2R-
GsαS) and D (gpH2R-GsαS) of NG-acylated 2-amino-4-methylthiazolylpropyl-guanidines (4.19-4.38) and 
the corresponding imidazolylpropylguanidines (3.56-3.57, 3.64-3.65, 3.68-3.73, 3.75-3.79, 3.82, 3.85, 
3.87, 3.89 and 3.97); pEC50 values derived from EC50 values listed in Table 4.2 and Table 3.2) The 
straight dotted lines represent the theoretical correlations that would have been obtained if pEC50 
values and efficacies had been identical in the two systems compared with each other. 
 
The 2-amino-4-methylthiazol-5-ylpropylguanidines proved to be weak to strong 
partial agonists at both, the hH2R-GsαS and gpH2R-GsαS. Introduction of a para methyl 
group in the aromatic ring system at the 3-phenylbutanoyl analogue (4.47→4.19) 
results in about the same potency at the human receptor, whereas potency at the 
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guinea pig receptor increased by a factor of three. The potency of the 3-
phenylpentanoyl analogue (4.21) was increased at both, the hH2R-GsαS and gpH2R-
GsαS. A methyl substituent in α-postion was tolerated in the phenyl (4.20) as well as in 
the cyclohexyl (4.32) compounds, whereas an ethyl substituent in α-position (4.22 
and 4.34) results in a decrease in potency and efficacy especially at hH2R-GsαS. The 
3-methyl-4-phenylbutanoyl compound (4.23) exhibits nearly the same potency as the 
3-phenylbutanoyl derivative (4.47) but with lower efficacy at both receptors. However, 
the introduction of meta or para methyl, methoxy or fluoro substituents, respectively, 
results in an increase in potency at the guinea pig, but not at the hH2R-GsαS with 
slightly lower efficacies. The meta position of methoxy and fluoro substituents is more 
favourable at both receptors, whereas for the methyl substituted derivative the para 
position was preferred, but not in terms of efficacy. An electron withdrawing 
substituent (4.28 and 4.29) increases the potency by a factor of two to three at 
gpH2R-GsαS (EC50 (4.28) = 4.8 nM, EC50 (4.29) = 7.4 nM), but not at hH2R-GsαS (EC50 
(4.28) = 27.4 nM, EC50 (4.29) = 36.2 nM). Compound 4.37 containing a p-
hydroxyphenyl group the 3-phenylbutanoyl derivative (4.47) is about ten times more 
potent at gpH2R-GsαS acting as a strong partial agonist and the selectivity towards the 
guinea pig receptor was strongly increased.  
In accordance with the structure-activity relationships of NG-acylated 
imidazolylpropylguanidines, the exchange of a phenyl ring against a cyclohexyl 
moiety results in the main in higher potency and efficacy at both receptors. The 3-
methyl-4-cyclohexylbutanoyl derivative is three and two times more potent at gpH2R-
GsαS (EC50 (4.35) = 12.4 nM, EC50 (4.23) = 33.2 nM) and hH2R-GsαS (EC50 (4.35) = 
25.5 nM, EC50 (4.23) = 41.2 nM), respectively, compared to its phenyl analogue. The 
enantiomers of the 3-cyclohexylbutanoyl derivative show an inverse preference 
(R>S) to the H2R than its corresponding imidazolylpropyl analogue (S>R) and also 
than its phenyl substituted analogue (S>R, data not shown8). Rather low eudismic 
ratios were found for the 2-amino-4-methylthiazol-5-ylpropylguanidines, too.  
The ratio of EC50 values, EC50 hH2R-GsαS to EC50 gpH2R-GsαS, was highest for 
compound 4.38 with a free amino group in the side chain. This compound exhibits 
moderate agonistic activity at hH2R-GsαS with EC50 = 158.4 nM, whereas it is 18 times 
more potent at gpH2R-GsαS (EC50 = 8.6 nM).  
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Table 4.2. Agonist efficacies and potencies at hH2R-GsαS and gpH2R-GsαS expressed in Sf9 cell 
membranes. 
hH2R-GsαS gpH2R-GsαS 
No 
efficacy EC50 [nM] rel. pot. efficacy EC50 [nM] rel. pot. 
EC50 hH2R-
GsαS/ EC50 
gpH2R-GsαS
HIS16 1.00 1260 ± 250 100 1.00 1200 ± 240 100 1.05 
AMT16 0.90 ± 0.06 450 ± 40 280 1.04 ± 0.05 440 ± 40  271 1.02 
4.478 0.82 47.9 2,630 0.98 22.4 5,370 2.04 
4.19 0.69 ± 0.06 49.35 ± 33.9 2,553 0.73 ± 0.07 7.6 ± 3.6 15,789 6.49 
4.20 0.75 ± 0.03 16.3 ± 6.1 7,730 0.68 2.4 50,000 6.79 
4.21 0.52 ± 0.04 20.4 ± 3.0 6,176 0.76 4.5 26,667 4.53 
4.22 0.49 ± 0.01 46.5 ± 19.6 2,709 0.62 5.6 21,428 8.30 
4.23 0.63 ± 0.03 41.2 ± 1.4 3,058 0.73 ± 0.03 33.2 ± 20.6 3,614 1.24 
4.24 0.55 ± 0.03 42.2 ± 9.1 2,985 0.69 ± 0.14 19.2 ± 1.8 6,250 2.19 
4.25 0.30 ± 0.05 21.2 ± 3.9 5,943 0.48 ± 0.09 14.9 ± 1.6 8,053 1.42 
4.26 0.66 ± 0.01 32.6 ± 17.5 3,865 0.66 ± 0.02 14.6 ± 5.3 8,219 2.23 
4.27 0.49 ± 0.02 71.4 ± 17.7 1,765 0.43  14.4 8,333 4.96 
4.28 0.56 ± 0.06 27.4 ± 2.9  4,598 0.72 ± 0.04 4.8 ± 0.2 25,000 5.71 
4.29 0.50 ± 0.06 36.2 ± 4.6 3,480 0.59 ± 0.04 7.4 ± 1.4 16,216 4.89 
4.508 0.56 9.1 13,804 0.81 7.1 16,982 1.23 
4.30 0.55 ± 0.02 24.3 ± 12.0 5,185 0.82 ± 0.05 17.5 ± 8.8 6,857 1.39 
4.31 0.66 ± 0.01 33.2 ± 7.5 3,795 0.90 ± 0.14 19.8 ± 4.3 6,060 1.68 
4.32 0.62 ± 0.04 10.1 ± 2.9 12,475 0.53 ± 0.22 8.6 ± 6.2 13,953 1.17 
4.33 0.65 14.0 9,000 0.77 7.1 16,901 1.97 
4.34 0.20 ± 0.01 38.3 ± 2.2 3,290 0.47 12.0 10,000 3.19 
4.35 0.40 25.5 4,941 0.56 12.4 9,677 2.05 
4.36 0.19 ± 0.02 10.8 ± 3.0 11,667 0.42 3.4 35,294 3.18 
4.37 0.84 ± 0.03 31.9 ± 3.7 3,949 0.77 2.9 41,379 11.00 
4.38 0.65 ± 0.07 158.4 ± 23.5 795 1.05 ± 0.18 8.6 ± 5.6 13,953 18.42 
4.40 0.83 ± 0.03 21.9 ± 0.5 5,753 0.76 ± 0.32 13.5 ± 6.1 8,888 1.62 
4.41 0.84 ± 0.11 20.3 ± 1.7 6,207 0.81 ± 0.01 5.3 ± 2.1 22,641 3.83 
4.42 0.68 ± 0.09 24.3 ± 1.4 5,185 0.89 ± 0.35 29.2 ± 18.7 4,109 0.83 
4.43 0.67 ± 0.09 33.9 ± 8.8 3,717 0.83 ± 0.05 7.9 ± 5.6 15,189 4.29 
4.44 0.71 ± 0.12 11.05 ± 5.9 11,403 1.02 2.2 57,273 5.02 
4.45 0.70 ± 0.12 15.9 ± 6.6 7,925 0.83 11.2 11,250 1.42 
4.46 0.66 ± 0.08 12.5 ± 5.7 10,080 0.97 18.6 6,452 0.67 
Steady state GTPase activity in Sf9 membranes expressing hH2R-GsαS and gpH2R-GsαS was determined as described in 
literature16. Reaction mixtures contained ligands at concentrations from 1 nM to 10 µM as appropriate to generate saturated 
concentration-response curves. Data were analyzed by nonlinear regression and were best fit to sigmoidal concentration-
response curves. Typical basal GTPase activities ranged between ~ 0.5 and 2.5 pmol/mg/min, and activities stimulated by 
histamine (100 µM) ranged between ~ 2 and 13 pmol/mg/min. The efficacy (Emax) of histamine was determined by nonlinear 
regression and was set to 1.0. The Emax values of other agonists were referred to this value. Data shown are  the ± SEM of two 
to three experiments or one experiment performed in duplicates each. The relative potency of histamine was set to 100, and the 
potencies of other agonists were referred to this value. The ratio of the EC50 values of H2R agonists for hH2R-GsαS and gpH2R-
GsαS were also calculated. 
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In Figure 4.4 the potencies of NG-acylated imidazolyl- (3.56, 3.77-3.78, 3.96, 3.101, 
3.102 and 3.105), 2-amino-4-methylthiazolyl- (4.21, 4.32-4.33 and 4.47-4.50) and 2-
aminothiazolylpropylguanidines (4.40-4.46) at hH2R-GsαS and gpH2R-GsαS are 
graphically presented to illustrate the contribution of the 4-methyl substituent. The 2-
aminothiazolylpropylguanidines lacking the 4-methyl substituent exhibit similar or 
even higher potencies and similar efficacies at hH2R-GsαS compared to the 2-amino-
4-methylthiazolyl derivatives and both exhibit similar or higher potencies compared to 
the imidazole analogues. At gpH2R-GsαS 3-phenyl- and 3-cyclohexylpentanoyl and 2-
methyl-3-cyclohexylpropanoyl substituted 2-aminothiazolylpropylguanidines are less 
potent than the ring-methylated analogues and the corresponding imidazolylpropyl-
guanidines, but show higher efficacies. For compounds with a 3-phenylbutanoyl, 3,4-
diphenylpropanoyl and 3-cyclohexylbutanoyl moiety, the “demethylated” 
aminothiazoles have higher H2R agonistic potencies than the corresponding 2-amino-
4-methylthiazolyl- and imidazolylpropylguanidines. Thus, the introduction of a methyl 
group in position 4 of the thiazole ring does not generally increase the agonistic 
activity of the NG-acylguanidines, i. e. the influence of the ring-methylation on the H2R 
agonistic potency is different in the acylguanidine and the thiazolylethylamine series. 
Chapter 4: NG-Acylated Aminothiazolylpropylguanidines 131 
pEC50
5 6 7 8 9 10
imidazolylpropylguanidines
2-amino-4-methylthiazol-5-ylpropylguanidines
2-aminothiazolylpropylguanidines
3-phenylpropanoyl
3-phenylbutanoyl
3-phenylpentanoyl
3,4-diphenylpropanoyl
3-cyclohexylbutanoyl
2-methyl-3-cyclohexylpropanoyl
3-cyclohexylpentanoyl
3.105
4.48
4.40
3.96
4.47
4.41
3.56
4.21
4.42
3.101
4.49
4.43
3.102
4.50
4.44
3.77
4.32
4.45
3.78
4.33
4.46
NG-substituent
gpH2R-GsαS
5 6 7 8 9 10
imidazolylpropylguanidines
2-amino-4-methylthiazol-5-ylpropylguanidines
2-aminothiazolylpropylguanidines
hH2R-GsαS
3-phenylpropanoyl
3-phenylbutanoyl
3-phenylpentanoyl
3,4-diphenylpropanoyl
3-cyclohexylbutanoyl
2-methyl-3-cyclohexylpropanoyl
3-cyclohexylpentanoyl
pEC50
3.105
4.48
4.40
3.96
4.47
4.41
3.56
4.21
4.42
3.101
4.49
4.43
3.102
4.50
4.44
3.77
4.32
4.45
3.78
4.33
4.46
NG-substituent
 
Figure 4.4. Comparison of the potencies of NG-acylated imidazolyl- (3.56, 3.77-3.78, 3.96, 3.101-
3.102 and 3.105), 2-amino-4-methylthiazol-5-yl- (4.21, 4.32-4.33 and 4.47-4.50) and 2-aminothiazol-5-
ylpropylguanidines (4.40-4.46) with same substitution patterns. 
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4.3.2. Receptor selectivity  
To study the histamine receptor selectivity, selected compounds were tested in the 
Ca2+-assay on human U-373 MG cells expressing the H1 receptor and in GTPase 
assays using membrane preparations of Sf9 insect cells espressing human H3 and 
H4 receptors.  
 
4.3.2.1. Histamine H1 receptor antagonism on U-373 MG cells (Ca2+-assay) 
On human U-373 cells, all compounds proved to be weak or very weak histamine 
H1R antagonists (activities in the micromolar range). A polar group in the side chain 
(4.37 and 4.38) seems to disfavour activity at the H1 receptor. 
 
Table 4.3. Histamine H1 receptor antagonism on U-373 MG human cells (Ca2+-assay). 
 
Histamine H1 receptor antagonism 
U-373 MG cells (Ca2+-assay) 
No IC50 [µM]a No IC50 [µM]a No IC50 [µM]a 
HIS - 4.27 37 4.37 >100 
AMT5 - 4.28 8 4.38 >100 
4.478 18 4.29 12 4.40 35 
4.19 28 4.508 10 4.41 44 
4.20 65 4.30 16 4.42 50 
4.21 31 4.31 7 4.43 17 
4.22 47 4.32 47 4.44 23 
4.23 11 4.33 12 4.45 34 
4.24 9 4.34 22 4.46 16 
4.25 17 4.35 10   
4.26 4 4.36 5   
a IC50 values for the inhibition of the histamine (30 µM) induced increase in cellular calcium, one experiment; procedure as 
described from Kracht, 200119. 
 
4.3.2.2. Activities on the human H3 and H4 receptors (GTPase assay) 
The NG-acylated imidazolylpropylguanidines described in chapter 3 show also affinity 
to the H3R due to the imidazol-4-yl moiety often found in highly potent H3R ligands. 
By the replacement of the imidazole ring against an 2-aminothiazole ring, these 
compounds are devoid of or exhibit low (4.45 and 4.46) H3R stimulatory effects at the 
concentration tested. Equally, the NG-acylated imidazolylpropylguanidines are full or 
nearly full H4R agonists with EC50 values in the nM range, the analogous 
aminothiazolylpropylguanidines proved to be very weak antagonists at hH4R 
membranes. 
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Table 4.4. Agonist efficacies and potencies at hH3R + Gαo + β1γ2 + RGS4 and hH4R-GAIP + Gαi2 + 
β1γ2 expressed in Sf9 cell membranes.  
hH3R + Gαo + β1γ2 + RGS4 hH4R-GAIP + Gαi2 + β1γ2 
No 
efficacy EC50 [nM] 
rel. 
pot. 
efficacy 
EC50 [nM] 
(IC50 [nM]) 
rel. 
pot. 
His 1.00 25.8 ± 3.1 100 1.00 11.6 ± 2.5 100 
4.32 -0.19 nd nd - (>10,000) - 
4.33 -0.16 nd nd - (>6000) - 
4.35 -0.17 nd nd - (>10,000) - 
4.38 0.06 nd nd - (>10,000) - 
4.43 0.03 nd nd - (>10,000) - 
4.44 -0.12 nd nd - (>10,000) - 
4.45 0.39 nd nd - (>10,000) - 
4.46 0.15 nd nd - (>10,000) - 
Steady state GTPase activity in Sf9 membranes expressing hH3R+Gαo+β1γ2+RGS4 and hH4R-GAIP+Gαi2+β1γ2 was determined 
as described in literature16. Reaction mixtures contained ligands at a concentration 10 µM (hH3R+Gαo+β1γ2+RGS4). Typical 
basal GTPase activities ranged between ~ 1.5 and 2.5 pmol/mg/min, and activities stimulated by histamine (10 µM) ranged 
between ~ 3.5 and 4.5 pmol/mg/min. The efficacy (Emax) of histamine was determined by nonlinear regression and was set to 
1.0. The Emax values of other agonists were referred to this value. Data shown are one experiment performed in duplicates each. 
The relative potency of histamine was set to 100. For antagonism, reaction mixtures contained histamine (100 nM) and ligands 
at concentrations from 0.1 nM to 100 µM. 
 
4.4. Summary 
Based on previous preliminary studies8, NG-acylated 2-amino-4-methylthiazol-5-
ylpropylguanidines were synthesized and investigated for H2R agonism at the guinea 
pig right atrium and on hH2R-GsαS and gpH2R-GsαS fusion proteins expressed in Sf9 
insect cells. Moreover, the compounds were studied on H1R of U-373 MG cells and in 
GTPase assays on membranes of Sf9 cells expressing hH3R+Gαo+β1γ2+RGS4 and 
hH4R-GAIP+Gαi2+β1γ2 to figure out the receptor selectivity for H2R especially over 
H3R and H4R in comparison to the analogous NG-acylated imidazol-4-ylpropyl-
guanidines. NG-acylated 2-amino-4-methylthiazol-5-ylpropylguanidines proved to be 
strong partial to full agonists at the guinea pig right atrium. By contrast to the 
imidazolylpropylguanidines derivatives containing a hydroxy or free amine function 
are 26 and 30 times more potent than histamine and turned out to be the most potent 
compounds in this series. The replacement of the imidazole ring against a 2-amino-4-
methylthiazol ring results in a slight decrease in efficacy but in similar or even higher 
potency at both hH2R-GsαS and gpH2R-GsαS. In agreement with the structure-activity 
relationships of imidazole series, the exchange of the phenyl against a cyclohexyl 
ring in the NG-alkanoyl substituent results in an increase in potency. The 
enantiomeric 3-cyclohexylbutanoyl derivatives show inverse preference (R>S) for the 
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H2R than the 3-phenylbutanoyl substituted8 and than corresponding analogue of the 
imidazolylpropylguanidine series (S>R), but again with a low eudismic ratio. In 
agreement with the imidazole series, a very high selectivity towards gpH2R-GsαS was 
found for compounds with polar groups in the side chain (4.37-4.38). Particularly a 
free amino group (4.38) enhanced the species selectivity (gpH2R-GsαS: EC50 = 8.6 
nM; hH2R-GsαS: EC50 = 158 nM). To proof the influence of the methyl substituent at 
the aminothiazole ring on the receptor selectivity, 2-aminothiazol-5-ylpropylguani-
dines lacking the 4-methyl group were investigated. In contrast to amthamine, the 
methyl group does neither enhance the agonistic activity for NG-acylated compounds 
in the GTPase assay nor at the guinea pig right atrium.  
As reported in chapter 3, NG-acylated imidazolylpropylguanidines are also potent 
agonists (or antagonists) at H3R and H4R in the GTPase assay. By contrast, the NG-
acylated 2-amino-4-methylthiazol-5-ylpropylguanidines turned out to be very weak 
antagonists at the hH1R (calcium assay), the gpH3R (guinea pig ileum)8 and the hH4R 
(GTPase assay). At the concentration tested, the 2-amino-4-methylthiazol-5-
ylpropylguanidines are also devoid of or exhibit low stimulatory (4.45 and 4.46) 
activities at the hH3R (GTPase assay). In summary, the bioisosteric replacement of 
the imidazole against an 2-aminothiazole ring represents a successful approach to 
the development of highly potent and selective H2R agonists.  
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4.5. Experimental section 
4.5.1. General conditions 
See Chapter 3. 
 
4.5.2. Preparation of the building blocks 4.17 and 4.18 
S-Methylthiouronium iodide (4.12)20 
Thiourea (10 g, 131 mmol) and methyl iodide (18.6 g, 131 mmol) in MeOH (100 ml) 
were refluxed for 1 h. After evaporation, the crude product was taken up in diethyl 
ether, sucked off and washed twice with diethyl ether to yield 4.12 as a white solid 
(27.96 g, 128 mmol, 98 %). The crude product was used in the next step without 
further purification. 1H-NMR (DMSO-d6) δ ppm: 8.88 (br s, 4H, NH2), 2.57 (s, 3H, 
CH3); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 91 (M+, 100). C2H7IN2S (218.06) 
N-tert-Butoxycarbonyl-S-methylthiourea (4.13) 
To a solution of 4.12 (27.74 g, 127 mmol) in DCM (200 ml) were added triethylamine 
(17.6 ml, 127 mmol) and Boc2O (27.76 g, 127 mmol) in DCM (50 ml) and stirred for 
24 h at room temperature. The mixture was subsequently washed with water and 
brine and the organic phase dried over MgSO4. After removing the solvent under 
reduced pressure, the crude product was subjected to flash chromatography 
(PE/EtOAc 90/10 v/v) yielding 4.13 as a white solid (18.13 g, 75 %). 1H-NMR (DMSO-
d6) δ ppm: 8.54 (br s, 2H, NH2), 2.31 (s, 3H, CH3), 1.40 (s, 9H, C(CH3)3); CI-MS 
(NH3) m/z (%): 191 (MH+, 69). C7H14N2O2S (190.26) 
N-Benzyloxycarbonyl-N`-tert-butoxycarbonyl-S-methyl-thiourea (4.14) 
To a solution of 4.13 (8.55 g, 44.9 mmol) in DCM/abs (100 ml) was added benzyl 
succinimidyl carbonate (CbzOSu) (11.2 g, 44.9 mmol) and stirred for 20 h at ambient 
temperature. The mixture was subsequently extracted with DCM and basified with 
Na2CO3 (pH 9-10). The organic phase was washed with water, dried over MgSO4 
and the solvent removed under reduced pressure. The crude product was subjected 
to flash chromatography (PE/EtOAc 90/10 v/v) yielding 4.14 as a white solid (12.41 g, 
85 %). 1H-NMR (CDCl3) δ ppm: 11.58 (br s, 1H, NH), 7.37 (m, 5H, Ar-H), 5.19 (s, 2H, 
CH2-Ar), 2.40 (s, 3H, CH3), 1.50 (s, 9H, C(CH3)3); CI-MS (NH3) m/z (%): 325 (MH+, 
100). C15H20N2O4S (324.40) 
2-(5-Hydroxypentyl)-1,3-dihydro-2H-isoindol-1,3-dione (4.1)1, 21 
5-Amino-1-pentanol (7 g, 67.5 mmol) and phthalic anhydride (10 g, 67.5 mmol) were 
heated to 80-100 °C for 3 h. After cooling, 40 ml ice cold water was added and 
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extracted three times with CHCl3. The organic phase was washed with 5 % NaHCO3 
and three times with H2O and the organic phase was dried over MgSO4. After 
removing the solvent under reduced pressure, the crude product was subjected to 
flash chromatography (PE/EtOAc 70/30 v/v) yielding 4.1 as a pale yellow solid (12.84 
g, 81 %). mp = 43 °C; 1H-NMR (CDCl3) δ ppm: 7.75 (m, 2H, Ar-H), 7.64 (m, 2H, Ar-
H), 3.58 (m, 4H, Pht-CH2, CH2OH), 2.16 (s, 1H, OH), 1.63 (m, 2H, Pht-CH2CH2), 1.53 
(m, 2H, CH2CH2OH), 1.34 (m, 2H, CH2CH2CH2OH); CI-MS (NH3) m/z (%): 251 
(M+NH4+, 100). C13H15NO3 (233.36) 
2-(5-Oxohexyl)-1,3-dihydro-2H-isoindol-1,3-dione (4.2)8 
A mixture of phthalimide (5.5 g, 37 mmol), 6-chlorohexan-2-one (10.06 g, 75 mmol), 
potassium carbonate (7.7 g, 56 mmol) in 90 ml DMF were heated to 80 °C for 24 
h. After cooling to room temperature, the mixture was added to ice cold water 
and extracted with CHCl3, the organic layer was dried over MgSO4 and 
evaporated under reduced pressure. The crude product was subjected to flash 
chromatography (PE/EtOAc 90/10 to 70/30 v/v) yielding 4.2 as a colourless solid 
(7.18 g, 79 %). 1H-NMR (CDCl3) δ ppm: 7.84 (m, 2H, Ar-H), 7.71 (m, 2H, Ar-H), 3.69 
(t, 2H, 3J = 6.9 Hz, CH2-Pht), 2.50 (t, 2H, 3J = 7.0 Hz, COCH2), 2.14 (s, 3H, CH3), 
1.66 (m, 4H, COCH2CH2, COCH2CH2CH2); CI-MS (NH3) m/z (%): 263 (M+NH4+, 
100). C14H15NO3 (245.10) 
5-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)pentanal (4.3)1 
Oxalyl chloride (2.9 ml, 33.75 mmol) in 65 ml CH2Cl2/abs was cooled to -50 °C and 
DMSO (5.1 ml, 71.6 mmol) in 25 ml CH2Cl2/abs was added under stirring and argon 
at such a rate that the temperature was maintained at -50 °C. After the addition was 
complete, stirring was continued for 15 min. A solution of 4.1 (6.33 g, 27 mmol) in 30 
ml CH2Cl2/abs was added slowly and stirring was continued for another 15 min. After 
the addition of NEt3 (20 ml, 148.5 mmol), the mixture was allowed to warm to room 
temperature, 80 ml H2O was added and stirring continued for 30 min. The organic 
phase was separated and washed with H2O to almost neutral reaction. The organic 
phase was dried over MgSO4 and the solvent removed under reduced pressure 
yielding crude 4.3 as a yellow oil (5.81 g, 93 %) which was stored under argon and 
used without further purification. 1H-NMR (CDCl3) δ ppm: 9.75 (t, 1H, 3J = 1.5 Hz, 
COH), 7.82 (m, 2H, Ar-H), 7.70 (m, 2H, Ar-H), 3.70 (t, 2H, 3J = 6.8 Hz, Pht-CH2), 2.50 
(m, 2H, CH2COH), 1.69 (m, 4H, Pht-CH2CH2CH2, Pht-CH2CH2CH2); CI-MS (NH3) m/z 
(%): 249 (M+NH4+, 100). C13H13NO3 (231.25) 
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General procedure for the bromination of 4.2 and 4.3 
To a solution of 4.2 or 4.3 (1 eq) in dioxane and DCM/abs bromine (1 eq) was slowly 
added so that the brown colour always disappeared and then stirred for 1 h at room 
temperature. Subsequently, the mixture was washed two times with water and 
extracted with EtOAc. The organic layer was dried over MgSO4 and evaporated 
under reduced pressure. The crude product was obtained as a yellow oil and used in 
the next step without further purification.  
2-(4-Bromo-5-oxohexyl)-1,3-dihydro-2H-isoindol-1,3-dione (4.4)22 
The title compound was prepared from 4.2 (16.42 g, 67 mmol) in 340 ml dioxane and 
220 ml DCM/abs and bromine (3.4 ml, 67 mmol) according to the general procedure 
yielding 4.4 as a yellow oil (21.6 g, 100 %). 1H-NMR (CDCl3) δ ppm: 7.85 (m, 2H, Ar-
H), 7.73 (m, 2H, Ar-H), 4.34 (m, 1H, COCH), 3.74 (t, 2H, 3J = 6.7 Hz, CH2-Pht), 2.37 
(s, 3H, Thiaz-4-CH3), 1.95 (m, 4H, COCHCH2CH2, COCHCH2CH2). C14H14NBrO3 
(323.01) 
2-Bromo-5-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)pentanal (4.5)1 
The title compound was prepared from 4.3 (5.77 g, 25 mmol) in 150 ml dioxane and 
100 ml DCM/abs and bromine accoding to the general procedure yielding 4.5 as a 
yellow oil (7.86 g, 100 %). 1H-NMR (CDCl3) δ ppm: 9.44 (d, 1H, 3J = 2.3 Hz, COH), 
7.83 (m, 2H, Ar-H), 7.71 (m, 2H, Ar-H),  4.34 (m, 1H, Br-H), 3.73 (t, 2H, 3J = 6.6 Hz, 
Pht-CH2), 1.87 (m, 4H, Pht-CH2CH2CH2, Pht-CH2CH2CH2), CI-MS (NH3) m/z (%): 
329 (MNH4+, 100). C13H12NO3Br (310.14) 
General procedure for the synthesis of the thiazoles 4.6 and 4.7   
To a stirred solution of crude 4.4 or 4.5 (1 eq) in DMF, a solution of thiourea (1 eq) in 
DMF was added and the mixture was heated at 100 °C for 3 h. After cooling and 
removing the solvent in vacuo, a mixture of EtOAc/MeOH (1:1 v/v) was added and 
stirred for 30 min. Subsequently, the precipitate was filtered off, washed with EtOAc 
and diethylether and the solid dried in vacuo. 
2-[3-(2-Amino-4-methylthiazol-5-yl)propyl]-1,3-dihydro-2H-isoindol-1,3-dione 
(4.6)1 
The title compound was prepared from crude 4.4 (24.5 g, 75.8 mmol) in 90 ml DMF 
and a solution of thiourea (5.77 g, 75.8 mmol) in 90 ml DMF according to the general 
procedure yielding 4.6 as a fawn solid (14.71 g, 64 %). 1H-NMR (DMSO-d6) δ ppm: 
7.84 (m, 4H, Ar-H), 3.61 (t, 2H, 3J = 7.0 Hz, CH2-Pht), 2.71 (t, 2H, 3J = 7.5 Hz, Thiaz-
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5-CH2), 2.14 (s, 3H, Thiaz-4-CH3), 1.87 (m, 2H, Thiaz-5-CH2CH2); CI-MS (NH3) m/z 
(%): 302 (MH+, 100). C15H15N3O2S (301.09) 
2-[3-(2-Aminothiazol-5-yl)propyl]-1,3-dihydro-2H-isoindol-1,3-dione (4.7)1 
The title compound was prepared from crude 4.5 (7.86 g, 25.3 mmol) in 20 ml DMF 
and a solution of thiourea (1.9 g, 25.3 mmol) in 20 ml DMF according to the general 
procedure yielding 4.7 as a light brown solid (14.71 g, 64 %). 1H-NMR (DMSO-d6) δ 
ppm: 7.84 (m, 4H, Ar-H), 7.20 (s, 1H, Thiaz-4-H), 3.62 (t, 2H, 3J = 6.9 Hz, CH2-Pht), 
2.79 (t, 2H, 3J = 7.4 Hz, Thiaz-5-CH2), 1.91 ( m, 2H, Thiaz-5-CH2CH2); CI-MS (NH3) 
m/z (%): 288 (MH+, 100). C14H13N3O2S (287.34) 
General procedure for tert-butyoxycarbonyl protection 
4.6 or 4.7 (1 eq), respectively, was dissolved in CHCl3 and Boc2O (1.08 eq) , NEt3 
(1.16) and DMAP (cat.) were added. The mixture was stirred over night at ambient 
temperature. The mixture was extracted with DCM, washed with 0.1N HCl, brine and 
water, dried over MgSO4 and the solvent removed under reduced pressure. The 
crude product was purified by flash chromatography.  
tert-Butyl 4-methyl-5-[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propyl]thiazol-2-
ylcarbamate (4.8)8 
The title compound was prepared from 4.6 (7.22 g, 24 mmol) in 60 ml CHCl3, Boc2O 
(5.8 g, 26 mmol), NEt3 (4 ml, 28 mmol) and DMAP (cat.) according to the general 
procedure (PE/EtOAc 80/20 v/v) to obtain 4.8 as a colourless foam-like solid (6.06 g, 
63 %). 1H-NMR (CDCl3) δ ppm: 7.84 (m, 2H, Ar-H), 7.71 (m, 2H, Ar-H), 3.74 (t, 2H, 3J 
= 7.1 Hz, CH2-Pht), 2.71 (t, 2H, 3J = 7.75 Hz, Thiaz-5-CH2), 2.22 (s, 3H, Thiaz-4-
CH3), 1.98 (m, 2H, Thiaz-5-CH2CH2), 1.51 (s, 9H, C(CH3)3); CI-MS (NH3) m/z (%): 
402 (MH+, 100). C20H23N3O4S (401.14) 
tert-Butyl 5-[3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propyl]thiazol-2-yl-
carbamate (4.9) 
The title compound was prepared from 4.7 (24.48 g, 85.2 mmol) in 220 ml CHCl3, 
Boc2O (20.1 g, 91.9 mmol), NEt3 (13.8 ml, 99.3 mmol) and DMAP (cat.) according to 
the general procedure (PE/EtOAc 60/40 v/v) to obtain 4.9 as a colourless foam-like 
solid (16.83 g, 51 %). mp = 166 °C; 1H-NMR (CDCl3) δ ppm: 7.83 (m, 2H, Ar-H), 7.71 
(m, 2H, Ar-H), 7.06 (s, 1H, Thiaz-4-H), 3.76 (t, 2H, 3J = 6.9 Hz, CH2-Pht), 2.79 (t, 2H, 
3J = 7.5 Hz, Thiaz-5-CH2), 2.04 (m, 2H, Thiaz-5-CH2CH2), 1.57 (s, 9H, Boc-CH3); CI-
MS (NH3) m/z (%): 388 (MH+, 100). C19H21N3O4S (387.45) 
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General procedure for hydrazinolysis of the phthalimides 4.8 and 4.9 
To a suspension of 4.8 or 4.9 (1 eq), respectively, in EtOH was added hydrazine-
monohydrate (5 eq). After stirring for 30 min at room temperature, the solution 
became clear and stirring was continued overnight. The mixture was cooled in an ice 
bath, the precipitate was removed by filtration and the filtrate concentrated to 
dryness. The crude product was subjected to flash chromatography (CHCl3/MeOH/ 
NEt3 94/5/1 v/v/v).  
tert-Butyl 5-(3-aminopropyl)-4-methylthiazol-2-ylcarbamate (4.10)8 
The title compound was prepared from 4.8 (6.4 g, 15.9 mmol) in 70 ml EtOH and 
hydrazine-monohydrate (3.9 ml, 79.8 mmol) according to the general procedure 
yielding 4.10 as a yellow oil (4.3 g, 100 %). 1H-NMR (CDCl3) δ ppm: 2.73 (m, 4H, 
CH2NH2, Thiaz-5-CH2), 2.23 (s, 3H, Thiaz-4-CH3), 1.75 (m, 2H, Thiaz-5-CH2CH2), 
1.51 (s, 9H, C(CH3)3); CI-MS (NH3) m/z (%): 272 (MH+, 100). C12H21N3O2S (271.14) 
tert-Butyl 5-(3-aminopropyl)thiazol-2-ylcarbamate (4.11) 
The title compound was prepared from 4.9 (17.24 g, 44.5 mmol) in 170 ml EtOH and 
hydrazine-monohydrate (10.8 ml, 223.3 mmol) according to the general procedure 
yielding 4.11 as a pale yellow solid (7.07 g, 62 %). mp = 109 °C; 1H-NMR (CDCl3) δ 
ppm: 7.02 (s, 1H, Thiaz-4-H), 2.77 (m, 4H, Thiaz-5-CH2, CH2NH2), 1.78 (m, 2H, 
Thiaz-5-CH2CH2), 1.56 (s, 9H, Boc-CH3); CI-MS (NH3) m/z (%): 258 (MH+, 100). 
C11H19N3O2S (257.35) 
General procedure for the guanidinylation reaction  
To a suspension of 4.10 or 4.11 (1 eq) 4.14 (1 eq) and HgCl2 (2 eq) in DCM/abs was 
added NEt3 (3 eq) and stirred at ambient temperature for 48 h. Subsequently, EtOAc 
was added and the precipitate filtered over Celite. The crude product was purified by 
flash chromatography (PE/EtOAc 80/20 v/v). 
tert-Butyl 5-[3-(N-benzyloxycarbonyl-N’-tert-butyloxycarbonylguanidino)-
propyl]-4-methylthiazol-2-ylcarbamate (4.15) 
The title compound was prepared from 4.10 (4.08 g, 15 mmol), 4.14 (4.88 g, 15 
mmol), HgCl2 (8.2 g, 30 mmol) and NEt3 (4.55 g, 6.24 ml, 45 mmol) in 500 ml 
DCM/abs and 500 ml EtOAc according to the general procedure yielding 4.15 as a 
colourless foam-like solid (6.3 g, 77 %). 1H-NMR (CDCl3) δ ppm: 11.35 (br s, 1H, 
NH), 8.47 (t, 1H, 3J = 5.3 Hz, CH2NH), 7.34 (m, 5H, Ar-H), 5.13 (s, 2H, CH2-Ar), 3.46 
(m, 2H, CH2NH), 2.69 (t, 2H, 3J =7.6 Hz, Thiaz-5-CH2), 2.20 (s, 3H, Thiaz-4-CH3), 
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1.88 (m, 2H, Thiaz-5-CH2CH2), 1.52 (s, 9H, C(CH3)3), 1.48 (s, 9H, C(CH3)3); ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 548 (MH+, 100). C26H37N5O6S (547.25) 
tert-Butyl 5-[3-(N-benzyloxycarbonyl-N’-tert-butyloxycarbonylguanidino)-
propyl]thiazol-2-ylcarbamate (4.16) 
The title compound was prepared from 4.11 (4 g, 15.5 mmol), 4.14 (5 g, 15.5 mmol), 
HgCl2 (8.42 g, 31 mmol) and NEt3 (6.4 ml, 46.5 mmol) in 500 ml DCM/abs and 500 
ml EtOAc according to the general procedure yielding 4.16 as a colourless foam-like 
solid (8.48 g, 100 %). mp = 140-142 °C; 1H-NMR (CDCl3) δ ppm: 11.35 (s, 1H, NH), 
8.47 (t, 1H, 3J = 5.4 Hz, CH2NH), 7.34 (m, 5H, Ar-H), 7.05 (s, 1H, Thiaz-4-H), 5.13 (s, 
2H, CH2-Ph), 3.47 (m, 2H, CH2NH), 2.77 (t, 2H, 3J = 7.5 Hz, Thiaz-5-CH2),1.92 (m, 
2H, Thiaz-5-CH2CH2), 1.55 (s, 9H, Boc-CH3), 1.48 (s, 9H, Boc-CH3); ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 534 (MH+, 100). C25H35N5O6S (533.64) 
General procedure for the hydrogenolytic cleavage of Cbz groups   
To a solution of 4.15 or 4.16 in a mixture of THF/MeOH (1:1) was added Pd/C (10 %) 
and hydrogenated by 8 bar for 3-4 days. The catalyst was removed by filtration over 
Celite and washed with MeOH. The solvent was removed in vacuo. 
tert-Butyl 5-[3-(N-tert-butoxycarbonylguanidino)propyl]-4-methylthiazol-2-yl-
carbamate (4.17) 
The title compound was prepared from 4.15 (5.8 g, 10.6 mmol) and 6 g of Pd/C (10 
%) in a mixture of 160 ml THF/MeOH (1:1) according to the general procedure 
yielding 4.17 as a colourless foam-like solid (4.38 g, 100 %). mp = 113 °C; 1H-NMR 
(CD3OD) δ ppm: 3.23 (t, 2H, 3J = 6.9 Hz, CH2NH), 2.75 (t, 2H, 3J = 7.5Hz, Thiaz-5-
CH2), 2.17 (s, 3H, Thiaz-4-CH3), 1.86 (m, 2H, Thiaz-5-CH2CH2), 1.52 (s, 9H, 
C(CH3)3), 1.47 (s, 9H, C(CH3)3); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 414 (MH+, 
100). C18H31N5O4S (413.53) 
tert-Butyl 5-[3-(N-tert-butoxycarbonylguanidino)propyl]thiazol-2-ylcarbamate 
(4.18) 
The title compound was prepared from 4.16 (5.8 g, 10.6 mmol) and 6 g of Pd/C (10 
%) in a mixture of 160 ml THF/MeOH (1:1) according to the general procedure 
yielding 4.18 as a colourless foam-like solid (3.39 g, 75 %). 1H-NMR (CDCl3) δ ppm: 
7.03 (s, 1H, Thiaz-4-H), 3.26 (t, 2H, 3J = 6.9 Hz, CH2NH), 2.84 (t, 2H, 3J = 7.2 Hz, 
Thiaz-5-CH2), 1.95 ( m, 2H, Thiaz-5-CH2CH2), 1.55 (s, 9H, Boc-CH3), 1.47 (s, 9H, 
C(CH3)3); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 400 (MH+, 100). C18H31N5O4S 
(399.50) 
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4.5.3. Preparation of Boc-protected aminothiazolylpropylguanidines 
4.19a-4.46a 
General procedure  
To a solution of carboxylic acid (1 eq), EDAC (1 eq) and HOBt-monohydrate (1 eq) in 
DCM/abs was added DIEA (1 eq) under argon and stirred for 15 min. To this mixture 
a solution of 4.17 or 4.18 (1 eq), respectively, in DCM/abs was added and stirred 
over night at room temperature. The solvent was removed under reduced pressure 
and EtOAc and water was added to the resulting crude mixture. The organic phase 
was separated and the aqueous phase extracted two times with EtOAc. After drying 
over MgSO4, the solvent removed in vacuo. The crude product was purified by flash-
chromatography (PE/EtOAc 80/20 v/v) unless otherwise indicated. 
tert-Butyl 5-[3-[N-tert-butoxycarbonyl-N´-(3-(4-methylphenyl)butanoyl)guani-
dino]propyl]-4-methylthiazol-2-ylcarbamate (4.19a) 
The title compound was prepared from 3-p-tolylbutanoic acid 3.27c (180 mg, 1 
mmol), EDAC (190 mg, 1 mmol),  HOBt-monohydrate (150 mg, 1 mmol), DIEA (0.17 
ml, 1 mmol) in 5 ml DCM/abs and 4.17 (410 mg, 1 mmol) in 5 ml DCM/abs according 
to the general procedure yielding 4.19a as a colourless foam-like solid (450 mg, 78 
%). 1H-NMR (CDCl3) δ ppm: 12.37 (s, 1H, NH), 8.94 (t, 1H, 3J = 5.2 Hz, CH2NH), 
7.11 (m, 4H, Ar-H), 3.42 (m, 2H, CH2NH), 3.28 (m, 1H, CHCH3), 2.69-2.55 (m, 4H, 
Thiaz-5-CH2, COCH2), 2.30 (s, 3H, (p-CH3)-Ar), 2.21 (s, 3H, Thiaz-4-CH3), 1.86 (m, 
2H, Thiaz-5-CH2CH2), 1.52 (s, 9H, C(CH3)3), 1.49 (s, 9H, C(CH3)3), 1.31 (d, 3H, 3J = 
6.9 Hz, CH3); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 574 (MH+, 100). 
C29H43N5O5S (573.75) 
tert-Butyl 5-[3-[N-tert-butoxycarbonyl-N´-(2-methyl-3-phenylpropanoyl)guani-
dino]propyl]-4-methylthiazol-2-ylcarbamate (4.20a) 
The title compound was prepared from 2-methyl-3-phenylpropanoic acid (160 mg, 1 
mmol), EDAC (190 mg, 1 mmol),  HOBt-monohydrate (150 mg, 1 mmol), DIEA (0.17 
ml, 1 mmol) in 5 ml DCM/abs and 4.17 (410 mg, 1 mmol) in 5 ml DCM/abs according 
to the general procedure yielding 4.20a as a yellow foam-like solid (400 mg, 71 %). 
1H-NMR (CDCl3) δ ppm: 12.44 (s, 1H, NH), 8.99 (t, 1H, 3J = 5.2 Hz, CH2NH), 7.28-
7.16 (m, 5H, Ar-H), 3.43 (m, 2H, CH2NH), 3.06 (m, 1H, COCH), 2.74-2.59 (m, 4H, 
Thiaz-5-CH2, CH2-Ar), 2.21 (s, 3H, Thiaz-4-CH3), 1.88 (m, 2H, Thiaz-5-CH2CH2), 
1.52 (s, 9H, C(CH3)3), 1.49 (s, 9H, C(CH3)3), 1.19 (d, 3H, 3J = 6.6 Hz, CH3),; ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 560 (MH+, 100). C28H41N5O5S (559.72) 
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tert-Butyl 5-[3-[N-tert-butoxycarbonyl-N´-(3-phenylpentanoyl)guanidino]-
propyl]-4-methylthiazol-2-ylcarbamate (4.21a) 
The title compound was prepared from 3-phenylpentanoic acid 3.21c (90 mg, 0.5 
mmol), EDAC (95 mg, 0.5 mmol),  HOBt-monohydrate (80 mg, 0.5 mmol), DIEA (0.09 
ml, 0.5 mmol) in 2.5 ml DCM/abs and 4.17 (210 mg, 0.5 mmol) in 2.5 ml DCM/abs 
according to the general procedure yielding 4.21a as a colourless foam-like solid 
(170 mg, 59 %). 1H-NMR (CDCl3) δ ppm: 12.34 (s, 1H, NH), 8.90 (t, 1H, 3J = 5.1 Hz, 
CH2NH) 7.32-7.17 (m, 5H, Ar-H), 3.40 (m, 2H, CH2NH), 3.03 (m, 1H, CH2CH), 2.76-
2.62 (m, 4H, COCH2, Thiaz-5-CH2), 2.19 (s, 3H, Thiaz-4-CH3), 1.86 (m, 2H, Thiaz-5-
CH2CH2) 1.74-1.60 (m, 2H, CH2CH3), 1.53 (s, 9H, C(CH3)3), 1.50 (s, 9H, C(CH3)3), 
0.81 (t, 3H, 3J = 7.3 Hz, CH3); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 574 (MH+, 
100). C29H43N5O5S (573.75) 
tert-Butyl 5-[3-[N-tert-butoxycarbonyl-N´-(2-benzylbutanoyl)guanidino]prop-yl]-
4-methylthiazol-2-ylcarbamate (4.22a) 
The title compound was prepared from 2-benzylbutanoic acid 3.51d (90 mg, 0.5 
mmol), EDAC (95 mg, 0.5 mmol),  HOBt-monohydrate (80 mg, 0.5 mmol), DIEA (0.09 
ml, 0.5 mmol) in 2.5 ml DCM/abs and 4.17 (210 mg, 0.5 mmol) in 2.5 ml DCM/abs 
according to the general procedure yielding 4.22a as a colourless foam-like solid 
(180 mg, 63 %). 1H-NMR (CDCl3) δ ppm: 12.34 (s, 1H, NH), 8.99 (t, 1H, 3J = 5.1 Hz, 
CH2NH), 7.26-7.17 (m, 5H, Ar-H), 3.42 (m, 2H, CH2NH), 2.93 (dd, 1H, 3J = 8.7 Hz, 2J 
= 13.9 Hz, CHH-Ar), 2.81 (dd, 1H, 3J = 6.5 Hz, 2J = 13.7 Hz, CHH-Ar), 2.69 (t, 2H, 3J 
= 7.6 Hz, Thiaz-5-CH2), 2.54 (m, 1H, COCH), 2.21 (s, 3H, Thiaz-4-CH3), 1.86 (m, 2H, 
Thiaz-5-CH2CH2), 1.67 (m, 2H, CH2CH3), 1.52 (s, 9H, C(CH3)3), 1.48 (s, 9H, 
C(CH3)3), 0.96 (t, 3H, 3J = 7.4 Hz, CH3); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
574 (MH+, 100). C29H43N5O5S (573.75) 
tert-Butyl 5-[3-[N-tert-butoxycarbonyl-N´-(3-methyl-4-phenylbutanoyl)guani-
dino]propyl]-4-methylthiazol-2-ylcarbamate (4.23a) 
The title compound was prepared from 3-methyl-4-phenylbutanoic acid 3.28c (190 
mg, 1.1 mmol), EDAC (210 mg, 1.1 mmol),  HOBt-monohydrate (170 mg, 1.1 mmol), 
DIEA (0.18 ml, 1.1 mmol)  in 5 ml DCM/abs and 4.17 (450 mg, 1.1 mmol) in 5 ml 
DCM/abs according to the general procedure yielding 4.23a as a colourless foam-like 
solid (360 mg, 63 %). 1H-NMR (CDCl3) δ ppm: 12.40 (s, 1H, NH), 8.99 (t, 1H, 3J = 5.2 
Hz, CH2NH), 7.29-7.17 (m, 5H, Ar-H), 3.44 (m, 2H, CH2NH), 2.70 (t, 2H, 3J = 7.5 Hz, 
Thiaz-5-CH2), 2.63 (dd, 3J = 6.8 Hz, 2J = 13.6 Hz, CHH-Ar), 2.55  (dd, 3J = 6.8 Hz, 2J 
Chapter 4: NG-Acylated Aminothiazolylpropylguanidines 143 
= 13.6 Hz, CHH-Ar), 2.38 (m, 2H, COCH2, CHCH3), 2.22 (s, 3H, Thiaz-4-CH3), 1.87 
(m, 2H, Thiaz-5-CH2CH2), 1.52 (s, 9H, C(CH3)3), 1.51 (s, 9H, C(CH3)3), 0.99 (d, 3H, 
3J = 6.4 Hz); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 574 (MH+, 100). C29H43N5O5S 
(573.74) 
tert-Butyl 5-[3-[N-tert-butoxycarbonyl-N´-(3-methyl-4-(3-methylphenyl)butan-
oyl)guanidino]propyl]-4-methylthiazol-2-ylcarbamate (4.24a) 
The title compound was prepared from 3-methyl-4-m-tolylbutanoic acid 3.31c(190 
mg, 1 mmol), EDAC (190 mg, 1 mmol),  HOBt-monohydrate (150 mg, 1 mmol), DIEA 
(0.17 ml, 1 mmol) in 5 ml DCM/abs and 4.17 (410 mg, 1 mmol) in 5 ml DCM/abs 
according to the general procedure yielding 4.24a as a pale yellow foam-like solid 
(500 mg, 85 %). 1H-NMR (CDCl3) δ ppm: 12.39 (s, 1H, NH), 9.00 (t, 1H, 3J = 5.2 Hz, 
CH2NH), 7.15 (m, 1H, Ar-H), 6.98 (t, 3H, Ar-H), 3.44 (m, 2H, CH2NH), 2.70 (t, 2H, 3J 
= 7.5 Hz, Thiaz-5-CH2), 2.60-2.40 (m, 5H, COCH2, CH3CH, CH2-Ar), 2.32 (s, 3H, (m-
CH3)-Ar), 2.21 (s, 3H, Thiaz-4-CH3), 1.87 (m, 2H, Thiaz-5-CH2CH2), 1.52 (s, 9H, 
C(CH3)3), 1.51 (s, 9H, C(CH3)3), 0.98 (d, 3H, 3J = 6.4 Hz, CH3); ES-MS (DCM/MeOH 
+ NH4OAc) m/z (%): 588 (MH+, 100). C30H45N5O5S (587.77) 
tert-Butyl 5-[3-[N-tert-butoxycarbonyl-N´-(3-methyl-4-(4-methylphenyl)butan-
oyl)guanidino]propyl]-4-methylthiazol-2-ylcarbamate (4.25a) 
The title compound was prepared from 3-methyl-4-p-tolylbutanoic acid 3.32c (190 
mg, 1 mmol), EDAC (190 mg, 1 mmol),  HOBt-monohydrate (150 mg, 1 mmol), DIEA 
(0.17 ml, 1 mmol) in 5 ml DCM/abs and 4.17 (410 mg, 1 mmol) in 5 ml DCM/abs 
according to the general procedure yielding 4.25a as a pale yellow foam-like solid 
(480 mg, 82 %). 1H-NMR (CDCl3)  δ ppm: 12.38 (s, 1H, NH), 9.00 (t, 1H, 3J = 5.2 Hz, 
CH2NH), 7.07 (m, 4H, Ar-H), 3.44 (m, 2H, CH2NH), 2.69 (t, 2H, 3J = 7.5 Hz, Thiaz-5-
CH2), 2.55 (m, 2H, CH2-Ar),  2.41-2.28 (m, 6H, COCH2, CH3CH, (m-CH3)-Ar), 2.19 (s, 
3H, Thiaz-4-CH3), 1.86 (m, 2H, Thiaz-5-CH2CH2), 1.52 (s, 9H, C(CH3)3), 1.50 (s, 9H, 
C(CH3)3), 0.97 (d, 3H, 3J = 6.4 Hz, CH3); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
588 (MH+, 100). C30H45N5O5S (587.77) 
tert-Butyl 5-[3-[N-tert-butoxycarbonyl-N´-[4-(3-methoxyphenyl)-3-methylbu-
tanoyl]guanidino]propyl]-4-methylthiazol-2-ylcarbamate (4.26a) 
The title compound was prepared from 4-(3-methoxyphenyl)-3-methylbutanoic acid 
3.35c (105 mg, 0.5 mmol), EDAC (95 mg, 0.5 mmol),  HOBt-monohydrate (80 mg, 
0.5 mmol), DIEA (0.09 ml, 0.5 mmol) in 2.5 ml DCM/abs and 4.17 (210 mg, 0.5 
mmol) in 2.5 ml DCM/abs according to the general procedure yielding 4.26a as a 
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colourless foam-like solid (200 mg, 66 %). 1H-NMR (CDCl3) δ ppm: 12.40 (s, 1H, 
NH), 9.00 (t, 1H, 3J = 5.2 Hz, CH2NH), 7.18 (m, 1H, Ar-H), 6.73 (m, 3H, Ar-H), 3.79 
(s, 3H, (p-OCH3)-Ar), 3.44 (m, 2H, CH2NH), 2.70 (t, 2H, 3J = 7.5 Hz, Thiaz-5-CH2), 
2.56 (t, 2H, 3J = 7.3 Hz, CH2-Ar), 2.39 (m, 3H, CHCH2, COCH2), 2.21 (s, 3H, Thiaz-4-
CH3), 1.87 (m, 2H, Thiaz-5-CH2CH2), 1.52 (s, 9H, C(CH3)3), 1.50 (s, 9H, C(CH3)3), 
0.99 (d, 3H, 3J = 6.4 Hz, CH3); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 604 (MH+, 
100). C30H45N5O6S (603.77) 
tert-Butyl 5-[3-[N-tert-butoxycarbonyl-N´-[4-(4-methoxyphenyl)-3-methylbu-
tanoyl]guanidino]propyl]-4-methylthiazol-2-ylcarbamate (4.27a) 
The title compound was prepared from 4-(4-methoxyphenyl)-3-methylbutanoic acid 
3.36c (105 mg, 0.5 mmol), EDAC (95 mg, 0.5 mmol),  HOBt-monohydrate (80 mg, 
0.5 mmol), DIEA (0.09 ml, 0.5 mmol) in 2.5 ml DCM/abs and 4.17 (210 mg, 0.5 
mmol) in 2.5 ml DCM/abs according to the general procedure yielding 4.27a as a 
colourless foam-like solid (200 mg, 66 %). 1H-NMR (CDCl3) δ ppm: 12.39 (s, 1H, 
NH), 9.00 (t, 1H, 3J = 5.2 Hz, CH2NH), 7.08 (m, 2H, Ar-H), 6.81 (m, 2H, Ar-H), 3.78 
(s, 3H, (m-OCH3)-Ar), 3.44 (m, 2H, CH2NH), 2.70 (t, 2H, 3J = 7.5 Hz, Thiaz-5-CH2), 
2.53 (t, 2H, 3J = 6.5 Hz, CH2-Ar), 2.36 (m, 3H, CHCH2, COCH2), 2.21 (s, 3H, Thiaz-4-
CH3), 1.87 (m, 2H, Thiaz-5-CH2CH2 ), 1.52 (s, 9H, C(CH3)3), 1.51 (s, 9H, C(CH3)3), 
0.97 (d, 3H, 3J = 6.3 Hz, CH3); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 604 (MH+, 
100). C30H45N5O6S (603.77) 
tert-Butyl 5-[3-[N-tert-butoxycarbonyl-N´-[4-(3-fluorophenyl)-3-methylbutano-yl]-
guanidino]propyl]-4-methylthiazol-2-ylcarbamate (4.28a) 
The title compound was prepared from 4-(3-fluorophenyl)-3-methylbutanoic acid 
3.33c (100 mg, 0.5 mmol), EDAC (95 mg, 0.5 mmol),  HOBt-monohydrate (80 mg, 
0.5 mmol), DIEA (0.09 ml, 0.5 mmol) in 2.5 ml DCM/abs and 4.17 (210 mg, 0.5 
mmol) in 2.5 ml DCM/abs according to the general procedure yielding 4.28a as a 
colourless foam-like solid (200 mg, 68 %). 1H-NMR (CDCl3) δ ppm: 12.38 (s, 1H, 
NH), 8.91 (t, 1H, 3J = 5.2 Hz, CH2NH), 7.16 (m, 1H, Ar-H), 6.84 (m, 3H, Ar-H), 3.38 
(m, 2H, CH2NH), 2.61 (m, 3H, Thiaz-5-CH2, CHH-Ar), 2.46 (dd, 3J = 7.1 Hz, 2J = 13.5 
Hz, CHH-Ar), 2.28 (m, 3H, CHCH2, COCH2), 2.14 (s, 3H, Thiaz-4-CH3), 1.80 (m, 2H, 
Thiaz-5-CH2CH2), 1.45 (s, 9H, C(CH3)3), 1.44 (s, 9H, C(CH3)3), 0.91 (d, 3H, 3J = 6.4 
Hz, CH3); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 592 (MH+, 100). C29H42FN5O5S 
(591.74) 
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tert-Butyl 5-[3-[N-tert-butoxycarbonyl-N´-[4-(4-fluorophenyl)-3-methylbutano-
yl]guanidino]propyl]-4-methylthiazol-2-ylcarbamate (4.29a) 
The title compound was prepared from 4-(4-fluorophenyl)-3-methylbutanoic acid 
3.34c (100 mg, 0.5 mmol), EDAC (95 mg, 0.5 mmol),  HOBt-monohydrate (80 mg, 
0.5 mmol), DIEA (0.09 ml, 0.5 mmol) in 2.5 ml DCM/abs and 4.17 (210 mg, 0.5 
mmol) in 2.5 ml DCM/abs according to the general procedure yielding 4.29a as a 
colourless foam-like solid (220 mg, 74 %). 1H-NMR (CDCl3) δ ppm: 12.43 (s, 1H, 
NH), 8.98 (t, 1H, 3J = 5.2 Hz, CH2NH), 7.12 (m, 2H, Ar-H), 6.95 (m, 2H, Ar-H), 3.45 
(m, 2H, CH2NH), 2.70 (t, 2H, 3J = 7.5 Hz, Thiaz-5-CH2), 2.61 (dd, 1H, 3J = 6.6 Hz, 2J 
= 13.4 Hz, CHH-Ar), 2.50 (dd, 1H, 3J = 6.9 Hz, 2J = 13.5 Hz, CHH-Ar), 2.35 (m, 3H, 
CHCH2, COCH2), 2.21 (s, 3H, Thiaz-4-CH3), 1.87 (m, 2H, Thiaz-5-CH2CH2), 1.52 (s, 
9H, C(CH3)3), 1.51 (s, 9H, C(CH3)3), 0.97 (d, 3H, 3J = 6.3 Hz, CH3); ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 592 (MH+, 100). C29H42FN5O5S (591.74) 
tert-Butyl 5-[3-[N-tert-butoxycarbonyl-N´-((R)-3-cyclohexylbutanoyl)guanidi-
no]propyl]-4-methylthiazol-2-ylcarbamate (4.30a) 
The title compound was prepared from (R)-3-cyclohexylbutanoic acid 3.40 (170 mg, 
1 mmol), EDAC (190 mg, 1 mmol),  HOBt-monohydrate (150 mg, 1 mmol), DIEA 
(0.17 ml, 1 mmol) in 5 ml DCM/abs and 4.17 (410 mg, 1 mmol) in 5 ml DCM/abs 
according to the general procedure yielding 4.30a as a colourless foam-like solid 
(270 mg, 48 %). 1H-NMR (CDCl3) δ ppm: 12.38 (s, 1H, NH), 9.05 (t, 1H, 3J = 5.1 Hz, 
CH2NH), 3.46 (m, 2H, CH2NH), 2.71 (t, 2H, 3J = 7.5 Hz, Thiaz-5-CH2), 2.48 (dd, 1H, 
3J = 5.1 Hz, 2J = 14.9 Hz, COCHH), 2.21 (s, 3H, Thiaz-4-CH3), 2.13 (dd, 1H, 3J = 9.1 
Hz, 2J = 14.9 Hz, COCHH), 1.89 (m, 3H, Thiaz-5-CH2CH2, CH3CH), 1.74-1.63 (m, 
6H, cHex-CH2), 1.52 (s, 9H, C(CH3)3), 1.50 (s, 9H, C(CH3)3), 1.23-1.01 (m, 7H, cHex-
CH2, cHex-CH), 0.92 (d, 3H, 3J = 6.8 Hz, CH3); ES-MS (DCM/MeOH + NH4OAc) m/z 
(%): 566 (MH+, 100). C28H47N5O5S (565.54) 
tert-Butyl 5-[3-[N-tert-butoxycarbonyl-N´-((S)-3-cyclohexylbutanoyl)guanidi-
no]propyl]-4-methylthiazol-2-ylcarbamate (4.31a) 
The title compound was prepared from (S)-3-cyclohexylbutanoic acid 3.41 (170 mg, 1 
mmol), EDAC (190 mg, 1 mmol),  HOBt-monohydrate (150 mg, 1 mmol), DIEA (0.17 
ml, 1 mmol) in 5 ml DCM/abs and 4.17 (410 mg, 1 mmol) in 5 ml DCM/abs according 
to the general procedure yielding 4.31a as a colourless foam-like solid (360 mg, 64 
%). 1H-NMR (CDCl3) δ ppm: 12.35 (s, 1H, NH), 9.05 (t, 1H, 3J = 5.1 Hz, CH2NH), 
3.47 (m, 2H, CH2NH), 2.70 (t, 2H, 3J = 7.5 Hz, Thiaz-5-CH2), 2.49 (dd, 1H, 3J = 5.1 
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Hz, 2J = 14.9 Hz, COCHH), 2.21 (s, 3H, Thiaz-4-CH3), 2.12 (dd, 1H, 3J = 9.1 Hz, 2J = 
14.9 Hz, COCHH), 1.90 (m, 3H, Thiaz-5-CH2CH2, CH3CH), 1.75-1.60 (m, 6H, cHex-
CH2), 1.52 (s, 9H, C(CH3)3), 1.50 (s, 9H, C(CH3)3), 1.22-1.02 (m, 7H, cHex-CH2, 
cHex-CH), 0.92 (d, 3H, 3J = 6.8 Hz, CH3); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
566 (MH+, 100). C28H47N5O5S (565.54) 
tert-Butyl 5-[3-[N-tert-butoxycarbonyl-N´-(3-cyclohexyl-2-methylpropanoyl)-
guanidino]propyl]-4-methylthiazol-2-ylcarbamate (4.32a) 
The title compound was prepared from 3-cyclohexyl-2-methylpropanoic acid 3.42 
(170 mg, 1 mmol), EDAC (190 mg, 1 mmol),  HOBt-monohydrate (150 mg, 1 mmol), 
DIEA (0.17 ml, 1 mmol) in 5 ml DCM/abs and 4.17 (410 mg, 1 mmol) in 5 ml 
DCM/abs according to the general procedure yielding 4.32a as a pale yellow foam-
like solid (390 mg, 69 %). 1H-NMR (CDCl3) δ ppm: 12.48 (s, 1H, NH), 9.05 (t, 1H, 3J = 
5.1 Hz, CH2NH), 3.45 (m, 2H, CH2NH), 2.70 (t, 3H, 3J = 7.5 Hz, Thiaz-5-CH2), 2.52 
(m, 1H, COCH), 2.21 (s, 3H, Thiaz-4-CH3), 1.87 (m, 2H, Thiaz-5-CH2CH2), 1.75-1.62 
(m, 6H, cHex-CH, CH2-cHex, cHex-CH2), 1.52 (s, 9H, C(CH3)3), 1.49 (s, 9H, 
C(CH3)3), 1.22 (m, 4H, cHex-CH2), 1.14 (d, 3H, 3J = 6.8 Hz, CH3), 0.87 (m, 2H, cHex-
CH2); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 566 (MH+, 100). C28H47N5O5S 
(565.75) 
tert-Butyl 5-[3-[N-tert-butoxycarbonyl-N´-(3-cyclohexylpentanoyl)guanidino]-
propyl]-4-methylthiazol-2-ylcarbamate (4.33a) 
The title compound was prepared from 3-cyclohexylpentanoic acid 3.43 (180 mg, 1 
mmol), EDAC (190 mg, 1 mmol),  HOBt-monohydrate (150 mg, 1 mmol), DIEA (0.17 
ml, 1 mmol) in 5 ml DCM/abs and 4.17 (410 mg, 1 mmol) in 5 ml DCM/abs according 
to the general procedure yielding 4.33a as a pale yellow foam-like solid (420 mg, 83 
%). 1H-NMR (CDCl3) δ ppm: 12.41 (s, 1H, NH), 9.05 (t, 1H, 3J = 5.2 Hz, CH2NH), 
3.45 (m, 2H, CH2NH), 2.70 (t, 2H, 3J = 7.5 Hz, Thiaz-5-CH2), 2.41 (dd, 1H, 3J = 5.9 
Hz, 2J = 15.4 Hz, COCHH), 2.21 (m, 3H, COCHH, Thiaz-4-CH3), 1.87 (m, 2H, Thiaz-
5-CH2CH2), 1.68 (m, 6H, cHex-CH, cHex-CH2), 1.52 (s, 9H, C(CH3)3), 1.50 (s, 9H, 
C(CH3)3), 1.34–1.03 (m, 8H, cHex-CH2, CH2CH3, CH2CH), 0.89 (t, 3H, 3J = 7.4 Hz, 
CH3); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 580 (MH+, 100). C29H49N5O5S 
(579.79) 
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tert-Butyl 5-[3-[N-tert-butoxycarbonyl-N´-[2-(cyclohexylmethyl)butanoyl]-guani-
dino]propyl]-4-methylthiazol-2-ylcarbamate (4.34a) 
The title compound was prepared from 2-(cyclohexylmethyl)butanoic acid 3.44 (90 
mg, 0.5 mmol), EDAC (95 mg, 0.5 mmol),  HOBt-monohydrate (80 mg, 0.5 mmol), 
DIEA (0.09 ml, 0.5 mmol) in 2.5 ml DCM/abs and 4.17 (210 mg, 0.5 mmol) in 2.5 ml 
DCM/abs according to the general procedure yielding 4.34a as a colourless foam-like 
solid (190 mg, 66 %). 1H-NMR (CDCl3) δ ppm: 12.53 (s, 1H, NH), 9.55 (s, 1H, 
CH2NH), 3.55 (m, 2H, CH2NH), 2.73 (t, 2H, 3J = 7.6 Hz, Thiaz-5-CH2), 2.39 (m, 1H, 
COCH), 2.30 (s, 3H, Thiaz-4-CH3), 1.96 (m, 2H, Thiaz-5-CH2CH2), 175-1.61 (m, 8H, 
cHex-CH2, CH2CH3), 1.56 (s, 9H, C(CH3)3), 1.50 (s, 9H, C(CH3)3), 1.35-1.15 (m, 5H, 
cHex-CH2, cHex-CH), 0.89 (m, 5H, CH3, CHCH2); ES-MS (DCM/MeOH + NH4OAc) 
m/z (%): 580 (MH+, 100). C29H49N5O5S (579.79) 
tert-Butyl 5-[3-[N-tert-butoxycarbonyl-N´-(4-cyclohexyl-3-methylbutanoyl)-
guanidino]propyl]-4-methylthiazol-2-ylcarbamate (4.35a) 
The title compound was prepared from 4-cyclohexyl-3-methylbutanoic acid 3.47 (180 
mg, 1 mmol), EDAC (190 mg, 1 mmol),  HOBt-monohydrate (150 mg, 1 mmol), DIEA 
(0.17 ml, 1 mmol) in 5 ml DCM/abs and 4.17 (410 mg, 1 mmol) in 5 ml DCM/abs 
according to the general procedure yielding 4.35a as a pale yellow foam-like solid 
(370 mg, 64 %). 1H-NMR (CDCl3) δ ppm: 12.40 (s, 1H, NH), 9.04 (t, 1H, 3J = 5.2 Hz, 
CH2NH), 3.45 (m, 2H, CH2NH), 2.70 (t, 2H, 3J = 7.5 Hz, Thiaz-5-CH2), 2.34 (dd, 1H, 
3J = 8.6 Hz, 3J = 17.5 Hz, COCHH), 2.22 (s, 3H, Thiaz-4-CH3), 2.15 (dd, 1H, 3J = 8.2 
Hz, 2J = 18.4 Hz, COCHH)1.87 (m, 2H, Thiaz-5-CH2CH2), 1.72-1.64 (m, 5H, cHex-
CH2, cHex-CH), 1.52 (s, 9H, C(CH3)3), 1.49 (s, 9H, C(CH3)3), 1.27-1.09 (m, 6H, 
cHex-CH2), 0.94 (d, 3H, 3J = 6.2 Hz, CH3), 0.87 (m, 2H, CH2-cHex); ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 580 (MH+, 100). C29H49N5O5S (579.79) 
tert-Butyl 5-[3-[N-tert-butoxycarbonyl-N´-[3-(cyclohexylmethyl)pentanoyl]-
guanidino]propyl]-4-methylthiazol-2-ylcarbamate (4.36a) 
The title compound was prepared from 3-(cyclohexylmethyl)pentanoic acid 3.50 (100 
mg, 0.5 mmol), EDAC (95 mg, 0.5 mmol),  HOBt-monohydrate (80 mg, 0.5 mmol), 
DIEA (0.09 ml, 0.5 mmol) in 2.5 ml DCM/abs and 4.17 (210 mg, 0.5 mmol) in 2.5 ml 
DCM/abs according to the general procedure yielding 4.36a as a colourless foam-like 
solid (250 mg, 84 %). 1H-NMR (CDCl3) δ ppm: 12.42 (s, 1H, NH), 9.05 (t, 1H, 3J = 5.2 
Hz, CH2NH), 3.46 (m, 2H, CH2NH), 2.69 (m, 2H, Thiaz-5-CH2), 2.27 (m, 2H, COCH2), 
2.20 (s, 3H, Thiaz-4-CH3), 1.92 (m, 2H, Thiaz-5-CH2CH2, CH2CH), 1.69 (m, 5H, 
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cHex-CH2, cHex-CH), 1.53 (s, 9H, C(CH3)3), 1.50 (s, 9H, C(CH3)3), 1.32-1.14 (m, 8H, 
cHex-CH2, CH2CH3), 0.88 (m, 5H, CH2-cHex, CH3); ES-MS (DCM/MeOH + NH4OAc) 
m/z (%): 594 (MH+, 100). C30H51N5O5S (593.82) 
tert-Butyl 5-[3-[N-tert-butoxycarbonyl-N´-[3-(4-hydroxyphenyl)propanoyl]-
guanidino]propyl]-4-methylthiazol-2-ylcarbamate (4.37a) 
The title compound was prepared from 3.54b (300 mg, 1 mmol), EDAC (190 mg, 1 
mmol), HOBt-monohydrate (1580 mg, 1 mmol), DIEA (0.17 ml, 1 mmol) in 5 ml 
DCM/abs and 4.17 (410 mg, 1 mmol) in 5 ml DCM/abs according to the general 
procedure. ES-MS (DCM/MeOH + NH4OAc) m/z (%): 694.3 (MH+, 100), 
C36H49N5O7S (693.85). Subsequently, the yellow foam-like solid (480 mg, 69 %) was 
dissolved in 20 ml EtOH, Pd/C (10 %) (0.45 g, cat.) was added and hydrogenated at 
8 bar for 6 days (TLC-control). The catalyst was filtered over Celite, the solvent 
removed in vacuo and 4.37a (340 mg) used in the next step without further 
purification (only the double bond was hydrogenated). 
tert-Butyl 5-[3-[N-tert-butoxycarbonyl-N´-(6-tert-butyloxycarbonylamino-3-
phenylhexanoyl)guanidino]propyl]-4-methylthiazol-2-ylcarbamate (4.38a) 
The title compound was prepared from 3.39c (150 mg, 0.5 mmol), EDAC (95 mg, 0.5 
mmol),  HOBt-monohydrate (80 mg, 0.5 mmol), DIEA (0.09 ml, 0.5 mmol) in 2.5 ml 
DCM/abs and 4.17 (210 mg, 0.5 mmol) in 2.5 ml DCM/abs according to the general 
procedure yielding 4.38a as a colourless foam-like solid (240 mg, 68 %). 1H-NMR 
(CDCl3) δ ppm: 12.35 (s, 1H, NH), 8.86 (t, 1H, 3J = 5.2 Hz, CH2NH), 7.21 (m, 5H, Ar-
H), 3.41 (m, 2H, CH2NH), 3.08 (m, 3H, CH2CH, CH2NH2), 2.68 (m, 4H, COCH2, 
Thiaz-5-CH2), 2.19 (s, 3H, Thiaz-4-CH3), 1.85 (m, 2H, Thiaz-5-CH2CH2), 1.71-1.61 
(m, 2H, CH2CH2CH2NH2), 1.52 (s, 9H, C(CH3)3), 1.49 (s, 9H, C(CH3)3), 1.41 (s, 9H, 
C(CH3)3), 1.24 (m, 2H, CH2CH2NH2); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 703 
(MH+, 100). C35H54N6O7S (702.90) 
10-(2-(tert-Butoxycarbonyl)-3-{3-[2-(tert-butoxycarbonylamino)-4-methylthiazol-
5-yl]propyl}guanidino)-10-oxodecanoic acid (4.39a) 
The title compound was prepared from 3.52 (150 mg, 0.5 mmol), EDAC (95 mg, 0.5 
mmol), HOBt-monohydrate (80 mg, 0.5 mmol), DIEA (0.09 ml, 0.5 mmol) in 2.5 ml 
DCM/abs and 4.17 (210 mg, 0.5 mmol) in 2.5 ml DCM/abs according to the general 
procedure yielding the Cbz-protected compound as a yellow oil, which was 
immediately dissolved in 10 ml MeOH and hydrogenated with Pd/C (cat.) as catalyst 
for 1 h at room temperature. After filtration over Celite, the solvent was removed 
Chapter 4: NG-Acylated Aminothiazolylpropylguanidines 149 
under reduced pressure to obtain 4.39a (0.21 g, 70 %) as a colourless foam-like 
solid. 1H-NMR (CDCl3) δ ppm: 3.47 (m, 2H, CH2NH), 2.70 (t, 2H, 3J = 7.1 Hz, Thiaz-
5-CH2), 2.33 (m, 4H, CH2COOH, COCH2), 2.16 (s, 3H, Thiaz-4-CH3), 1.88 (m, 2H, 
Thiaz-5-CH2CH2), 1.64 (m, 4H, COCH2CH2, CH2CH2COOH), 1.53 (s, 9H, C(CH3)3), 
1.49 (s, 9H, C(CH3)3), 1.33 (s, 8H, (CH2)4); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
598 (MH+, 100). C28H47N5O7S (597.77) 
tert-Butyl 5-[3-[N-tert-butoxycarbonyl-N´-(3-phenylpropanoyl)guanidino]-
propyl]thiazol-2-ylcarbamate (4.40a) 
The title compound was prepared from 3-phenylpropanoic acid (75 mg, 0.5 mmol), 
EDAC (95 mg, 0.5 mmol),  HOBt-monohydrate (800 mg, 0.5 mmol), DIEA (0.09 ml, 
0.5 mmol) in 2.5 ml DCM/abs and 4.18 (200 mg, 0.5 mmol) in 2.5 ml DCM/abs 
according to the general procedure (PE/EtOAC 70/30 v/v) yielding 4.40a as a 
colourless foam-like solid (160 mg, 60 %). 1H-NMR (CDCl3) δ ppm: 12.47 (s, 1H, 
NH), 8.98 (t, 1H, 3J = 5.2 Hz, CH2NH), 7.25 (m, 5H, Ar-H), 7.04 (s, 1H, Thiaz-4-H), 
3.47 (m, 2H, CH2NH), 3.00 (t, 2H, 3J = 7.7 Hz, COCH2CH2), 2.72 (m, 4H, Thiaz-5-
CH2, COCH2), 1.92 (m, 2H, Thiaz-5-CH2CH2), 1.56 (s, 9H, C(CH3)3), 1.49 (s, 9H, 
C(CH3)3); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 532 (MH+, 100). C26H37N5O5S 
(531.67) 
tert-Butyl 5-[3-[N-tert-butoxycarbonyl-N´-(3-phenylbutanoyl)guanidino]-propyl]-
thiazol-2-ylcarbamate (4.41a) 
The title compound was prepared from 3-phenylbutanoic acid (80 mg, 0.5 mmol), 
EDAC (95 mg, 0.5 mmol),  HOBt-monohydrate (800 mg, 0.5 mmol), DIEA (0.09 ml, 
0.5 mmol) in 2.5 ml DCM/abs and 4.18 (200 mg, 0.5 mmol) in 2.5 ml DCM/abs 
according to the general procedure (PE/EtOAC 70/30 v/v) yielding 4.41a as a 
colourless foam-like solid (210 mg, 77 %). 1H-NMR (CDCl3) δ ppm: 12.39 (s, 1H, 
NH), 8.93 (t, 1H, 3J = 5.3 Hz, CH2NH), 7.26 (m, 5H, Ar-H), 7.03 (s, 1H, Thiaz-4-H), 
3.44 (m, 2H, CH2NH), 3.30 (m, 1H, CH2CH), 2.77 (t, 2H, 3J = 7.4 Hz, Thiaz-5-CH2), 
2.63 (m, 2H, COCH2), 1.89 (m, 2H, Thiaz-5-CH2CH2), 1.57 (s, 9H, C(CH3)3), 1.50 (s, 
9H, C(CH3)3), 1.33 (d, 3H, 3J = 6.9 Hz, CH3); ES-MS (DCM/MeOH + NH4OAc) m/z 
(%): 546 (MH+, 100). C27H39N5O5S (545.69) 
tert-Butyl 5-[3-[N-tert-butoxycarbonyl-N´-(3-phenylpentanoyl)guanidino]pro-
pyl]thiazol-2-ylcarbamate (4.42a) 
The title compound was prepared from 3-phenylpentanoic acid 3.21c (90 mg, 0.5 
mmol), EDAC (95 mg, 0.5 mmol),  HOBt-monohydrate (800 mg, 0.5 mmol), DIEA 
Chapter 4: NG-Acylated Aminothiazolylpropylguanidines 150 
(0.09 ml, 0.5 mmol) in 2.5 ml DCM/abs and 4.18 (200 mg, 0.5 mmol) in 2.5 ml 
DCM/abs according to the general procedure (PE/EtOAC 70/30 v/v) yielding 4.42a as 
a colourless foam-like solid (250 mg, 89 %). 1H-NMR (CDCl3) δ ppm: 12.34 (s, 1H, 
NH), 8.90 (t, 1H, 3J = 5.2 Hz, CH2NH), 7.02 (s, 1H, Thiaz-4-H), 3.42 (m, 2H, CH2NH), 
3.04 (m, 1H, CHCH2CH3), 2.76-2.65 (m, 4H, Thiaz-5-CH2, COCH2), 1.89 (m, 2H, 
Thiaz-5-CH2CH2), 1.76-1.63 (m, 2H, CH2CH3), 1.56 (s, 9H, C(CH3)3), 1.50 (s, 9H, 
C(CH3)3), 0.81 (t, 3H, 3J = 7.3 Hz, CH3); CI-MS (NH3) m/z (%): 560 (MH+, 100). 
C28H41N5O5S (559.72) 
tert-Butyl 5-[3-[N-tert-butoxycarbonyl-N´-(3,3-diphenylpropanoyl)guanidino]-
propyl]thiazol-2-ylcarbamate (4.43a) 
The title compound was prepared from 3,3-diphenylpropanoic acid (110 mg, 0.5 
mmol), EDAC (95 mg, 0.5 mmol),  HOBt-monohydrate (800 mg, 0.5 mmol), DIEA 
(0.09 ml, 0.5 mmol) in 2.5 ml DCM/abs and 4.18 (200 mg, 0.5 mmol) in 2.5 ml 
DCM/abs according to the general procedure (PE/EtOAC 70/30 v/v) yielding 4.43a as 
a colourless foam-like solid (230 mg, 76 %).  1H-NMR (CDCl3) δ ppm: 12.51 (s, 1H, 
NH), 8.84 (t, 1H, 3J = 5.4 Hz, CH2NH), 7.29-7.15 (m, 10H, Ar-H), 7.02 (s, 1H, Thiaz-
4-H), 4.58 (t, 1H, 3J = 7.7 Hz, CH2CH), 3.42 (m, 2H, CH2NH), 3.13 (dd, 2H, 3J = 7.9 
Hz, 2J = 15.1 Hz, COCH2), 2.76 (m, 2H, Thiaz-5-CH2), 1.87 (m, 2H, Thiaz-5-
CH2CH2), 1.56 (s, 9H, C(CH3)3), 1.50 (s, 9H, C(CH3)3); ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 608 (MH+, 100). C32H41N5O5S (607.76) 
tert-Butyl 5-[3-[N-tert-butoxycarbonyl-N´-(3-cyclohexylbutanoyl)guanidino]-
propyl]thiazol-2-ylcarbamate (4.44a) 
The title compound was prepared from 3-cyclohexylbutanoic acid (85 mg, 0.5 mmol), 
EDAC (95 mg, 0.5 mmol),  HOBt-monohydrate (800 mg, 0.5 mmol), DIEA (0.09 ml, 
0.5 mmol) in 2.5 ml DCM/abs and 4.18 (200 mg, 0.5 mmol) in 2.5 ml DCM/abs 
according to the general procedure (PE/EtOAC 70/30 v/v) yielding 4.44a as a 
colourless foam-like solid (220 mg, 58 %). 1H-NMR (CDCl3) δ ppm: 12.38 (s, 1H, 
NH), 9.06 (t, 1H, 3J = 5.2 Hz, CH2NH), 7.04 (s, 1H, Thiaz-4-H), 3.48 (m, 2H, CH2NH), 
2.79 (t, 2H, 3J = 7.4 Hz, Thiaz-5-CH2), 2.49 (dd, 1H, 3J = 5.1 Hz, 2J = 14.9 Hz, 
COCHH), 2.12 (dd, 1H, 3J = 9.2 Hz, 2J = 14.9 Hz, COCHH), 1.92 (m, 3H, Thiaz-5-
CH2CH2, CH2CH), 1.74-1.63 (m, 5H, cHex-CH2, cHex-CH),  1.20-1.02 (m, 6H, cHex-
CH2), 1.56 (s, 9H, C(CH3)3), 1.50 (s, 9H, C(CH3)3), 0.92 (d, 3H, 3J = 6.8 Hz, CH3); 
ES-MS (DCM/MeOH + NH4OAc) m/z (%): 552 (MH+, 100). C27H45N5O5S (551.74) 
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tert-Butyl 5-[3-[N-tert-butoxycarbonyl-N´-(3-cyclohexyl-2-methylpropanoyl)-
guanidino]propyl]thiazol-2-ylcarbamate (4.45a) 
The title compound was prepared from 3-cyclohexyl-2-methylpropanoic acid 3.42 (85 
mg, 0.5 mmol), EDAC (95 mg, 0.5 mmol),  HOBt-monohydrate (800 mg, 0.5 mmol), 
DIEA (0.09 ml, 0.5 mmol) in 2.5 ml DCM/abs and 4.18 (200 mg, 0.5 mmol) in 2.5 ml 
DCM/abs according to the general procedure (PE/EtOAC 70/30 v/v) yielding 4.45a as 
a colourless foam-like solid (210 mg, 76 %). 1H-NMR (CDCl3) δ ppm: 12.48 (s, 1H, 
NH), 9.07 (t, 1H, 3J = 5.2 Hz, CH2NH), 7.04 (s, 1H, Thiaz-4-H), 3.48 (m, 2H, CH2NH), 
2.80 (t, 2H, 3J = 7.4 Hz, Thiaz-5-CH2), 2.52 (m, 1H, CHCH3), 1.92 (m, 2H, Thiaz-5-
CH2CH2), 1.75-1.61 (m, 6H, cHex-CH2, CH2-Ar), 1.57 (s, 9H, C(CH3)3), 1.50 (s, 9H, 
C(CH3)3), 1.29-1.17 (m, 8H, cHex-CH2, cHex-CH, CH3), 0.89 (m, 2H, cHex-CH2); CI-
MS (NH3) m/z (%): 552 (MH+, 100). C27H45N5O5S (551.72) 
tert-Butyl 5-[3-[N-tert-butoxycarbonyl-N´-(3-cyclohexylpentanoyl)guanidino]-
propyl]thiazol-2-ylcarbamate (4.46a) 
The title compound was prepared from 3-cyclohexylpentanoic acid 3.43(80 mg, 0.5 
mmol), EDAC (95 mg, 0.5 mmol),  HOBt-monohydrate (800 mg, 0.5 mmol), DIEA 
(0.09 ml, 0.5 mmol) in 2.5 ml DCM/abs and 4.18 (200 mg, 0.5 mmol) in 2.5 ml 
DCM/abs according to the general procedure (PE/EtOAC 70/30 v/v) yielding 4.46a as 
a colourless foam-like solid (80 mg, 28 %). 1H-NMR (CDCl3) δ ppm: 12.41 (s, 1H, 
NH), 9.06 (t, 1H, 3J = 5.1 Hz, CH2NH), 7.05 (s, 1H, Thiaz-4-H), 3.48 (m, 2H, CH2NH), 
2.79 (t, 2H, 3J = 7.4 Hz, Thiaz-5-CH2), 2.42 (dd, 1H, 3J = 5.9 Hz, 2J = 15.5 Hz, 
COCHH), 2.21 (dd, 1H, 3J = 7.7 Hz, 2J = 15.4 Hz, COCHH), 1.92 (m, 2H, Thiaz-5-
CH2CH2), 1.75-1.60 (m, 6H, cHex-CH2, CH2CH, cHex-CH), 1.31-1.05 1.56 (s, 9H, 
C(CH3)3), 1.50 (s, 9H, C(CH3)3), (m, 8H, cHex-CH2, CH2CH3), 0.89 (t, 3H, 3J = 7.5 
Hz, CH3); CI-MS (NH3) m/z (%): 566 (MH+, 100). C28H47N5O5S (565.76) 
 
4.5.4. Preparation of the deprotected acylguanidines 4.19-4.46 
General procedure  
To a solution of the protected acylguanidine in CH2Cl2/abs was added TFA (20 %) 
and the mixture was stirred at ambient temperatur until the Boc groups were 
removed (3-5 h). Subsequently, the solvent was removed in vacuo and the residue 
was purified by preparative RP-HPLC (for general conditions see chapter 3). All 
compounds were obtained as trifluoroacetic acid salts. 
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N-[3-(2-Amino-4-methylthiazol-5-yl)propyl]-N´-(3-(4-methylphenyl)butanoyl)-
guanidine (4.19) 
The title compound was prepared from 4.19a (430 mg, 0.75 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 4.19 as a 
colourless oil (340 mg, 75 %). 1H-NMR (CD3OD) δ ppm: 7.07 (m, 4H, Ar-H), 3.29 (m, 
3H, CH2NH, CH3CH), 2.69 (m, 4H, Thiaz-5-CH2, COCH2), 2.23 (s, 3H, (p-CH3)-Ar), 
2.12 (s, 3H, Thiaz-4-CH3), 1.85 (m, 2H, Thiaz-5-CH2CH2), 1.26 (d, 3H, 3J = 7.0 Hz, 
CH3); 13C (CD3OD) δ ppm: 176.35 (quat. C=O), 170.42 (quat. Thiaz-2-C), 155.26 
(quat. C=NH), 143.27 (quat. Thiaz-4-C), 137.24 (quat. Ar-C), 132.58 (quat. Ar-C), 
130.25 (+, 2 Ar-CH), 127.82 (+, 2 Ar-CH), 118.24 (quat. Thiaz-5-C), 46.25 (-, 
COCH2), 41.47 (-, CH2NH), 37.34 (+, CHCH3), 29.62 (-, Thiaz-5-CH2CH2), 23.57 (-, 
Thiaz-5-CH2), 22.37 (+, (p-CH3)-Ar), 21.16 (+, CH3), 11.48 (+, Thiaz-4-CH3); HRMS: 
EI-MS: m/z for (C19H27N5OS) calcd. 373.1936,  found 373.19282; prep. HPLC: 
MeCN/0.1% TFA/aq (30/70). C19H27N5OS  · 2TFA (601.5) 
N-[3-(2-Amino-4-methylthiazol-5-yl)propyl]-N´-(2-methyl-3-phenylpropanoyl)-
guanidine (4.20) 
The title compound was prepared from 4.20a (390 mg, 0.69 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 4.20 as a 
colourless oil (340 mg, 83 %). 1H-NMR (CD3OD) δ ppm: 7.22 (m, 5H, Ar-H), 3.32 (m 
(overlap with solvent peaks), 2H, CH2NH) , 2.99 (dd, 1H, 3J = 7.6 Hz, 2J = 12.7 Hz,  
CHH-Ar), 2.89 (m, 1H, COCH), 2.70 (m, 3H, Thiaz-5-CH2, CHH-Ar), 2.16 (s, 3H, 
Thiaz-4-CH3), 1.88 (m, 2H, Thiaz-5-CH2CH2), 1.19 (d, 3H, 3J = 6.6 Hz, CH3); 13C 
(CD3OD) δ ppm: 180.28 (quat. C=O), 170.37 (quat. Thiaz-2-C), 155.29 (quat. C=NH), 
140.03 (quat. Thiaz-4-C), 132.60 (quat. Ar-C), 130.13 (+, 2 Ar-CH), 129.55 (+, 2 Ar-
CH), 127.69 (+, Ar-CH), 118.41 (quat. Thiaz-5-C), 45.04 (+, COCH), 41.58 (-, CH2-
Ar), 40.62 (-, CH2NH), 29.65 (-, Thiaz-5-CH2CH2), 23.60 (-, Thiaz-5-CH2), 17.09 (+, 
CH3), 11.46 (+, Thiaz-CH3); HRMS: EI-MS: m/z for (C18H25N5OS) calcd. 359.1779, 
found 359.17716; prep. HPLC: MeCN/0.1% TFA/aq (20/80-40/60). C18H25N5OS · 
2TFA (587.47) 
N-[3-(2-Amino-4-methylthiazol-5-yl)propyl]-N´-(3-phenylpentanoyl)guanidine 
(4.21) 
The title compound was prepared from 4.21a (150 mg, 0.26 mmol) in 5 ml 
CH2Cl2/abs and 1 ml TFA according to the general procedure yielding 4.21 as a 
colourless oil (60 mg, 38 %). 1H-NMR (CD3OD) δ ppm: 7.22 (m, 5H, Ar-H), 3.27 (t, 
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2H, 3J = 6.1 Hz, CH2NH), 3.04 (m, 1H, CH2CH), 2.83 (dd, 1H, 3J = 6.2 Hz, 2J = 15.1 
Hz, COCHH), 2.74 (dd, 1H, 3J = 9.1 Hz, 2J = 15.1 Hz, COCHH), 2.66 (t, 2H, 3J = 7.6 
Hz, Thiaz-5-CH2), 2.14 (s, 3H, Thiaz-4-CH3), 1.85 (m, 2H, Thiaz-5-CH2CH2) 1.68 (m, 
2H, CH2CH3), 0.78 (t, 3H, 3J = 7.4 Hz, CH3); 13C (CD3OD) δ ppm: 176.24 (quat. 
C=O), 170.38 (quat. Thiaz-2-C), 155.17 (quat. C=NH), 144.45 (quat. Ar-C), 132.59 
(quat. Thiaz-4-C), 129.58 (+, 2 Ar-CH), 128.79 (+, 2 Ar-CH), 127.78 (+,Ar-CH), 
118.33 (quat. Thiaz-5-C), 45.17 (+, CH2CH), 44.76 (-, CH2NH), 41.44 (-, COCH2), 
30.21 (-, Thiaz-5-CH2CH2), 29.60 (-, Thiaz-5-CH2), 23.52 (-, CH2CH3), 12.26 (+, CH3), 
11.44 (+, Thiaz-CH3); HRMS: EI-MS: m/z for (C18H25N5OS) calcd. 373.1936,  found 
373.19443; prep. HPLC: MeCN/0.1% TFA/aq (25/75-40/60). C19H27N5OS · 2TFA 
(601.53) 
N-[3-(2-Amino-4-methylthiazol-5-yl)propyl]-N´-(2-benzylbutanoyl)guanidine 
(4.22) 
The title compound was prepared from 4.22a (170 mg, 0.29 mmol) in 5 ml 
CH2Cl2/abs and 1 ml TFA according to the general procedure yielding 4.22 as a 
colourless oil (70 mg, 38 %). 1H-NMR (CD3OD) δ ppm: 7.19 (m, 5H, Ar-H), 3.28 (m 
(overlap with solvent peaks), 2H, CH2NH), 2.85 (m, 3H, COCH, CH2-Ar), 2.65 (t, 2H, 
3J = 7.4 Hz, Thiaz-5-CH2 ), 2.14 (s, 3H, Thiaz-4-CH3), 1.85 (m, 2H, Thiaz-5-CH2CH2), 
1.72 (m, 1H,CHHCH3), 1.60 (m, 1H, CHHCH3), 0.94 (t, 3H, 3J = 7.4 Hz, CH3); 13C 
(CD3OD) δ ppm: 179.97 (quat. C=O), 170.40 (quat. Thiaz-2-C), 155.07 (quat. C=NH), 
140.04 (quat. Thiaz-4-C), 132.59 (quat. Ar-C), 130.08 (+, 2 Ar-CH), 129.55 (+, 2 Ar-
CH), 127.65 (+, Ar-CH), 118.26  (quat. Thiaz-5-C), 52.51 (+, COCH), 41.47 (-, 
CHCH2), 39.30 (-, CH2NH), 29.58 (-, Thiaz-5-CH2CH2), 26.30 (-, Thiaz-5-CH2), 23.57 
(-, CH2CH3), 11.92 (+, CH3), 11.47 (+, Thiaz-CH3); HRMS: EI-MS: m/z for 
(C19H27N5OS) calcd. 373.1936, found 373.19376; prep. HPLC: MeCN/0.1% TFA/aq 
(25/75-40/60). C19H27N5OS · 2TFA (615.52) 
N-[3-(2-Amino-4-methylthiazol-5-yl)propyl]-N´-(3-methyl-4-phenylbutanoyl)-
guanidine (4.23) 
The title compound was prepared from 4.23a (340 mg, 0.59 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 4.23 as a pale 
yellow oil (240 mg, 68 %). 1H-NMR (CD3OD) δ ppm: 7.19 (m, 5H, Ar-H), 3.31 (t, 2H, 
3J = 6.7 Hz, CH2NH), 2.67 (t, 2H, 3J = 7.5 Hz, Thiaz-5-CH2), 2.51 (m, 3H, CH2-Ar, 
CH3CH), 2.30 (m, 2H, COCH2), 2.15 (s, 3H, Thiaz-4-CH3) ppm 1.87 (m, 2H, Thiaz-5-
CH2CH2), 0.94 (d, 3H, 3J = 6.2Hz); 13C (CD3OD) δ ppm: 176.95 (quat. C=O), 170.42 
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(quat. Thiaz-2-C), 155.29 (quat. C=NH), 141.39 (quat. Thiaz-4-C), 132.58 (quat. Ar-
C), 130.38 (+, 2 Ar-CH), 129.37 (+, 2 Ar-CH), 127.25 (+,Ar-CH), 118.29 (quat. Thiaz-
5-C), 44.59 (-, COCH2), 43.96 (-, CH2-Ar), 41.54 (-, CH2NH), 33.43 (+, CHCH3), 
29.69 (-, Thiaz-5-CH2CH2), 23.64 (-, Thiaz-5-CH2), 19.97 (+, CH3), 11.49 (+, Thiaz-4-
CH3); HRMS: EI-MS: m/z for (C19H27N5OS) calcd. 373.1936, found 373.19356; prep. 
HPLC: MeCN/0.1% TFA/aq (30/70). C19H27N5OS · 2TFA (601.49) 
N-[3-(2-Amino-4-methylthiazol-5-yl)propyl]-N´-(3-methyl-4-(3-methylphenyl)-
butanoyl)guanidine (4.24) 
The title compound was prepared from 4.24a (410 mg, 0.69 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 4.24 as a pale 
yellow oil (290 mg, 68 %). C20H29N5OS * 2TFA (), 1H-NMR (CD3OD) δ ppm: 7.13 (m, 
1H, Ar-H), 6.97 (m, 3H, Ar-H), 3.33 (m (overlap with solvent peaks), 2H, CH2NH), 
2.70 (t, 2H, 3J = 7.6 Hz), 2.57-2.38 (m, 5H, COCH2, CH3CH, CH2-Ar), 2.29 (s, 3H, (m-
CH3)-Ar), 2.18 (s, 3H, Thiaz-4-CH3), 1.89 (m, 2H, Thiaz-5-CH2CH2), 0.96 (d, 3H, 3J = 
6.2 Hz, CH3); 13C (CD3OD) δ ppm: 176.82 (quat. C=O), 170.36 (quat. Thiaz-2-C), 
155.20 (quat. C=NH), 141.28 (quat. Thiaz-4-C), 139.00 (quat. C-Ph), 132.58 (quat. 
Ar-C), 131.06 (+, Ar-CH), 129.26 (+, Ar-CH), 127.92 (+, Ar-CH), 127.42 (+, Ar-CH), 
118.41 (quat. Thiaz-5-C), 44.57 (-, COCH2), 43.92 (-, CH2-Ar), 41.57 (-, CH2NH), 
33.42 (+, CHCH3), 29.72 (-, Thiaz-5-CH2CH2), 23.61 (-, Thiaz-5-CH2), 21.50 (+, (m-
CH3)-Ar), 20.03 (+, CH3), 11.45 (+, Thiaz-CH3); HRMS: EI-MS: m/z for (C20H29N5OS) 
calcd. 387.20928, found 387.20964; prep. HPLC: MeCN/0.1% TFA/aq (25/75-50/50). 
C20H29N5OS · 2TFA (615.52) 
N-[3-(2-Amino-4-methylthiazol-5-yl)propyl]-N´-(3-methyl-4-(4-methylphenyl)-
butanoyl)guanidine (4.25) 
The title compound was prepared from 4.25a (460 mg, 0.78 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 4.25 as a pale 
yellow oil (320 mg, 67 %). 1H-NMR (CD3OD) δ ppm: 7.01 (m, 4H, Ar-H), 3.30 (t, 2H, 
3J = 6.8 Hz, CH2NH), 2.66 (t, 2H, 3J = 7.5 Hz, Thiaz-5-CH2), 2.48 (m, 3H, COCH2, 
CH3CH), 2.29 (m, 2H, CH2-Ar), 2.24 (s, 3H, (p-CH3)-Ar), 2.14 (s, 3H, Thiaz-4-CH3), 
1.86 (m, 2H, Thiaz-5-CH2CH2), 0.92 (d, 3H, 3J = 6.1 Hz, CH3); 13C (CD3OD) δ ppm: 
177.06 (quat. C=O), 170.40 (quat. Thiaz-2-C), 155.27 (quat. C=NH), 138.19 (quat. 
Thiaz-4-C), 136.76 (quat. C-Ph), 132.56 (quat. Ar-C), 130.31 (+, 2 Ar-CH), 129.99 (+, 
2 Ar-CH), 118.24 (quat. Thiaz-5-C), 44.58 (-, COCH2), 43.58 (-, CH2-Ar), 41.54 (-, 
CH2NH), 33.50 (+, CHCH3), 29.71 (-, Thiaz-5-CH2CH2), 23.64 (-, Thiaz-5-CH2), 21.23 
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(+, (p-CH3)-Ar), 20.07 (+, CH3), 11.49 (+, Thiaz-CH3); HRMS: EI-MS: m/z for 
(C20H29N5OS) calcd. 387.2093, found 387.20934; prep. HPLC: MeCN/0.1% TFA/aq 
(30/70). C20H29N5OS · 2TFA (615.52) 
N-[3-(2-Amino-4-methylthiazol-5-yl)propyl]-N´-[4-(3-methoxyphenyl)-3-methyl-
butanoyl]guanidine (4.26) 
The title compound was prepared from 4.26a (180 mg, 0.29 mmol) in 5 ml 
CH2Cl2/abs and 1 ml TFA according to the general procedure yielding 4.26 as a pale 
yellow oil (80 mg, 44 %). 1H-NMR (CD3OD) δ ppm: 7.15 (m, 1H, Ar-H), 6.73 (m, 3H, 
Ar-H), 3.75 (s, 3H, (p-OCH3)-Ar), 3.31 (t, 2H, 3J = 6.6 Hz, CH2NH), 2.69 (t, 2H, 3J = 
7.5 Hz, Thiaz-5-CH2), 2.53 (m, 3H, CHCH2, CH2-Ar), 2.32 (m, 2H, COCH2), 2.16 (s, 
3H, Thiaz-4-CH3), 1.88 (m, 2H, Thiaz-5-CH2CH2), 0.96 (d, 3H, 3J = 6.1 Hz, CH3); 13C 
(CD3OD) δ ppm: 176.88 (quat. C=O), 170.39 (quat. Thiaz-2-C), 161.18 (quat. Ar-C), 
155.25 (quat. C=NH), 142.97 (quat. Thiaz-4-C), 132.60 (quat. Ar-CH), 130.33 (+, Ar-
CH), 122.74 (+, Ar-CH), 118.36 (quat. Thiaz-5-C), 115.92 (+, Ar-CH), 112.69 (+, Ar-
CH), 55.60 (+, OCH3), 44.54 (-, COCH2), 44.00 (-, CHCH2), 41.54 (-, CH2NH), 33.35 
(+, CHCH3), 29.68 (-, Thiaz-5-CH2CH2), 23.62 (-, Thiaz-5-CH2), 20.09 (+, CH3), 11.46 
(+, Thiaz-CH3); HRMS: EI-MS: m/z for (C20H29N5O2S) calcd. 403.2042, found 
403.20446; prep. HPLC: MeCN/0.1% TFA/aq (25/75-50/50). C20H29N5O2S · 2TFA 
(631.52) 
N-[3-(2-Amino-4-methylthiazol-5-yl)propyl]-N´-[4-(4-methoxyphenyl)-3-methyl-
butanoyl]-guanidine (4.27) 
The title compound was prepared from 4.27a (180 mg, 0.29 mmol) in 5 ml 
CH2Cl2/abs and 1 ml TFA according to the general procedure yielding 4.27 as a pale 
yellow oil (110 mg, 60 %). 1H-NMR (CD3OD) δ ppm: 7.07 (m, 2H, Ar-H), 6.80 (m, 2H, 
Ar-H), 3.73 (s, 3H, (m-OCH3)-Ar), 3.32 (m (overlap with solvent peaks), 2H, CH2NH), 
2.69 (t, 2H, 3J = 7.6 Hz, Thiaz-5-CH2), 2.48 (m, 3H, CHCH2, CH2-Ar), 2.28 (m, 2H, 
COCH2), 2.16 (s, 3H, Thiaz-4-CH3), 1.88 (m, 2H, Thiaz-5-CH2CH2), 0.95 (d, 3H, 3J = 
6.2 Hz, CH3); 13C (CD3OD) δ ppm: 176.98 (quat. C=O), 170.39 (quat. Thiaz-2-C), 
159.62 (quat. Ar-C), 155.24 (quat. C=NH), 133.29 (quat. Thiaz-4-C), 132.57 (quat. 
Ar-C), 131.37 (+, 2 Ar-CH), 118.32 (quat. Thiaz-5-C), 114.73 (+, 2 Ar-CH), 55.69 (+, 
OCH3), 44.56 (-, COCH2), 43.16 (-, CHCH2), 41.53 (-, CH2NH), 33.67 (+, CHCH3), 
29.68 (-, Thiaz-5-CH2CH2), 23.63 (-, Thiaz-5-CH2), 20.13 (+, CH3), 11.46 (+, Thiaz-
CH3); HRMS: EI-MS: m/z for (C20H29N5O2S) calcd. 403.2042, found 403.20523; prep. 
HPLC: MeCN/0.1% TFA/aq (25/75-50/50). C20H29N5O2S · 2TFA (631.52) 
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N-[3-(2-Amino-4-methylthiazol-5-yl)propyl]-N´-[4-(3-fluorophenyl)-3-methyl-
butanoyl]guanidine (4.28) 
The title compound was prepared from 4.28a (190 mg, 0.32 mmol) in 5 ml 
CH2Cl2/abs and 1 ml TFA according to the general procedure yielding 4.28 as a pale 
yellow oil (140 mg, 71 %). 1H-NMR (CD3OD) δ ppm: 7.24 (m, 1H, Ar-H), 6.91 (m, 3H, 
Ar-H), 3.32 (m (overlap with solvent peaks), 2H, CH2NH), 2.69 (t, 2H, 3J = 7.4 Hz, 
Thiaz-5-CH2), 2.53 (m, 3H, CHCH2, CH2-Ar), 2.35 (m, 2H, COCH2), 2.16 (s, 3H, 
Thiaz-4-CH3), 1.86 (m, 2H, Thiaz-5-CH2CH2), 0.94 (d, 3H, 3J = 6.1 Hz, CH3); 13C 
(CD3OD) δ ppm: 176.78 (quat. C=O), 170.41 (quat. Thiaz-2-C), 164.29 (d, quart., 1J 
= 243.9 Hz, Ar-CF), 155.28 (quat. C=NH), 144.36 (d, quart., 3J = 7.2 Hz,  Ar-C), 
132.58 (quat. Thiaz-4-C), 131.01 (d, +, 3J = 8.3 Hz, Ar-CH), 126.24 (+, d, 4J = 2.5 Hz, 
Ar-CH), 118.31 (quat. Thiaz-5-C), 116.94 (+, d, 3J = 20.9 Hz, Ar-CH), 113.91 (+, d, 3J 
= 21.1 Hz, Ar-CH), 44.44 (-, COCH2), 43.51 (-, CHCH2), 41.55 (-, CH2NH), 33.24 (+, 
CHCH3), 29.68 (-, Thiaz-5-CH2CH2), 23.63 (-, Thiaz-5-CH2), 19.81 (+, CH3), 11.46 (+, 
Thiaz-CH3); HRMS: EI-MS: m/z for (C19H26FN5OS) calcd. 391.1842, found 391.1842; 
prep. HPLC: MeCN/0.1% TFA/aq (25/75-50/50). C19H26FN5OS · 2TFA (619.49) 
N-[3-(2-Amino-4-methylthiazol-5-yl)propyl]-N´-[4-(4-fluorophenyl)-3-methyl-
butanoyl]guanidine (4.29) 
The title compound was prepared from 4.29a (200 mg, 0.34 mmol) in 5 ml 
CH2Cl2/abs and 1 ml TFA according to the general procedure yielding 4.29 as a pale 
yellow oil (100 mg, 47 %). 1H-NMR (CD3OD) δ ppm: 7.17 (m, 2H, Ar-H), 6.96 (m, 2H, 
Ar-H), 3.32 (m (overlap with solvent peaks), 2H, CH2NH), 2.69 (t, 2H, 3J = 7.3 Hz, 
Thiaz-5-CH2), 2.51 (m, 3H, CHCH2, CH2-Ar), 2.30 (m, 2H, COCH2), 2.16 (s, 3H, 
Thiaz-4-CH3), 1.89 (m, 2H, Thiaz-5-CH2CH2), 0.94 (d, 3H, 3J = 5.4 Hz, CH3); 13C 
(CD3OD) δ ppm: 176.84 (quat. C=O), 170.40 (quat. Thiaz-2-C), 162.93 (d, quart., 1J 
= 242.5 Hz, Ar-CF), 155.27 (quat. C=NH), 137.35 (d, quart., 4J = 3.3 Hz,  Ar-C), 
132.58 (quat. Thiaz-4-C), 132.00 (d, +, 3J = 7.8 Hz, 2 Ar-CH),  118.32 (quat. Thiaz-5-
C), 115.91 (d, +, 2J = 21.3 Hz, 2 Ar-CH), 44.46 (-, COCH2), 43.02 (-, CHCH2), 41.54 
(-, CH2NH), 33.48 (+, CHCH3), 29.69 (-, Thiaz-5-CH2CH2), 23.63 (-, Thiaz-5-CH2), 
19.85 (+, CH3), 11.46 (+, Thiaz-CH3); HRMS: EI-MS: m/z for (C19H26FN5OS) calcd. 
391.1842, found 391.18328; prep. HPLC: MeCN/0.1% TFA/aq (25/75-50/50). 
C19H26FN5OS · 2TFA (619.49) 
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N-[3-(2-Amino-4-methylthiazol-5-yl)propyl]-N´-((R)-3-cyclohexylbutanoyl)-guani-
dine (4.30) 
The title compound was prepared from 4.30a (250 mg, 0.44 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 4.30 as a 
colourless oil (240 mg, 92 %). 1H-NMR (CD3OD) δ ppm: 3.35 (t, 2H, 3J = 6.9 Hz, 
CH2NH), 2.70 (t, 2H, 3J = 7.5 Hz, Thiaz-5-CH2), 2.55 (dd, 1H, 3J = 5.1 Hz, 2J = 15.0 
Hz, COCHH),  2.23-2.17 (m, 4H, COCHH, Thiaz-4-CH3), 1.90 (m, 3H, Thiaz-5-
CH2CH2, CH3CH), 1.68 (m, 6H, cHex-CH2), 1.09 (m, 7H, cHex-CH2, cHex-CH), 0.90 
(d, 3H, 3J = 6.8 Hz, CH3); 13C (CD3OD) δ ppm: 177.61 (quat. C=O), 170.42 (quat. 
Thiaz-2-C), 155.38 (quat. C=NH), 132.58 (quat. Thiaz-4-C), 118.31 (quat. Thiaz-5-C), 
43.94 (+, cHex-CH), 42.71 (-, COCH2), 41.56 (-, CH2NH), 36.46 (+, CHCH3), 31.47 (-, 
cHex-CH2), 30.02 (-, cHex-CH2), 29.69 (-, Thiaz-5-CH2CH2), 27.84 (-, cHex-CH2), 
27.74 (-, 2 cHex-CH2), 23.63 (-, Thiaz-5-CH2), 16.62 (+, CH3), 11.46 (+, Thiaz-4-
CH3); HRMS: EI-MS: m/z for (C18H31N5OS) calcd. 365.2249, found 365.22467; prep. 
HPLC: MeCN/0.1% TFA/aq (35/65). C18H31N5OS · 2TFA (593.52) 
N-[3-(2-Amino-4-methylthiazol-5-yl)propyl]-N´-((S)-3-cyclohexylbutanoyl)guani-
dine (4.31) 
The title compound was prepared from 4.31a (340 mg, 0.60 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 4.31 as a 
colourless oil (320 mg, 90 %). 1H-NMR (CD3OD) δ ppm: 3.35 (t, 2H, 3J = 6.7 Hz, 
CH2NH), 2.69 (t, 2H, 3J = 7.5 Hz, Thiaz-5-CH2), 2.54 (dd, 1H, 3J = 5.0 Hz, 2J = 15.0 
Hz, COCHH),  2.23-2.16 (m, 4H, COCHH, Thiaz-4-CH3), 1.89 (m, 3H, Thiaz-5-
CH2CH2, CH3CH), 1.69 (m, 6H, cHex-CH2), 1.09 (m, 7H, cHex-CH2, cHex-CH), 0.88 
(d, 3H, 3J = 6.8 Hz, CH3); 13C (CD3OD) δ ppm: 177.67 (quat. C=O), 170.43 (quat. 
Thiaz-2-C), 155.39 (quat. C=NH), 132.58 (quat. Thiaz-4-C), 118.27 (quat. Thiaz-5-C), 
43.93 (+, cHex-CH), 42.72 (-, COCH2), 41.56 (-, CH2NH), 36.37 (+, CHCH3), 31.46 (-, 
cHex-CH2), 30.02 (-, cHex-CH2), 29.70 (-, Thiaz-5-CH2CH2), 27.84 (-, cHex-CH2), 
27.74 (-, 2 cHex-CH2), 23.65 (-, Thiaz-5-CH2), 16.64 (+, CH3), 11.48 (+, Thiaz-4-
CH3); HRMS: EI-MS: m/z for (C18H31N5OS) calcd. 365.2249, found 365.22575; prep. 
HPLC: MeCN/0.1% TFA/aq (35/65). C18H31N5OS · 2TFA (593.52) 
N-[3-(2-Amino-4-methylthiazol-5-yl)propyl]-N´-(3-cyclohexyl-2-methylpropano-
yl)guanidine (4.32) 
The title compound was prepared from 4.32a (370 mg, 0.65 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 4.32 as a 
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colourless oil (320 mg, 82 %). 1H-NMR (CD3OD) δ ppm: 3.36 (t, 2H, 3J = 6.9 Hz, 
CH2NH), 2.69 (m, 3H, Thiaz-5-CH2, COCH), 2.17 (s, 3H, Thiaz-4-CH3), 1.91 (m, 2H, 
Thiaz-5-CH2CH2), 1.66 (m, 7H, cHex-CH, CH2-cHex, cHex-CH2), 1.23 (m, 4H, cHex-
CH2), 1.14 (d, 3H, 3J = 6.8 Hz, CH3), 0.88 (m, 2H, cHex-CH2); 13C (CD3OD) δ ppm: 
181.53 (quat. C=O), 170.43 (quat. Thiaz-2-C), 155.60 (quat. C=NH), 132.57 (quat. 
Thiaz-4-C), 118.27 (quat. Thiaz-5-C), 42.28 (-, CHCH2), 41.59 (-, CH2NH), 40.26 (+, 
CHCH3), 36.65 (+, cHex-CH), 34.51 (-, cHex-CH2), 34.24 (-, cHex-CH2), 29.67 (-, 
Thiaz-5-CH2CH2), 27.60 (-, cHex-CH2), 27.35 (-, cHex-CH2), 27.32 (-, cHex-CH2), 
23.65 (-, Thiaz-5-CH2), 17.96 (+, CH3), 11.48 (+, Thiaz-CH3); HRMS: EI-MS: m/z for 
(C18H31N5OS) calcd. 365.22493, found 365.22560; prep. HPLC: MeCN/0.1% TFA/aq 
(25/75-50/50). C18H31N5OS · 2TFA (593.52) 
N-[3-(2-Amino-4-methylthiazol-5-yl)propyl]-N´-(3-cyclohexylpentanoyl)guani-
dine (4.33) 
The title compound was prepared from 4.33a (400 mg, 0.65 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 4.33 as a pale 
yellow oil (320 mg, 76 %). 1H-NMR (CD3OD) δ ppm: 3.35 (t, 2H, 3J = 6.9 Hz, 
CH2NH), 2.71 (t, 2H, 3J = 7.6 Hz, Thiaz-5-CH2), 2.50 (dd, 1H, 3J = 6.2 Hz, 2J = 15.6 
Hz, COCHH), 2.32 (dd, 1H, 3J = 7.5 Hz, 2J = 15.6 Hz, COCHH), 2.18 (s, 3H, Thiaz-4-
CH3), 1.91 (m, 2H, Thiaz-5-CH2CH2), 1.68 (m, 6H, cHex-CH, cHex-CH2), 1.39 – 1.07 
(m, 8H, cHex-CH2, CH2CH3, CH2CH), 0.89 (t, 3H, 3J = 7.4 Hz, CH3); 13C (CD3OD) δ 
ppm: 177.82 (quat. C=O), 170.38 (quat. Thiaz-2-C), 155.32 (quat. C=NH), 132.59 
(quat. Thiaz-4-C), 118.41 (quat. Thiaz-5-C), 42.99 (-, COCH2), 41.59 (+, cHex-CH), 
41.45 (-, CH2NH), 39.71 (+, CH2CH), 31.18 (-, cHex-CH2), 30.35 (-, cHex-CH2), 29.72 
(-, Thiaz-5-CH2CH2), 27.91 (-, cHex-CH2), 27.89 (-, cHex-CH2), 27.79 (-, cHex-CH2), 
24.75 (-, CH2CH3), 23.60 (-, Thiaz-5-CH2), 12.05 (+, CH3), 11.44 (+, Thiaz-CH3); 
HRMS: EI-MS: m/z for (C19H33N5OS) calcd. 379.2405, found 379.24061; prep. HPLC: 
MeCN/0.1% TFA/aq (25/75-40/60). C19H33N5OS · 2TFA (607.54) 
N-[3-(2-Amino-4-methylthiazol-5-yl)propyl]-N´-[2-(cyclohexylmethyl)butanoyl]-
guanidine (4.34) 
The title compound was prepared from 4.34a (180 mg, 0.31 mmol) in 5 ml 
CH2Cl2/abs and 1 ml TFA according to the general procedure yielding 4.34 as a pale 
yellow oil (90 mg, 48 %). 1H-NMR (CD3OD) δ ppm: 3.36 (t, 2H, 3J = 6.9 Hz, CH2NH), 
2.72 (t, 2H, 3J = 7.6 Hz, Thiaz-5-CH2), 2.55 (m, 1H, COCH), 2.18 (s, 3H, Thiaz-4-
CH3), 1.92 (m, 2H, Thiaz-5-CH2CH2), 1.64 (m, 8H, cHex-CH2, CH2CH3), 1.27 (m, 5H, 
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cHex-CH2, cHex-CH), 0.89 (m, 5H, CH3, CHCH2); 13C (CD3OD) δ ppm: 180.86 (quat. 
C=O), 170.38 (quat. Thiaz-2-C), 155.30 (quat. C=NH), 132.60 (quat. Thiaz-4-C), 
118.39 (quat. Thiaz-5-C), 47.86 (+, COCH), 41.64 (-, CH2NH), 40.67 (-, CHCH2), 
36.99 (+, cHex-CH), 34.79 (-, cHex-CH2), 34.19 (-, cHex-CH2), 29.66 (-, Thiaz-5-
CH2CH2), 27.57 (-, cHex-CH2), 27.36 (-, cHex-CH2), 27.33 (-, cHex-CH2), 27.20 (-, 
CH2CH3), 23.62 (-, Thiaz-CH2), 11.90 (+, Thiaz-CH3), 11.46 (+, CH3); HRMS: EI-MS: 
m/z for (C19H33N5OS) calcd. 379.2406, found 379.24131; prep. HPLC: MeCN/0.1% 
TFA/aq (30/70-50/50). C19H33N5OS · 2TFA (607.54) 
N-[3-(2-Amino-4-methylthiazol-5-yl)propyl]-N´-(4-cyclohexyl-3-methylbutanoyl)-
guanidine (4.35) 
The title compound was prepared from 4.35a (340 mg, 0.59 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 4.35 as a pale 
yellow oil (300 mg, 84 %). 1H-NMR (CD3OD) δ ppm: 3.35 (t, 2H, 3J = 7.0 Hz, 
CH2NH), 2.71 (t, 2H, 3J = 7.6 Hz, Thiaz-5-CH2), 2.44 (dd, 1H, 3J = 5.7 Hz, 2J = 14.8 
Hz, COCHH), 2.25-2.18 (m, 4H, COCHH, Thiaz-4-CH3), 2.10 (m, 1H, CHCH3), 1.91 
(m, 2H, Thiaz-5-CH2CH2), 1.72 (m, 5H, cHex-CH2, cHex-CH), 1.20 (m, 6H, cHex-
CH2), 0.94 (d, 3H, 3J = 6.5 Hz, CH3), 0.83 (m, 2H, CH2); 13C (CD3OD) δ ppm: 176.96 
(quat. C=O), 170.36 (quat. Thiaz-2-C), 155.28 (quat. C=NH), 132.59 (quat. Thiaz-4-
C), 118.44 (quat. Thiaz-5-C), 45.80 (-, COCH2), 45.59 (-, CHCH2), 41.61 (-, CH2NH), 
36.10 (-, cHex-CH2), 35.13, (+, cHex-CH), 34.14 (-, cHex-CH2), 29.73 (-, Thiaz-5-
CH2CH2), 28.32 (+, CHCH3), 27.78 (-, cHex-CH2), 27.48 (-, cHex-CH2), 27.40 (-, 
cHex-CH2), 23.61 (-, Thiaz-5-CH2), 20.06 (+, CH3), 11.46 (+, Thiaz-CH3); HRMS: EI-
MS: m/z for (C19H33N5OS) calcd. 379.2405, found 379.24108; prep. HPLC: 
MeCN/0.1% TFA/aq (30/70-50/50). C19H33N5OS · 2TFA (607.54) 
N-[3-(2-Amino-4-methylthiazol-5-yl)propyl]-N´-[3-(cyclohexylmethyl)pentanoyl]-
guanidine (4.36) 
The title compound was prepared from 4.36a (340 mg, 0.59 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 4.36 as a pale 
yellow oil (300 mg, 84 %). 1H-NMR (CD3OD)  δ ppm: 3.35 (t, 2H, 3J = 6.9 Hz, 
CH2NH), 2.71 (t, 2H, 3J = 7.6 Hz, Thiaz-5-CH2), 2.38 (m, 2H, COCH2), 2.18 (s, 3H, 
Thiaz-4-CH3), 1.91 (m, 3H, Thiaz-5-CH2CH2, CH2CH), 1.71 (m, 5H, cHex-CH2, cHex-
CH), 1.24 (m, 8H, cHex-CH2, CH2CH3), 0.89 (m, 5H, CH2-cHex, CH3); 13C (CD3OD) δ 
ppm: 177.37 (quat. C=O), 170.38 (quat. Thiaz-2-C), 155.32 (quat. C=NH), 132.58 
(quat. Thiaz-4-C), 118.41 (quat. Thiaz-5-C), 42.66 (-, COCH2, CHCH2), 41.57 (-, 
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CH2NH), 36.14 (+, CHCH2), 34.82 (-, cHex-CH2), 34.69 (-, cHex-CH2), 34.40 (+, 
cHex-CH), 29.73 (-, Thiaz-5-CH2CH2), 27.78 (-, cHex-CH2), 27.55 (-, CH2CH3), 27.46 
(-, 2 cHex-CH2), 23.59 (-, Thiaz-5-CH2), 11.45 (+, CH3), 10.92 (+, Thiaz-CH3); HRMS: 
EI-MS: m/z for (C20H35N5OS) calcd. 393.2562, found 393.25625; prep. HPLC: 
MeCN/0.1% TFA/aq (35/65-55/45). C20H35N5OS · 2TFA (621.57) 
N-[3-(2-Amino-4-methylthiazol-5-yl)propyl]-N´-[3-(4-hydroxyphenyl)butanoyl]-
guanidine (4.37) 
The title compound was prepared from 4.37a (340 mg) in 5 ml CH2Cl2/abs and 5 ml 
TFA according to the general procedure yielding 4.37 as a pale yellow oil (200 mg, 
51 %, over two steps). 1H-NMR (CD3OD) δ ppm: 7.06 (m, 2H, Ar-H), 6.69 (m, 2H, Ar-
H), 5.49 (s, 1H, (p-OH)-Ar), 3.30 (t, 2H, 3J = 5.8 Hz, CH2NH), 3.22 (m, 1H, CHCH3), 
2.68 (m, 4H, COCH2, Thiaz-5-CH2), 2.15 (s, 3H, Thiaz-4-CH3), 1.88 (m, 2H, Thiaz-5-
CH2CH2), 1.28 (d, 3H, 3J = 7.0 Hz, CH3); 13C (CD3OD) δ ppm: 176.22 (quat. C=O), 
170.36 (quat. Thiaz-2-C), 157.15 (quat. Ar-C), 155.16 (quat. C=NH), 137.04 (quat. 
Thiaz-4-C), 132.59 (quat. Ar-C), 128.85 (+, 2 Ar-CH), 118.40 (quat. Thiaz-5-C), 
116.32 (+, 2 Ar-CH), 46.60 (-, COCH2), 41.51 (-, CH2NH), 37.10 (+, CHCH3), 29.64 (-, 
Thiaz-5-CH2CH2), 23.53 (-,Thiaz-5-CH2), 22.46 (+, CH3), 11.44 (+, Thiaz-CH3); 
HRMS: EI-MS: m/z for (C18H25N5O2S) calcd. 375.1729, found 375.17203; prep. 
HPLC: MeCN/0.1% TFA/aq (15/85-40/60). C18H25N5O2S · 2TFA (603.47) 
N-[3-(2-Amino-4-methylthiazol-5-yl)propyl]-N´-[6-amino-3-phenylhexanoyl]-
guanidine (4.38) 
The title compound was prepared from 4.38a (220 mg, 0.31 mmol) in 5 ml 
CH2Cl2/abs and 1 ml TFA according to the general procedure yielding 4.38 as a pale 
yellow oil (190 mg, 82 %). 1H-NMR (CD3OD) δ ppm: 7.25 (m, 5H, Ar-H), 3.27 (m 
(overlap with solvent peaks), 2H, CH2NH), 3.18 (m, 1H, CH2CH), 2.84 (m, 4H, 
CH2NH2, COCH2), 2.66 (t, 2H, 3J = 7.6 Hz, Thiaz-5-CH2), 2.14 (s, 3H, Thiaz-4-CH3), 
1.77 (m, 4H, Thiaz-5-CH2CH2, CH2CH2CH2NH2), 1.49 (m, 2H, CH2CH2NH2); 13C 
(CD3OD) δ ppm: 174.99 (quat. C=O), 169.56 (quat. Thiaz-2-C), 142.85 (quat. C=NH), 
131.76 (quat. Ar-C), 129.02 (+, 2 Ar-CH), 128.00 (+, 2 Ar-CH), 127.35 (+, Ar-CH), 
117.53 (quat. Thiaz-5-C), 43.98 (-, CH2NH2), 42.08 (+, CH2CH), 40.62 (-, CH2NH), 
39.73 (-, COCH2), 33.03 (-, CH2CH2CH2NH2), 28.77 (-, Thiaz-5-CH2CH2), 25.81 (-, 
CH2CH2NH2), 22.71 (-, Thiaz-5-CH2), 10.61 (+, Thiaz-CH3); HRMS: EI-MS: m/z for 
(C20H30N6OS) calcd. 402.22018, found 402.22013; prep. HPLC: MeCN/0.1% TFA/aq 
(10/90-35/65). C20H30N6OS · 3TFA (744.53) 
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10-{3-[3-(2-Amino-4-methylthiazol-5-yl)propyl]guanidino}-10-oxodecanoic acid 
(4.39) 
The title compound was prepared from 4.39a (190 mg, 0.32 mmol) in 5 ml 
CH2Cl2/abs and 1 ml TFA according to the general procedure yielding 4.39 as a pale 
yellow oil (100 mg, 50 %). 1H-NMR (CD3OD) δ (ppm): 3.35 (t, 2H, 3J = 6.8 Hz, 
CH2NH), 2.71 (t, 2H, 3J = 7.6 Hz, Thiaz-5-CH2), 2.47 (t, 2H, 3J = 7.4 Hz, CH2COOH), 
2.27 (t, 2H, 3J = 7.4 Hz, COCH2), 2.18 (s, 3H, Thiaz-4-CH3), 1.90 (m, 2H, Thiaz-5-
CH2CH2), 1.62 (m, 4H, COCH2CH2, CH2CH2COOH), 1.34 (s, 8H, (CH2)4); 13C 
(CD3OD) δ (ppm): 177.75 (quat. COOH), 177.51 (quat. C=O), 170.40 (quart., Thiaz-
2-C), 155.39 (quart., C=NH), 132.61 (quart., Thiaz-4-C), 118.39 (quart., Thiaz-5-C), 
41.58 (-, CH2NH), 37.76 (-, COCH2), 34.97 (-, CH2COOH), 30.19 (-, 3 CH2), 29.92 (-, 
CH2), 29.70 (-, Thiaz-5-CH2), 26.07 (-, CH2), 25.46(-, Thiaz-5-CH2CH2), 23.63 (-, 
CH2), 11.47 (+, Thiaz-5-CH3); HRMS: EI-MS: m/z for (C18H31N5O3S) calcd. 
397.21476, found 397.21411; prep. HPLC: MeCN/0.1% TFA/aq (20/80-40/60). 
C18H31N5O3S · 2TFA (625.51) 
N-[3-(2-Aminothiazol-5-yl)propyl]-N´-(3-phenylpropanoyl)guanidine (4.40) 
The title compound was prepared from 4.40a (150 mg, 0.28 mmol) in 5 ml 
CH2Cl2/abs and 1 ml TFA according to the general procedure yielding 4.40 as a 
colourless oil (70 mg, 45 %). 1H-NMR (CD3OD) δ ppm: 7.22 (m, 5H, Ph), 7.00 (s, 1H, 
Thiaz-4-H), 3.35 (t, 2H, 3J = 6.9 Hz, COCH2CH2), 2.97 (t, 2H, 3J = 7.3 Hz, CH2NH), 
2.77 (m, 4H, Thiaz-5-CH2, COCH2), 1.94 (m, 2H, Thiaz-5-CH2CH2); 13C-NMR 
(CD3OD) δ ppm: 176.47 (quat. C=O), 171.83 (quat. Thiaz-2-C), 155.25 (quat. C=NH), 
141.35 (quat. C-Ph), 129.63 (+, 2 CH-Ph), 129.46 (+, 2 CH-Ph), 127.52 (+, CH-Ph), 
126.38 (quat. Thiaz-5-C), 123.37 (+, Thiaz-4-C), 41.52 (-, Thiaz-5-CH2), 39.54 (-, 
CH2NH), 31.27 (-, COCH2), 29.49 (-, COCH2CH2), 24.88 (-, Thiaz-5-CH2CH2); HRMS: 
EI-MS: m/z for (C16H21N5OS) calcd. 331.14668, found 331.14624; prep. HPLC: 
MeCN/0.1% TFA/aq (20/80-50/50). C16H21N5OS  · 2TFA (559.43) 
N-[3-(2-Aminothiazol-5-yl)propyl]-N´-(3-phenylbutanoyl)guanidine (4.41) 
The title compound was prepared from 4.41a (190 mg, 0.35 mmol) in 5 ml 
CH2Cl2/abs and 1 ml TFA according to the general procedure yielding 4.41 as a 
colourless oil (120 mg, 60 %). 1H-NMR (CD3OD) δ ppm: 7.22 (m, 5H, Ph), 6.99 (s, 
1H, Thiaz-4-H), 3.31 (m, 3H, CH2NH, CH2CH), 2.74 (m, 4H, Thiaz-5-CH2, COCH2), 
1.92 (m, 2H, Thiaz-5-CH2CH2), 1.31 (d, 3H, 3J = 7.0 Hz, CH3); 13C-NMR (CD3OD) δ 
ppm: 176.03 (quat. C=O), 171.84 (quat. Thiaz-2-C), 155.20 (quat. C=NH), 146.42 
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(quat. C-Ph), 129.67 (+, 2 CH-Ph), 127.93 (+, 2 CH-Ph), 127.71 (+, CH-Ph), 126.35 
(quat. Thiaz-5-C), 123.32 (+, Thiaz-4-C), 46.15 (-, Thiaz-5-CH2), 41.46 (-, COCH2), 
37.65 (+, CH2CH), 29.44 (-, CH2NH), 24.85 (-, Thiaz-5-CH2CH2), 22.26 (+, CH3); 
HRMS: EI-MS: m/z for (C17H23N5OS) calcd. 345.16233, found 345.16249; prep. 
HPLC: MeCN/0.1% TFA/aq (20/80-40/60). C17H23N5OS  · 2TFA (573.44) 
N-[3-(2-Aminothiazol-5-yl)propyl]-N´-(3-phenylpentanoyl)guanidine (4.42) 
The title compound was prepared from 4.42a (230 mg, 0.41 mmol) in 5 ml 
CH2Cl2/abs and 1 ml TFA according to the general procedure yielding 4.42 as a 
colourless oil (110 mg, 46 %). 1H-NMR (CD3OD) δ ppm: 7.23 (m, 5H, Ar-H), 6.96 (s, 
1H, Thiaz-4-H), 3.29 (t, 2H, 3J = 7.0 Hz, CH2NH), 3.03 (m, 1H, CHCH2CH3), 2.83-
2.70 (m, 4H, Thiaz-5-CH2, COCH2), 1.89 (m, 2H, Thiaz-5-CH2CH2), 1.76-1.61 (m, 2H, 
CH2CH3), 0.78 (t, 3H, 3J = 7.3 Hz, CH3); 13C-NMR (CD3OD) δ ppm: 176.26 (quat. 
C=O), 171.86 (quat. Thiaz-2-C), 155.18 (quat. C=NH), 144.46 (quat. Ar-C), 129.57 
(+, 2 Ar-CH), 128.80 (+, 2 Ar-CH), 127.77 (+, Ar-CH), 126.24 (quat. Thiaz-5-C), 
123.27 (+, Thiaz-4-C), 45.17 (+, CHCH2CH3), 44.76 (-, Thiaz-5-CH2), 41.33 (-, 
CH2NH), 30.19 (-, COCH2), 29.40 (-, Thiaz-5-CH2CH2), 24.82 (-, CH2CH3), 12.27 (+, 
CH3); HRMS: EI-MS: m/z for (C18H25N5OS) calcd. 359.17798, found 359.17797; 
prep. HPLC: MeCN/0.1% TFA/aq (20/80-40/60). C18H25N5OS  · 2TFA (587.47) 
N-[3-(2-Aminothiazol-5-yl)propyl]-N´-(3,3-diphenylpropanoyl)guanidine (4.43) 
The title compound was prepared from 4.43a (210 mg, 0.34 mmol) in 5 ml 
CH2Cl2/abs and 1 ml TFA according to the general procedure yielding 4.43 as a 
colourless oil (90 mg, 41 %). 1H-NMR (CD3OD) δ ppm: 7.21 (m, 10H, Ar-H), 6.97 (s, 
1H, Thiaz-4-H), 4.59 (t, 1H, 3J = 8.0 Hz, CH2CH), 3.26 (m, 4H, CH2NH, COCH2), 2.71 
(t, 2H, 3J = 7.6 Hz, Thiaz-5-CH2), 1.90 (m, 2H, Thiaz-5-CH2CH2); 13C-NMR (CD3OD) 
δ ppm: 175.58 (quat. C=O), 171.84 (quat. Thiaz-2-C), 155.14 (quat. C=NH), 144.51 
(quat. C-Ph), 129.70 (+, 4 CH-Ph), 128.84 (+, 4 CH-Ph), 127.79 (+, 2 CH-Ph), 126.23 
(quat. Thiaz-5-C), 123.28 (+, Thiaz-4-C), 48.10 (+, CH2CH), 43.78 (-, COCH2), 41.36 
(-, Thiaz-5-CH2), 29.37 (-, CH2NH), 24.80 (-, Thiaz-5-CH2CH2); HRMS: EI-MS: m/z 
for (C22H25N5OS) calcd. 407.17798, found 407.17921, prep. HPLC: MeCN/0.1% 
TFA/aq (25/75-50/50). C22H25N5OS  · 2TFA (635.51) 
N-[3-(2-Aminothiazol-5-yl)propyl]-N´-(3-cyclohexylbutanoyl)guanidine (4.44) 
The title compound was prepared from 4.44a (200 mg, 0.36 mmol) in 5 ml 
CH2Cl2/abs and 1 ml TFA according to the general procedure yielding 4.44 as a 
colourless oil (110 mg, 53 %). 1H-NMR (CD3OD) δ ppm: 7.01 (s, 1H, Thiaz-4-H), 3.37 
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(m, 2H, CH2NH), 2.77 (t, 2H, 3J = 7.3 Hz, Thiaz-5-CH2), 2.56 (dd, 1H, 3J = 5.1Hz, 2J = 
15.1Hz, COCHH), 2.22 (dd, 1H, 3J = 9.1 Hz, 2J = 15.0 Hz, COCHH), 1.92 (m, 3H, 
Thiaz-5-CH2CH2, CH2CH), 1.77-1.65 (m, 5H, cHex-CH2, cHex-CH), 1.28-1.04 (m, 6H, 
cHex-CH2), 0.92 (d, 3H, 3J = 6.8 Hz, CH3); 13C-NMR (CD3OD) δ ppm: 177.38 (quat. 
C=O), 171.80 (quat. Thiaz-2-C), 155.28 (quat. C=NH), 126.36 (quat. Thiaz-5-C), 
123.52 (+, Thiaz-4-C), 43.95 (+, cHex-CH), 42.72 (-, COCH2), 41.53 (-, Thiaz-5-CH2), 
36.40 (+, CH2CH), 31.47 (-, CH2NH), 30.04 (-, cHex-CH2), 29.51 (-, cHex-CH2), 27.84 
(-, Thiaz-5-CH2CH2), 27.73 (-, 2 cHex-CH2), 24.90 (-, cHex-CH2), 16.61 (+, CH3); 
HRMS: EI-MS: m/z for (C17H29N5OS) calcd. 351.20928, found 351.20847; prep. 
HPLC: MeCN/0.1% TFA/aq (25/75-50/50). C17H29N5OS · 2TFA (579.49)  
N-[3-(2-Aminothiazol-5-yl)propyl]-N´-(3-cyclohexyl-2-methylpropanoyl)guani-
dine (4.45) 
The title compound was prepared from 4.45a (200 mg, 0.36 mmol) in 5 ml 
CH2Cl2/abs and 1 ml TFA according to the general procedure yielding 4.45 as a 
colourless oil (170 mg, 81 %). 1H-NMR (CD3OD) δ ppm: 7.00 (s, 1H, Thiaz-4-H), 3.37 
(t, 2H, 3J = 6.9 Hz, CH2NH), 2.77 (t, 2H, 3J = 7.5 Hz, Thiaz-5-CH2), 2.68 (m, 1H, 
CHCH3), 1.96 (m, 2H, Thiaz-5-CH2CH2), 1.75-1.60 (m, 6H, cHex-CH2, CH2-Ar), 1.24 
(m, 5H, cHex-CH2, cHex-CH), 1.15 (d, 3H, 3J = 6.9 Hz, CH3), 0.89 (m, 2H, cHex-
CH2); 13C-NMR (CD3OD) δ ppm: 180.52 (quat. C=O), 170.98 (quat. Thiaz-2-C), 
154.68 (quat. C=NH), 125.37 (quat. Thiaz-5-C), 122.39 (+, Thiaz-4-C), 41.36 (-, 
Thiaz-5-CH2), 40.61 (-, CH2-cHex), 39.37 (+, COCH), 35.75 (+, cHex-CH), 33.63 (-, 
CH2NH), 33.35 (-, cHex-CH2), 28.57 (-, Thiaz-5-CH2CH2), 26.71 (-, cHex-CH2), 26.46 
(-, cHex-CH2), 26.43 (-, cHex-CH2), 24.03 (-, cHex-CH2), 17.03 (+, CH3); HRMS: EI-
MS: m/z for (C17H29N5OS) calcd. 351.20928, found 351.20880; prep. HPLC: 
MeCN/0.1% TFA/aq (25/75-50/50). C17H29N5OS  · 2TFA (579.49) 
N-[3-(2-Aminothiazol-5-yl)propyl]-N´-(3-cyclohexylpentanoyl)guanidine (4.46) 
The title compound was prepared from 4.46a (80 mg, 0.14 mmol) in 5 ml CH2Cl2/abs 
and 1 ml TFA according to the general procedure yielding 4.46 as a colourless oil (70 
mg, 84 %). 1H-NMR (CD3OD) δ ppm: 7.01 (s, 1H, Thiaz-4-H), 3.37 (t, 2H, 3J = 7.0 
Hz, CH2NH), 2.77 (t, 2H, 3J = 7.5 Hz, Thiaz-5-CH2), 2.50 (dd, 1H, 3J = 6.1 Hz, 2J = 
15.7 Hz, COCHH), 2.32 (dd, 1H, 3J = 7.5 Hz, 2J = 15.7 Hz, COCHH), 1.96 (m, 2H, 
Thiaz-5-CH2CH2), 1.69 (m, 6H, cHex-CH2, CH2CH, cHex-CH), 1.19 (m, 8H, cHex-
CH2, CH2CH3), 0.89 (t, 3H, 3J = 7.4 Hz, CH3); 13C-NMR (CD3OD) δ ppm: 177.73 
(quat. C=O), 170.60 (quat. Thiaz-2-C), 155.06 (quat. C=NH), 126.35 (quat. Thiaz-5-
Chapter 4: NG-Acylated Aminothiazolylpropylguanidines 164 
C), 123.36 (+, Thiaz-4-C), 42.94 (+, cHex-CH), 41.52 (-, Thiaz-5-CH2), 41.41 (+, 
CH2CH), 39.71 (-, COCH2), 31.19 (-, CH2NH), 30.34 (-, cHex-CH2), 29.51 (-, cHex-
CH2), 27.88 (-, 2 cHex-CH2), 27.79 (-, Thiaz-5-CH2CH2), 24.89 (-, cHex-CH2), 24.75 
(-, CH2CH3), 12.05 (+, CH3); HRMS: EI-MS: m/z for (C18H31N5OS) calcd. 365.22493, 
found 365.22445; prep. HPLC: MeCN/0.1% TFA/aq (30/70-50/50). C18H31N5OS  · 
2TFA (593.51) 
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Chapter 5 
“Bivalent” Histamine H2 Receptor Agonists 
 
5.1. Introduction 
G-protein coupled receptors (GPCRs) are integral membrane proteins, representing 
the largest class of cell surface receptors and provide the targets of an increasing 
number of therapeutic agents. For a long time, GPCRs were regarded to function as 
monomeric entities, but now it is widely accepted that they form homo- and hetero-
oligomeric complexes1-4. Histamine H1-H4 receptors are also known to exist as 
oligomers5-11. This prompted us to design bivalent ligands with different spacer 
lengths as pharmacological tools for the investigation of hypothetical dimeric 
histamine receptors. Bivalent ligands are thought to exhibit a greater potency than 
that corresponding to double concentration of a monovalent ligand. This concept has 
been studied, for instance, for opioid receptors in more detail12. The ligands have to 
display a correct spacer length to be able to bridge neighbouring receptors. For 
opioid receptors, the distance between the recognition sites of a contact dimer with a 
TM5/TM6 interface is about 27 Å as suggested from molecular modelling13. 
Therefore, ligands with spacer lengths between 6 and 27 Å were synthesized and 
investigated for histamine H2 receptor (H2R) agonism at the spontaneously beating 
guinea pig right atrium as well as hH2R-GsαS and gpH2R-GsαS in a membrane steady-
state GTPase assay. 
The histamine H2 receptor isoforms of human14, guinea pig15, rat16 and canine17 are 
closely related to each other with an overall amino acid sequence identity of more 
than 80 % and more than 90 % within the seven α-helical transmembrane domains. 
Recent studies showed that the cH2R exhibits an increased constitutive activity 
compared to hH2R, gpH2R and rH2R and differences in potencies and efficacies of 
compounds between hH2R-GsαS and cH2R-GsαS18, 19. To further study the different 
activation of histamine H2R isoforms, the synthesized bivalent agonists were 
investigated in GTPase assays at cH2R-GsαS and mutant membranes (hH2R-C17Y-
A271D-GsαS and hH2R-C17Y-GsαS).  
Furthermore, in addition to amino acids in the TM domains, residues of the second 
extracellular (e2) loop were suggested to contribute to the ligand binding pocket of 
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class 1 GPCRs20, 21. Very recently, the high-resolution crystal structure of the human 
β2-adrenergic receptor pointed out that part of the e2 loop is held out of the binding 
cavity by a pair of disulfide bridges and a short helical segment within the loop22, 23. 
Recent studies revealed that the e2 loop of H2R does not contribute to the 
interactions of N-[3-(1H-imidazol-4-yl)propyl]guanidines and NG-acylated analogues, 
an indication that participation of the e2 loop may apply not for all class 1 GPCRs18, 
24. As an alternative to binding to receptor dimers, it is conceivable that bivalent 
ligands interact with two different binding sites at one and the same receptor 
molecule. An interaction with the e2 loop region cannot be ruled out. Therefore, the 
“double pharmacophore ligands” were investigated at chimeric receptors combining 
gpH2R and an e2 loop containing four amino acids of hH2R and vice versa using 
membrane preparations of Sf9 cells expressing hH2R-gpE2-GsαS and gpH2R-hE2-
GsαS (GTPase assay). Additionally, the compounds were tested at hH3R and hH4R for 
receptor selectivity. 
 
5.2. Chemistry 
In principle, the coupling of two equivalents of trityl-protected imidazolylpropyl-
guanidine 3.7 with one equivalent of different alkanedioic acids appears feasible to 
synthesize a library of bivalent acylguanidine-type H2R agonists. However, the 
reaction of 3.7 with dicarboxylic acids in the presence of NaH and CDI as a coupling 
reagent failed as only mono-acylation (5.1a) occurred. The trityl group was removed 
by treatment of 5.1a with TFA in DCM to obtain 5.1 (Scheme 5.1).  
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Scheme 5.1. Coupling of imidazolylpropylguanidine 3.7 with alkanedioic acids; Reagents and 
conditions: (i) CDI (1.2 eq), NaH (60 % dispersion in mineral oil) (2 eq), THF/abs, 3-4h, rt; (ii) 20 % 
TFA, DCM, 5-6 h, rt. 
 
Mono-Boc protected guanidines can be coupled to carboxylic acids with EDAC, HOBt 
and DIEA in a one-pot reaction at high yields. This method was applied to the 
synthesis of bivalent H2R agonists. The required building block 5.5 was prepared 
from the alcohol 3.4 which was converted to the primary amine 5.3 via the 
phthalimide 5.2 and subsequent treatment with hydrazine monohydrate. The free 
amine was then coupled to the guanidinylating reagent 4.14 by analogy with the 
procedure described for the aminothiazoles in chapter 4. The Cbz-group was cleaved 
by hydrogenation to yield the mono-Boc protected guanidine 5.5 (Scheme 5.2). 
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Scheme 5.2. Synthesis of N-tert-butoxycarbonyl-N-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine 5.5; 
Reagents and conditions: (i) phthalimide (1 eq), PPh3 (1 eq), DIAD (1 eq), THF/abs, 24 h, rt; (ii) 
N2H2·H2O (5 eq), EtOH, 1 h, reflux; (iii) 4.14 (1 eq), HgCl2 (2 eq), NEt3 (3 eq), DCM/abs, 48 h, rt; (v) 
H2, Pd/C (10 %), MeOH/THF (1:1), 8 bar, 8-9 d, rt. 
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The mono-Boc-protected guanidine building blocks 4.17 and 5.5, respectively, were 
coupled to different alkanedioic acids using EDAC, HOBt and DIEA as standard 
coupling reagents. Removal of the protecting groups under acidic conditions gave the 
bivalent ligands 5.6-5.12 (Scheme 5.3).  
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No R2 n 
5.6 imidazol-4-yl 8 
5.7 2-amino-4-methylaminothiazol-5-yl 4 
5.8 2-amino-4-methylaminothiazol-5-yl 6 
5.9 2-amino-4-methylaminothiazol-5-yl 8 
5.10 2-amino-4-methylaminothiazol-5-yl 10 
5.11 2-amino-4-methylaminothiazol-5-yl 14 
5.12 2-amino-4-methylaminothiazol-5-yl 20 
 
Scheme 5.3. Synthesis of bivalent NG-acylated hetarylpropylguanidines 5.6-5.12; Reagents and 
conditions: (i) EDAC (1 eq), HOBt (1 eq), DIEA (1 eq), DCM/abs, 24 h, rt; (ii) 20 % TFA, DCM/abs, 3-5 
h, rt. 
 
5.3. Pharmacological results and discussion 
All compounds were tested for histamine H2R agonism at the spontaneously beating 
guinea pig right atrium (positive chronotropic response) (Table 5.1) and in a 
membrane steady-state GTPase assay at hH2R-GsαS, gpH2R-GsαS and cH2R-GsαS 
fusion proteins expressed in Sf9 insect cells (Table 5.2). Furthermore, the bivalent 
ligands were tested at an hH2R-GsαS double mutant with Cys17→Tyr17 and Ala-
271→Asp271 exchanges (hH2R-C17Y-A271D-GsαS) and a mutant with 
Cys17→Tyr17 exchange (hH2R-C17Y-GsαS) in the sequence of the hH2R as well as 
mutant hH2R-GsαS with an exchange of four amino acids in the e2 loop against amino 
acids derived from the gpH2R (hH2R-gpE2-GsαS) and a reverse mutant gpH2R-GsαS 
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with the corresponding amino acids derived from the hH2R (gpH2R-hE2-GsαS) (Table 
5.3 and Table 5.4) to study species-selectivity and the role of the e2 loop. The 
compounds were tested for histamine H1R antagonism on U-373 MG human cells in 
the Ca2+-assay (Table 5.5) and on the human histamine H3 and H4 receptor in 
GTPase assay (Table 5.6). 
 
5.3.1. Histamine H2 receptor agonism 
5.3.1.1. Agonistic activity on the spontaneously beating guinea pig right atrium 
The bivalent ligands proved to be strong partial to full agonists at the spontaneously 
beating guinea pig right atrium (Table 5.1).  
 
Table 5.1. Histamine H2 receptor agonism at the spontaneously beating guinea pig right atrium. 
R N
H
N
H
NH O
OH
O
n
R N
H
N
H
NH O
N
H
O
n NH
NH
R
5.1, 4.39 5.6-5.12  
   
H2R agonism -  isolated guinea pig 
right atrium 
No. R n 
pEC50 ± 
SEMa 
rel. 
pot.b 
Emax ± 
SEM (%)c 
HIS - - 6.00 ± 0.10 100 100 ± 2 
AMT25 - - 6.21 ± 0.09 160 95 ± 2 
5.1 imidazol-4-yl 8 6.36 ± 0.12 231 90 ± 1 
4.39d 2-amino-4-methylthiazol-5-yl 8 6.92 ± 0.10 826 63 ± 5 
5.6 imidazol-4-yl 8 9.09 ± 0.06 122,000 87 ± 2 
5.7 2-amino-4-methylthiazol-5-yl 4 nd nd nd 
5.8 2-amino-4-methylthiazol-5-yl 6 9.48 ± 0.03 302,000 64 ± 3 
5.9 2-amino-4-methylthiazol-5-yl 8 8.84 ± 0.14 69,200 64 ± 4 
5.10 2-amino-4-methylthiazol-5-yl 10 nd nd nd 
5.11 2-amino-4-methylthiazol-5-yl 14 6.13 ± 0.14 135 53 ± 11 
5.12 2-amino-4-methylthiazol-5-yl 20 nd nd nd 
a pEC50 was calculated from the mean shift ∆pEC50 of the agonist curve relative to the histamine reference curve by equation: 
pEC50 = 6.00 + ∆pEC50; data shown are the ± SEM of three to five experiments; b relative potency to histamine = 100 %; c 
efficacy, maximal response (%), relative to the maximal increase in heart rate induced by the reference compound histamine; d 
for experimental data see chapter 4. 
 
Compound 5.8 with a spacer of six carbon atoms between the carbonyl groups is 
about 3000 times more potent than histamine and turned out to be the most potent 
agonist at the guinea pig right atrium known so far. With increasing the spacer length, 
potency and efficacy are decreasing. It is more likely that 5.8 containing an 
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insufficient spacer length to occupy two vicinal receptors assign a second binding site 
at the same receptor. Compounds 5.1 and 4.39 with only one pharmacophore and a 
carboxylic acid function are significantly less potent than the bivalent analogues. 
 
5.3.1.2. Agonistic activity at hH2R-GsαS, gpH2R-GsαS and cH2R-GsαS fusion 
proteins 
The synthesized compounds were potent full or partial H2 receptor agonists at hH2R-
GsαS, gpH2R-GsαS and cH2R-GsαS membranes in the GTPase assay (Table 5.2). With 
increasing the spacer length from four (~6 Å) to twenty (~27 Å) C-atoms between the 
carbonyl functions, the potency peaks with an octamethylene chain (~11 Å) at both, 
hH2R-GsαS and gpH2R-GsαS. In agreement with previous studies, these compounds 
exhibit higher potencies and efficacies at gpH2R-GsαS compared to hH2R-GsαS27-29. 
Figure 5.1 shows the correlation between potencies and efficacies at gpH2R-GsαS and 
hH2R-GsαS of the “double pharmacophore ligands”. Interestingly, compounds 5.7-5.9 
are 27 to 49 times more potent at the gpH2R-GsαS compared to hH2R-GsαS and 
therefore exhibit the highest selectivities towards gpH2R-GsαS among acylguanidines 
known so far. Moreover, compound 5.9 has an EC50 value of 0.46 nM at gpH2R-GsαS 
and is among the most potent acylguanidine-type H2R agonists identified in the 
GTPase assay. Further extension of the spacer length results in a significant drop in 
potency up to a complete loss of agonistic acitivity at hH2R-GsαS. These results 
challenge the model of bivalent ligandes as compounds bridging the binding pockets 
of receptor dimers in the case of the H2R agonistic acylguanidines. The occupation of 
two neighbouring receptors is impossible because of an insufficient spacer length in 
the case of the highly potent agonist 5.9, whereas an estimated optimal spacer 
length results in weak agonism (5.12, gpH2R-GsαS) or loss of activity (5.12, hH2R-
GsαS). 
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Table 5.2. Agonist efficacies and potencies of bivalent agonists at hH2R-GsαS, gpH2R-GsαS and cH2R-
GsαS expressed in Sf9 cell membranes. 
hH2R-GsαS gpH2R-GsαS 
No. 
efficacy EC50 [nM] 
rel. 
pot. 
efficacy EC50 [nM] rel. pot. 
EC50 hH2R-
GsαS/ EC50 
gpH2R-
GsαS 
HIS26 1.00 990 ± 92 100 1.00 850 ± 340 100 1.16 
AMT26 0.91 ± 0.02 190 ± 50 521 1.04 ± 0.01 190 ± 42  447 1.00 
5.1 0.67 ± 0.03 81.3 ± 12.1 1,218 0.97 ± 0.04 182.5 ± 99.3 465 0.44 
4.39a 0.51 48.9 2,024 0.61 35.5 2,394 1.38 
5.6 0.82 ± 0.04 6.3 ± 0.9 20,000 0.98 ± 0.05 1.2 ± 0.4 100,000 5.25 
5.7 0.63 ± 0.03 62.4 ± 39.9 2020 0.91 ± 0.01 1.9 ± 1.2 63,158 32.8 
5.8 0.58 ± 0.02 32.6 ± 22.4 3,865 0.81 ± 0.03 0.66 ± 0.2 181,818 49.4 
5.9 0.53 ± 0.04 12.4 ± 6.4 10,161 0.79 ± 0.07 0.46 ± 0.1 260,869 26.9 
5.10 0.44 ± 0.06 14.6 ± 6.8 8,630 0.66 ± 0.05 3.5 ± 2.2 34,285 4.17 
5.11 0.12 ± 0.02 32.8 ± 15.6 3,841 0.51 ± 0.02 23.3 ± 11.0 5,150 1.4 
5.12 (- - -)b 0.58 ± 0.02 537.3 ± 239.4 223 - 
 
cH2R-GsαS 
No. 
efficacy EC50 [nM] 
rel. 
pot. 
  HIS19 1.00 290 ± 50 100 
AMT19 0.90 ± 0.04 110 ± 66 264 
5.6 1.21 ± 0.18 151.8 ± 150.2 191 
5.7 0.85 ± 0.07 31.6 ± 9.2 918 
5.8 0.82 ± 0.07 5.2 ± 3.9 5,577
5.9 0.79 ± 0.10 5.5 ± 1.4 5,273
5.10 0.81 ± 0.04 9.8 ± 5.4 2,959
5.11 0.39 ± 0.04 19.7 ± 0.2 1,472
5.12 0.22 ± 0.00 285.9 ± 131 101 
a for experimental data see chapter 4; b no agonistic acitvity. 
Steady state GTPase activity in Sf9 membranes expressing hH2R-GsαS, gpH2R-GsαS and cH2R-GsαS was determined as described 
in the literature19, 27. Reaction mixtures contained ligands at concentrations from 1 nM to 10 µM or 10 pM to 100 nM, 
respectively, as appropriate to generate saturated concentration-response curves. Data were analyzed by nonlinear regression 
and were best fit to sigmoidal concentration-response curves. Typical basal GTPase activities ranged between ~ 0.5 and 2.5 
pmol/mg/min, and activities stimulated by histamine (100 µM) ranged between ~ 2 and 13 pmol/mg/min. The efficacy (Emax) of 
histamine was determined by nonlinear regression and was set to 1.0. The Emax values of other agonists were referred to this 
value. Data shown are the mean ± SEM of two to five experiments performed in duplicates each. The relative potency of 
histamine was set to 100, and the potencies of other agonists were referred to this value. The ratios of the EC50 values of H2R 
agonists for hH2R-GsαS and gpH2R-GsαS were also calculated. 
 
The exchange of the aminothiazole ring against an imidazole ring in derivative 5.9 
decreased potency about three-fold at gpH2R-GsαS (EC50 (5.9) = 0.46 nM, EC50 (5.6) 
= 1.2 nM), whereas the potency at hH2R-GsαS is two-fold increased (EC50 (5.9) = 
Chapter 5: „Bivalent“ Histamine H2 Receptor Agonists 174 
12.4 nM, EC50 (5.6) = 6.3 nM). Compounds having a free carboxylic acid (5.1 and 
4.39) exhibit lower potencies compared to their double pharmacophore analogues. 
Here in turn the aminothiazole derivative (4.39) shows higher agonistic activity than 
the imidazole analogue (5.1) but lower efficacy. Compounds 5.7-5.12 exhibited 
higher EC50 values and efficacies at cH2R-GsαS than at hH2R-GsαS. This result is in 
agreement with recent studies19. An exception is compound 5.6, which is more 
efficacious but was less potent at cH2R-GsαS compared to hH2R-GsαS. 
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Figure 5.1.  Correlation between the potencies (A) and efficacies (B) of acylated bivalent ligands at 
hH2R-GsαS and gpH2R-GsαS fusion proteins in the GTPase assay. Agonist potencies and efficacies 
were taken from Table 5.1. The pEC50 values were derived from the EC50 shown in Table 5.1. The 
straight dotted line represents the correlation that would have been obtained if pEC50 values had been 
identical in the two systems. 
 
5.3.1.3. Agonistic activity on different histamine H2 receptor mutants  
5.3.1.3.1. Potencies and efficacies on hH2R-C17Y-A271D-GsαS and hH2R-C17Y-GsαS  
The data of compounds 5.6-5.12, which were investigated for agonism in the 
GTPase assay on the hH2R-GsαS mutants hH2R-C17Y-A271D-GsαS and hH2R-C17Y-
GsαS, are summarized in Table 5.3. Except for compounds 5.10 and 5.11, the ligands 
showed enhanced potencies and efficacies on hH2R-C17Y-A271D-GsαS compared to 
hH2R-GsαS. In accordance with the data for hH2R-GsαS, the optimal spacer was an 8- 
to 10-membered carbon chain, and further extension of the distance (up to ~27 Å) 
between the two pharmacophores resulted in total loss of agonistic activity. 
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Generally, potencies and efficacies of the agonists were still lower at hH2R-C17Y-
A271D-GsαS than at gpH2R-GsαS except for 5.10, which was nearly equieffective at 
both fusion proteins. Thus, the sensitivity of the hH2R-C17Y-A271D-GsαS double 
mutant against agonist stimulation is close to that of the guinea pig H2R isoform 
although not exactly the same. These results further support the hypothesis that both 
Tyr-17 and Asp-271 contribute largely to enhanced potencies and efficacies of 
acylguanidines at gpH2R by forming an H-Bond stabilizing an active receptor 
confirmation26, 27. However, the residual differences in potencies and efficacies 
suggest that additional amino acids are involved in the species-selective activation of 
histamine H2 receptors. 
 
Table 5.3. Efficacies and potencies of bivalent agonists at hH2R-C17Y-A271D-GsαS and hH2R-C17Y-
GsαS expressed in Sf9 cell membranes. 
hH2R-C17Y-A271D-GsαS hH2R-C17Y-GsαS 
No. 
efficacy EC50 [nM] 
rel. 
pot. 
efficacy EC50 [nM] rel. pot. 
HIS26 1.00 320 ± 9 100 1.00 260 ± 110 100 
AMT26 0.97 ± 0.01 65 ± 6 490 0.86 ± 0.19 120 ± 20 217 
5.6 0.97 ± 0.07 0.65 ± 0.15 49,230 0.99 7 3,714 
5.7 0.81 ± 0.00 7.6 ± 1.6 4,210 0.49 65 400 
5.8 0.83 ± 0.02 2.5 ± 0.5 12,800 0.31 10 2,600 
5.9 0.78 ± 0.01 2.0 ± 0.6 16,000 0.23 46 565 
5.10 0.71 ± 0.01 8.8 ± 3.9 3,636 0.27 14 1,857 
5.11 0.17 ± 0.01 41.8 ± 19.8 765 (- - -)a 
5.12 (- - -)a (- - -)a 
a no agonistic activity. 
Steady state GTPase activity in Sf9 membranes expressing hH2R-C17Y-A271D-GsαS and hH2R-C17Y-GsαS was determined as 
described in literature18, 26. Reaction mixtures contained ligands at concentrations from 1 nM to 10 µM or 0.1 nM to 100 nM, 
respectively, as appropriate to generate saturated concentration-response curves. Data were analyzed by nonlinear regression 
and were best fit to sigmoidal concentration-response curves. Typical basal GTPase activities ranged between ~ 2.5 and 3.0  
(1.25 for hH2R-C17Y-GsαS) pmol/mg/min, and activities stimulated by histamine (100 µM) ranged between ~ 12.5 and 13 (1.8 for 
hH2R-C17Y-GsαS) pmol/mg/min. The efficacy (Emax) of histamine was determined by nonlinear regression and was set to 1.0. 
The Emax values of other agonists were referred to this value. Data shown are the ± SEM of one to two experiments performed in 
duplicates each. The relative potency of histamine was set to 100, and the potencies of other agonists were referred to this 
value.  
 
A single point mutation of Cys17→Tyr17 significantly decreased the potencies and 
efficacies of the bivalent agonists compared to “wild-type” hH2R-GsαS and gpH2R-
GsαS. These results are opposite to recent studies where alkyl- and acylguanidines 
showed enhanced or similar potencies and efficacies at hH2R-C17Y-GsαS compared 
to hH2R-GsαS18. 
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5.3.1.3.2. Potencies and efficacies on hH2R-gpE2-GsαS and gpH2R-hE2-GsαS  
To study the influence of the e2 loop on the species selectivity of bivalent NG-
acylated guanidines, the synthesized compounds were tested on hH2R-GsαS and 
gpH2R-GsαS which are reciprocally mutated at four positions in the e2 loop (hH2R-
gpE2-GsαS and gpH2R-hE2-GsαS). The efficacies and potencies at hH2R-gpE2-GsαS 
and gpH2R-hE2-GsαS are listed in Table 5.4. 
 
Table 5.4. Efficacies and potencies of bivalent agonists at hH2R-gpE2-GsαS and gpH2R-hE2-GsαS 
expressed in Sf9 cell membranes. 
hH2R-gpE2-GsαS gpH2R-hE2-GsαS 
No 
efficacy EC50 [nM] 
rel. 
pot. 
efficacy EC50 [nM] rel. pot. 
HIS18 1.00 700 ± 190 100 1.00 1400 ± 280 100 
AMT18 0.94 ± 0.05 140 ± 30 500 0.94 ± 0.06 310 ± 110 452 
5.6 0.81 3.6 19,444 1.11 1.2 116,666 
5.7 0.63 55 1,273 0.96 7.9 17,721 
5.8 0.64 49 1,428 1.00 2.2 63,636 
5.9 0.65 7 10,000 0.88 3 46,667 
5.10 0.54 8 8,750 0.75 12 11,667 
5.11 0.21 49 1,428 0.49 32 4,375 
5.12 (- - -)a 0.29 645 217 
a no agonistic activity. 
Steady state GTPase activity on Sf9 membranes expressing hH2R-C17Y-A271D-GsαS and hH2R-C17Y-GsαS was determined as 
described in literature18, 24. Reaction mixtures contained ligands at concentrations from 1 nM to 10 µM as appropriate to 
generate saturated concentration-response curves. Data were analyzed by nonlinear regression and were best fit to sigmoidal 
concentration-response curves. Typical basal GTPase activities ranged between ~ 0.5 and 1.0 pmol/mg/min, and activities 
stimulated by histamine (100 µM) ranged between ~ 2.8 and 4.5 pmol/mg/min. The efficacy (Emax) of histamine was determined 
by nonlinear regression and was set to 1.0. The Emax values of other agonists were referred to this value. Data shown are the ± 
SEM of one experiment performed in duplicates. The relative potency of histamine was set to 100, and the potencies of other 
agonists were referred to this value.  
 
The compounds 5.6-5.12 were similarly potent and efficacious at hH2R-gpE2-GsαS 
and “wild-type” hH2R-GsαS and somewhat different between gpH2R-hE2-GsαS and 
“wild-type” gpH2R-GsαS. Figure 5.2 displays the correlation of pEC50 values between 
wild-type and e2 mutated H2R. At gpH2R-hE2-GsαS, ligands 5.7-5.10 were three to 
five times less potent than at wild-type gpH2R-GsαS and 5.6, 5.11 and 5.12 showed 
similar potencies at wild-type and mutant gpH2R. As demonstrated recently, the 
second extracellular loop does not contribute to species-selectivity of small histamine 
H2R agonists as well as N-[3-(1H-imidazol-4-yl)propyl]guanidines and NG-acylated 
derivatives at human and guinea pig H2R isoforms18, 24. This appears to apply to the 
bivalent ligands, too. The slightly reduced potencies of compounds 5.7-5.11 at 
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gpH2R-hE2-GsαS vs. gpH2R-GsαS may derive from minor conformational changes of 
the gpH2R binding pocket.  
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Figure 5.2. Correlation between the potencies of acylated bivalent ligands at hH2R-GsαS and hH2R-
gpE2-GsαS (A) and gpH2R-GsαS and gpH2R-hE2-GsαS (B) fusion proteins in the GTPase assay. Agonist 
potencies were taken from Table 5.2 and Table 5.4. The pEC50 values were derived from the EC50 
shown in Table 5.2 and Table 5.4. The straight dotted line represents the correlation that would have 
been obtained if pEC50 values had been identical in the two systems. 
 
5.3.2. Receptor selectivity 
5.3.2.1. Activity at histamine H1 receptors (Ca2+ assay on U-373 MG cells) 
On human U-373 cells, all investigated compounds proved to be weak or very weak 
histamine H1R antagonists (Table 5.5).  
 
Table 5.5. Histamine H1 receptor antagonism on U-373 MG human cells (Ca2+-assay). 
Histamine H1 receptor antagonism 
U-373 MG cells (Ca2+-assay) 
No IC50 [µM]a No. IC50 [µM]a No. IC50 [µM]a 
HIS - 5.9 5 5.10 7 
AMT25 - 5.6 31 5.11 2 
5.1 27 5.7 31 5.12 >100 
4.39 >100 5.8 24   
a IC50 values for the inhibition of the histamine (30 µM) induced increase in cellular calcium, one experiment; procedure as 
described from Kracht, 200130. 
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5.3.2.2. Agonistic potency and efficacy at hH3R and hH4R membranes  
As shown in chapter 4 for “monovalent” H2R agonists, the exchange of imidazole with 
a 2-amino-4-methylthiazole ring favours the selectivity for H2R, in particular over H3R 
and H4R. This is also true for the bivalent ligands. The compounds containing two 2-
amino-4-methylthiazole rings are devoid of or exhibit low (5.8-5.10) H3R stimulatory 
effects at the concentration tested. Furthermore, these compounds proved to be very 
weak H4R antagonists in the GTPase assay (Table 5.6) whereas the imidazole 
analogue 5.6 is a potent partial agonist with an EC50 value of 2.8 nM.   
 
Table 5.6. Agonist efficacies and potencies at hH3R+Gαo+β1γ2+RGS4 and hH4R-GAIP+Gαi2+β1γ2 
expressed in Sf9 cell membranes for bivalent ligands. 
hH3R+Gαo+β1γ2+RGS4 hH4R-GAIP+Gαi2+β1γ2 
No 
efficacy EC50 [nM] 
rel. 
pot. 
efficacy 
EC50 [nM] 
(IC50 [nM]) 
rel. 
pot. 
His 1.00 25.8 ± 3.1 100 1.00 11.6 ± 2.5 100 
5.6 - 0.25 nd nd 0.36 2.8 414 
5.7 - 0.25 nd nd - (>10,000) - 
5.8 0.24 nd nd - (>7,000) - 
5.9 0.36 nd nd  - (>10,000) - 
5.10 0.27 nd nd - (>10,000) - 
5.11 - 0.47 nd nd  - (>10,000) - 
5.12 - 0.17 nd nd - (>10,000) - 
Steady state GTPase activity in Sf9 membranes expressing hH3R+Gαo+β1γ2+RGS4 and hH4R-GAIP+Gαi2+β1γ2 was determined 
as described27. Reaction mixtures contained ligands at concentrations from 0.1 nM to 100 µM as appropriate to generate 
saturated concentration-response curves. Data were analyzed by nonlinear regression and were best fitted to sigmoidal 
concentration-response curves. Typical basal GTPase activities ranged between ~ 1.5 and 2.5 pmol/mg/min, and activities 
stimulated by histamine (10 µM) ranged between ~ 3.5 and 4.5 pmol/mg/min. The efficacy (Emax) of histamine was determined 
by nonlinear regression and was set to 1.0. The Emax values were referred to this value. Data shown are one experiment 
performed in duplicates each. The relative potency of histamine was set to 100, and the potencies of other agonists were 
referred to this value. For antagonism, reaction mixtures contained histamine (100 nM) and ligands at concentrations from 0.1 
nM to 100 µM (hH4R-GAIP+Gαi2+β1γ2). For efficacy, reaction mixtures contained ligands at a concentration of 10 µM 
(hH3R+Gαo+β1γ2+RGS4). 
 
5.4. Summary 
Bivalent ligands were synthesized by connecting the essential partial structures, i. e. 
the hetarylpropylguanidine portion, of guanidine-type histamine H2R agonists by NG-
acylation with alkanedioic acids of different length. The resulting symmetric 
compounds, containing either two imidazol-4-ylpropylguanidine or two 2-amino-4-
methylthiazol-5-ylpropylguanidine moieties, were tested for H2R agonism on the 
spontaneously beating guinea pig right atrium as well as in GTPase assay at hH2R-
GsαS, gpH2R-GsαS and cH2R-GsαS fusion proteins to study the species-selectivity. 
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Most strikingly, the combination of two 2-amino-4-methylthiazol-5-ylpropylguanidine 
moieties with an octanedioyl spacer (compound 5.8) resulted in the most potent 
agonist at the guinea pig right atrium known so far: This compound proved to be 
about 3000 times more potent than histamine. As previously found for all N-[3-(1H-
imidazol-4-yl)propyl]guanidines and NG-acylated derivatives in the GTPase assay, 
the highly potent H2R agonist 5.8 turned out to be more potent at gpH2R-GsαS than at 
hH2R-GsαS. Interestingly, the substances with hexanedioyl to decanedioyl spacer 
moieties displayed the highest selectivity for the guinea pig receptor among all known 
acylguanidine-type H2R agonists. Furthermore, 5.9 with a spacer length of about 
11 Å is one of the most potent agonists at gpH2R-GsαS with an EC50 value of 0.46 nM. 
Increasing the spacer length resulted in a significant decrease in potency and 
efficacy up to a total loss in potency at hH2R-GsαS. Due to insufficient spacer length 
for interaction with both binding pockets of H2R dimers in the case of the most potent 
H2R agonists and lack of potency in the case of compounds supposed to have 
optimal spacer lengths, it is concluded that only one receptor is occupied by one 
ligand. The dramatic increase in potency results from interaction with an additional 
(allosteric?) binding site rather than from occupation of a receptor dimer. The EC50 
values and efficacies are higher at cH2R-GsαS compared to hH2R-GsαS. In agreement 
with previous studies19, this is not specific for the guanidine-type agonists but due to 
the increased constitutive activity of cH2R-GsαS compared to hH2R-GsαS  
As predicted by molecular modelling and verified by site-directed mutagenesis 
studies, the preference of the guanidine-type agonists for the gpH2R is strongly 
dependent on two amino acids, Tyr-17 and Asp-271 in TM1 and TM7, which are 
thought to form an H-bond stabilizing an active receptor conformation26, 27. The 
bivalent ligands were tested at hH2R-GsαS mutants, hH2R-C17Y-A271D-GsαS and 
hH2R-C17Y-GsαS. In agreement with recent data for monovalent ligands, the bivalent 
acylguanidine-type agonists turned out to be more potent and efficient at the double 
mutant hH2R-C17Y-A271D-GsαS but still less potent than at gpH2R-GsαS. This 
indicates that the species-selectivity is not determined by these two amino acids 
alone. The compounds were less active on hH2R-C17Y-GsαS.  
Based on the crystal structure of rhodopsin21, the participation of residues of the e2 
loop to the binding pocket was proposed for some members of class 1 GPCRs20 and 
experimentally demonstrated for the dopamine D2 receptor31, the adenosine A2a 
receptor32 and the M3 muscarinic acetylcholine receptor33. However, the very recently 
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resolved crystal structure of the human β2-adrenergic receptor did not confirm a 
contribution of the e2 loop to ligand binding22, 23. Concerning human and guinea pig 
histamine H2 receptors, there is no hint from recent site-directed mutagenesis studies 
that the e2 loop contributes to the species-selectivity of N-[3-(1H-imidazol-4-
yl)propyl]guanidines and NG-acylated analogues18, 24. This is also true for the bivalent 
ligands presented in this study, i. e. there is no hint to an interaction with the e2 loop, 
too. All investigated compounds exhibited similar potencies and efficacies at “wild-
type” hH2R-GsαS and gpH2R-GsαS compared to the corresponding mutants in which 
four “critical” amino acids in the e2 loop were reciprocally mutated (hH2R-gpE2-GsαS 
and gpH2R-hE2-GsαS).  
In order to explore in more detail the high degree of species-selectivity of the bivalent 
ligands towards gpH2R-GsαS and to elaborate the structure-activity relationships with 
respect to the role and the interaction site of the second hetarylalkylguanidine moiety, 
it is necessary to synthesize and pharmacologically characterize additional com-
pounds with different spacer lengths, more bulky spacers and distinct pharmaco-
phores as well as non-H2R-specific groups.  
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5.5. Experimental section 
5.5.1. General conditions 
see chapter 3. 
 
5.5.2. Preparation of NG-Boc-protected imidazolylpropylguanidine 5.5 
3-(1-Trityl-1H-imidazol-4-yl)propan-1-amine (5.3) 
3-(1-Trityl-1H-imidazol-4-yl)propan-1-ol (4 g, 11 mmol), phthalimide (1.6 g, 11 mmol) 
and PPh3 (2.8 g, 11 mmol) were suspended in 100 ml THF/abs and cooled to 0 °C. 
DIAD (2.2 g, 2.1 ml, 11 mmol) was slowly added drop by drop, so that the yellow 
colour always disappeared. The mixture was allowed to warm to room temperature 
and stirred for 24 h. The solvent was evaporated in vacuo and the crude product 
suspended in 60 ml EtOH. After addition of hydrazine hydrate (2.7 ml, 55 mmol) the 
mixture was heated at refluxed for 1 h, cooled to room temperature and filtered to 
remove the precipitate. The solvent was evaporated under reduced pressure and the 
residue was subjected to flash chromatography to obtain 5.3 (2.34 g, 58 %) as a 
yellow oil. 1H-NMR (CDCl3) δ ppm: 7.32 (m, 10H, CPh3, Im-2-H), 7.12 (m, 6H, CPh3), 
6.52 (d, 1H, 4J = 1.2 Hz, Im-5-H), 2.74 (t, 2H, 3J = 6.9 Hz, CH2NH2), 2.59 (t, 2H, 3J = 
7.4 Hz, Im-4-CH2), 1.78 (m, 2H, Im-4-CH2CH2); ES-MS (DCM/MeOH + NH4OAc) m/z 
(%): 368 (MH+, 100). C25H25N3 (367.48) 
N-Benzyloxycarbonyl-N´-tert-butoxycarbonyl-N´´-[3-(1-trityl-1H-imidazol-4-
yl)propyl]guanidine (5.4) 
The title compound was prepared by analogy with the procedure described for 4.15 
and 4.16 (Chapter 4) from 5.3 (2.03 g, 5.5 mmol), 4.14 (1.79 g, 5.5 mmol), HgCl2 
(3.05 g, 11.2 mmol) and NEt3 (1.7 g, 2.33 ml, 17 mmol) in 250 ml DCM/abs. Flash 
chromatography (CHCl3/MeOH 97.5/2.5 v/v)) yielded 5.4 as a colourless foam-like 
solid (3.54 g, 100 %). 1H-NMR (CDCl3) δ ppm: 7.47 (d, 1H, 4J = 1.2 Hz, Im-2-H), 
7.34-7.10 (m, 20H, Ar-H, CPh3), 6.58 (d, 1H, 4J = 0.9 Hz, Im-5-H), 5.11 (s, 2H, CH2), 
3.40 (m, 2H, CH2NH2), 2.60 (t, 2H, 3J = 7.6 Hz, Im-4-CH2), 1.87 (m, 2H, Im-4-
CH2CH2), 1.45 (s, 9H, Boc-CH3); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 644 
(MH+, 100). C39H41N5O4 (643.77) 
N-tert-Butoxycarbonyl-N´-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine (5.5) 
The title compound was prepared by analogy with the procedure described for 4.17 
and 4.18 (Chapter 4) from 5.4 (1.5 g, 2.33 mmol) by hydrogenation over Pd/C (10 %) 
(1 g) in a mixture of 60 ml THF/MeOH (1:1) at 8 bar for 8-9 days yielding 5.5 as a 
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colourless foam-like solid (1.05 g, 88 %). 1H-NMR (CDCl3) δ ppm: 7.34-7.10 (m, 16H, 
Im-2-H, CPh3), 6.57 (s, 1H, Im-5-H), 3.41 (m, 2H, CH2NH2), 2.56 (m, 2H, Im-4-CH2), 
1.86 (m, 2H, Im-4-CH2CH2), 1.46 (s, 9H, C(CH3)3); ES-MS (DCM/MeOH + NH4OAc) 
m/z (%): 510 (MH+, 100). C31H35NO2 (509.64) 
 
5.5.3. Preparation of NG-tert-butoxycarbonyl-protected acylguanidines 
5.1a, 5.6a-5.12a 
General procedure  
To a solution of carboxylic acid (0.5 eq), EDAC (1 eq) and HOBt-monohydrate (1 eq) 
in DCM/abs was added DIEA (1 eq) under argon and stirred for 15 min. To this 
mixture a solution of 4.17 or 5.5 (1 eq) DCM/abs was added and stirred overnight at 
room temperature. The solvent was removed under reduced pressure, EtOAc and 
water were added to the residue,, the organic phase was separated, and the 
aqueous layer extracted two times with EtOAc. After drying over MgSO4, the organic 
solvent was removed in vacuo. The crude product was purified by flash 
chromatography (PE/EtOAc 70/30-50/50 v/v) unless otherwise indicated. 
10-Oxo-10-{3-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidino}decanoic acid (5.1a) 
The title compound was prepared from CDI (180 mg, 1.1 mmol), decanedioic acid 
(100 mg, 0.5 mmol), 3.7 (410 mg, 1 mmol) and NaH (60 % dispersion in mineral oil) 
(80 mg, 2 mmol) in THF/abs according to the general procedure yielding 5.1a as a 
colourless foam-like solid (140 mg, 47 %). 1H-NMR (CDCl3) δ ppm: 7.67 (s, 1H, Im-2-
H), 7.35-7.11 (m, 15H, CPh3), 6.56 (d, 1H, 4J = 1.1 Hz, Im-5-H), 3.75 (m, 2H, 
CH2NH), 2.56 (m, 2H, Im-4-CH2), 2.46 (t, 2H, 3J = 7.5 Hz, CH2COOH), 2.25 (m, 2H, 
COCH2), 1.86 (m, 4H, Im-4-CH2CH2, COCH2CH2), 1.68 (m, 2H, CH2CH2COOH), 1.33 
(m, 8H, (CH2)4); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 594 (MH+, 100). 
C36H43N5O3 (593.75) 
N1,N10-Bis{N-(tert-butoxycarbonyl)-[3-(1-trityl-1H-imidazol-4-yl)propyl]carbami-
midoyl}decanediamide (5.6a) 
The title compound was prepared from decanedioic acid (100 mg, 0.5 mmol), EDAC 
(190 mg, 1 mmol), HOBt-monohydrate (150 mg, 1 mmol), DIEA (0.17 ml, 1 mmol) in 
5 ml DCM/abs and 5.5 (510 mg, 1 mmol) in 5 ml DCM/abs according to the general 
procedure (flash chromatography CHCl3/MeOH 95/5 v/v) yielding 5.6a (0.18 g, 30 %) 
as a yellow oil. 1H-NMR (CDCl3) δ ppm: 7.33-7.12 (m, 32H, Im-2-H, CPh3), 6.53 (d, 
2H, 4J = 1.0 Hz, Im-5-H), 3.43 (m, 4H, CH2NH), 2.59 (t, 4H, 3J = 7.6 Hz, Im-4-CH2), 
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2.34 (m, 4H, COCH2), 1.90 (m, 4H, Im-4-CH2CH2), 1.65 (m, 4H, COCH2CH2), 1.49 (s, 
18H, C(CH3)3), 1.27 (m, 8H, (CH2)4); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 1185 
(MH+, 100). C72H84N10O5 (1184.66) 
N1,N6-Bis(N-(tert-butoxycarbonyl)-N´-{3-[2-(tert-butoxycarbonyl)amino-4-
methylthiazol-5-yl]propyl}carbamimidoyl)hexanediamide (5.7a) 
The title compound was prepared from hexanedioic acid (75 mg, 0.5 mmol), EDAC 
(190 mg, 1 mmol),  HOBt-monohydrate (150 mg, 1 mmol), DIEA (0.17 ml, 1 mmol) in 
5 ml DCM/abs and 4.17 (410 mg, 1 mmol) in 5 ml DCM/abs according to the general 
procedure yielding 5.7a (0.21 g, 45 %) as a colourless foam-like solid. 1H-NMR 
(CDCl3) δ ppm: 12.46 (s, 2H, NH), 8.91 (t, 2H, 3J = 5.4 Hz, CH2NH), 3.46 (m, 4H, 
CH2NH), 2.72 (m, 4H, Thiaz-5-CH2), 2.29 (m, 4H, COCH2), 2.21 (s, 6H, Thiaz-4-
CH3), 1.88 (td, 4H, Thiaz-5-CH2CH2), 1.65 (m, 4H, (CH2)2), 1.52 (s, 18H, C(CH3)3), 
1.49 (s, 18H, C(CH3)3); ES-MS (DCM/MeOH + NH4OAc) m/z (%): 937 (MH+, 100). 
C42H68N10O10S2 (936.46) 
N1,N8-Bis(N-(tert-butyoxycarbonyl)-N´-{3-[2-(tert-butoxycarbonyl)amino-4-
methylthiazol-5-yl]propyl}carbamimidoyl)octanediamide (5.8a) 
The title compound was prepared from octanedioic acid (90 mg, 0.5 mmol), EDAC 
(190 mg, 1 mmol),  HOBt-monohydrate (150 mg, 1 mmol), DIEA (0.17 ml, 1 mmol) in 
5 ml DCM/abs and 4.17 (410 mg, 1 mmol) in 5 ml DCM/abs according to the general 
procedure yielding 5.8a (0.21 g, 43 %) as a colourless foam-like solid. 1H-NMR 
(CDCl3) δ ppm: 12.42 (s, 2H, NH), 9.01 (t, 2H, 3J = 5.4 Hz, CH2NH), 3.45 (m, 4H, 
CH2NH), 2.70 (t, 4H, 3J = 7.4 Hz, Thiaz-5-CH2), 2.35 (m, 4H, 3J = 7.5 Hz, COCH2), 
2.22 (s, 6H, Thiaz-4-CH3), 1.88 (m, 4H, Thiaz-5-CH2CH2), 1.66 (m, 4H, COCH2CH2), 
1.52 (s, 18H, C(CH3)3), 1.49 (s, 18H, C(CH3)3), 1.36 (m, 4H, (CH2)2); ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 965 (MH+, 100). C44H72N10O10S2 (964.49) 
N1,N10-Bis(N-(tert-butyoxycarbonyl)-N´-{3-[2-(tert-butoxycarbonyl)amino-4-
methylthiazol-5-yl]propyl}carbamimidoyl)decanediamide (5.9a) 
The title compound was prepared from decanedioic acid (100 mg, 0.5 mmol), EDAC 
(190 mg, 1 mmol),  HOBt-monohydrate (150 mg, 1 mmol), DIEA (0.17 ml, 1 mmol) in 
5 ml DCM/abs and 4.17 (410 mg, 1 mmol) in 5 ml DCM/abs according to the general 
procedure yielding 5.9a (0.23 g, 46 %) as a colourless foam-like solid. 1H-NMR 
(CDCl3) δ ppm: 12.40 (s, 2H, NH), 9.02 (t, 2H, 3J = 5.2 Hz, CH2NH), 3.45 (m, 4H, 
CH2NH), 2.70 (t, 4H, 3J = 7.4 Hz, Thiaz-5-CH2), 2.35 (t, 4H, 3J = 7.5 Hz, COCH2), 
2.21 (s, 6H, Thiaz-4-CH3), 1.87 (m, 4H, Thiaz-5-CH2CH2), 1.66 (m, 4H, COCH2CH2), 
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1.51 (s, 18H, C(CH3)3), 1.49 (s, 18H, C(CH3)3), 1.32 (m, 8H, (CH2)4); ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 993 (MH+, 100). C46H76N10O10S2 (992.5) 
N1,N12-Bis(N-(tert-butyoxycarbonyl)-N´-{3-[2-(tert-butoxycarbonyl)amino-4-
methylthiazol-5-yl]propyl}carbamimidoyl)dodecanediamide (5.10a) 
The title compound was prepared from dodecanedioic acid (120 mg, 0.5 mmol), 
EDAC (190 mg, 1 mmol), HOBt-monohydrate (150 mg, 1 mmol), DIEA (0.17 ml, 1 
mmol) in 5 ml DCM/abs and 4.17 (410 mg, 1 mmol) in 5 ml DCM/abs according to the 
general procedure yielding 5.10a (0.34 g, 66 %) as a colourless foam-like solid. 1H-
NMR (CDCl3) δ ppm: 12.39 (s, 2H, NH), 9.02 (t, 2H, 3J = 5.2 Hz, CH2NH), 3.45 (m, 
4H, CH2NH), 2.70 (t, 4H, 3J = 7.2 Hz, Thiaz-5-CH2), 2.34 (t, 4H, 3J = 7.5 Hz, COCH2), 
2.21 (s, 6H, Thiaz-4-CH3), 1.87 (m, 4H, Thiaz-5-CH2CH2), 1.65 (m, 4H, COCH2CH2), 
1.52 (s, 18H, C(CH3)3), 1.50 (s, 18H, C(CH3)3), 1.27 (m, 12H, (CH2)6); ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 1021 (MH+, 100). C48H80N10O10S2 (1020.55) 
N1,N16-Bis(N-(tert-butyoxycarbonyl)-N´-{3-[2-(tert-butoxycarbonyl)amino-4-
methylthiazol-5-yl]propyl}carbamimidoyl)hexadecanediamide (5.11a) 
The title compound was prepared from hexadecanedioic acid (140 mg, 0.5 mmol), 
EDAC (190 mg, 1 mmol), HOBt-monohydrate (150 mg, 1 mmol), DIEA (0.17 ml, 1 
mmol) in 5 ml DCM/abs and 4.17 (410 mg, 1 mmol) in 5 ml DCM/abs according to the 
general procedure yielding 5.11a (0.29 g, 54 %) as a colourless foam-like solid. 1H-
NMR (CDCl3) δ ppm: 12.39 (s, 2H, NH), 9.03 (t, 2H, 3J = 5.2 Hz, CH2NH), 3.44 (m, 
4H, CH2NH), 2.70 (t, 4H, 3J = 7.4 Hz, Thiaz-5-CH2), 2.39 (t, 4H, 3J = 7.5 Hz, COCH2), 
2.22 (s, 6H, Thiaz-4-CH3), 1.87 (m, 4H, Thiaz-5-CH2CH2), 1.66 (m, 4H, COCH2CH2), 
1.52 (s, 18H, C(CH3)3), 1.50 (s, 18H, C(CH3)3), 1.27 (m, 20H, (CH2)10); ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 1077 (MH+, 85). C52H88N10O10S2 (1076.61) 
N1,N22-Bis(N-(tert-butyoxycarbonyl)-N´-{3-[2-(tert-butoxycarbonyl)amino-4-
methylthiazol-5-yl]propyl}carbamimidoyl)docosanediamide (5.12a) 
The title compound was prepared from docosanedioic acid (185 mg, 0.5 mmol), 
EDAC (190 mg, 1 mmol), HOBt-monohydrate (150 mg, 1 mmol), DIEA (0.17 ml, 1 
mmol) in 5 ml DCM/abs and 4.17 (410 mg, 1 mmol) in 5 ml DCM/abs according to the 
general procedure yielding 5.12a (0.35 g, 60 %) as a colourless foam-like solid. 1H-
NMR (CDCl3) δ ppm: 12.40 (s, 2H, NH), 9.04 (t, 2H, 3J = 5.2 Hz, CH2NH), 3.45 (m, 
4H, CH2NH), 2.70 (t, 4H, 3J = 7.5 Hz, Thiaz-5-CH2), 2.39 (t, 4H, 3J = 7.5 Hz, COCH2), 
2.21 (s, 6H, Thiaz-4-CH3), 1.87 (m, 4H, Thiaz-5-CH2CH2), 1.67 (m, 4H, COCH2CH2), 
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1.52 (s, 18H, C(CH3)3), 1.50 (s, 18H, C(CH3)3), 1.27 (m, 32H, (CH2)16); ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 1161 (MH+, 85). C58H100N10O10S2 (1160.71) 
 
5.5.4. Preparation of deprotected acylguanidines 5.1, 5.6-5.12 
General procedure  
To a solution of the Boc-protected acylguanidine in CH2Cl2/abs were added TFA and 
stirred at ambient temperatur until the Boc groups were removed (3-5 h). 
Subsequently, the solvent was removed in vacuo and the residue was purified by 
preparative RP-HPLC (for general conditions see chapter 3). All compounds were 
obtained as trifluoroacetic acid salts. 
10-{3-[3-(1H-imidazol-4-yl)propyl]guanidino}-10-oxodecanoic acid (5.1) 
The title compound was prepared from 5.1a (130 mg, 0.22 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 5.1 as a white 
solid (90 mg, 71 %). 1H-NMR (CD3OD) δ (ppm): 8.80 (s, 1H, Im-2-H), 7.36 (s, 1H, Im-
5-H), 3.38 (t, 2H, 3J = 6.8 Hz, CH2NH), 2.83 (t, 2H, 3J = 7.6 Hz, Im-4-CH2), 2.47 (t, 
2H, 3J = 7.3 Hz, CH2COOH), 2.27 (t, 2H, 3J = 7.4 Hz, COCH2), 2.03 (m, 2H, Im-4-
CH2CH2), 1.62 (m, 4H, COCH2CH2, CH2CH2COOH), 1.34 (m, 8H, (CH2)4); 13C 
(CD3OD) δ (ppm): 177.74 (quat. COOH), 177.45 (quat. C=O), 155.40 (quart., C=NH), 
134.97(+, Im-2-C), 134.32 (quart., Im-4-C), 117.13 (+, Im-5-C), 41.55 (-, CH2NH), 
37.75 (-, COCH2), 34.98 (-, CH2COOH), 30.20 (-, Im-4-CH2, CH2), 30.16 (-, CH2), 
29.92 (-, Im-4-CH2), 27.97 (-, CH2), 26.07 (-, CH2), 25.44 (-, CH2), 22.56 (-, CH2); 
HRMS: EI-MS: m/z for (C17H29N5O3) calcd. 351.22704, found 351.22665; prep. 
HPLC: MeCN/0.1% TFA/aq (25/75). C17H29N5O3 · 2TFA (579.21) 
N1,N10-Bis{N-[3-(1H-imidazol-4-yl)propyl]carbamimidoyl}decanediamide (5.6) 
The title compound was prepared from 5.6a (160 mg, 0.13 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 5.6 as a pale 
yellow oil (30 mg, 23 %). 1H-NMR (CD3OD) δ ppm: 8.81 (d, 1H, 4J = 1.3 Hz, Im-2-H), 
7.37 (d, 1H, 4J = 0.9 Hz, Im-5-H), 3.38 (t, 4H, 3J = 6.9 Hz, CH2NH), 2.84 (t, 4H, 3J = 
7.6 Hz, Im-4-CH2), 2.47 (t, 4H, 3J = 7.4 Hz, COCH2), 2.03 (m, 4H, Im-4-CH2CH2), 
1.65 (m, 4H, COCH2CH2), 1.35 (m, 8H, (CH2)4); 13C (CD3OD) δ (ppm): 177.45 (quat. 
C=O), 155.42 (quat. C=NH), 134.97 (+, Im-2-C), 134.33 (quat. Im-4-C), 117.14 (+, 
Im-5-C), 41.54 (-, CH2NH), 37.75 (-, COCH2), 30.17 (-, Im-4-CH2), 29.95 (-, Im-4-
CH2CH2), 27.98 (-, COCH2CH2CH2CH2), 25.45 (-, COCH2CH2CH2), 22.56 (-, 
COCH2CH2); HRMS: FAB-MS: m/z for ([C24H40N10O2 + H]+) calcd. 501.33357, found 
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501.34199; prep. HPLC: MeCN/0.1% TFA/aq (15/85-30/70). C24H40N10O2 · 4TFA 
(956.60) 
N1,N6-Bis{N-[3-(2-amino-4-methylthiazol-5-yl)propyl]carbamimidoyl}hexane-
diamide (5.7) 
The title compound was prepared from 5.7a (190 mg, 0.20 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 5.7 as a pale 
yellow oil (130 mg, 64 %). 1H-NMR (CD3OD) δ ppm: 3.35 (t, 4H, 3J = 6.8 Hz, 
CH2NH), 2.71 (t, 4H, 3J = 7.5 Hz, Thiaz-5-CH2), 2.52 (m, 4H, COCH2), 2.17 (s, 6H, 
Thiaz-4-CH3), 1.90 (m, 4H, Thiaz-5-CH2CH2), 1.71 (m, 4H, (CH2)2); 13C (CD3OD) δ 
(ppm): 177.09 (quart., C=O), 170.42 (quart., Thiaz-2-C), 155.37 (quart., C=NH), 
132.59 (quart., Thiaz-4-C), 118.35 (quart., Thiaz-5-C), 41.58 (-, CH2NH), 37.20 (-, 
COCH2), 29.67 (-, Thiaz-5-CH2), 24.51 (-, Thiaz-5-CH2CH2), 23.64 (-, COCH2CH2), 
11.45 (+, Thiaz-5-CH3); HRMS: FAB-MS: m/z for ([C22H36N10O2S2 + H]+) calcd. 
537.2464, found 537.25507; prep. HPLC: MeCN/0.1% TFA/aq (10/90-30/70). 
C22H36N10O2S2 · 4TFA (992.68) 
N1,N8-Bis{N-[3-(2-amino-4-methylthiazol-5-yl)propyl]carbamimidoyl}octane-
diamide (5.8) 
The title compound was prepared from 5.8a (190 mg, 0.19 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 5.8 as a 
colourless foam-like solid (110 mg, 57 %). 1H-NMR (CD3OD) δ ppm: 3.35 (t, 4H, 3J = 
6.9 Hz, CH2NH), 2.71 (t, 4H, 3J = 7.6 Hz, Thiaz-5-CH2), 2.48 (t, 4H, 3J = 7.4 Hz, 
COCH2), 2.18 (s, 6H, Thiaz-4-CH3), 1.90 (m, 4H, Thiaz-5-CH2CH2), 1.66 (m, 4H, 
COCH2CH2), 1.39 (m, 4H, (CH2)2); 13C (CD3OD) δ (ppm): 177.39 (quart., C=O), 
170.40 (quart., Thiaz-2-C), 155.38 (quart., C=NH), 132.60 (quart., Thiaz-4-C), 118.40 
(quart., Thiaz-5-C), 41.58 (-, CH2NH), 37.64 (-, COCH2), 29.70 (-, Thiaz-5-CH2), 
29.59 (-, COCH2CH2CH2), 25.23 (-, Thiaz-5-CH2CH2), 23.63 (-, COCH2CH2), 11.45 
(+, Thiaz-5-CH3); HRMS: FAB-MS: m/z for ([C24H40N10O2S2 + H]+) calcd. 565.27771, 
found 565.28476; prep. HPLC: MeCN/0.1% TFA/aq (15/85-40/60). C24H40N10O2S2 · 
4TFA (1020.73) 
N1,N10-Bis{N-[3-(2-amino-4-methylthiazol-5-yl)propyl]carbamimidoyl}decane-
diamide (5.9) 
The title compound was prepared from 5.9a (200 mg, 0.19 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 5.9 as a 
colourless foam-like solid (120 mg, 57 %). 1H-NMR (CD3OD) δ ppm: 3.35 (t, 4H, 3J = 
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6.8 Hz, CH2NH), 2.70 (t, 4H, 3J = 7.5 Hz, Thiaz-5-CH2), 2.45 (t, 4H, 3J = 7.4 Hz, 
COCH2), 2.16 (s, 6H, Thiaz-4-CH3), 1.90 (m, 4H, Thiaz-5-CH2CH2), 1.63 (m, 4H, 
COCH2CH2), 1.33 (m, 8H, (CH2)4); 13C (CD3OD) δ (ppm): 177.57 (quart., C=O), 
170.43 (quart., Thiaz-2-C), 155.41 (quart., C=NH), 132.59 (quart., Thiaz-4-C), 118.33 
(quart., Thiaz-5-C), 41.56 (-, CH2NH), 37.75 (-, COCH2), 30.13 (-, Thiaz-5-CH2), 
29.90 (-, CH2), 29.68 (-, CH2), 25.46 (-, Thiaz-5-CH2CH2), 23.64 (-, COCH2CH2), 
11.46 (+, Thiaz-5-CH3); HRMS: FAB-MS: m/z for ([C26H44N10O2S2 + H]+) calcd. 
593.309, found 593.3161; prep. HPLC: MeCN/0.1% TFA/aq (25/75). C26H44N10O2S2 · 
4TFA (1048.78) 
N1,N12-Bis{N-[3-(2-amino-4-methylthiazol-5-yl)propyl]carbamimidoyl}dodecane-
diamide (5.10) 
The title compound was prepared from 5.10a (320 mg, 0.31 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 5.10 as a 
colourless foam-like solid (180 mg, 53 %). 1H-NMR (CD3OD) δ ppm: 3.35 (t, 4H, 3J = 
6.7 Hz, CH2NH), 2.70 (t, 4H, 3J = 7.4 Hz, Thiaz-5-CH2), 2.45 (t, 4H, 3J = 7.3 Hz, 
COCH2), 2.16 (s, 6H, Thiaz-4-CH3), 1.90 (m, 4H, Thiaz-5-CH2CH2), 1.63 (m, 4H, 
COCH2CH2), 1.30 (m, 12H, (CH2)6); 13C (CD3OD) δ (ppm): 177.66 (quart., C=O), 
170.43 (quart., Thiaz-2-C), 155.42 (quart., C=NH), 132.59 (quart., Thiaz-4-C), 118.31 
(quart., Thiaz-5-C), 41.57 (-, CH2NH), 37.80 (-, COCH2), 30.47 (-, Thiaz-5-CH2), 
30.32 (-, CH2) , 29.98 (-, CH2), 29.70 (-, CH2), 25.51 (-, Thiaz-5-CH2CH2), 23.65 (-, 
COCH2CH2), 11.48 (+, Thiaz-5-CH3); HRMS: FAB-MS: m/z for ([C28H48N10O2S2 + 
H]+) calcd. 621.34031, found 621.34693; prep. HPLC: MeCN/0.1% TFA/aq (25/75-
40/60). C28H48N10O2S2 · 4TFA (1076.84) 
N1,N16-Bis{N-[3-(2-amino-4-methylthiazol-5-yl)propyl]carbamimidoyl}hexa-
decanediamide (5.11) 
The title compound was prepared from 5.11a (260 mg, 0.24 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 5.11 as a pale 
yellow oil (170 mg, 62 %). 1H-NMR (CD3OD) δ ppm: 3.35 (t, 4H, 3J = 6.8 Hz, 
CH2NH), 2.71 (t, 4H, 3J = 7.5 Hz, Thiaz-5-CH2), 2.46 (t, 4H, 3J = 7.4 Hz, COCH2), 
2.17 (s, 6H, Thiaz-4-CH3), 1.90 (m, 4H, Thiaz-5-CH2CH2), 1.64 (m, 4H, COCH2CH2), 
1.27 (m, 20H, (CH2)10); 13C (CD3OD) δ (ppm): 177.61 (quart., C=O), 170.42 (quart., 
Thiaz-2-C), 155.41 (quart., C=NH), 132.59 (quart., Thiaz-4-C), 118.33 (quart., Thiaz-
5-C), 41.57 (-, CH2NH), 37.80 (-, COCH2), 30.78 (-, Thiaz-5-CH2), 30.73 (-, CH2), 
30.60 (-, CH2), 30.40 (-, CH2), 30.03 (-, CH2), 29.70 (-, CH2), 25.54 (-, Thiaz-5-
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CH2CH2), 23.65 (-, COCH2CH2), 11.48 (+, Thiaz-5-CH3); HRMS: FAB-MS: m/z for 
([C32H56N10 O2S2 + H]+) calcd. 677.4029, found 677.40894; prep. HPLC: MeCN/0.1% 
TFA/aq (25/75-50/50). C32H56N10O2S2 · 4TFA (1132.94) 
N1,N22-Bis{N-[3-(2-amino-4-methylthiazol-5-yl)propyl]carbamimidoyl}docosane-
diamide (5.12) 
The title compound was prepared from 5.12a (330 mg, 0.24 mmol) in 10 ml 
CH2Cl2/abs and 2 ml TFA according to the general procedure yielding 5.12 as a pale 
yellow foam-like solid (150 mg, 43 %). 1H-NMR (CD3OD) δ ppm: 3.35 (t, 4H, 3J = 6.8 
Hz, CH2NH), 2.71 (t, 4H, 3J = 7.6 Hz, Thiaz-5-CH2), 2.46 (t, 4H, 3J = 7.4 Hz, COCH2), 
2.17 (s, 6H, Thiaz-4-CH3), 1.90 (m, 4H, Thiaz-5-CH2CH2), 1.64 (m, 4H, COCH2CH2), 
1.27 (m, 32H, (CH2)16); 13C (CD3OD) δ (ppm): 177.58 (quart., C=O), 170.42 (quart., 
Thiaz-2-C), 155.42 (quart., C=NH), 132.59 (quart., Thiaz-4-C), 118.34 (quart., Thiaz-
5-C), 41.56 (-, CH2NH), 37.79 (-, COCH2), 30.87 (-, 4 CH2), 30.78 (-, Thiaz-5-CH2), 
30.64 (-, CH2), 30.43 (-, CH2), 30.06 (-, CH2) , 29.71 (-, CH2), 25.55 (-, Thiaz-5-
CH2CH2), 23.65 (-, COCH2CH2), 11.48 (+, Thiaz-5-CH3); HRMS: FAB-MS: m/z for 
([C38H68O2N10S2 + H]+) calcd. 761.4968, found 761.50289; prep. HPLC: MeCN/0.1% 
TFA/aq (35/65-60/40). C38H68N10O2S2 · 4TFA (1217.1) 
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Summary 
 
Potent and selective histamine H2 receptor (H2R) agonists are valuable pharmaco-
logical tools and might be of therapeutic value as drugs, for example in the treatment 
of severe congestive heart failure, acute myelogenous leukaemia and inflammatory 
diseases. At the beginning of this project arpromidine and related N-[3-(1H-imidazol-
4-yl)propyl]guanidines were known as the most potent H2R agonists, achieving up to 
400 times the potency of histamine on the isolated spontaneously beating guinea pig 
right atrium. Previous studies from our group have shown that the strong basicity of 
those compounds is considerably reduced by introduction of a carbonyl group 
adjacent to the guanidine moiety while the agonistic acitivity is more or less retained. 
Investigations of prototypical acylguanidines revealed improved pharmacokinetic 
properties, in particular oral bioavailability and penetration across the blood brain 
barrier. However, the H2R agonistic activity turned out to be species-dependent: 
guanidines and NG-acylated guanidines were less potent and efficacious at the 
human (h) than at the guinea pig (gp) H2R. Moreover, the imidazolylpropylguanidines 
had considerable activity at H3R and H4R.  
 
The aim of this thesis was to synthesize and elaborate the structure-activity 
relationships, in particular to improve the potency and selectivity of acylguanidine-
type H2R agonist. Therefore, numerous NG-acylated [3-(1H-imidazol-4-
yl)propyl]guanidines and [3-(2-amino-4-methylthiazol-5-yl)propyl]guanidines with 
different alkanoyl substituents including “bivalent ligands” were prepared and 
pharmacologically characterized (cooperation with Prof. Dr. S. Elz and Prof. Dr. R. 
Seifert, University of Regensburg).  
 
NG-Acylated [3-(1H-imidazol-4-yl)propyl]guanidines. The synthesized compounds 
were investigated for agonism on the gp right atrium and in a steady-state GTPase 
activity assay using membranes with fusion proteins of hH2R and gpH2R and the 
short splice variant of Gsα, GsαS. In general, a methyl or ethyl branched three-
membered alkanoyl chain between the guanidine moiety and an aromatic or alicyclic 
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ring system favours high potency at the gpH2R. By contrast, the hH2R 
prefers/tolerates compounds with longer and more ramified NG-alkanoyl chains, 
presumably due to a more flexible binding pocket. Polar substituents strongly shifted 
the species selectivity towards gpH2R, whereas aliphatic substituents were preferred 
by the hH2R. In accordance with previous data of alkyl- and acylguanidines, most 
compounds proved to be more potent and efficacious at the gpH2R compared to the 
hH2R. Strikingly, also compounds with similar or even slightly higher potency and 
efficacy at the hH2R were found, indicating that, in principle, potent and selective 
compounds for the human receptor can be developed. For receptor selectivity, 
representative compounds were tested at hH1R (calcium assay on U-373 MG cells) 
as well as in GTPase assays on hH3R and hH4R expressed in Sf9 cells. On human 
U-373 cells only weak antagonistic activity was found. Surprisingly, several NG-
acylated imidazolylpropylguanidines turned out to be potent agonists on the hH3R 
and hH4R in the GTPase assay (pEC50 values around 8-9). 
  
NG-Acylated [3-(2-amino-4-methylthiazol-5-yl)propyl]guanidines. The bioisosteric 
replacement of the imidazole against a 2-amino-4-methylthiazole ring led to 
equipotent or even more potent partial H2R agonists and turned out to be key to 
obtain highly H2R-selective agonists, devoid of activity on H3R and H4R. In contrast to 
the H2R agonist amthamine (2-amino-4-methylthiazol-5-ethanamine), the 4-methyl 
group in the thiazole ring of acylguanidine-type H2R agonists did enhance the 
agonistic potency neither in the GTPase assay nor at the gp right atrium.  
 
“Bivalent” H2R agonists. According to the “bivalent ligand approach”, symmetric 
compounds were synthesized by connecting either two imidazol-4-ylpropylguanidine 
or two 2-amino-4-methylthiazol-5-ylpropylguanidine moieties by NG-acylation with 
alkanedioic acids of different length. Most strikingly, the combination of two 2-amino-
4-methylthiazol-5-ylpropylguanidine moieties with an octanedioyl spacer resulted in 
the most potent agonist at the gp atrium known so far (pEC50 9.45; 3000-fold potency 
of histamine). This result is in good agreement with the data from the GTPase assay. 
However, the spacer groups of these bivalent H2R agonists are too short to allow 
simultaneous binding to both receptor molecules of a H2R dimer. Elongation of the 
spacer up to a length predicted to be optimal for binding to receptor dimers (22-27 Å) 
resulted in a dramatic decrease or total loss of H2R agonism. The exceptionally high 
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potency of the most prominent bivalent H2R agonists can be explained by binding to 
an additional (allosteric?) binding site at the same receptor molecule rather than by 
“bridging” of a receptor dimer. Further investigations of the bivalent ligands on mutant 
H2R-GsαS fusion proteins (transmembrane domains, e2 loop) confirmed the key role 
of the non-conserved Tyr-17 and Asp-271 in TM1 and TM7 in the gpH2R for species-
selective H2R activation and suggest that the second extracellular loop does not 
participate in direct ligand-receptor interactions.   
 
In conclusion, numerous potent histamine H2R agonists were identified among the 
synthesized NG-acylated hetarylpropylguanidines. A major problem, selectivity for 
H2R over H3R and H4R, was solved by bioisosteric replacement of the imidazol-4-yl 
with a 2-amino-4-methylthiazol-5-yl ring. The most potent and selective H2R agonists 
were obtained according to the bivalent ligand approach by combining two guanidine-
type H2R agonist pharmacophores by alkanedioic acids. The results of this thesis 
represent a promising step towards the development of guanidine-type H2R agonists 
for in vivo investigations. 
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Appendix 1: Abbreviations 
abs     absolute 
AMT     amthamine 
aq     aqueous 
Ar     aryl 
ARP     arpromidine 
Bn     benzyl 
Boc     tert-butoxycarbonyl 
cAMP     cyclic 3´,5´-adenosine monophosphate 
Cbz     benzyloxycarbonyl 
CDI     N, N´-carbonyldiimidazole 
cHex     cyclohexyl 
cH2R     canine histamine H2 receptor 
conc     concentrated 
d     day 
DCM     dichloromethane 
DIAD     diisopropyl azodicarboxylate 
DIEA     N,N-diisopropylethylamine 
DMAP    p-dimethylaminopyridine 
DMF      dimethylformamide 
DMSO    dimethylsulfoxid 
e2 second extracellular loop of a G-protein coupled 
receptor 
EC50 agonist concentration which induces 50 % of the 
maximum effect 
EDAC N-(3-dimethylaminopropyl)-N´-ethylcarbodiimide 
hydrochloride 
GDP guanosine diphosphate 
GPCR    G-protein coupled receptor 
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gpH2R    guinea pig histamine H2 receptor 
gpH2R-hE2-GsαS fusion protein of the guinea pig H2 receptor bearing 
Asp-167→Gly-167, Asp-169→His-169, Ile-
171→Thr-171 and Val-172→Ser-172 mutations and 
the short splice variant of Gsα 
GsαS     short splice variant of Gsα 
GTP     guanosine triphosphate 
h     hours 
H1R, H2R, H3R, H4R  histamine receptor subtypes 
(c/gp/h/r)H2R-GsαS fusion proteins of histamine H2 receptor species 
isoforms and the short splice variant of Gsα 
hH2R     human histamine H2 receptor 
hH2R-C17Y-A271D-GsαS fusion protein of the human histamine H2 receptor 
bearing a Cys-17→Tyr-17 and Ala-271→Asp-271 
mutation and the short splice variant of Gsα 
hH2R-C17Y-GsαS fusion protein of the human histamine H2 receptor 
bearing a Cys-17→Tyr-17 mutation and the short 
splice variant of Gsα 
hH2R-gpE2-GsαS fusion protein of the guinea pig H2 receptor bearing 
Gly-167→Asp-167, His-169→Asp-169, Thr-
171→Ile-171 and Ser-172→Val-172 mutations and 
the short splice variant of Gsα 
HIS histamine 
HOBt     1-hydroxybenzotriazole hydrate 
HPLC     high-pressure liquid spectroscopy 
HR-MS    high resolution mass spectroscopy 
IMP     impromidine 
min     minutes 
MPM     p-methoxybenzyl 
NMR      nuclear magnetic resonance 
MS     mass spectroscopy 
ppm     parts per million 
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py-1 2,6-dimethyl-4-[(E)-2-(2,3,6,7-tetrahydro-1H,5H-
pyrido[3,2,1-ij]quinolin-9-yl)-vinyl]pyranylium 
tetrafluoro borate 
rt     room temperature 
SEM     standard error of the mean 
Sf9     Spodoptera frugiperda insect cell line 
TFA     trifluoroacetic acid 
TM transmembrane domain of a G-protein coupled 
receptor 
TM1-TM7 numbering of transmembrane domains of a G-
protein coupled receptor 
 
Appendix 2: Combustion analysis data 
 
Calculated Found 
No Formula 
C H N C H N 
3.20 C25H22N2O2 78.51 5.90 7.32 78.37 5.88 7.27 
3.21c C11H14O2 74.13 7.92  74.26 7.59  
3.22c C12H16O2 74.97 8.39  74.73 8.19  
3.23c C13H18O2 75.69 8.80  75.77 8.78  
3.24c C16H16O2 79.97 6.71  80.08 6.75  
3.28c C11H14O2·C12H23N 76.83 10.37 3.90 76.45 10.46 3.75 
3.29c C12H16O2·C12H23N 77.16 10.52 3.75 76.90 10.41 3.50 
3.30c C13H18O2 ·C12H23N 77.47 10.66 3.61 77.23 10.57 3.23 
3.26c C16H22O2 ·C12H23N·0.25 H2O 77.82 10.61 3.24 77.79 10.38 3.03 
3.25c C17H18O2 80.28 7.13  80.13 6.96  
3.27c C11H14O2 74.13 7.92  74.06 8.29  
3.39c C17H25NO4·C12H23N 71.27 9.96 5.73 71.24 9.57 5.59 
3.33c C11H13FO2·C12H23N·0.25 H2O 72.31 9.63 3.67 72.54 9.36 3.49 
3.34c C11H13FO2·C12H23N·0.15 H2O 72.65 9.62 3.68 72.74 9.43 3.37 
3.36c C12H16O3·C12H23N·0.75H2O 71.51 10.13 3.47 71.11 9.75 3.36 
3.35c C12H16O3 ·C12H23N·0.5 H2O 72.65 10.11 3.53 72.36 9.87 3.18 
3.31c C12H16O2 ·C12H23N·H2O 73.61 10.55 3.58 73.56 10.23 3.34 
3.32c C12H16O2 ·C12H23N·0.5 H2O 75.35 10.54 3.66 75.36 10.20 3.14 
3.37c C13H18O2·C12H23N·0.3 H2O 76.40 10.67 3.56 76.61 10.23 3.14 
3.43 C11H20O2·C12H23N·0.1 H2O 75.19 11.85 3.81 75.05 11.85 3.56 
3.45 C12H22O2 ·C12H23N 75.93 11.95 3.69 76.06 12.19 3.49 
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3.46 C13H24O2 ·C12H23N·0.25H2O 75.42 12.02 3.52 75.71 11.30 3.44 
3.47 C11H20O2 ·C12H23N 75.56 11.86 3.83 75.34 11.75 3.51 
3.48 C12H22O2 ·C12H23N·0.1 H2O 75.57 11.94 3.67 75.22 11.96 3.63 
3.49 C13H24O2 ·C12H23N·0.5 H2O 74.75 12.02 3.48 74.66 11.89 3.20 
3.40 C10H18O2 ·C12H23N 75.16 11.75 3.98 74.96 11.67 3.65 
3.41 C10H18O2 ·C12H23N 75.16 11.75 3.98 75.06 11.59 3.73 
3.42 C10H18O2 ·C12H23N 75.16 11.75 3.98 75.10 11.43 3.76 
3.50 C12H22O2·C12H23N 75.93 11.95 3.69 75.72 11.97 3.44 
3.44 C11H20O2 ·C12H23N 75.56 11.86 3.83 75.19 11.48 3.60 
3.51d C11H14O2 ·C12H23N·0.25 H2O 75.88 10.38 3.85 75.50 10.41 3.62 
3.53b C17H16O3·0.25H2O 74.84 6.10  75.17 6.08  
 
 
Appendix 3: HPLC purity data 
 
No tR [min] k` purity [%] No tR [min] k` purity [%] 
3.55 12.77 2.85 100 4.19 15.23 3.59 100 
3.57 13.88 3.18 100 4.20 14.08 3.24 100 
3.58a 14.83 3.47 92 4.21 15.27 3.60 98 
3.59a 16.47 3.96 100 4.22 15.03 3.53 99 
3.60a 16.32 3.92 100 4.23 15.22 3.59 100 
3.61a 17.55 4.29 95 4.24 16.63 4.01 100 
3.62 18.92 4.70 84 4.25 16.43 3.95 99 
3.63a 13.26 2.99 100 4.26 15.31 3.61 99 
3.64a 13.98 3.21 100 4.27 15.22 3.59 100 
3.65a 13.90 3.19 100 4.28 15.79 3.76 98 
3.66a 15.43 3.65 100 4.29 15.72 3.74 93 
3.67a 16.79 4.06 97 4.30 16.85 4.08 98 
3.68a 15.23 3.59 100 4.31 16.82 4.07 97 
3.69 15.48 3.67 98 4.32 16.85 4.08 100 
3.70a 14.43 3.35 100 4.33 18.08 4.45 100 
3.71a 14.38 3.33 100 4.34 17.84 4.38 96 
3.72 14.31 3.31 100 4.35 18.52 4.58 100 
3.73a 13.82 3.16 100 4.36 19.64 4.92 100 
3.74a 16.68 4.03 99 4.37 11.39 2.43 100 
3.75a 15.59 3.69 100 4.38 9.14 1.75 99 
3.76a 15.62 3.71 100 4.39 12.94 2.90 94 
3.77 15.72 3.74 89 4.40 12.80 2.86 100 
3.78 16.97 4.11 96 4.41 13.61 3.10 99 
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3.79 16.74 4.05 97 4.42 14.83 3.47 95 
3.80 17.99 4.42 99 4.43 16.35 3.93 99 
3.81 19.50 4.88 100 4.44 16.54 3.98 98 
3.82 17.41 4.25 97 4.45 16.34 3.92 95 
3.83a 19.91 5.00 100 4.46 17.64 4.32 100 
3.84b 18.28 4.51 99 5.1 11.97 2.61 97 
3.85 18.54 4.59 98 5.6 9.66 1.91 96 
3.86 10.60 2.19 83 5.7 8.27 1.49 93 
3.87 10.21 2.08 97 5.8 9.51 1.87 89 
3.88 6.29 0.89 100 5.9 10.90 2.28 100 
3.89 7.85 1.37 97 5.10 12.77 2.85 95 
3.90 15.22 3.59 100 5.11 15.89 3.79 96 
3.91 11.83 2.57 100 5.12b 18.53 4.58 100 
3.92b 18.03 4.43 66     
a 0.02 % TFA/aq; b gradient: 0 min: MeCN/0.05% TFA/aq 10/90, 20 min: 70/30; 
 
Analytical HPLC was performed on a system from Thermo Separation Products 
equipped with a SN 400 controller, P4000 pump, an AS3000 autosampler and a 
Spectra Focus UV-VIS detector. Stationary phase was an Eurosphere-100 C-18 (250 
x 4.0, 5 µm) column (Knauer) thermostated at 30 °C. As mobile phase gradients of 
MeCN/0.02 or 0.05 % TFA/aq were used (flow rate = 0.7 ml/min). Absorbance was 
detected at 210 nm. 
The following gradient mode was used: 0 min: MeCN/0.05% TFA/aq 10/90, 20 min: 
60/40, 20-23 min: 95/5, -33 min 95/5. 
t0 (Eurosphere-100 C-18) = 3.318 min; k´= (tR-t0)/t0.  
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Short lecture and poster presentations: 
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Buschauer, A, NG-acylated hetarylpropylguanidines-centrally active selective 
histamine H2 receptor agonists, poster contribution, abstract no. A17, Annual Meeting 
of the German Pharmaceutical Society (DPhG), Erlangen, October 10-13, 2007. 
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